patient_id,cancer_type,age_years,sex,ecog_ps_baseline,treatment_line,smoking_status,pack_years,bmi_kg_m2,prior_autoimmune_flag,autoimmune_type,steroid_use_baseline_flag,antibiotic_use_flag,prior_lines_systemic,metastatic_sites,brain_mets_flag,gut_microbiome_diversity,pdl1_tps_pct,pdl1_cps_score,tmb_mut_per_mb,tmb_high_flag,msi_status,dmmr_flag,til_score_pct,til_category,cd8_density_cells_mm2,cd4_cd8_ratio,foxp3_treg_density,tumor_volume_mm3,target_lesion_count,sum_target_lesions_baseline_mm,neoantigen_load,ifn_gamma_signature,t_cell_inflamed_ges,pdl1_response_group,tmb_response_quintile,cpi_agent,cpi_class,treatment_duration_weeks,cycle_number,treatment_status,combination_chemo_flag,combination_vegf_flag,abs_lymphocyte_count_k_ul,abs_neutrophil_count_k_ul,nlr_ratio,plr_ratio,ldh_u_l,ldh_elevated_flag,crp_mg_l,il6_pg_ml,il10_pg_ml,ifn_gamma_pg_ml,cd4_count_cells_ul,cd8_count_cells_ul,nk_cell_pct,regulatory_t_pct,response_biomarker_tier,combined_biomarker_score,ctdna_baseline_copies_ml,immune_cell_ratio_score,genomic_loss_hla_flag,b2m_mutation_flag,stk11_mutation_flag,keap1_mutation_flag,msi_h_response_adj_orr,best_overall_response,objective_response_flag,disease_control_flag,percent_change_target_lesions,response_depth_pct,sum_target_lesions_baseline_mm,sum_target_lesions_nadir_mm,time_to_response_weeks,dor_weeks,pseudoprogression_flag,hyperprogression_flag,ctdna_change_8wk_pct,ctdna_clearance_flag,irae_any_flag,irae_grade3plus_flag,irae_organ_count,irae_onset_weeks,irae_resolved_flag,time_to_irae_resolution_weeks,cpi_held_flag,cpi_discontinued_irae_flag,corticosteroid_flag,prednisone_peak_mg_day,prednisone_taper_weeks,infliximab_flag,mycophenolate_flag,ivig_flag,endocrine_replacement_flag,irae_hospitalization_flag,irae_icu_flag,cpi_rechallenge_flag,rechallenge_irae_recurrence_flag,dermatitis_grade,colitis_grade,pneumonitis_grade,hepatitis_grade,hypothyroidism_grade,hyperthyroidism_grade,adrenal_insufficiency_grade,hypophysitis_grade,nephritis_grade,myocarditis_grade,arthralgia_grade,alt_u_l,ast_u_l,tbili_mg_dl,creatinine_mg_dl,tsh_miu_l,ft4_ng_dl,cortisol_am_ug_dl,troponin_i_ng_ml,ck_u_l,pfs_weeks,pfs_event_flag,os_weeks,os_event_flag,landmark_12mo_pfs_flag,landmark_24mo_os_flag,long_term_responder_flag,time_to_next_treatment_weeks,post_cpi_treatment,cause_of_death
HC-ONC-013-000001,Melanoma,65,Male,1,First-line,Former,25.1,21.4,0,None,0,1,0,3,0,3.63,52.2,91.3,2.54,0,MSS,0,7.4,TIL-low,112,1.21,49,1499,3,19.0,16,-0.113,0.058,PD-L1-high,Q1,Nivolumab,Anti-PD-1,21.3,7,Completed_2yr,0,0,1.22,4.09,3.36,459,329,1,13.5,6.5,5.0,5.09,1058,461,6.9,6.4,Tier1_FDA-approved,22.5,726,2.24,0,0,0,0,,PR,1,1,-30.0,30.0,19.0,13.3,16.7,38.2,0,0,-72.6,0,1,0,2,18.6,1,6.5,0,0,1,69,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,19,17,1.34,0.68,1.295,1.05,18.6,0.0235,17114,107.5,1,165.8,1,1,1,1,110.9,Clinical_Trial,Other
HC-ONC-013-000002,Hodgkin,83,Female,1,Second-line,Former,5.6,20.5,0,None,0,0,1,6,1,3.91,0.0,0.0,6.21,0,MSS,0,67.0,TIL-high,1249,0.72,15,4122,1,111.2,46,0.224,0.462,PD-L1-negative,Q1,Nivolumab,Anti-PD-1,41.5,13,Discontinued_Progression,0,0,1.23,1.87,1.52,312,269,1,22.6,6.3,7.6,3.34,617,586,17.0,2.2,Tier2_emerging,21.2,91,20.0,0,0,0,0,,PD,0,0,63.8,0.0,111.2,111.2,,,0,1,118.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,26,0.56,0.71,1.146,1.17,14.2,0.0024,128,7.4,0,73.3,1,0,0,0,11.3,BSC,Other
HC-ONC-013-000003,Urothelial,72,Female,3,Third+,Former,28.4,28.4,0,None,0,0,4,7,0,2.3,50.5,70.8,16.51,1,MSS,0,51.5,TIL-high,1297,0.61,38,837,2,77.6,83,-1.484,-0.726,PD-L1-high,Q3,Durvalumab,Anti-PD-L1,46.0,15,Completed_2yr,0,0,1.0,4.09,4.08,336,274,1,16.3,0.3,10.7,16.0,549,452,15.0,6.2,Tier1_FDA-approved,39.6,423,20.0,0,0,0,0,,PR,1,1,-30.9,30.9,77.6,53.6,22.6,12.7,0,0,-81.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,35,37,0.53,1.1,2.831,0.98,25.9,0.007,74,69.0,1,103.0,1,1,0,0,74.0,None,Disease_Progression
HC-ONC-013-000004,RCC,54,Female,0,First-line,Former,37.5,24.5,0,None,0,0,0,3,0,2.59,0.0,0.0,7.46,0,MSS,0,19.4,TIL-intermediate,358,1.53,6,913,5,45.1,29,1.452,1.38,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,52.6,17,Active,0,0,1.36,6.32,4.64,310,262,1,5.0,4.3,2.5,5.97,1276,460,18.9,5.6,Tier3_exploratory,5.3,336,20.0,0,0,0,0,,PR,1,1,-36.9,36.9,45.1,28.4,12.2,16.8,0,0,-76.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,26,1.48,0.88,3.578,1.16,16.7,0.0277,143,19.9,0,49.5,0,0,0,0,24.4,BSC,None
HC-ONC-013-000005,NSCLC,50,Female,0,First-line,Former,24.2,35.6,0,None,0,0,0,6,0,3.25,80.7,100.0,62.49,1,MSS,0,52.4,TIL-high,1186,1.18,49,3678,4,43.2,424,-0.948,-0.8,PD-L1-high,Q5,Pembrolizumab+Chemo,Combination,35.3,11,Active,1,0,1.3,5.31,4.09,257,115,0,31.1,20.5,7.4,3.23,589,697,8.6,4.5,Tier1_FDA-approved,67.0,133,20.0,0,0,0,0,,SD,0,1,-18.4,18.4,43.2,35.3,,,0,0,47.4,0,1,0,2,4.7,1,8.4,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,2,15,16,0.95,0.81,1.438,1.66,24.6,0.0264,26626,16.9,0,68.2,0,0,0,0,23.9,Targeted,None
HC-ONC-013-000006,NSCLC,66,Female,1,First-line,Never,0.0,31.3,0,None,0,1,0,4,0,4.02,0.0,0.0,3.89,0,MSS,0,21.4,TIL-intermediate,605,1.83,56,646,1,20.9,28,1.253,1.29,PD-L1-negative,Q1,Atezolizumab,Anti-PD-L1,25.7,8,Discontinued_Progression,0,0,0.64,9.59,15.05,347,241,0,53.6,48.3,19.2,2.37,1456,420,13.5,3.2,Tier3_exploratory,2.0,108,10.61,0,0,0,0,,PR,1,1,-52.3,52.3,20.9,10.0,8.1,6.7,0,0,-78.4,0,1,0,1,1.6,1,7.7,0,0,1,37,10,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,40,45,0.53,0.86,3.291,1.04,28.5,0.0044,42,25.0,1,64.9,0,0,0,0,29.2,Chemotherapy,None
HC-ONC-013-000007,NSCLC,45,Female,1,Second-line,Former,36.3,28.9,0,None,1,0,1,5,1,3.6,0.0,0.0,48.55,1,MSI-L,0,14.3,TIL-intermediate,363,1.76,60,1139,4,59.6,359,-0.09,0.501,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,90.7,30,Discontinued_Progression,0,0,2.18,3.93,1.8,73,103,0,31.1,2.7,30.2,4.23,200,446,14.1,6.4,Tier1_FDA-approved,30.1,1601,5.95,1,0,0,0,,SD,0,1,17.3,0.0,59.6,59.6,,,0,0,34.2,0,1,0,2,2.0,1,14.8,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,18,15,0.5,0.7,0.241,3.19,22.6,0.0364,105,34.9,0,51.5,0,0,0,0,38.8,Chemotherapy,None
HC-ONC-013-000008,HNSCC,82,Female,0,Second-line,Never,0.0,29.1,0,None,0,0,1,2,0,3.4,0.0,0.0,11.02,1,MSS,0,10.5,TIL-intermediate,221,0.74,24,3522,2,124.1,67,1.176,1.247,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,38.5,12,Discontinued_irAE,0,0,4.0,5.72,1.43,259,184,0,32.8,12.9,6.7,2.05,1327,325,15.5,3.1,Tier1_FDA-approved,7.4,32,8.84,0,0,0,0,,PD,0,0,45.0,0.0,124.1,124.1,,,0,0,19.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,40,39,1.33,0.74,2.986,1.34,27.5,0.0107,55,10.1,0,26.4,0,0,0,0,16.0,Clinical_Trial,None
HC-ONC-013-000009,RCC,75,Female,0,Second-line,Former,17.0,33.2,0,None,0,0,1,5,1,3.26,0.0,0.0,15.95,1,MSS,0,44.6,TIL-intermediate,917,0.67,42,21267,3,87.1,116,1.135,0.351,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,47.7,15,Completed_2yr,0,0,2.1,6.66,3.17,145,139,0,7.0,26.0,7.6,10.21,1046,499,17.6,9.3,Tier1_FDA-approved,18.4,826,20.0,0,0,0,0,,SD,0,1,17.4,0.0,87.1,87.1,,,0,0,51.7,0,1,0,2,2.3,0,,0,0,1,59,9,0,0,0,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,0,38,38,1.02,0.91,10.502,0.77,16.0,0.0347,168,50.6,1,57.9,0,0,0,0,57.7,Chemotherapy,None
HC-ONC-013-000010,TNBC,55,Female,0,Second-line,Never,0.0,30.7,0,None,0,0,1,1,0,3.52,70.8,59.4,25.79,1,MSS,0,24.4,TIL-intermediate,533,1.91,103,3739,2,58.8,79,0.43,0.174,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,22.5,7,Discontinued_Complete_Response,0,0,1.52,12.0,7.89,438,240,0,35.7,7.5,43.3,1.05,936,862,8.4,5.2,Tier1_FDA-approved,47.2,1334,5.12,0,0,0,0,,SD,0,1,20.0,0.0,58.8,58.8,,,0,0,17.4,0,1,1,1,8.9,0,,1,0,1,104,2,0,0,0,0,1,0,0,0,0,0,4,0,0,0,0,0,0,0,0,26,22,0.44,0.82,1.317,1.13,28.4,0.0361,134,4.1,1,18.8,0,0,0,0,9.5,Chemotherapy,None
HC-ONC-013-000011,NSCLC,40,Female,2,First-line,Never,0.0,29.0,0,None,0,1,0,7,0,3.36,95.9,100.0,51.66,1,MSI-H,1,31.0,TIL-intermediate,548,1.76,103,3188,3,112.2,183,0.509,0.425,PD-L1-high,Q5,Pembrolizumab+Chemo,Combination,42.8,14,Discontinued_Progression,1,0,1.61,4.82,2.99,227,237,0,14.1,0.5,18.3,4.01,847,431,11.4,2.6,Tier1_FDA-approved,76.5,291,5.27,0,1,0,0,0.495,CR,1,1,-100.0,100.0,112.2,0.0,14.1,22.4,0,0,-78.9,0,1,0,1,13.7,1,5.7,0,0,1,42,7,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,13,15,1.36,0.89,0.8,1.44,16.1,0.0196,180,74.9,0,133.4,0,1,1,0,80.9,Targeted,None
HC-ONC-013-000012,Hodgkin,77,Female,0,Third+,Former,27.9,21.6,1,Psoriasis,1,0,3,2,0,2.38,10.2,11.4,26.52,1,MSS,0,28.8,TIL-intermediate,706,1.33,32,3419,2,46.7,92,0.423,-0.432,PD-L1-low,Q4,Nivolumab,Anti-PD-1,17.9,5,Active,0,0,1.39,2.66,1.91,249,255,1,20.3,9.9,4.5,7.3,1467,454,8.9,4.0,Tier1_FDA-approved,24.7,436,20.0,0,0,0,0,,PR,1,1,-62.7,62.7,46.7,17.4,10.1,10.9,0,0,-47.7,0,1,1,3,19.0,0,,1,0,1,105,7,1,0,0,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,2,31,34,0.83,0.69,1.962,0.84,16.1,0.0167,30447,33.8,1,42.3,0,0,0,0,37.3,None,None
HC-ONC-013-000013,HNSCC,59,Female,0,First-line,Never,0.0,41.8,0,None,0,0,0,3,0,3.24,44.6,41.4,1.07,0,MSS,0,13.1,TIL-intermediate,268,0.72,37,499,1,83.8,7,-2.0,-0.403,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,17.2,5,Discontinued_Progression,0,0,1.71,6.85,4.01,115,231,0,17.6,18.4,4.5,5.89,1112,639,11.7,4.4,Tier3_exploratory,25.1,2311,7.05,0,0,0,0,,PR,1,1,-30.0,30.0,83.8,58.7,15.5,36.1,0,0,-41.3,0,1,0,3,3.6,1,5.2,0,0,1,28,2,0,0,0,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,1,35,30,1.49,0.69,3.336,1.14,27.8,0.0116,184,38.7,0,66.0,0,0,0,0,43.0,Chemotherapy,None
HC-ONC-013-000014,NSCLC,75,Male,0,First-line,Former,34.7,21.0,0,None,0,0,0,4,0,2.34,53.3,67.6,6.37,0,MSS,0,35.5,TIL-intermediate,985,2.09,81,2077,1,72.8,21,0.118,0.065,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,46.5,15,Discontinued_Progression,0,0,1.62,11.39,7.01,407,148,0,10.8,2.4,15.9,2.52,629,526,15.5,9.8,Tier1_FDA-approved,31.0,140,12.01,0,1,1,1,,SD,0,1,0.0,0.0,72.8,72.8,,,0,0,80.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,23,21,0.64,0.83,3.244,0.94,22.0,0.0317,41,82.6,1,112.6,1,1,1,0,89.6,Chemotherapy,Disease_Progression
HC-ONC-013-000015,NSCLC,41,Female,1,Second-line,Former,32.8,24.9,0,None,0,0,1,4,0,3.26,78.6,100.0,5.3,0,MSS,0,14.3,TIL-intermediate,377,3.11,10,1745,4,111.2,29,-1.116,-0.528,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,32.6,10,Discontinued_Progression,0,0,1.18,3.81,3.24,335,176,0,5.2,5.4,3.3,7.6,384,1046,3.7,3.2,Tier1_FDA-approved,35.1,164,20.0,0,0,0,0,,PR,1,1,-31.0,31.0,111.2,76.8,6.0,43.3,0,0,-67.6,0,1,0,1,5.0,1,7.7,0,0,1,42,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,17,18,0.93,0.83,4.32,1.03,26.4,0.0085,79,69.5,1,153.4,0,1,1,0,74.6,Clinical_Trial,None
HC-ONC-013-000016,NSCLC,53,Female,0,Second-line,Never,0.0,18.2,0,None,0,0,1,3,1,2.82,56.1,46.6,3.94,0,MSS,0,13.9,TIL-intermediate,336,1.89,26,2660,2,16.9,21,0.171,-0.186,PD-L1-high,Q1,Pembrolizumab+Chemo,Combination,43.9,14,Completed_2yr,1,0,3.23,6.82,2.11,323,317,1,11.2,1.8,17.6,2.21,953,567,17.5,4.8,Tier1_FDA-approved,30.3,192,12.44,0,0,0,0,,SD,0,1,4.4,0.0,16.9,16.9,,,0,0,103.7,0,1,0,1,5.0,1,4.5,0,0,1,39,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,34,24,0.51,1.13,3.02,1.18,26.4,0.0246,21241,46.0,1,76.1,1,0,0,0,49.5,Chemotherapy,Disease_Progression
HC-ONC-013-000017,Melanoma,61,Male,1,First-line,Former,5.9,29.2,0,None,0,1,0,1,0,5.0,43.2,46.5,10.04,1,MSS,0,37.0,TIL-intermediate,757,1.08,96,2079,2,46.0,46,-1.143,-1.349,PD-L1-low,Q2,Nivolumab+Ipilimumab,Combination,18.5,6,Active,0,0,0.91,8.28,9.11,163,342,1,32.7,0.3,9.7,4.4,900,667,6.3,3.9,Tier1_FDA-approved,42.7,2317,7.8,0,0,0,0,,CR,1,1,-100.0,100.0,46.0,0.0,11.8,36.7,0,0,-100.0,1,1,1,3,5.8,0,,1,0,0,0,0,0,0,0,0,1,0,0,0,1,3,0,0,0,2,0,0,0,0,0,26,25,0.83,0.62,0.299,2.75,23.6,0.0226,55,41.8,1,97.8,0,0,0,0,45.9,Chemotherapy,None
HC-ONC-013-000018,RCC,61,Female,0,Third+,Never,0.0,27.3,0,None,0,0,3,3,0,3.17,24.1,20.1,17.24,1,MSS,0,44.0,TIL-intermediate,798,1.69,72,2852,4,14.5,127,-1.185,-1.013,PD-L1-low,Q3,Pembrolizumab,Anti-PD-1,37.6,12,Hold_irAE,0,0,2.2,7.45,3.39,166,113,0,7.8,25.3,11.2,7.55,444,789,10.5,6.0,Tier1_FDA-approved,38.1,2803,10.93,0,0,0,0,,CR,1,1,-100.0,100.0,14.5,0.0,16.0,18.8,0,0,-100.0,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,16,14,0.51,1.2,3.689,0.89,15.4,0.0105,59,97.6,0,125.6,1,1,1,0,103.7,Chemotherapy,Disease_Progression
HC-ONC-013-000019,Melanoma,55,Male,2,Third+,Never,0.0,30.3,0,None,0,1,3,6,0,2.08,0.0,0.0,22.93,1,MSS,0,29.7,TIL-intermediate,790,0.83,44,1244,5,69.6,88,1.605,1.073,PD-L1-negative,Q4,Nivolumab+Ipilimumab,Combination,28.0,9,Active,0,0,1.58,4.77,3.01,274,100,0,29.8,7.4,6.0,6.49,883,785,18.2,4.0,Tier1_FDA-approved,22.2,50,17.56,1,0,0,0,,SD,0,1,20.0,0.0,69.6,69.6,,,0,0,46.8,0,1,0,2,1.0,1,6.1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,38,43,0.67,1.17,73.294,0.44,24.5,0.0384,112,22.2,1,37.2,0,0,0,0,28.5,Clinical_Trial,None
HC-ONC-013-000020,NSCLC,68,Male,0,First-line,Former,23.4,17.8,0,None,0,0,0,7,0,3.09,0.0,0.0,47.75,1,MSI-H,1,10.2,TIL-intermediate,227,2.8,10,1940,2,128.5,227,1.069,0.978,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,37.5,12,Discontinued_Progression,0,0,3.53,3.16,1.0,173,139,0,25.5,50.3,4.5,2.61,728,647,13.6,2.7,Tier1_FDA-approved,24.8,1825,20.0,0,0,0,0,0.455,PD,0,0,42.6,0.0,128.5,128.5,,,0,0,88.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,38,42,0.62,0.93,3.752,1.47,13.1,0.0332,163,37.0,1,48.4,0,0,0,0,39.4,Chemotherapy,None
HC-ONC-013-000021,RCC,48,Female,1,Third+,Never,0.0,32.1,0,None,0,0,2,7,0,3.62,46.4,82.7,6.69,0,MSS,0,12.3,TIL-intermediate,227,1.72,32,414,2,59.8,46,-0.004,0.078,PD-L1-low,Q2,Nivolumab+Ipilimumab,Combination,19.6,6,Discontinued_Progression,0,0,1.89,4.3,2.28,304,338,1,9.0,20.7,23.8,11.68,903,568,13.7,4.6,Tier3_exploratory,32.3,1378,6.88,0,0,0,0,,PD,0,0,27.2,0.0,59.8,59.8,,,0,0,68.7,0,1,0,1,3.9,1,4.2,0,0,1,49,7,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,21,18,0.64,1.03,1.964,1.2,15.6,0.0018,183,28.2,1,62.2,1,0,0,0,32.9,None,Disease_Progression
HC-ONC-013-000022,NSCLC,59,Male,2,First-line,Current,36.8,22.5,0,None,0,0,0,1,0,4.54,0.0,0.0,16.98,1,MSS,0,21.2,TIL-intermediate,380,0.68,21,1232,2,59.6,54,0.185,0.284,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,46.6,15,Discontinued_irAE,0,0,1.43,5.64,3.95,83,368,1,48.9,4.8,6.1,4.8,1118,1005,6.1,4.4,Tier1_FDA-approved,18.0,4148,17.27,1,0,0,0,,PD,0,0,48.4,0.0,59.6,59.6,,,0,0,145.7,0,1,1,1,28.9,1,5.8,1,1,1,113,2,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,12,13,1.46,1.16,1.116,0.98,23.6,0.017,126,25.7,1,38.2,0,0,0,0,29.7,Chemotherapy,None
HC-ONC-013-000023,NSCLC,62,Female,1,First-line,Never,0.0,25.8,0,None,0,0,0,2,1,2.73,33.2,31.9,32.33,1,MSI-H,1,24.8,TIL-intermediate,434,1.42,43,9595,5,114.9,206,-0.248,-0.317,PD-L1-low,Q4,Pembrolizumab+Chemo,Combination,55.6,18,Active,1,0,1.49,7.06,4.73,192,126,0,8.5,6.7,5.3,8.12,1348,580,6.8,3.8,Tier1_FDA-approved,23.7,719,9.86,0,0,0,0,0.356,PR,1,1,-40.1,40.1,114.9,68.8,24.1,30.9,0,0,-36.0,0,1,0,1,10.9,1,4.1,0,0,1,23,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,29,33,0.35,0.75,1.149,1.03,28.3,0.0146,57,43.8,0,94.0,1,0,0,0,47.7,None,Other
HC-ONC-013-000024,Melanoma,67,Female,1,First-line,Never,0.0,31.2,0,None,0,1,0,3,0,1.93,0.0,0.0,28.29,1,MSS,0,5.2,TIL-low,138,2.08,17,2651,1,122.7,200,0.57,0.59,PD-L1-negative,Q4,Nivolumab+Ipilimumab,Combination,18.0,5,Active,0,0,1.68,5.3,3.16,601,234,0,55.1,14.6,6.9,15.23,1173,512,16.7,3.9,Tier1_FDA-approved,8.7,378,7.67,1,0,0,0,,CR,1,1,-100.0,100.0,122.7,0.0,15.6,89.8,0,0,-84.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,20,19,0.9,0.79,4.434,1.52,25.9,0.0345,43,49.2,1,81.5,1,0,0,0,55.9,BSC,Disease_Progression
HC-ONC-013-000025,Melanoma,69,Male,0,Third+,Former,22.6,27.8,0,None,0,0,3,1,0,3.85,36.4,48.0,24.51,1,MSS,0,30.8,TIL-intermediate,569,1.4,15,1763,4,76.5,188,-0.676,0.336,PD-L1-low,Q4,Nivolumab+Ipilimumab,Combination,20.2,6,Active,0,0,1.04,3.71,3.55,305,501,1,18.8,23.6,8.6,10.96,684,471,9.1,7.4,Tier1_FDA-approved,36.6,2248,20.0,1,1,0,0,,PR,1,1,-30.0,30.0,76.5,53.6,11.7,34.2,0,0,-36.8,0,1,0,2,4.0,1,8.2,1,0,1,46,11,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,12,9,1.06,0.67,2.993,0.85,18.0,0.0111,44574,33.6,0,88.1,1,0,0,0,37.2,BSC,Disease_Progression
HC-ONC-013-000026,Urothelial,47,Male,0,Second-line,Never,0.0,28.2,0,None,0,0,1,7,0,2.1,81.3,77.6,12.52,1,MSI-L,0,21.3,TIL-intermediate,487,1.44,6,17595,5,107.4,92,0.994,0.949,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,42.2,14,Discontinued_Progression,0,0,1.21,5.92,4.88,266,247,0,12.0,10.9,3.2,10.98,1011,255,9.5,4.4,Tier1_FDA-approved,35.7,1151,20.0,0,0,0,0,,SD,0,1,11.7,0.0,107.4,107.4,,,0,0,2.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37,40,1.09,0.94,1.197,1.31,26.8,0.0389,160,31.3,1,47.9,1,0,0,0,34.2,Chemotherapy,Disease_Progression
HC-ONC-013-000027,NSCLC,42,Male,1,First-line,Never,0.0,30.5,0,None,0,0,0,2,0,2.85,56.3,97.0,5.43,0,MSS,0,0.0,TIL-low,0,0.89,88,353,3,36.9,25,-0.253,0.253,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,44.9,14,Active,0,0,0.81,6.89,8.53,660,408,1,5.0,27.8,4.7,5.23,919,764,16.8,2.7,Tier1_FDA-approved,20.4,11700,0.5,0,0,0,0,,PR,1,1,-30.0,30.0,36.9,25.8,6.0,8.6,0,0,-63.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,40,34,1.21,0.7,1.574,1.16,29.4,0.0086,135,21.3,1,59.0,0,0,0,0,23.7,Clinical_Trial,None
HC-ONC-013-000028,RCC,76,Female,3,First-line,Never,0.0,28.6,0,None,0,0,0,3,1,2.99,56.6,88.2,6.77,0,MSS,0,6.1,TIL-low,144,2.19,24,478,3,135.1,40,-0.42,-0.105,PD-L1-high,Q2,Nivolumab+Ipilimumab,Combination,45.6,15,Hold_irAE,0,0,1.14,5.42,4.75,76,330,1,11.2,5.2,4.5,8.46,500,130,6.8,4.1,Tier1_FDA-approved,24.0,1699,5.76,0,0,0,0,,PR,1,1,-46.7,46.7,135.1,72.0,7.1,34.0,1,0,-85.2,0,1,1,2,3.7,1,6.3,1,1,1,150,8,1,0,0,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,0,21,20,1.21,1.16,1.988,1.61,18.0,0.0103,129,37.6,0,64.0,0,0,0,0,41.2,BSC,None
HC-ONC-013-000029,RCC,64,Female,1,Second-line,Never,0.0,24.8,0,None,0,0,1,4,0,3.14,63.2,96.9,7.43,0,MSS,0,12.4,TIL-intermediate,350,1.19,38,14119,5,165.9,25,0.022,-0.739,PD-L1-high,Q2,Nivolumab+Ipilimumab,Combination,43.9,14,Discontinued_Complete_Response,0,0,1.71,2.95,1.72,163,127,0,9.9,2.2,14.5,5.32,1019,599,13.3,5.1,Tier1_FDA-approved,31.1,508,8.97,0,0,0,0,,CR,1,1,-100.0,100.0,165.9,0.0,23.5,62.8,1,0,-63.5,0,1,0,1,15.5,1,6.0,1,0,1,10,7,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,32,23,1.45,0.86,0.724,1.59,15.4,0.0263,38,36.6,1,89.0,1,0,0,0,39.1,Clinical_Trial,Disease_Progression
HC-ONC-013-000030,NSCLC,52,Female,1,First-line,Current,20.2,25.7,0,None,0,0,0,3,0,3.75,86.0,100.0,9.17,0,MSS,0,18.9,TIL-intermediate,530,0.56,33,1911,5,100.8,39,-0.591,-0.877,PD-L1-high,Q2,Pembrolizumab+Chemo,Combination,25.2,8,Discontinued_Progression,1,0,1.86,4.09,2.2,200,182,0,3.5,6.8,3.6,1.7,1457,559,12.2,2.3,Tier1_FDA-approved,42.9,69,15.59,1,0,1,0,,PR,1,1,-46.5,46.5,100.8,53.9,6.1,63.8,0,0,-41.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,11,1.21,1.15,0.934,1.49,15.6,0.0071,100,76.0,1,98.9,1,1,0,0,78.2,Clinical_Trial,Disease_Progression
HC-ONC-013-000031,RCC,79,Male,1,Third+,Never,0.0,27.6,0,None,0,0,2,5,0,2.65,61.0,61.0,15.51,1,MSS,0,48.3,TIL-intermediate,1052,1.37,14,1351,1,10.0,54,0.329,0.425,PD-L1-high,Q3,Atezolizumab+Bevacizumab,Combination,25.3,8,Discontinued_Progression,0,1,0.75,7.2,9.64,376,204,0,9.8,9.5,1.8,5.71,910,1048,12.0,8.3,Tier1_FDA-approved,44.8,169,20.0,1,0,0,0,,PR,1,1,-54.1,54.1,10.0,4.6,6.0,38.1,0,0,-77.9,0,1,0,1,40.5,1,1.0,1,0,1,47,4,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,21,19,1.29,0.72,3.547,1.18,19.2,0.0348,124,48.8,1,102.9,1,0,0,0,51.0,Chemotherapy,Disease_Progression
HC-ONC-013-000032,NSCLC,62,Female,1,Second-line,Former,28.7,22.0,0,None,0,0,1,3,0,2.98,30.7,31.0,53.35,1,MSI-H,1,23.6,TIL-intermediate,359,2.69,12,429,3,57.7,244,-0.537,-0.328,PD-L1-low,Q5,Pembrolizumab,Anti-PD-1,17.7,5,Active,0,0,1.56,2.24,1.44,379,211,0,5.5,1.7,1.5,5.5,422,234,9.4,6.7,Tier1_FDA-approved,47.1,47,20.0,0,0,0,0,0.403,CR,1,1,-100.0,100.0,57.7,0.0,7.8,25.2,1,0,-81.8,0,1,1,3,16.2,1,3.6,1,0,1,112,12,0,0,0,1,1,0,0,0,2,0,0,0,0,0,3,0,0,0,2,13,14,0.94,1.02,3.647,1.43,5.7,0.0052,25281,43.0,1,122.2,1,0,1,0,45.4,Targeted,Disease_Progression
HC-ONC-013-000033,NSCLC,75,Female,0,First-line,Current,35.7,31.5,1,MS,0,0,0,5,0,3.19,55.2,82.2,11.63,1,MSS,0,7.4,TIL-low,158,1.36,15,3094,4,104.5,86,0.469,0.501,PD-L1-high,Q2,Atezolizumab,Anti-PD-L1,12.3,4,Discontinued_irAE,0,0,2.07,1.57,1.0,159,317,1,21.9,1.5,2.3,7.15,909,420,9.1,7.9,Tier1_FDA-approved,28.2,292,9.88,0,0,0,0,,PR,1,1,-43.7,43.7,104.5,58.8,6.0,41.3,0,0,-79.9,0,1,0,1,3.2,1,5.6,0,0,1,39,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,12,8,1.09,0.99,4.453,1.44,5.3,0.0384,31,25.4,1,66.2,1,0,0,0,27.9,Chemotherapy,Disease_Progression
HC-ONC-013-000034,MSI-H_CRC,61,Female,1,Third+,Never,0.0,27.9,0,None,0,0,3,2,0,3.32,94.5,96.4,74.4,1,MSI-H,1,39.0,TIL-intermediate,939,3.93,19,3475,2,63.1,352,1.216,1.568,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,44.7,14,Discontinued_Progression,0,0,1.54,9.53,6.17,403,246,0,45.0,12.6,22.0,4.05,536,573,6.6,5.8,Tier1_FDA-approved,80.6,1618,20.0,0,0,0,0,0.449,PR,1,1,-41.5,41.5,63.1,36.9,12.1,50.9,0,0,-42.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,28,0.87,0.84,0.77,1.13,25.2,0.0342,64,75.3,1,92.3,1,1,0,0,80.1,None,Disease_Progression
HC-ONC-013-000035,Hodgkin,85,Male,2,First-line,Current,32.9,26.9,0,None,0,0,0,3,0,3.28,0.0,0.0,13.86,1,MSS,0,33.0,TIL-intermediate,770,2.04,44,486,2,130.9,81,-0.719,-0.069,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,8.5,2,Active,0,0,1.28,5.79,4.52,200,100,0,3.6,4.5,7.5,2.44,1159,560,14.4,0.8,Tier1_FDA-approved,9.6,401,17.11,0,0,0,0,,SD,0,1,9.2,0.0,130.9,130.9,,,0,0,9.1,0,1,0,1,8.3,1,8.5,0,0,1,58,7,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,34,37,0.63,1.14,4.057,1.68,21.5,0.0329,191,3.1,0,71.8,1,0,0,0,3.2,Clinical_Trial,Disease_Progression
HC-ONC-013-000036,HNSCC,82,Female,0,Third+,Never,0.0,32.5,0,None,0,0,2,2,0,3.55,75.9,100.0,62.48,1,MSI-H,1,24.9,TIL-intermediate,616,1.95,18,1528,1,103.5,323,-0.131,0.551,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,79.0,26,Active,0,0,1.4,6.07,4.34,448,104,0,67.5,6.1,11.0,7.58,1057,490,8.7,8.1,Tier1_FDA-approved,70.6,1868,20.0,0,0,0,0,0.371,PR,1,1,-44.0,44.0,103.5,58.0,8.3,29.9,1,0,-46.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,24,17,0.68,0.86,1.769,1.78,29.5,0.0165,116,85.9,0,111.4,0,1,1,0,88.5,Chemotherapy,None
HC-ONC-013-000037,Melanoma,58,Female,1,Second-line,Current,28.1,25.9,0,None,0,1,1,2,0,3.88,16.1,25.5,5.3,0,MSS,0,28.7,TIL-intermediate,497,1.55,134,1209,1,51.7,28,0.461,0.324,PD-L1-low,Q1,Nivolumab+Ipilimumab,Combination,58.1,19,Discontinued_Complete_Response,0,0,1.33,2.62,1.97,146,100,0,10.7,4.8,11.3,1.57,849,584,16.8,3.3,Tier3_exploratory,14.4,669,3.68,1,0,0,0,,PR,1,1,-54.1,54.1,51.7,23.7,6.0,43.7,0,0,-68.7,0,1,0,1,16.4,0,,0,0,1,10,6,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,26,28,0.73,0.72,1.811,1.11,20.3,0.0205,150,44.0,1,98.0,1,0,0,0,47.8,Targeted,Disease_Progression
HC-ONC-013-000038,NSCLC,72,Female,0,Second-line,Never,0.0,25.6,0,None,0,0,1,7,0,3.51,86.5,100.0,2.51,0,MSS,0,38.1,TIL-intermediate,942,1.59,75,2458,3,81.3,20,-0.436,-0.665,PD-L1-high,Q1,Nivolumab,Anti-PD-1,62.4,20,Completed_2yr,0,0,1.28,6.48,5.07,230,219,0,4.6,45.8,7.7,14.4,801,348,10.9,3.4,Tier1_FDA-approved,42.2,220,12.39,0,0,1,1,,SD,0,1,-8.2,8.2,81.3,74.6,,,0,0,86.0,0,1,0,1,9.8,1,4.3,0,0,1,20,5,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,18,14,0.71,1.19,1.009,1.6,12.2,0.0183,82,10.6,1,38.1,0,0,0,0,16.9,Clinical_Trial,None
HC-ONC-013-000039,TNBC,68,Female,1,First-line,Former,15.4,24.1,0,None,0,0,0,1,0,3.56,31.2,49.7,6.52,0,MSS,0,39.5,TIL-intermediate,701,1.45,63,472,4,44.2,29,0.464,0.25,PD-L1-low,Q2,Pembrolizumab+Chemo,Combination,71.1,23,Active,1,0,1.77,5.14,2.91,192,226,0,26.0,33.6,7.0,3.72,836,671,6.7,5.3,Tier2_emerging,28.7,460,10.95,0,0,0,0,,CR,1,1,-100.0,100.0,44.2,0.0,11.7,53.9,0,0,-66.5,0,1,0,1,25.6,0,,0,0,1,38,5,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,32,34,0.94,0.86,4.445,1.3,20.5,0.0385,130,74.5,0,110.1,1,1,0,0,78.0,Chemotherapy,Disease_Progression
HC-ONC-013-000040,Melanoma,77,Male,0,Third+,Former,35.4,28.2,0,None,0,0,3,2,0,1.93,85.6,100.0,18.65,1,MSS,0,44.6,TIL-intermediate,1171,1.42,30,8122,4,72.7,114,0.555,-0.069,PD-L1-high,Q3,Nivolumab,Anti-PD-1,26.0,8,Discontinued_irAE,0,0,4.0,2.03,1.0,415,231,0,7.8,1.7,17.0,5.45,902,136,10.8,7.8,Tier1_FDA-approved,52.5,819,20.0,0,0,0,0,,PR,1,1,-50.6,50.6,72.7,35.9,18.0,4.0,0,0,-53.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,19,0.6,0.72,4.424,1.26,28.7,0.0023,91,27.6,1,68.2,0,0,0,0,31.3,Clinical_Trial,None
HC-ONC-013-000041,NSCLC,49,Female,1,First-line,Former,38.5,28.0,0,None,0,0,0,2,0,3.24,0.0,0.0,6.47,0,MSS,0,33.6,TIL-intermediate,675,2.15,111,5426,5,57.8,33,1.083,1.429,PD-L1-negative,Q2,Durvalumab,Anti-PD-L1,60.8,20,Completed_2yr,0,0,1.22,9.14,7.46,188,124,0,11.2,3.9,8.3,7.01,668,595,9.9,7.1,Tier2_emerging,10.7,497,6.03,0,0,1,0,,SD,0,1,20.0,0.0,57.8,57.8,,,0,0,32.6,0,1,0,2,9.7,1,7.3,0,0,1,19,3,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,106,103,0.92,0.82,3.959,1.19,13.7,0.0155,80,7.7,1,25.0,0,0,0,0,11.5,Chemotherapy,None
HC-ONC-013-000042,Melanoma,69,Female,1,First-line,Former,19.5,23.2,0,None,0,0,0,7,0,3.58,72.9,75.0,9.84,0,MSS,0,9.4,TIL-low,241,1.03,28,1169,1,127.0,33,-0.606,0.032,PD-L1-high,Q2,Nivolumab+Ipilimumab,Combination,12.4,4,Active,0,0,1.45,4.85,3.34,240,281,1,8.1,20.5,22.6,7.19,484,480,17.0,6.8,Tier1_FDA-approved,37.7,506,8.31,0,0,0,0,,PD,0,0,67.1,0.0,127.0,127.0,,,0,0,104.5,0,1,1,2,1.9,1,9.2,1,0,0,0,0,1,0,0,0,1,0,0,0,2,4,0,0,0,0,0,0,0,0,0,15,13,1.4,0.97,0.863,1.09,16.0,0.0378,100,13.6,1,82.3,1,0,0,0,14.0,Targeted,Disease_Progression
HC-ONC-013-000043,NSCLC,73,Male,0,First-line,Former,16.9,25.6,0,None,0,0,0,7,0,3.78,0.0,0.0,43.92,1,MSI-H,1,53.1,TIL-high,835,0.96,32,1395,2,164.6,239,-0.943,-0.305,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,3.1,1,Discontinued_Progression,0,0,1.61,3.68,2.28,315,287,1,5.4,15.2,12.1,1.45,1242,803,10.2,4.4,Tier1_FDA-approved,34.2,127,20.0,0,0,0,0,0.452,PR,1,1,-46.2,46.2,164.6,88.6,11.1,59.1,0,0,-67.7,0,1,0,1,3.3,1,7.8,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,14,11,0.79,0.91,3.867,1.72,24.9,0.015,108,99.0,1,137.5,0,1,1,0,104.3,Clinical_Trial,None
HC-ONC-013-000044,MSI-H_CRC,39,Female,1,Second-line,Never,0.0,23.2,0,None,0,0,1,3,0,2.65,0.0,0.0,19.47,1,MSS,0,40.9,TIL-intermediate,863,0.94,38,1535,2,22.8,138,-0.308,0.433,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,53.3,17,Completed_2yr,0,0,1.25,3.71,2.96,321,107,0,25.1,7.0,4.5,8.66,784,951,10.6,4.3,Tier1_FDA-approved,32.9,211,20.0,0,0,0,0,,PR,1,1,-59.1,59.1,22.8,9.3,12.5,24.9,0,0,-100.0,1,1,0,1,18.9,0,,0,0,1,49,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,23,17,0.57,0.98,3.038,1.54,17.3,0.0161,86,54.6,1,69.4,1,1,0,0,59.8,Targeted,Disease_Progression
HC-ONC-013-000045,NSCLC,46,Female,1,First-line,Never,0.0,23.0,0,None,0,0,0,7,0,2.67,43.6,39.9,33.35,1,MSI-H,1,7.5,TIL-low,191,4.59,58,711,3,10.0,117,-0.968,-1.591,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,7.3,2,Completed_2yr,0,0,2.56,1.64,1.0,381,100,0,9.1,1.9,5.0,5.71,950,534,19.1,5.7,Tier1_FDA-approved,34.0,11940,3.24,0,0,0,0,0.405,PR,1,1,-46.2,46.2,10.0,5.4,9.6,36.7,1,0,-57.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,14,0.72,1.0,1.015,1.24,25.8,0.025,74,78.5,1,101.3,1,1,0,0,84.1,Targeted,Disease_Progression
HC-ONC-013-000046,TNBC,36,Female,2,Second-line,Former,55.6,17.9,0,None,0,0,1,3,1,2.74,37.0,39.7,18.38,1,MSI-H,1,73.1,TIL-high,1344,2.15,55,1062,2,70.2,62,0.564,0.633,PD-L1-low,Q3,Atezolizumab,Anti-PD-L1,104.0,34,Discontinued_Progression,0,0,0.64,6.03,9.44,272,200,0,2.9,3.3,4.1,2.7,986,878,14.5,4.7,Tier1_FDA-approved,48.8,2547,20.0,0,0,0,0,0.408,PR,1,1,-30.0,30.0,70.2,49.1,8.7,71.0,0,0,-100.0,1,1,1,1,7.7,1,3.0,1,1,1,119,2,0,0,0,0,0,0,1,1,0,0,3,0,0,0,0,0,0,0,0,34,34,1.35,0.67,1.547,1.55,19.5,0.0355,136,22.4,1,85.9,1,0,0,0,31.5,BSC,Disease_Progression
HC-ONC-013-000047,Melanoma,57,Male,0,Third+,Former,25.5,25.3,0,None,0,1,4,4,0,3.63,0.0,0.0,33.6,1,MSS,0,51.2,TIL-high,1378,1.92,23,1307,4,19.3,127,-1.162,-1.352,PD-L1-negative,Q4,Nivolumab,Anti-PD-1,43.2,14,Active,0,0,1.33,5.11,3.83,199,491,1,21.1,4.0,19.6,2.46,997,537,20.3,6.8,Tier1_FDA-approved,21.0,44,20.0,0,0,0,0,,SD,0,1,20.0,0.0,19.3,19.3,,,0,0,5.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37,44,1.43,0.79,3.257,1.52,26.3,0.0122,95,5.6,0,63.8,1,0,0,0,7.0,Targeted,Disease_Progression
HC-ONC-013-000048,RCC,69,Male,1,First-line,Current,36.1,18.0,0,None,0,1,0,7,0,4.03,48.6,61.0,4.41,0,MSS,0,19.5,TIL-intermediate,477,0.97,22,12525,4,81.8,30,2.0,1.196,PD-L1-low,Q1,Atezolizumab+Bevacizumab,Combination,50.1,16,Active,0,1,2.29,4.07,1.78,205,469,1,3.6,10.3,5.3,3.43,548,407,18.3,6.7,Tier3_exploratory,23.2,12,20.0,0,0,0,0,,PR,1,1,-36.7,36.7,81.8,51.7,8.6,53.1,0,0,-57.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,20,1.36,1.05,3.714,1.07,21.9,0.037,64,38.5,1,74.8,1,0,0,0,39.5,Clinical_Trial,Disease_Progression
HC-ONC-013-000049,RCC,79,Female,0,Second-line,Former,45.0,24.2,0,None,1,0,1,1,0,2.87,60.5,100.0,51.62,1,MSI-H,1,12.4,TIL-intermediate,296,2.25,55,5630,1,110.0,342,1.296,0.622,PD-L1-high,Q5,Atezolizumab+Bevacizumab,Combination,17.2,5,Discontinued_Complete_Response,0,1,1.47,8.49,5.79,248,266,1,3.8,57.1,3.9,1.59,397,949,7.6,6.2,Tier1_FDA-approved,45.2,452,5.29,0,0,0,0,0.414,PR,1,1,-30.6,30.6,110.0,76.4,16.3,15.2,0,0,-68.4,0,1,0,2,27.5,1,2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,25,28,0.64,0.99,3.892,0.98,13.5,0.0117,159,37.4,0,63.9,0,0,0,0,42.8,BSC,None
HC-ONC-013-000050,NSCLC,61,Male,3,First-line,Current,24.1,23.4,0,None,0,0,0,2,0,3.93,12.2,11.0,35.59,1,MSS,0,17.4,TIL-intermediate,354,1.56,59,5550,3,139.8,207,0.013,0.338,PD-L1-low,Q5,Pembrolizumab,Anti-PD-1,43.2,14,Completed_2yr,0,0,1.19,2.24,1.89,277,139,0,40.1,3.2,9.5,17.78,723,704,16.9,0.0,Tier1_FDA-approved,21.1,1541,5.9,0,0,0,0,,PR,1,1,-30.0,30.0,139.8,97.9,17.1,47.9,0,0,-64.1,0,1,0,1,4.7,1,9.5,0,0,1,10,7,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,26,26,0.77,0.65,2.675,1.64,19.0,0.032,153,43.2,1,89.0,1,0,0,0,46.5,Chemotherapy,Other
HC-ONC-013-000051,Hodgkin,80,Female,2,Third+,Former,36.8,31.8,0,None,0,1,4,1,0,3.3,38.4,58.4,10.67,1,MSS,0,54.3,TIL-high,1207,1.84,24,2818,2,88.1,57,0.867,0.635,PD-L1-low,Q2,Nivolumab,Anti-PD-1,5.0,1,Discontinued_Progression,0,0,1.97,3.33,1.69,227,312,1,3.7,2.2,6.8,14.72,1019,601,19.6,5.3,Tier1_FDA-approved,39.1,185,20.0,0,0,0,0,,SD,0,1,-12.3,12.3,88.1,77.3,,,0,0,96.9,0,1,0,2,10.1,1,4.9,1,0,1,49,2,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,50,37,1.47,0.79,2.638,1.61,18.0,0.0115,181,18.8,0,81.6,0,0,0,0,20.8,Chemotherapy,None
HC-ONC-013-000052,Urothelial,44,Male,1,Second-line,Never,0.0,21.4,0,None,0,0,1,5,0,3.1,61.4,91.3,80.0,1,MSI-H,1,39.2,TIL-intermediate,938,1.01,9,473,1,72.3,500,-1.637,-0.31,PD-L1-high,Q5,Durvalumab,Anti-PD-L1,59.6,19,Discontinued_Progression,0,0,2.37,2.93,1.24,247,160,0,1.2,6.5,9.4,6.43,682,737,19.7,4.8,Tier1_FDA-approved,77.0,1868,20.0,0,0,0,0,0.381,PR,1,1,-50.9,50.9,72.3,35.5,19.8,68.6,0,0,-84.9,0,1,0,1,7.6,1,12.5,1,0,1,32,7,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,12,14,0.69,1.16,3.237,1.8,26.6,0.0038,124,31.8,0,64.3,0,0,0,0,35.2,BSC,None
HC-ONC-013-000053,MSI-H_CRC,40,Female,2,First-line,Never,0.0,22.7,0,None,0,1,0,7,1,3.03,79.6,71.3,40.66,1,MSI-H,1,45.3,TIL-intermediate,1000,1.79,28,1720,5,10.0,278,2.0,0.899,PD-L1-high,Q5,Nivolumab,Anti-PD-1,13.0,4,Discontinued_Progression,0,0,1.79,3.9,2.17,115,136,0,22.7,25.5,33.5,3.75,794,655,16.9,5.3,Tier1_FDA-approved,65.5,441,20.0,0,0,0,0,0.363,CR,1,1,-100.0,100.0,10.0,0.0,11.8,11.9,0,0,-59.1,0,1,0,2,10.1,1,6.2,0,0,1,35,4,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,30,23,0.47,1.12,12.848,0.58,23.2,0.0319,78,1.6,1,30.1,1,0,0,0,4.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000054,MSI-H_CRC,60,Male,1,Second-line,Former,9.0,24.6,0,None,1,0,1,2,0,3.8,25.1,43.2,80.0,1,MSI-H,1,36.8,TIL-intermediate,938,1.33,55,5794,5,81.0,500,-0.59,0.0,PD-L1-low,Q5,Pembrolizumab,Anti-PD-1,45.0,15,Discontinued_Progression,0,0,1.2,4.64,3.87,342,100,0,9.0,1.3,15.3,3.83,1538,586,16.8,3.5,Tier1_FDA-approved,55.4,316,16.75,0,0,0,0,0.454,SD,0,1,-2.9,2.9,81.0,78.6,,,0,0,22.3,0,1,0,1,5.2,1,11.1,0,0,1,57,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,20,20,0.64,1.59,1.182,1.34,26.0,0.0181,177,19.9,1,61.6,1,0,0,0,27.3,BSC,None
HC-ONC-013-000055,RCC,65,Female,1,First-line,Former,33.1,23.6,0,None,0,1,0,1,0,3.46,78.0,100.0,4.28,0,MSS,0,42.5,TIL-intermediate,913,1.12,140,399,2,82.9,30,-0.12,0.009,PD-L1-high,Q1,Atezolizumab+Bevacizumab,Combination,16.1,5,Discontinued_Complete_Response,0,1,1.98,5.56,2.81,268,211,0,9.8,42.3,7.6,8.22,346,335,10.5,2.4,Tier1_FDA-approved,43.2,1254,6.48,0,0,0,0,,PR,1,1,-36.2,36.2,82.9,52.9,6.0,38.4,0,0,-39.8,0,1,0,1,9.2,1,9.6,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,25,28,1.46,0.64,3.459,1.5,18.7,0.0158,41694,12.6,1,79.4,0,0,0,0,21.1,Chemotherapy,None
HC-ONC-013-000056,MSI-H_CRC,60,Female,0,First-line,Never,0.0,33.3,0,None,0,0,0,7,0,5.0,25.2,29.4,8.4,0,MSS,0,29.4,TIL-intermediate,530,2.38,13,3881,2,105.6,52,-1.856,-1.931,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,6.9,2,Discontinued_Progression,0,0,1.4,3.77,2.68,404,146,0,8.9,6.0,2.4,18.29,673,546,7.8,5.9,Tier3_exploratory,28.5,182,20.0,0,0,0,0,,SD,0,1,7.4,0.0,105.6,105.6,,,0,0,28.4,0,1,0,1,11.8,1,4.2,0,0,1,34,11,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,17,15,0.8,0.96,1.867,1.38,24.5,0.0173,141,48.2,0,96.7,0,0,0,0,48.9,BSC,None
HC-ONC-013-000057,NSCLC,36,Female,1,Second-line,Former,51.3,20.8,0,None,0,1,1,7,0,2.52,0.0,0.0,12.54,1,MSS,0,35.5,TIL-intermediate,646,0.76,24,29352,2,51.7,66,0.486,-0.168,PD-L1-negative,Q3,Atezolizumab,Anti-PD-L1,30.2,10,Discontinued_Progression,0,0,2.22,2.89,1.3,245,210,0,15.4,3.1,5.0,2.84,1469,725,10.2,4.3,Tier1_FDA-approved,26.9,262,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,51.7,0.0,9.8,34.5,0,0,-66.8,0,1,0,1,2.1,1,2.1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,15,12,1.42,0.61,2.035,1.51,13.2,0.0242,62,78.4,0,109.7,0,1,0,0,79.4,Chemotherapy,None
HC-ONC-013-000058,NSCLC,59,Female,0,First-line,Current,26.8,24.6,0,None,0,0,0,4,0,3.61,77.1,81.5,45.42,1,MSS,0,15.7,TIL-intermediate,237,2.19,24,6465,4,62.6,333,-1.106,-0.739,PD-L1-high,Q5,Atezolizumab,Anti-PD-L1,13.0,4,Active,0,0,2.98,10.41,3.49,103,100,0,5.7,1.1,13.1,1.83,887,575,3.7,6.1,Tier1_FDA-approved,56.3,1102,9.48,0,0,0,0,,PR,1,1,-33.7,33.7,62.6,41.5,6.0,6.2,0,0,-94.2,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,15,0.42,1.0,0.811,0.94,12.7,0.011,137,67.3,1,78.0,1,1,0,0,69.8,None,Disease_Progression
HC-ONC-013-000059,NSCLC,45,Male,2,First-line,Former,32.3,28.2,0,None,0,0,0,4,0,2.78,0.0,0.0,9.38,0,MSS,0,26.5,TIL-intermediate,516,2.32,98,9866,2,20.9,72,0.102,0.617,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,47.8,15,Discontinued_Progression,0,0,0.58,12.0,20.0,205,218,0,53.3,17.3,2.9,15.46,688,780,18.7,3.7,Tier3_exploratory,17.1,385,5.21,0,0,0,0,,PR,1,1,-52.6,52.6,20.9,9.9,6.0,45.8,0,0,-95.1,1,1,1,1,13.9,1,4.3,1,0,1,93,6,0,0,0,0,1,1,0,0,3,0,0,0,0,0,0,0,0,0,0,12,14,1.22,1.04,2.854,0.8,17.2,0.01,173,13.2,1,26.6,0,0,0,0,15.8,BSC,None
HC-ONC-013-000060,Melanoma,69,Female,1,First-line,Never,0.0,30.9,0,None,0,1,0,2,0,2.5,96.6,81.1,31.99,1,MSS,0,18.3,TIL-intermediate,480,1.06,32,2350,5,10.0,100,-0.544,-0.095,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,16.8,5,Discontinued_Progression,0,0,1.72,4.81,2.79,221,100,0,2.8,6.0,41.0,1.07,1251,677,10.6,7.8,Tier1_FDA-approved,60.1,7067,14.55,0,0,0,0,,SD,0,1,20.0,0.0,10.0,10.0,,,0,0,89.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,18,22,0.41,0.9,0.874,0.89,25.9,0.0194,122,8.6,1,82.2,1,0,0,0,11.0,Clinical_Trial,Disease_Progression
HC-ONC-013-000061,Melanoma,65,Male,1,Second-line,Former,55.7,24.6,0,None,1,0,1,5,0,3.19,68.5,100.0,44.07,1,MSI-L,0,19.2,TIL-intermediate,516,1.09,16,5776,2,35.7,144,-1.078,-1.23,PD-L1-high,Q5,Nivolumab,Anti-PD-1,22.4,7,Hold_irAE,0,0,0.82,3.07,3.73,355,345,1,19.0,9.1,7.5,2.0,917,424,18.5,7.0,Tier1_FDA-approved,56.5,1142,20.0,1,0,0,0,,CR,1,1,-100.0,100.0,35.7,0.0,14.4,21.2,0,0,-73.5,0,1,1,1,7.9,0,,1,0,1,88,3,0,0,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,0,0,31,32,0.54,0.6,4.153,1.18,21.6,0.0024,110,41.5,1,110.0,0,0,0,0,45.1,Clinical_Trial,None
HC-ONC-013-000062,NSCLC,49,Male,0,First-line,Never,0.0,16.9,0,None,0,0,0,4,0,3.31,0.0,0.0,44.3,1,MSS,0,14.3,TIL-intermediate,259,1.47,52,764,3,17.2,345,-0.804,-0.553,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,35.6,11,Discontinued_Progression,0,0,4.0,9.37,2.34,87,260,1,23.2,2.5,7.7,3.68,796,336,5.8,5.6,Tier1_FDA-approved,18.0,1036,4.89,0,0,0,0,,CR,1,1,-100.0,100.0,17.2,0.0,7.8,113.6,0,0,-52.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,30,34,1.04,1.0,2.984,1.13,19.4,0.0254,199,54.0,1,103.2,0,1,0,0,57.1,Targeted,None
HC-ONC-013-000063,HNSCC,54,Male,0,First-line,Never,0.0,25.7,0,None,0,0,0,4,0,5.0,6.4,9.2,15.74,1,MSS,0,40.2,TIL-intermediate,1181,1.9,24,4699,5,93.5,69,0.226,1.144,PD-L1-low,Q3,Nivolumab,Anti-PD-1,19.3,6,Discontinued_Progression,0,0,1.37,2.17,1.59,250,174,0,5.7,5.0,4.3,1.29,958,569,17.4,4.6,Tier1_FDA-approved,19.6,375,20.0,0,0,0,0,,PD,0,0,38.6,0.0,93.5,93.5,,,0,0,45.1,0,1,1,2,8.5,0,,1,1,1,140,9,0,0,0,0,1,1,0,0,1,0,0,4,0,0,0,0,0,0,0,1386,1001,13.86,1.09,4.461,1.67,28.1,0.0323,34,44.3,1,89.0,1,0,0,0,45.6,Chemotherapy,Other
HC-ONC-013-000064,Melanoma,48,Male,0,Second-line,Never,0.0,33.3,1,Thyroiditis,0,0,1,5,0,3.05,59.2,60.4,2.08,0,MSS,0,9.0,TIL-low,203,1.53,12,3965,3,59.3,15,-1.281,-0.713,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,24.3,8,Completed_2yr,0,0,2.22,3.79,1.71,316,265,1,4.4,4.1,11.0,10.91,703,495,9.5,6.7,Tier1_FDA-approved,29.4,1498,15.62,0,0,0,0,,PD,0,0,53.9,0.0,59.3,59.3,,,0,0,53.6,0,1,0,2,3.1,1,7.3,0,0,1,10,11,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,10,8,1.1,0.95,1.483,0.88,21.0,0.0286,86,44.7,1,103.2,1,0,0,0,46.6,Targeted,Disease_Progression
HC-ONC-013-000065,NSCLC,60,Female,1,Second-line,Never,0.0,27.9,0,None,0,1,1,1,0,2.3,0.0,0.0,18.44,1,MSS,0,8.9,TIL-low,256,2.05,16,2560,5,58.5,91,-0.749,-0.613,PD-L1-negative,Q3,Nivolumab,Anti-PD-1,56.8,18,Active,0,0,1.63,3.16,1.95,176,123,0,33.7,6.5,2.9,8.9,595,667,5.6,5.8,Tier1_FDA-approved,16.9,249,15.06,0,0,0,0,,CR,1,1,-100.0,100.0,58.5,0.0,19.5,32.9,0,0,-70.8,0,1,0,1,12.4,1,2.5,1,0,1,49,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,14,12,1.47,1.03,3.218,1.24,23.0,0.0188,186,14.0,0,32.4,1,0,0,0,21.1,Clinical_Trial,Disease_Progression
HC-ONC-013-000066,RCC,72,Female,0,First-line,Former,27.2,27.7,0,None,0,0,0,4,0,3.42,19.4,30.5,31.3,1,MSS,0,51.8,TIL-high,1327,3.98,133,8771,1,40.6,113,0.663,0.644,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,13.6,4,Discontinued_Progression,0,0,1.2,2.51,2.1,254,208,0,4.5,3.3,41.8,2.83,866,456,20.1,5.5,Tier1_FDA-approved,33.6,616,9.9,0,0,0,0,,SD,0,1,20.0,0.0,40.6,40.6,,,0,0,-20.0,0,1,0,1,1.4,1,7.3,0,0,1,47,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,35,25,0.36,0.65,4.358,1.76,29.7,0.0225,10908,78.5,1,131.6,0,1,1,0,81.8,None,None
HC-ONC-013-000067,NSCLC,49,Male,2,First-line,Former,20.7,21.2,0,None,0,0,0,3,0,1.54,72.8,92.7,11.33,1,MSS,0,34.7,TIL-intermediate,896,1.28,45,947,5,10.0,39,2.0,1.582,PD-L1-high,Q2,Atezolizumab,Anti-PD-L1,7.8,2,Active,0,0,1.14,3.9,3.42,179,298,1,6.6,1.2,21.2,12.47,597,477,17.5,7.1,Tier1_FDA-approved,34.8,102,19.48,0,0,0,0,,PR,1,1,-30.0,30.0,10.0,7.0,8.1,49.9,0,0,-89.5,0,1,0,1,7.0,1,7.7,0,0,1,54,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,18,16,0.53,1.03,1.694,1.3,21.4,0.002,122,13.7,1,77.2,1,0,0,0,16.9,BSC,Disease_Progression
HC-ONC-013-000068,HNSCC,67,Male,1,First-line,Former,32.3,20.7,0,None,0,0,0,6,0,3.13,0.0,0.0,58.56,1,MSS,0,0.0,TIL-low,0,0.7,36,1445,5,140.3,222,0.478,0.058,PD-L1-negative,Q5,Nivolumab,Anti-PD-1,21.6,7,Completed_2yr,0,0,3.11,2.91,1.0,170,100,0,29.6,195.2,16.2,14.29,903,811,13.1,7.9,Tier1_FDA-approved,23.1,1918,0.5,0,0,0,0,,PD,0,0,47.2,0.0,140.3,140.3,,,0,0,27.0,0,1,0,1,2.1,1,3.8,0,0,1,47,9,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,37,28,1.07,0.97,0.885,0.93,26.1,0.0357,138,34.0,1,47.4,0,0,0,0,35.0,Targeted,None
HC-ONC-013-000069,NSCLC,54,Female,0,First-line,Current,27.7,26.6,0,None,0,0,0,6,0,3.21,0.0,0.0,13.26,1,MSI-H,1,11.5,TIL-intermediate,211,2.49,27,2027,3,40.0,56,-0.917,-0.299,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,26.9,8,Active,0,0,2.42,4.51,1.87,199,160,0,12.6,1.4,2.4,4.09,1006,630,12.2,2.5,Tier1_FDA-approved,14.4,624,7.54,0,0,1,1,0.382,SD,0,1,17.3,0.0,40.0,40.0,,,0,0,134.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,36,35,1.38,0.8,3.036,1.09,19.4,0.0222,85,23.6,0,45.9,1,0,0,0,26.6,BSC,Disease_Progression
HC-ONC-013-000070,Hodgkin,51,Male,1,First-line,Never,0.0,19.4,0,None,0,0,0,4,0,3.84,8.1,13.7,20.32,1,MSS,0,3.8,TIL-low,57,3.83,42,526,3,63.5,111,-0.367,-0.385,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,34.0,11,Discontinued_Progression,0,0,3.59,4.54,1.27,172,198,0,2.0,9.2,8.7,3.13,1156,459,14.2,2.9,Tier1_FDA-approved,5.4,7893,1.33,0,0,0,0,,PR,1,1,-30.0,30.0,63.5,44.4,13.1,29.0,0,0,-51.4,0,1,1,1,27.7,1,5.2,1,0,1,116,10,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,15,10,1.26,1.01,1.964,1.43,12.7,0.013,42,44.9,0,64.7,0,0,0,0,50.9,Chemotherapy,None
HC-ONC-013-000071,Urothelial,59,Male,1,Second-line,Former,4.2,30.4,0,None,1,0,1,1,0,3.98,78.3,100.0,32.39,1,MSS,0,5.7,TIL-low,148,2.01,41,2374,5,21.8,211,0.032,0.379,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,24.0,8,Discontinued_Progression,0,0,1.69,3.28,1.95,344,182,0,69.9,0.9,19.4,27.32,1238,604,13.0,3.4,Tier1_FDA-approved,41.4,14595,3.52,1,0,0,0,,PR,1,1,-37.3,37.3,21.8,13.7,8.1,45.8,0,0,-62.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37,31,0.86,0.99,1.592,0.81,27.0,0.0122,77,43.0,1,63.6,1,0,0,0,48.2,Targeted,Other
HC-ONC-013-000072,NSCLC,48,Male,1,Second-line,Former,34.3,22.3,0,None,0,0,1,7,0,2.8,96.9,100.0,16.45,1,MSS,0,0.0,TIL-low,0,0.96,42,230,5,118.9,130,-0.349,-0.125,PD-L1-high,Q3,Pembrolizumab+Chemo,Combination,53.8,17,Discontinued_irAE,1,0,1.85,3.72,2.01,169,415,1,7.2,0.7,11.9,7.98,778,876,8.0,2.0,Tier1_FDA-approved,46.7,1268,0.5,0,0,0,0,,CR,1,1,-100.0,100.0,118.9,0.0,12.2,54.7,0,0,-100.0,1,1,1,3,10.3,1,10.6,1,1,1,98,3,0,0,0,0,1,0,1,1,1,0,0,0,0,3,0,0,0,0,1,29,33,1.19,0.96,0.135,2.61,29.0,0.0261,87,71.3,0,127.3,1,1,1,0,76.9,Targeted,Disease_Progression
HC-ONC-013-000073,NSCLC,54,Female,1,Second-line,Current,28.1,26.4,0,None,0,1,1,1,0,3.08,97.3,100.0,1.29,0,MSS,0,17.9,TIL-intermediate,481,1.55,36,6351,4,85.7,7,0.903,0.783,PD-L1-high,Q1,Pembrolizumab+Chemo,Combination,4.7,1,Completed_2yr,1,0,1.48,3.99,2.7,156,114,0,8.1,8.3,3.3,5.5,1050,659,9.9,4.9,Tier1_FDA-approved,44.5,447,13.0,1,0,0,0,,CR,1,1,-100.0,100.0,85.7,0.0,8.8,24.2,0,0,-64.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,29,23,0.55,0.71,3.516,1.37,19.8,0.0232,112,45.8,0,70.0,1,0,0,0,47.4,None,Disease_Progression
HC-ONC-013-000074,HNSCC,46,Female,2,First-line,Never,0.0,17.1,0,None,0,0,0,2,0,2.59,0.0,0.0,7.77,0,MSS,1,2.9,TIL-low,58,0.94,66,1912,1,46.9,43,0.217,-0.249,PD-L1-negative,Q2,Nivolumab,Anti-PD-1,27.3,9,Discontinued_Complete_Response,0,0,1.47,6.72,4.57,592,147,0,15.7,9.1,4.4,13.34,1048,719,21.8,6.2,Tier3_exploratory,7.3,98,0.87,0,0,0,0,,CR,1,1,-100.0,100.0,46.9,0.0,6.8,28.8,0,0,-64.6,0,1,0,2,22.6,1,7.5,0,0,1,63,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,36,26,0.32,0.78,2.442,1.5,21.1,0.0081,19747,57.6,0,117.6,1,1,0,0,59.2,Targeted,Disease_Progression
HC-ONC-013-000075,TNBC,84,Female,1,Second-line,Former,26.0,24.5,0,None,0,0,1,3,0,2.3,0.0,0.0,35.78,1,MSS,0,41.2,TIL-intermediate,1124,2.27,34,968,1,64.3,201,0.908,0.134,PD-L1-negative,Q5,Pembrolizumab+Chemo,Combination,24.6,8,Hold_irAE,1,0,1.09,4.16,3.83,396,100,0,22.8,33.6,5.1,5.71,998,450,25.4,5.0,Tier1_FDA-approved,22.4,1567,20.0,0,0,0,0,,SD,0,1,-5.9,5.9,64.3,60.5,,,0,0,42.1,0,1,0,2,23.5,1,7.3,0,0,1,20,4,0,0,0,1,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,22,18,0.98,1.19,14.482,0.61,19.6,0.0166,119,7.6,0,62.5,1,0,0,0,13.9,Chemotherapy,Disease_Progression
HC-ONC-013-000076,Urothelial,61,Male,3,First-line,Former,46.6,20.6,0,None,0,1,0,1,0,3.45,44.0,53.0,5.89,0,MSS,0,0.0,TIL-low,0,0.84,15,664,2,147.1,34,-0.314,0.284,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,41.1,13,Active,0,0,1.71,6.77,3.97,96,426,1,86.6,11.9,4.6,2.99,756,805,19.8,3.9,Tier3_exploratory,18.6,553,0.5,0,0,0,0,,SD,0,1,13.7,0.0,147.1,147.1,,,0,0,-20.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,32,36,1.28,0.86,1.266,1.76,29.9,0.0267,63,26.1,1,79.8,0,0,0,0,31.8,Chemotherapy,None
HC-ONC-013-000077,Urothelial,52,Male,2,Third+,Never,0.0,15.0,1,Thyroiditis,0,0,2,5,0,2.18,93.0,100.0,9.96,0,MSS,0,21.2,TIL-intermediate,374,1.42,20,1364,5,77.1,56,1.326,0.756,PD-L1-high,Q2,Durvalumab,Anti-PD-L1,90.3,30,Hold_irAE,0,0,1.2,6.01,5.0,167,177,0,2.3,6.2,25.1,4.78,592,1064,14.4,7.3,Tier1_FDA-approved,54.2,904,17.81,0,0,0,0,,PR,1,1,-45.6,45.6,77.1,42.0,11.6,22.0,0,0,-93.8,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,30,30,0.82,0.64,1.695,1.39,28.3,0.0123,61,118.1,1,177.9,0,1,1,1,121.5,Clinical_Trial,None
HC-ONC-013-000078,NSCLC,63,Female,0,Second-line,Never,0.0,29.2,0,None,0,1,1,3,0,2.87,0.0,0.0,4.76,0,MSS,0,13.8,TIL-intermediate,277,1.0,7,4130,5,72.7,14,-0.166,0.043,PD-L1-negative,Q1,Pembrolizumab,Anti-PD-1,32.0,10,Hold_irAE,0,0,1.97,5.96,3.03,276,161,0,27.8,2.4,1.6,10.29,1051,442,10.3,5.3,Tier3_exploratory,0.4,5403,20.0,0,0,0,0,,PD,0,0,20.0,0.0,72.7,72.7,,,0,0,51.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,33,33,0.98,1.14,2.449,1.46,12.7,0.0204,90,25.3,0,63.2,1,0,0,0,31.0,Chemotherapy,Disease_Progression
HC-ONC-013-000079,Melanoma,59,Female,2,First-line,Former,39.6,34.7,0,None,0,0,0,6,0,2.4,71.2,94.3,60.67,1,MSS,1,42.5,TIL-intermediate,899,1.76,168,3489,5,42.3,183,-0.971,-0.736,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,104.0,34,Discontinued_Complete_Response,0,0,1.76,8.97,5.08,288,195,0,25.6,44.6,12.5,0.91,388,364,8.0,5.7,Tier1_FDA-approved,75.7,117,5.32,0,0,0,0,,PR,1,1,-38.1,38.1,42.3,26.2,12.9,4.0,0,0,-77.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,30,21,0.81,0.7,2.489,1.66,26.0,0.0107,111,104.0,0,125.6,0,1,1,1,105.6,None,None
HC-ONC-013-000080,NSCLC,58,Male,0,Second-line,Former,62.1,32.1,0,None,0,1,1,3,0,3.64,0.0,0.0,55.33,1,MSS,0,41.2,TIL-intermediate,833,1.37,66,775,5,10.0,193,2.0,1.649,PD-L1-negative,Q5,Atezolizumab,Anti-PD-L1,20.2,6,Completed_2yr,0,0,1.85,2.56,1.38,116,275,1,10.6,22.5,2.6,3.56,820,635,8.3,7.3,Tier1_FDA-approved,31.7,101,12.43,0,0,0,0,,SD,0,1,6.7,0.0,10.0,10.0,,,0,0,18.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,12,0.92,0.84,0.599,1.66,22.8,0.0037,88,11.4,1,26.0,1,0,0,0,12.9,Targeted,Disease_Progression
HC-ONC-013-000081,HNSCC,68,Female,2,First-line,Never,0.0,29.9,1,Psoriasis,0,0,0,5,0,4.64,3.2,3.7,5.5,0,MSS,0,31.8,TIL-intermediate,841,1.8,17,655,1,73.6,19,-1.825,-1.399,PD-L1-low,Q1,Nivolumab,Anti-PD-1,4.0,1,Active,0,0,3.22,3.54,1.1,437,238,0,26.8,1.7,3.4,13.55,200,775,9.2,4.8,Tier2_emerging,17.9,283,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,73.6,0.0,10.5,19.4,0,0,-65.9,0,1,0,1,20.3,1,7.4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,19,16,1.36,0.77,4.273,0.83,12.5,0.0158,128,56.8,1,95.6,0,1,0,0,57.6,Targeted,None
HC-ONC-013-000082,TNBC,70,Female,1,Second-line,Former,18.7,24.4,0,None,0,1,1,4,0,2.16,17.3,24.9,13.91,1,MSS,0,33.5,TIL-intermediate,551,1.67,26,3977,3,93.0,91,-0.739,-0.511,PD-L1-low,Q3,Pembrolizumab+Chemo,Combination,12.8,4,Discontinued_Progression,1,0,1.62,10.82,6.66,370,753,1,31.0,7.7,1.5,2.98,499,582,22.8,9.1,Tier1_FDA-approved,21.6,1383,20.0,0,0,0,0,,PR,1,1,-30.0,30.0,93.0,65.1,9.1,17.8,0,0,-89.9,0,1,1,3,8.0,0,,1,1,1,119,7,0,0,0,1,1,0,0,0,0,0,0,3,1,0,0,0,0,0,1,1908,1656,8.81,1.18,2.671,1.08,20.0,0.0288,83,15.0,1,28.5,1,0,0,0,19.8,BSC,Disease_Progression
HC-ONC-013-000083,Melanoma,54,Male,2,First-line,Never,0.0,30.5,0,None,0,0,0,5,0,1.72,30.4,31.8,6.6,0,MSS,0,49.8,TIL-intermediate,1009,1.01,20,760,4,124.0,27,-0.627,0.017,PD-L1-low,Q2,Nivolumab,Anti-PD-1,25.3,8,Discontinued_Progression,0,0,2.23,3.94,1.77,311,251,1,3.1,8.8,4.8,15.44,637,389,21.0,4.1,Tier2_emerging,24.9,927,20.0,0,0,0,0,,PR,1,1,-56.3,56.3,124.0,54.2,7.1,57.3,0,0,-94.0,1,1,0,1,6.2,0,,1,0,1,24,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,17,17,0.31,0.83,0.579,1.05,14.7,0.0091,60,33.1,1,117.5,1,0,0,0,37.6,Targeted,None
HC-ONC-013-000084,NSCLC,54,Male,2,First-line,Former,42.5,32.6,0,None,0,0,0,5,0,3.1,83.1,75.6,16.57,1,MSI-H,1,0.0,TIL-low,0,2.26,114,1943,3,10.0,124,2.0,1.786,PD-L1-high,Q3,Atezolizumab,Anti-PD-L1,21.0,6,Active,0,0,3.75,1.1,1.0,482,159,0,70.1,4.9,24.7,13.9,1229,578,15.7,9.0,Tier1_FDA-approved,38.0,105,0.5,0,0,0,0,0.422,SD,0,1,-17.6,17.6,10.0,8.2,,,0,0,71.7,0,1,0,1,12.3,1,8.0,1,0,1,43,9,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,107,121,1.26,1.03,3.305,0.81,27.7,0.0297,177,23.0,1,58.0,0,0,0,0,26.0,BSC,None
HC-ONC-013-000085,Melanoma,57,Female,2,Third+,Never,0.0,27.2,0,None,0,0,2,4,0,3.21,40.3,64.3,19.27,1,MSS,0,0.0,TIL-low,0,1.61,11,2098,3,35.0,147,1.807,0.822,PD-L1-low,Q3,Nivolumab,Anti-PD-1,8.7,2,Discontinued_irAE,0,0,2.78,4.05,1.46,307,151,0,2.6,18.7,9.1,4.25,1106,720,7.2,3.1,Tier1_FDA-approved,27.3,1255,0.5,0,0,0,0,,PR,1,1,-42.5,42.5,35.0,20.1,6.0,41.9,0,0,-88.3,0,1,0,1,17.1,1,1.0,0,0,1,39,5,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,21,16,1.04,0.96,0.785,1.68,12.2,0.0264,64,42.7,1,111.6,0,0,0,0,45.2,BSC,None
HC-ONC-013-000086,Melanoma,33,Male,1,First-line,Current,9.8,20.6,0,None,0,0,0,4,0,3.37,56.0,50.3,25.29,1,MSS,1,18.7,TIL-intermediate,546,1.01,36,2629,1,56.8,199,1.494,1.876,PD-L1-high,Q4,Nivolumab+Ipilimumab,Combination,27.4,9,Discontinued_irAE,0,0,2.62,4.79,1.83,306,165,0,3.9,20.0,2.8,2.84,734,519,16.5,6.0,Tier1_FDA-approved,39.3,67,14.76,0,0,0,0,,PR,1,1,-39.3,39.3,56.8,34.5,9.8,57.5,0,0,-93.2,1,1,1,3,14.6,1,7.0,1,0,1,129,9,0,0,0,0,0,1,0,0,2,2,0,0,0,0,0,0,0,3,0,13,14,1.18,0.63,3.385,1.12,27.7,10.1851,194,48.0,0,98.3,1,0,0,0,56.8,BSC,Other
HC-ONC-013-000087,Urothelial,42,Female,0,Second-line,Never,0.0,24.0,0,None,0,0,1,4,0,2.84,14.7,15.7,16.42,1,MSS,0,53.8,TIL-high,1603,5.0,30,5064,4,79.9,126,-0.331,-0.042,PD-L1-low,Q3,Atezolizumab,Anti-PD-L1,22.2,7,Discontinued_Progression,0,0,1.46,1.21,1.0,533,100,0,9.4,5.9,16.7,3.56,1119,721,10.8,3.7,Tier1_FDA-approved,35.5,115,20.0,0,0,0,0,,SD,0,1,6.4,0.0,79.9,79.9,,,0,0,33.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,15,11,1.38,0.83,3.306,1.15,28.9,0.0379,198,15.2,0,73.1,1,0,0,0,18.7,None,Disease_Progression
HC-ONC-013-000088,TNBC,77,Female,0,First-line,Never,0.0,35.0,0,None,0,0,0,4,0,3.04,0.0,0.0,55.32,1,MSI-H,1,36.0,TIL-intermediate,587,2.09,64,397,5,74.2,241,2.0,0.679,PD-L1-negative,Q5,Atezolizumab,Anti-PD-L1,10.3,3,Discontinued_Progression,0,0,1.81,8.73,4.83,424,204,0,83.5,5.3,19.8,37.78,1166,833,1.2,7.2,Tier1_FDA-approved,42.6,339,9.03,1,0,0,0,0.455,SD,0,1,5.3,0.0,74.2,74.2,,,0,0,6.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,19,16,0.64,0.83,4.44,0.9,13.3,0.0346,148,63.4,0,124.6,0,1,1,0,70.1,BSC,None
HC-ONC-013-000089,MSI-H_CRC,80,Male,1,Second-line,Never,0.0,26.1,0,None,1,0,1,4,0,3.49,93.1,100.0,38.81,1,MSI-H,1,31.7,TIL-intermediate,614,1.53,30,182,1,75.1,215,0.368,0.406,PD-L1-high,Q5,Nivolumab,Anti-PD-1,19.9,6,Discontinued_Progression,0,0,0.97,3.14,3.22,161,296,1,9.0,44.6,8.0,20.08,852,648,13.4,4.0,Tier1_FDA-approved,58.2,176,19.81,0,0,0,0,0.396,PR,1,1,-61.0,61.0,75.1,29.3,18.3,8.2,0,0,-50.0,0,1,1,3,5.1,1,1.8,1,0,1,160,4,0,0,0,1,1,0,0,0,3,0,1,0,1,0,0,0,0,0,0,24,19,0.9,1.19,1.868,1.79,25.0,0.0224,115,2.0,1,11.0,0,0,0,0,5.7,Clinical_Trial,None
HC-ONC-013-000090,Melanoma,58,Male,0,Second-line,Never,0.0,15.0,0,None,0,0,1,5,1,4.03,0.0,0.0,2.61,0,MSI-L,0,0.0,TIL-low,0,3.35,8,915,1,96.3,10,0.977,0.395,PD-L1-negative,Q1,Nivolumab,Anti-PD-1,67.2,22,Active,0,0,2.01,5.28,2.62,336,147,0,11.8,22.6,37.6,4.95,485,594,7.8,5.6,Tier3_exploratory,0.0,1533,0.5,0,0,0,0,,SD,0,1,2.9,0.0,96.3,96.3,,,0,0,85.2,0,1,0,1,14.4,1,6.7,0,0,1,49,5,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,36,42,1.02,1.09,1.077,1.63,21.9,0.0222,165,23.6,0,77.6,0,0,0,0,26.5,None,None
HC-ONC-013-000091,NSCLC,67,Female,1,First-line,Former,5.8,19.2,0,None,0,0,0,2,0,1.64,92.7,100.0,8.55,0,MSS,0,34.2,TIL-intermediate,911,4.14,27,15707,4,43.9,60,0.18,0.325,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,20.2,6,Discontinued_Progression,0,0,1.84,4.0,2.18,176,134,0,51.0,8.1,14.3,2.76,838,766,8.0,3.7,Tier1_FDA-approved,45.0,620,20.0,0,0,0,0,,PD,0,0,33.0,0.0,43.9,43.9,,,0,0,100.2,0,1,0,1,17.0,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,25,20,0.71,1.11,0.867,1.37,29.2,0.0116,178,39.5,1,67.3,1,0,0,0,46.3,Chemotherapy,Disease_Progression
HC-ONC-013-000092,TNBC,64,Female,0,First-line,Never,0.0,24.4,0,None,0,0,0,2,1,2.9,63.3,67.6,72.84,1,MSI-H,1,59.1,TIL-high,1414,1.53,15,20468,2,117.4,500,-0.049,-0.051,PD-L1-high,Q5,Pembrolizumab+Chemo,Combination,46.5,15,Discontinued_Progression,1,0,1.66,2.35,1.41,315,428,1,9.0,1.0,12.8,4.92,871,429,10.7,6.9,Tier1_FDA-approved,71.2,5701,20.0,0,0,0,0,0.428,CR,1,1,-100.0,100.0,117.4,0.0,25.6,4.4,0,0,-72.0,0,1,0,1,2.7,0,,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,30,29,1.32,0.79,0.787,1.57,26.4,0.036,151,84.1,1,202.6,0,1,1,0,89.7,None,None
HC-ONC-013-000093,Urothelial,85,Male,2,First-line,Former,0.0,31.7,0,None,0,0,0,1,0,3.37,66.0,55.5,32.81,1,MSI-H,1,31.8,TIL-intermediate,785,1.96,35,16275,1,97.3,238,-0.252,-0.114,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,38.6,12,Discontinued_Complete_Response,0,0,2.49,2.62,1.06,311,100,0,3.7,11.2,3.9,5.45,530,409,9.5,3.7,Tier1_FDA-approved,56.2,278,20.0,0,0,0,0,0.5,CR,1,1,-100.0,100.0,97.3,0.0,6.0,31.4,0,0,-37.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,23,18,1.14,0.8,3.741,1.58,24.5,0.035,47,50.7,0,101.0,1,0,0,0,54.7,Chemotherapy,Other
HC-ONC-013-000094,RCC,74,Female,1,First-line,Never,0.0,25.1,0,None,0,0,0,2,0,2.47,52.5,79.1,19.67,1,MSI-H,1,10.6,TIL-intermediate,278,1.01,104,1434,3,67.2,102,-0.21,-0.582,PD-L1-high,Q3,Nivolumab+Ipilimumab,Combination,27.1,9,Discontinued_Progression,0,0,1.02,2.81,2.76,123,100,0,8.0,17.1,12.2,1.66,1010,547,11.8,8.4,Tier1_FDA-approved,35.7,336,2.65,0,0,0,0,0.41,PR,1,1,-30.0,30.0,67.2,47.0,17.9,25.3,1,0,-64.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,36,34,1.18,0.91,3.374,1.46,28.7,0.0292,31,40.4,1,42.2,0,0,0,0,46.7,Chemotherapy,None
HC-ONC-013-000095,Urothelial,59,Male,2,First-line,Never,0.0,31.8,0,None,0,0,0,6,0,4.58,0.0,0.0,5.31,0,MSS,0,9.4,TIL-low,158,1.53,8,213,3,144.0,36,0.608,0.86,PD-L1-negative,Q1,Durvalumab,Anti-PD-L1,16.8,5,Discontinued_Complete_Response,0,0,3.17,7.71,2.43,230,113,0,48.0,0.3,8.8,4.78,984,502,11.6,3.0,Tier3_exploratory,2.5,2479,17.56,1,0,0,0,,PD,0,0,47.6,0.0,144.0,144.0,,,0,0,-13.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,30,27,1.27,0.98,4.404,0.97,14.9,0.0059,63,13.4,1,81.8,1,0,0,0,22.5,BSC,Disease_Progression
HC-ONC-013-000096,Melanoma,49,Male,0,Second-line,Never,0.0,23.9,0,None,0,0,1,2,0,2.69,72.2,65.1,5.16,0,MSS,0,0.6,TIL-low,17,1.49,17,109,5,142.3,18,0.367,-0.358,PD-L1-high,Q1,Nivolumab+Ipilimumab,Combination,23.9,7,Discontinued_Complete_Response,0,0,2.36,4.16,1.76,279,100,0,13.1,10.0,11.2,12.91,1034,439,2.6,2.3,Tier1_FDA-approved,31.3,352,0.94,0,0,0,0,,PR,1,1,-49.2,49.2,142.3,72.3,16.7,20.1,0,0,-68.4,0,1,0,1,10.5,1,7.4,1,0,1,25,10,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,87,63,0.61,1.04,1.737,1.52,18.8,0.0277,62,34.1,0,64.1,0,0,0,0,36.7,Targeted,None
HC-ONC-013-000097,RCC,41,Male,2,Third+,Never,0.0,16.7,0,None,0,0,3,5,0,3.17,0.0,0.0,19.42,1,MSS,0,21.3,TIL-intermediate,544,1.81,21,865,1,117.3,62,-0.031,-0.573,PD-L1-negative,Q3,Atezolizumab+Bevacizumab,Combination,37.2,12,Discontinued_Progression,0,1,1.6,3.45,2.15,197,243,0,84.0,4.5,4.3,1.06,984,966,19.6,6.9,Tier1_FDA-approved,22.2,3793,20.0,0,0,0,0,,SD,0,1,20.0,0.0,117.3,117.3,,,0,0,28.1,0,1,1,2,11.6,1,1.0,1,1,1,105,9,0,0,0,0,1,0,1,0,0,3,0,0,0,0,0,0,0,0,1,24,27,1.19,1.09,3.712,1.37,27.2,0.0106,61,14.0,0,45.2,0,0,0,0,18.9,Targeted,None
HC-ONC-013-000098,Melanoma,63,Female,2,Third+,Never,0.0,24.0,0,None,0,0,3,4,0,3.64,0.0,0.0,7.72,0,MSS,0,3.8,TIL-low,90,1.95,24,1426,5,10.0,52,1.51,1.089,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,22.9,7,Discontinued_irAE,0,0,1.55,2.81,1.81,286,167,0,25.5,5.7,8.2,8.68,1119,1034,7.1,3.8,Tier3_exploratory,14.1,908,3.6,0,0,0,0,,SD,0,1,1.0,0.0,10.0,10.0,,,0,0,41.8,0,1,0,1,16.0,0,,0,0,1,29,6,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,35,38,1.23,1.12,0.872,1.52,13.8,0.0082,117,21.8,0,67.3,0,0,0,0,25.0,Chemotherapy,None
HC-ONC-013-000099,NSCLC,51,Male,1,Second-line,Former,38.1,28.2,0,None,0,1,1,4,0,2.73,50.0,83.5,29.13,1,MSI-H,1,2.3,TIL-low,66,2.18,60,8611,1,143.2,149,-2.0,-0.399,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,15.5,5,Completed_2yr,0,0,2.0,8.15,4.08,366,179,0,6.4,2.5,3.8,13.46,846,529,7.2,5.0,Tier1_FDA-approved,34.8,12,1.08,0,0,0,0,0.355,CR,1,1,-100.0,100.0,143.2,0.0,12.6,14.5,0,0,-66.4,0,1,0,1,17.1,0,,0,0,1,43,4,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,41,34,1.31,0.61,4.116,1.34,28.8,0.0299,118,52.8,1,136.3,1,1,1,0,54.9,Chemotherapy,Disease_Progression
HC-ONC-013-000100,NSCLC,43,Female,1,Second-line,Former,32.8,27.8,0,None,0,0,1,7,0,1.72,54.0,50.7,27.24,1,MSS,0,13.6,TIL-intermediate,348,1.86,29,5122,4,111.8,217,0.51,0.13,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,9.9,3,Discontinued_Progression,0,0,3.03,9.32,3.08,241,357,1,12.8,6.2,1.3,2.86,961,618,10.4,4.4,Tier1_FDA-approved,24.5,2360,11.6,0,0,0,0,,PR,1,1,-36.6,36.6,111.8,70.8,14.0,41.3,0,0,-71.6,0,1,0,1,5.4,1,4.9,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,37,37,0.89,1.08,0.707,1.76,25.4,0.0375,153,35.5,1,110.0,0,0,0,0,37.6,Chemotherapy,None
HC-ONC-013-000101,NSCLC,53,Male,1,Second-line,Former,22.8,20.2,0,None,0,0,1,7,0,2.86,0.0,0.0,6.11,0,MSS,1,12.7,TIL-intermediate,228,0.9,46,2375,1,160.3,21,0.718,0.781,PD-L1-negative,Q1,Pembrolizumab,Anti-PD-1,66.0,21,Completed_2yr,0,0,1.72,8.1,4.72,274,142,0,5.2,39.3,16.4,17.38,781,562,11.5,2.4,Tier3_exploratory,8.1,1586,4.85,0,0,0,0,,PD,0,0,36.7,0.0,160.3,160.3,,,0,0,63.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,15,0.91,0.97,3.652,1.43,19.9,0.0051,64,26.3,1,62.4,0,0,0,0,33.5,Chemotherapy,None
HC-ONC-013-000102,TNBC,48,Female,0,First-line,Former,3.4,24.7,0,None,0,0,0,7,0,4.02,24.3,23.7,9.6,0,MSS,0,29.2,TIL-intermediate,627,1.03,20,622,2,129.5,70,1.147,1.225,PD-L1-low,Q2,Pembrolizumab+Chemo,Combination,27.8,9,Discontinued_Progression,1,0,1.75,5.73,3.28,489,295,1,6.2,4.3,2.2,2.58,725,821,19.3,4.8,Tier3_exploratory,27.7,1681,20.0,0,0,0,0,,PD,0,0,72.6,0.0,129.5,129.5,,,0,0,115.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,39,43,0.42,0.92,1.729,1.37,18.1,0.0072,46,22.4,1,45.8,0,0,0,0,22.7,Clinical_Trial,None
HC-ONC-013-000103,Melanoma,81,Female,1,Third+,Former,19.6,39.9,0,None,0,0,4,5,0,2.93,16.4,28.9,16.93,1,MSS,0,27.0,TIL-intermediate,605,1.25,40,571,3,143.1,91,-0.065,0.368,PD-L1-low,Q3,Nivolumab+Ipilimumab,Combination,39.5,13,Discontinued_Progression,0,0,1.66,5.18,3.12,310,427,1,200.0,23.5,8.1,6.38,1301,861,13.3,7.5,Tier1_FDA-approved,23.5,23,14.76,0,0,0,0,,CR,1,1,-100.0,100.0,143.1,0.0,13.9,65.1,0,0,-76.4,0,1,0,1,18.6,1,7.0,1,0,1,29,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,19,19,1.32,0.98,1.225,1.64,14.7,0.0093,143,10.4,0,37.0,0,0,0,0,15.5,BSC,None
HC-ONC-013-000104,RCC,71,Male,1,Second-line,Never,0.0,20.3,0,None,0,0,1,6,0,2.52,82.1,100.0,2.12,0,MSS,0,21.2,TIL-intermediate,335,1.43,62,2453,4,115.1,15,0.208,-0.031,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,30.8,10,Active,0,0,3.36,2.44,1.0,271,160,0,33.7,2.8,9.6,3.51,287,245,14.8,7.0,Tier1_FDA-approved,44.0,149,5.32,0,0,0,0,,SD,0,1,6.3,0.0,115.1,115.1,,,0,0,9.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,9,0.94,1.13,3.318,1.18,13.7,0.0376,112,38.0,0,63.8,1,0,0,0,40.4,BSC,None
HC-ONC-013-000105,MSI-H_CRC,60,Female,0,Second-line,Former,30.1,29.8,0,None,0,0,1,2,0,3.94,0.0,0.0,13.2,1,MSI-H,1,29.8,TIL-intermediate,874,2.79,18,4173,3,133.9,94,0.986,0.046,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,64.8,21,Hold_irAE,0,0,1.42,3.96,2.79,152,290,1,28.8,18.4,9.6,3.51,1163,695,13.4,5.5,Tier1_FDA-approved,16.9,167,20.0,0,0,0,0,0.36,PR,1,1,-43.3,43.3,133.9,76.0,6.0,44.2,0,0,-33.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,28,1.01,0.93,4.084,1.12,19.6,0.0275,143,71.4,0,87.7,1,1,0,0,79.0,Targeted,Other
HC-ONC-013-000106,NSCLC,78,Female,1,First-line,Current,27.9,16.0,0,None,0,0,0,5,0,2.94,43.0,51.5,16.63,1,MSS,0,22.7,TIL-intermediate,385,0.92,62,2894,5,159.8,126,1.491,-0.209,PD-L1-low,Q3,Atezolizumab,Anti-PD-L1,34.2,11,Completed_2yr,0,0,1.63,3.18,1.95,342,178,0,6.5,7.4,5.9,2.74,714,339,13.2,7.2,Tier1_FDA-approved,25.4,114,6.11,0,0,0,0,,CR,1,1,-100.0,100.0,159.8,0.0,16.1,6.0,0,0,-82.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,13,11,0.45,0.7,3.557,1.3,27.2,0.0268,95,20.9,1,63.3,0,0,0,0,24.4,None,None
HC-ONC-013-000107,Melanoma,61,Female,0,First-line,Former,29.8,30.8,0,None,0,0,0,1,0,2.79,5.5,6.3,18.97,1,MSS,0,5.1,TIL-low,131,1.38,35,522,4,88.7,85,-0.301,-0.312,PD-L1-low,Q3,Nivolumab,Anti-PD-1,30.2,10,Discontinued_irAE,0,0,2.96,1.8,1.0,289,318,1,58.5,11.3,9.2,7.84,675,952,13.5,2.9,Tier1_FDA-approved,7.7,5502,3.64,0,0,0,0,,SD,0,1,2.9,0.0,88.7,88.7,,,0,0,59.4,0,1,0,1,1.8,1,13.2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,30,24,1.02,0.86,1.752,1.38,21.6,0.0202,158,32.5,0,70.0,0,0,0,0,35.8,Targeted,None
HC-ONC-013-000108,Urothelial,50,Female,0,First-line,Former,33.8,22.0,0,None,0,0,0,4,0,3.32,80.3,83.1,78.09,1,MSS,0,21.6,TIL-intermediate,488,2.66,76,3947,2,17.1,500,0.267,0.749,PD-L1-high,Q5,Durvalumab,Anti-PD-L1,75.3,25,Active,0,0,1.75,7.6,4.35,465,100,0,36.6,7.5,10.8,8.84,978,688,2.3,4.3,Tier1_FDA-approved,71.4,396,6.34,0,0,0,0,,CR,1,1,-100.0,100.0,17.1,0.0,13.5,56.4,0,0,-83.1,0,1,0,1,10.7,1,6.4,0,0,1,39,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,37,39,0.35,1.15,1.914,1.02,20.1,0.0214,146,41.5,0,101.2,1,0,0,0,48.6,Chemotherapy,Disease_Progression
HC-ONC-013-000109,NSCLC,79,Female,0,Third+,Former,24.4,28.5,1,Thyroiditis,0,0,3,7,0,3.82,52.7,67.5,14.05,1,MSS,0,22.3,TIL-intermediate,342,1.42,28,3014,3,67.7,53,1.679,0.445,PD-L1-high,Q3,Durvalumab,Anti-PD-L1,47.0,15,Discontinued_Progression,0,0,2.6,3.16,1.22,250,100,0,80.0,16.0,13.3,4.26,453,435,10.8,5.8,Tier1_FDA-approved,39.5,382,11.79,0,0,0,0,,PR,1,1,-42.1,42.1,67.7,39.2,11.9,16.5,1,0,-59.3,0,1,0,1,2.2,0,,1,0,1,55,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,38,30,1.41,1.09,1.257,1.48,17.7,0.012,141,13.6,1,28.2,0,0,0,0,19.3,None,None
HC-ONC-013-000110,NSCLC,67,Female,2,First-line,Former,56.2,20.0,0,None,0,0,0,3,0,5.0,0.0,0.0,25.48,1,MSS,0,0.0,TIL-low,0,2.08,45,500,1,95.6,87,-2.0,-0.85,PD-L1-negative,Q4,Durvalumab,Anti-PD-L1,9.6,3,Discontinued_Progression,0,0,1.15,8.15,7.12,99,165,0,76.2,0.3,29.6,1.51,655,552,17.8,4.7,Tier1_FDA-approved,7.3,923,0.5,1,0,0,0,,PR,1,1,-30.0,30.0,95.6,66.9,6.6,23.1,0,0,-71.5,0,1,1,2,13.2,1,3.5,1,1,1,152,6,0,0,0,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,0,28,21,1.34,0.72,3.796,1.6,14.8,0.0069,35,25.3,1,63.1,1,0,0,0,30.5,Clinical_Trial,None
HC-ONC-013-000111,NSCLC,48,Male,1,First-line,Former,14.7,28.0,0,None,0,0,0,1,1,3.86,60.4,86.5,10.22,1,MSS,0,34.9,TIL-intermediate,970,1.54,32,705,1,83.0,53,-0.69,-0.889,PD-L1-high,Q2,Atezolizumab,Anti-PD-L1,13.5,4,Hold_irAE,0,0,1.52,6.96,4.59,105,128,0,2.8,1.3,8.9,6.19,645,542,30.0,4.5,Tier1_FDA-approved,41.8,948,20.0,0,0,0,0,,PR,1,1,-32.3,32.3,83.0,56.2,10.7,11.6,0,0,-80.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,26,23,0.53,1.03,0.928,1.38,29.8,0.0307,176,9.3,0,28.8,0,0,0,0,14.9,None,None
HC-ONC-013-000112,NSCLC,58,Male,2,Third+,Former,19.5,22.0,0,None,0,1,2,7,0,4.13,27.2,28.7,15.92,1,MSS,0,6.8,TIL-low,155,1.87,31,4131,1,30.1,114,1.466,0.933,PD-L1-low,Q3,Nivolumab,Anti-PD-1,53.5,17,Hold_irAE,0,0,2.99,5.92,1.98,353,155,0,4.0,12.2,7.8,6.28,834,705,6.0,2.6,Tier1_FDA-approved,21.5,3,4.84,0,0,0,0,,SD,0,1,5.4,0.0,30.1,30.1,,,0,0,66.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,40,45,1.01,0.75,4.113,1.32,12.5,0.0189,94,26.4,1,60.9,1,0,0,0,28.3,Targeted,Disease_Progression
HC-ONC-013-000113,MSI-H_CRC,50,Female,1,First-line,Current,15.1,22.9,0,None,0,0,0,6,0,2.8,0.0,0.0,16.82,1,MSI-H,1,36.6,TIL-intermediate,675,1.47,41,1365,4,14.8,90,1.093,1.009,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,59.3,19,Discontinued_Progression,0,0,1.26,6.09,4.84,184,180,0,4.5,0.6,3.6,3.77,659,808,14.1,0.8,Tier1_FDA-approved,26.7,153,16.07,0,0,0,0,0.385,PR,1,1,-30.0,30.0,14.8,10.4,15.4,52.3,0,0,-70.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,27,22,1.02,0.81,2.905,1.09,17.6,0.0107,53,16.9,0,47.9,0,0,0,0,22.4,BSC,None
HC-ONC-013-000114,HNSCC,44,Female,0,First-line,Never,0.0,28.7,0,None,0,0,0,1,0,2.38,92.1,89.3,1.8,0,MSS,0,37.5,TIL-intermediate,630,2.3,51,12173,2,50.4,13,0.522,-0.016,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,34.1,11,Active,0,0,1.55,3.29,2.12,304,287,1,4.7,3.9,10.5,19.96,1380,370,9.1,6.6,Tier1_FDA-approved,49.1,48,12.12,0,0,0,0,,SD,0,1,18.1,0.0,50.4,50.4,,,0,0,65.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,38,33,1.26,0.88,2.855,1.71,25.8,0.025,158,9.9,1,39.9,0,0,0,0,13.5,Chemotherapy,None
HC-ONC-013-000115,TNBC,72,Female,1,First-line,Never,0.0,24.3,0,None,1,1,0,5,0,3.25,53.9,95.2,17.68,1,MSS,0,58.5,TIL-high,1197,0.76,12,3299,2,112.3,118,-0.449,-0.184,PD-L1-high,Q3,Atezolizumab,Anti-PD-L1,34.7,11,Discontinued_Progression,0,0,1.83,11.35,6.21,259,163,0,16.8,6.9,12.6,1.28,1439,968,22.2,5.5,Tier1_FDA-approved,38.8,735,20.0,0,0,0,0,,PR,1,1,-51.6,51.6,112.3,54.4,15.4,28.3,0,0,-76.2,0,1,0,1,21.9,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,37,32,1.21,0.86,3.851,1.55,21.4,0.009,113,18.1,1,44.7,1,0,0,0,22.8,None,Disease_Progression
HC-ONC-013-000116,HNSCC,83,Female,1,Second-line,Former,38.1,28.4,0,None,0,0,1,2,0,3.29,0.0,0.0,59.35,1,MSI-H,1,20.5,TIL-intermediate,386,1.37,104,1008,2,143.2,240,-0.882,-0.737,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,40.0,13,Discontinued_irAE,0,0,1.11,4.58,4.13,225,133,0,6.9,2.7,6.3,0.76,293,921,5.2,6.8,Tier1_FDA-approved,35.6,262,3.68,0,0,0,0,0.35,PR,1,1,-65.7,65.7,143.2,49.1,7.0,12.0,0,0,-98.6,1,1,0,2,1.2,1,1.5,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,19,16,1.49,0.62,3.17,1.28,17.6,0.0196,35,19.0,0,76.7,0,0,0,0,24.0,Chemotherapy,None
HC-ONC-013-000117,HNSCC,44,Male,0,Third+,Former,14.4,25.5,0,None,0,0,2,4,0,2.34,8.7,11.2,55.91,1,MSI-H,1,14.6,TIL-intermediate,329,1.91,7,1786,3,116.7,433,-0.591,-0.002,PD-L1-low,Q5,Nivolumab,Anti-PD-1,27.8,9,Discontinued_Complete_Response,0,0,1.4,5.21,3.73,233,168,0,96.8,3.2,11.4,2.5,1063,425,15.1,4.1,Tier1_FDA-approved,43.2,413,20.0,1,0,0,0,0.352,PD,0,0,31.7,0.0,116.7,116.7,,,0,0,24.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,10,11,0.72,1.06,1.717,1.46,29.9,0.0082,163,30.4,0,62.1,0,0,0,0,32.2,Chemotherapy,None
HC-ONC-013-000118,NSCLC,67,Male,1,First-line,Never,0.0,26.8,0,None,0,0,0,6,0,3.06,57.9,65.7,41.17,1,MSI-H,1,34.2,TIL-intermediate,1009,2.15,19,1951,4,122.3,136,1.548,1.046,PD-L1-high,Q5,Nivolumab,Anti-PD-1,43.7,14,Discontinued_Progression,0,0,1.72,3.24,1.88,159,136,0,81.8,10.2,5.8,7.91,1158,615,5.0,3.6,Tier1_FDA-approved,55.4,18,20.0,0,0,0,0,0.398,PR,1,1,-38.8,38.8,122.3,74.8,15.7,47.7,0,0,-57.9,0,1,0,2,7.6,1,9.3,1,0,1,22,2,0,0,0,1,1,0,0,0,2,0,0,0,2,0,0,0,0,0,0,23,21,0.45,1.11,10.678,0.46,23.1,0.0299,104,47.1,0,70.6,0,0,0,0,52.2,Chemotherapy,None
HC-ONC-013-000119,MSI-H_CRC,53,Male,0,Third+,Never,0.0,28.7,0,None,0,1,2,6,0,3.52,18.5,23.1,11.79,1,MSI-H,1,47.1,TIL-intermediate,1114,3.48,31,754,1,76.8,88,-0.628,-0.349,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,9.4,3,Discontinued_Progression,0,0,1.68,2.81,1.67,243,126,0,12.1,24.8,12.6,1.93,1063,942,10.4,5.0,Tier1_FDA-approved,23.3,253,20.0,0,0,0,0,0.465,PR,1,1,-36.0,36.0,76.8,49.1,7.8,23.5,0,0,-46.4,0,1,0,1,11.1,1,10.3,1,0,1,70,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,36,39,0.99,0.92,1.192,0.86,17.3,0.0132,158,13.5,0,55.3,1,0,0,0,17.1,Clinical_Trial,Disease_Progression
HC-ONC-013-000120,RCC,55,Female,1,First-line,Never,0.0,24.7,0,None,0,0,0,3,0,3.49,56.5,77.4,26.71,1,MSI-H,1,10.7,TIL-intermediate,304,1.36,46,605,3,10.3,121,0.101,0.84,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,87.8,29,Discontinued_irAE,0,0,2.75,5.69,2.07,183,100,0,86.1,2.3,15.3,2.04,703,847,11.8,6.7,Tier1_FDA-approved,32.2,2149,6.47,0,0,0,0,0.437,PR,1,1,-30.0,30.0,10.3,7.2,15.9,53.2,0,0,-52.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,35,36,1.22,0.7,2.356,1.0,27.3,0.0178,158,51.8,0,89.7,1,0,0,0,53.3,Chemotherapy,Disease_Progression
HC-ONC-013-000121,HNSCC,53,Male,1,Third+,Never,0.0,21.5,0,None,0,0,2,1,0,3.6,14.2,17.5,15.88,1,MSI-H,1,8.1,TIL-low,200,3.45,117,4195,2,61.8,87,-0.754,-0.121,PD-L1-low,Q3,Pembrolizumab,Anti-PD-1,49.7,16,Discontinued_Progression,0,0,3.05,5.0,1.64,203,207,0,54.0,3.7,15.2,9.59,827,533,17.3,4.5,Tier1_FDA-approved,10.4,3341,1.69,0,0,0,0,0.427,SD,0,1,-11.4,11.4,61.8,54.7,,,0,0,72.9,0,1,1,1,10.6,1,1.0,1,1,1,160,2,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,3,0,0,28,25,0.64,7.17,0.941,0.88,14.7,0.0297,47,13.0,0,20.3,0,0,0,0,16.7,None,None
HC-ONC-013-000122,MSI-H_CRC,50,Male,0,Second-line,Former,32.0,23.8,0,None,0,0,1,3,1,3.43,52.0,63.2,67.08,1,MSI-H,1,0.0,TIL-low,0,1.19,7,4986,1,69.6,343,0.843,0.16,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,39.9,13,Discontinued_Progression,0,0,1.17,3.02,2.58,208,151,0,7.8,3.1,8.1,6.49,676,763,6.6,6.6,Tier1_FDA-approved,60.2,1186,0.5,0,0,0,0,0.35,PR,1,1,-51.6,51.6,69.6,33.7,10.4,44.6,1,0,-97.8,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,15,13,0.58,0.68,3.112,1.31,20.3,0.0261,134,36.8,1,54.4,0,0,0,0,40.8,None,None
HC-ONC-013-000123,Melanoma,61,Male,0,Second-line,Former,32.5,32.5,0,None,0,1,1,2,0,2.79,91.6,100.0,4.26,0,MSS,0,22.3,TIL-intermediate,621,3.2,22,3731,4,60.1,16,-0.539,-0.366,PD-L1-high,Q1,Nivolumab,Anti-PD-1,21.0,6,Discontinued_irAE,0,0,1.72,2.18,1.27,218,325,1,1.6,0.4,3.2,6.06,774,1199,15.3,3.0,Tier1_FDA-approved,43.8,54,20.0,1,0,0,0,,SD,0,1,-12.7,12.7,60.1,52.5,,,0,0,3.9,0,1,0,1,20.9,1,7.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,13,14,1.26,0.7,1.177,1.42,27.1,0.0162,91,8.1,0,31.9,1,0,0,0,13.2,BSC,Disease_Progression
HC-ONC-013-000124,NSCLC,51,Male,1,First-line,Former,19.6,27.1,0,None,0,0,0,7,0,2.79,0.0,0.0,4.54,0,MSS,0,18.8,TIL-intermediate,414,2.48,6,11141,5,82.2,22,-0.098,-0.097,PD-L1-negative,Q1,Atezolizumab,Anti-PD-L1,12.5,4,Discontinued_Complete_Response,0,0,2.16,2.38,1.1,388,100,0,9.8,8.8,4.5,8.37,537,621,12.1,4.7,Tier3_exploratory,4.5,2668,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,82.2,0.0,12.5,91.6,1,0,-93.6,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,39,37,1.2,1.13,3.956,1.18,29.7,0.0037,123,47.3,1,67.2,1,0,0,0,46.5,BSC,Disease_Progression
HC-ONC-013-000125,NSCLC,64,Female,1,Third+,Former,34.9,22.3,0,None,0,0,2,2,0,2.24,51.6,84.2,23.33,1,MSI-H,1,37.0,TIL-intermediate,1038,1.04,34,944,2,97.7,92,-1.683,-0.97,PD-L1-high,Q4,Pembrolizumab+Chemo,Combination,26.1,8,Discontinued_Progression,1,0,3.02,8.15,2.7,229,153,0,6.4,22.7,11.9,3.19,866,473,13.4,4.9,Tier1_FDA-approved,41.6,1195,20.0,0,0,0,0,0.414,PR,1,1,-65.1,65.1,97.7,34.1,18.6,16.5,0,0,-80.4,0,1,1,2,11.0,1,6.6,1,1,0,0,0,0,0,0,0,1,0,0,0,1,4,0,0,0,0,0,0,0,0,0,23,26,0.54,0.89,3.302,1.33,18.9,0.036,45,28.2,1,53.2,0,0,0,0,33.0,None,None
HC-ONC-013-000126,Melanoma,60,Male,0,Second-line,Never,0.0,28.5,0,None,0,1,1,7,0,4.63,76.3,80.1,26.71,1,MSS,0,25.4,TIL-intermediate,492,1.92,41,13482,2,114.1,107,-1.613,0.294,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,42.2,14,Discontinued_Complete_Response,0,0,2.2,3.3,1.5,408,496,1,15.0,25.0,52.4,3.31,449,634,16.8,7.5,Tier1_FDA-approved,48.6,338,11.71,0,0,0,0,,PR,1,1,-54.4,54.4,114.1,52.0,22.8,8.5,0,0,-60.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,29,34,1.34,0.67,4.066,0.89,14.5,0.0013,130,48.9,0,70.0,1,0,0,0,51.8,None,Disease_Progression
HC-ONC-013-000127,HNSCC,58,Female,3,First-line,Never,0.0,28.8,0,None,0,0,0,3,0,3.21,18.4,25.9,16.31,1,MSS,0,40.0,TIL-intermediate,678,1.61,118,613,2,68.9,64,0.008,0.19,PD-L1-low,Q3,Pembrolizumab,Anti-PD-1,40.1,13,Active,0,0,1.85,3.78,2.04,528,125,0,13.3,2.6,5.6,8.57,840,649,5.6,5.4,Tier1_FDA-approved,34.8,19,5.7,1,0,0,0,,CR,1,1,-100.0,100.0,68.9,0.0,10.6,18.1,0,0,-59.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37,39,0.46,0.75,0.848,1.57,22.2,0.0289,162,26.7,0,47.4,1,0,0,0,32.3,None,None
HC-ONC-013-000128,HNSCC,50,Male,0,Second-line,Former,14.9,29.1,0,None,0,0,1,4,0,3.02,0.0,0.0,17.26,1,MSI-H,1,9.5,TIL-low,265,2.25,36,536,2,10.0,94,-1.325,-1.813,PD-L1-negative,Q3,Nivolumab,Anti-PD-1,24.6,8,Active,0,0,2.15,9.26,4.3,375,178,0,13.0,1.6,10.6,1.53,525,495,16.1,8.5,Tier1_FDA-approved,5.4,1686,7.16,1,0,0,0,0.478,SD,0,1,10.5,0.0,10.0,10.0,,,0,0,23.9,0,1,0,2,8.1,1,8.4,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,36,43,0.43,1.17,0.206,2.26,29.0,0.0369,198,3.8,0,74.8,1,0,0,0,7.8,None,Disease_Progression
HC-ONC-013-000129,NSCLC,54,Male,1,First-line,Current,8.8,21.6,0,None,0,0,0,2,0,2.46,52.0,60.8,10.51,1,MSS,0,37.1,TIL-intermediate,883,1.47,76,219,1,60.7,73,2.0,0.929,PD-L1-high,Q2,Atezolizumab,Anti-PD-L1,38.7,12,Completed_2yr,0,0,2.16,2.56,1.18,320,109,0,20.6,7.6,4.7,0.81,962,688,9.2,2.3,Tier1_FDA-approved,42.9,166,11.47,0,0,0,0,,SD,0,1,16.6,0.0,60.7,60.7,,,0,0,100.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,27,27,0.72,0.91,4.023,1.43,24.0,0.0127,84,28.6,1,52.1,0,0,0,0,31.9,Chemotherapy,None
HC-ONC-013-000130,RCC,70,Male,3,Third+,Former,31.5,23.1,0,None,0,0,4,3,0,5.0,72.1,92.8,35.94,1,MSS,0,12.1,TIL-intermediate,342,1.41,53,1059,4,81.7,210,-2.0,-2.166,PD-L1-high,Q5,Nivolumab+Ipilimumab,Combination,56.5,18,Discontinued_Progression,0,0,1.14,3.12,2.74,288,102,0,3.6,20.0,3.4,3.17,696,349,17.5,5.3,Tier1_FDA-approved,49.0,678,6.33,0,0,0,0,,SD,0,1,-9.2,9.2,81.7,74.2,,,0,0,79.9,0,1,1,3,12.4,1,4.5,1,1,1,106,5,1,0,0,1,1,0,0,0,0,3,0,0,2,0,0,0,0,0,3,25,18,1.36,0.91,87.253,0.51,22.8,0.0039,29118,17.4,1,47.5,1,0,0,0,21.0,Chemotherapy,Other
HC-ONC-013-000131,Melanoma,67,Male,0,First-line,Never,0.0,23.1,0,None,1,1,0,1,0,2.34,62.3,69.4,12.28,1,MSS,0,31.7,TIL-intermediate,920,3.27,23,988,3,128.9,92,-0.8,-0.645,PD-L1-high,Q3,Nivolumab+Ipilimumab,Combination,3.6,1,Discontinued_Progression,0,0,1.78,3.05,1.71,377,434,1,18.4,8.9,4.3,9.44,987,467,13.7,5.4,Tier1_FDA-approved,46.2,447,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,128.9,0.0,10.8,26.3,1,0,-24.3,0,1,0,2,4.1,0,,0,0,1,37,5,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,32,31,1.13,0.92,4.496,0.98,17.6,0.0105,92,34.2,1,58.6,1,0,0,0,38.9,Clinical_Trial,Disease_Progression
HC-ONC-013-000132,NSCLC,49,Male,0,Second-line,Current,3.4,24.7,0,None,0,0,1,3,0,2.86,24.2,22.7,33.71,1,MSI-H,1,0.0,TIL-low,0,1.57,11,3399,1,57.3,208,0.017,-0.984,PD-L1-low,Q4,Pembrolizumab+Chemo,Combination,28.4,9,Discontinued_Progression,1,0,2.96,10.06,3.41,256,218,0,7.8,10.5,1.4,5.5,1224,752,11.0,6.2,Tier1_FDA-approved,32.3,4055,0.5,1,0,0,0,0.352,PD,0,0,23.8,0.0,57.3,57.3,,,0,0,67.7,0,1,1,3,2.2,1,6.1,0,0,1,122,12,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,3,0,0,55,44,0.77,3.9,1.703,1.32,22.9,0.0129,33,10.7,1,103.6,1,0,0,0,16.5,Chemotherapy,Other
HC-ONC-013-000133,NSCLC,62,Male,0,First-line,Former,0.0,29.2,0,None,1,1,0,3,0,3.53,53.4,54.1,9.59,0,MSS,0,23.5,TIL-intermediate,530,2.49,41,2423,4,100.5,62,-0.365,-0.655,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,50.6,16,Active,0,0,1.52,12.0,7.91,400,214,0,14.9,29.1,21.8,8.9,1377,249,9.0,3.4,Tier1_FDA-approved,33.3,334,12.62,0,0,0,0,,SD,0,1,-21.7,21.7,100.5,78.7,,,0,0,55.7,0,1,0,1,5.9,1,6.2,0,0,1,79,7,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,29,25,0.49,1.18,1.347,1.58,27.9,0.0182,99,27.0,1,71.2,0,0,0,0,29.2,Chemotherapy,None
HC-ONC-013-000134,Melanoma,70,Female,0,First-line,Former,38.0,28.0,0,None,0,0,0,5,0,3.68,0.0,0.0,22.56,1,MSS,0,0.0,TIL-low,0,1.47,10,432,3,91.6,143,-1.104,-1.423,PD-L1-negative,Q4,Nivolumab,Anti-PD-1,34.2,11,Discontinued_Progression,0,0,1.74,6.53,3.76,333,100,0,31.7,3.0,1.2,0.89,200,781,16.1,8.4,Tier1_FDA-approved,8.3,394,0.5,0,0,0,0,,PR,1,1,-41.8,41.8,91.6,53.3,15.5,93.4,0,0,-89.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,10,1.16,0.65,2.16,1.21,18.8,0.021,185,22.1,0,60.8,0,0,0,0,25.4,BSC,None
HC-ONC-013-000135,MSI-H_CRC,40,Male,0,First-line,Former,45.7,28.4,0,None,0,0,0,2,0,3.97,0.0,0.0,22.55,1,MSI-H,1,30.2,TIL-intermediate,736,3.79,93,1129,2,81.8,118,-0.958,-0.383,PD-L1-negative,Q4,Pembrolizumab,Anti-PD-1,41.4,13,Active,0,0,1.5,6.63,4.43,204,240,0,3.6,5.7,6.0,5.77,650,198,18.3,5.0,Tier1_FDA-approved,19.6,4307,7.83,1,0,0,0,0.367,PR,1,1,-56.0,56.0,81.8,36.0,8.9,56.1,0,0,-70.1,0,1,0,2,5.0,1,3.9,0,0,1,25,3,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,35,29,1.02,1.02,0.535,1.17,16.4,0.0286,63,32.0,1,91.8,0,0,0,0,39.0,Clinical_Trial,None
HC-ONC-013-000136,Melanoma,67,Female,1,First-line,Never,0.0,33.3,0,None,0,1,0,4,0,4.65,59.5,86.9,29.34,1,MSI-L,0,26.6,TIL-intermediate,716,1.17,29,1158,4,117.2,189,-0.991,-0.594,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,32.3,10,Discontinued_Progression,0,0,0.65,3.35,5.13,383,357,1,9.2,52.5,2.9,7.56,809,254,9.3,2.8,Tier1_FDA-approved,44.5,150,20.0,0,0,0,0,,PR,1,1,-30.0,30.0,117.2,82.0,16.3,66.3,0,0,-71.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,40,34,1.49,0.63,4.044,0.94,20.7,0.0352,111,7.7,1,31.9,0,0,0,0,11.0,Clinical_Trial,None
HC-ONC-013-000137,RCC,53,Female,0,First-line,Never,0.0,29.9,0,None,1,0,0,4,0,3.6,60.8,100.0,4.4,0,MSS,0,12.2,TIL-intermediate,234,1.21,86,215,2,53.6,15,-0.287,-0.021,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,104.0,34,Discontinued_Progression,0,0,1.66,11.87,7.14,256,356,1,10.8,5.8,3.6,1.52,1038,500,6.3,5.0,Tier1_FDA-approved,21.8,1369,2.69,0,0,0,0,,PD,0,0,48.2,0.0,53.6,53.6,,,0,0,49.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,39,35,1.22,0.87,1.574,1.39,18.8,0.0187,127,33.7,0,113.5,0,0,1,0,38.5,None,None
HC-ONC-013-000138,TNBC,67,Female,1,First-line,Never,0.0,25.8,0,None,0,0,0,5,0,2.36,97.1,100.0,80.0,1,MSI-H,1,19.0,TIL-intermediate,443,3.53,23,557,4,57.0,500,1.952,1.119,PD-L1-high,Q5,Pembrolizumab+Chemo,Combination,5.9,1,Completed_2yr,1,0,1.86,5.12,2.75,232,280,1,7.3,1.6,22.2,8.93,405,657,15.5,4.4,Tier1_FDA-approved,87.5,299,18.46,0,0,0,0,0.427,PR,1,1,-47.6,47.6,57.0,29.9,23.1,50.0,0,0,-67.4,0,1,0,3,13.1,1,6.8,1,0,1,11,9,0,0,0,1,0,0,0,0,1,2,0,0,0,0,1,0,0,0,0,21,18,0.42,1.14,2.586,1.63,20.5,0.0294,61,11.4,0,29.2,0,0,0,0,12.9,Clinical_Trial,None
HC-ONC-013-000139,Melanoma,51,Female,3,Second-line,Never,0.0,20.6,0,None,0,0,1,7,0,2.99,17.9,15.3,21.31,1,MSI-H,1,32.7,TIL-intermediate,838,1.32,41,717,5,79.5,147,0.078,-0.65,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,30.8,10,Discontinued_Progression,0,0,1.34,6.87,5.11,193,114,0,30.0,3.3,8.7,4.1,605,865,4.8,10.6,Tier1_FDA-approved,27.9,90,19.95,0,0,0,0,0.42,SD,0,1,-4.6,4.6,79.5,75.8,,,0,0,3.1,0,1,0,1,11.6,1,7.2,0,0,1,10,8,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,26,20,1.17,1.06,2.994,1.36,13.7,0.0058,86,29.2,1,70.5,1,0,0,0,29.8,Targeted,Disease_Progression
HC-ONC-013-000140,Hodgkin,39,Male,2,First-line,Never,0.0,22.9,0,None,0,1,0,6,0,3.45,0.0,0.0,11.25,1,MSS,0,37.9,TIL-intermediate,645,3.67,39,10101,2,54.4,48,1.183,0.967,PD-L1-negative,Q2,Nivolumab,Anti-PD-1,8.4,2,Active,0,0,1.04,4.25,4.09,266,234,0,5.9,2.4,3.4,52.3,939,612,5.5,7.1,Tier1_FDA-approved,11.0,404,16.12,0,0,0,0,,SD,0,1,-17.4,17.4,54.4,44.9,,,0,0,50.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,19,0.61,0.8,3.664,0.97,18.1,0.0135,185,29.7,1,44.0,1,0,0,0,31.6,Chemotherapy,Disease_Progression
HC-ONC-013-000141,Hodgkin,41,Male,1,First-line,Former,23.0,25.2,0,None,0,0,0,7,0,4.85,0.0,0.0,8.1,0,MSS,0,30.2,TIL-intermediate,822,2.58,32,2275,2,100.3,55,0.507,1.265,PD-L1-negative,Q2,Nivolumab,Anti-PD-1,12.5,4,Discontinued_Progression,0,0,1.16,3.92,3.38,403,280,1,7.0,11.3,4.6,0.79,925,551,6.7,5.1,Tier2_emerging,2.6,1139,20.0,0,0,0,0,,SD,0,1,-15.5,15.5,100.3,84.7,,,0,0,83.1,0,1,0,2,6.1,1,7.7,0,0,1,62,5,0,0,0,1,1,0,0,0,0,0,0,0,2,0,0,0,0,0,2,19,17,1.45,0.93,43.019,0.59,26.9,0.0055,36361,46.9,1,115.0,1,0,0,0,49.5,Targeted,Disease_Progression
HC-ONC-013-000142,NSCLC,61,Male,0,Second-line,Former,20.0,30.6,0,None,0,0,1,4,0,2.08,0.0,0.0,27.14,1,MSS,0,20.6,TIL-intermediate,497,1.53,23,4002,2,51.5,83,1.114,0.873,PD-L1-negative,Q4,Atezolizumab,Anti-PD-L1,24.6,8,Active,0,0,2.24,10.29,4.6,382,100,0,6.0,2.5,4.0,13.4,1013,716,9.9,4.8,Tier1_FDA-approved,6.7,3073,20.0,0,0,1,1,,PR,1,1,-54.3,54.3,51.5,23.5,13.9,77.5,0,0,-88.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,24,26,0.32,0.7,3.369,0.83,19.2,0.0273,138,77.0,0,89.0,1,1,0,0,83.1,Chemotherapy,Disease_Progression
HC-ONC-013-000143,Melanoma,64,Male,1,First-line,Former,45.1,26.4,0,None,0,0,0,3,0,4.16,76.7,100.0,7.05,0,MSS,0,59.6,TIL-high,1741,0.67,45,299,1,89.1,29,-2.0,-1.413,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,12.2,4,Active,0,0,3.63,5.87,1.62,292,114,0,36.3,10.2,7.1,3.27,1033,426,5.3,6.9,Tier1_FDA-approved,56.2,3685,20.0,0,1,0,0,,SD,0,1,-5.5,5.5,89.1,84.2,,,0,0,-14.4,0,1,0,1,8.3,1,4.1,0,0,1,57,6,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,32,37,0.59,1.17,0.971,1.64,29.4,0.0355,53,58.8,1,99.9,0,1,0,0,65.1,Chemotherapy,None
HC-ONC-013-000144,Melanoma,50,Female,1,Third+,Never,0.0,23.2,0,None,0,0,4,5,1,3.34,69.8,100.0,10.17,1,MSS,0,37.3,TIL-intermediate,750,1.63,16,7578,3,76.0,34,-0.304,-0.897,PD-L1-high,Q2,Nivolumab,Anti-PD-1,88.9,29,Active,0,0,2.87,9.26,3.23,330,312,1,7.4,3.1,8.5,1.23,1002,628,2.3,7.0,Tier1_FDA-approved,40.9,259,20.0,0,0,0,0,,PR,1,1,-60.0,60.0,76.0,30.4,16.0,4.9,1,0,-86.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,11,0.9,1.03,3.317,1.72,24.8,0.0348,144,73.4,1,85.2,0,1,0,0,73.6,Chemotherapy,None
HC-ONC-013-000145,NSCLC,68,Male,1,Third+,Current,8.5,22.8,0,None,0,0,2,1,0,3.87,74.5,99.2,42.92,1,MSS,0,37.4,TIL-intermediate,622,1.73,13,8616,2,88.6,296,1.307,0.33,PD-L1-high,Q5,Pembrolizumab+Chemo,Combination,82.0,27,Discontinued_Progression,1,0,0.96,5.09,5.29,462,310,1,19.3,0.6,33.7,2.94,958,360,6.3,0.0,Tier1_FDA-approved,58.0,92,20.0,1,0,0,0,,PR,1,1,-39.3,39.3,88.6,53.7,13.3,51.0,0,0,-85.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,22,20,0.39,0.82,4.177,1.4,18.6,0.0134,77,12.4,1,42.6,1,0,0,0,15.3,BSC,Disease_Progression
HC-ONC-013-000146,NSCLC,41,Male,0,Second-line,Current,6.4,26.2,0,None,0,0,1,2,0,3.12,13.9,23.6,48.68,1,MSS,0,26.5,TIL-intermediate,600,2.96,90,164,2,61.6,330,-0.572,-0.117,PD-L1-low,Q5,Pembrolizumab+Chemo,Combination,22.1,7,Active,1,0,2.32,2.93,1.26,227,100,0,87.9,10.7,1.6,5.6,917,617,15.2,6.3,Tier1_FDA-approved,37.6,250,6.59,0,0,0,0,,PR,1,1,-37.3,37.3,61.6,38.6,13.2,35.9,0,0,-100.0,1,1,1,1,31.6,1,8.2,1,1,1,152,8,1,0,0,0,0,1,0,0,0,4,0,0,0,0,0,0,0,0,0,27,28,0.71,0.79,0.84,1.68,16.5,0.0099,69,33.8,1,59.5,0,0,0,0,39.2,BSC,None
HC-ONC-013-000147,RCC,60,Female,2,Second-line,Former,40.6,30.9,0,None,0,0,1,2,0,2.53,23.6,20.8,14.3,1,MSI-H,1,22.5,TIL-intermediate,366,3.65,59,776,1,66.4,101,1.762,1.594,PD-L1-low,Q3,Nivolumab+Ipilimumab,Combination,40.6,13,Discontinued_Progression,0,0,1.26,3.35,2.65,140,298,1,11.3,8.8,7.2,10.28,1099,574,5.6,5.1,Tier1_FDA-approved,20.1,69,6.1,0,0,0,0,0.405,SD,0,1,-1.9,1.9,66.4,65.2,,,0,0,-20.0,0,1,0,3,12.7,1,2.4,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,16,13,0.9,0.74,0.967,0.88,24.3,0.0114,51,4.1,1,80.4,1,0,0,0,7.9,Clinical_Trial,Other
HC-ONC-013-000148,RCC,46,Female,1,Third+,Current,20.1,34.5,0,None,0,0,3,2,0,3.8,97.0,96.2,9.1,0,MSI-H,1,0.0,TIL-low,0,1.17,35,3278,1,83.8,28,1.484,1.021,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,33.4,11,Completed_2yr,0,0,1.31,4.72,3.61,469,210,0,37.0,13.8,5.7,17.77,228,439,10.3,2.4,Tier1_FDA-approved,45.5,291,0.5,0,0,0,0,0.399,SD,0,1,20.0,0.0,83.8,83.8,,,0,0,119.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,13,0.84,1.07,2.729,1.03,17.4,0.0119,38,22.0,0,30.0,0,0,0,0,29.0,None,None
HC-ONC-013-000149,NSCLC,53,Female,0,First-line,Former,46.0,25.5,0,None,0,0,0,3,0,3.72,3.0,3.8,36.88,1,MSS,1,9.8,TIL-low,153,2.46,125,3918,5,88.1,203,-0.469,0.118,PD-L1-low,Q5,Atezolizumab,Anti-PD-L1,56.8,18,Discontinued_Progression,0,0,1.37,3.28,2.39,188,296,1,64.8,3.3,15.8,13.98,1363,633,21.7,6.8,Tier1_FDA-approved,20.9,242,1.21,0,1,1,1,,PR,1,1,-71.2,71.2,88.1,25.4,7.7,39.2,0,0,-37.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,26,24,0.85,0.86,0.686,1.12,28.7,0.0041,195,38.6,0,79.7,1,0,0,0,44.0,Chemotherapy,Disease_Progression
HC-ONC-013-000150,NSCLC,61,Male,1,First-line,Current,1.0,26.3,0,None,0,1,0,1,1,3.98,27.1,37.6,5.19,0,MSS,0,12.8,TIL-intermediate,336,2.42,27,801,4,79.8,34,-0.503,0.052,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,39.7,13,Active,0,0,2.19,2.58,1.18,173,146,0,34.0,2.9,9.8,2.07,239,632,11.8,9.5,Tier3_exploratory,16.7,1201,12.0,1,0,0,0,,PD,0,0,41.2,0.0,79.8,79.8,,,0,0,-1.3,0,1,1,1,5.9,1,1.0,1,0,1,130,6,0,0,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,0,0,29,30,1.35,0.8,1.25,1.57,14.1,0.0061,100,40.7,0,92.1,1,0,0,0,44.2,Clinical_Trial,Disease_Progression
HC-ONC-013-000151,MSI-H_CRC,50,Male,1,First-line,Never,0.0,20.4,1,RA,0,0,0,5,1,3.19,0.0,0.0,32.51,1,MSI-H,1,1.3,TIL-low,29,2.82,95,1253,2,148.2,123,-1.014,-0.355,PD-L1-negative,Q4,Pembrolizumab,Anti-PD-1,1.0,1,Active,0,0,2.42,8.17,3.38,100,277,1,12.0,12.0,11.8,11.07,576,835,13.7,6.1,Tier1_FDA-approved,6.8,15,0.5,0,0,0,0,0.46,CR,1,1,-100.0,100.0,148.2,0.0,23.2,70.4,0,0,-84.0,0,1,0,3,6.0,1,2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,1,29,31,0.91,1.14,0.138,2.8,12.5,0.0092,162,91.1,0,172.4,1,1,1,0,94.8,Chemotherapy,Disease_Progression
HC-ONC-013-000152,NSCLC,56,Male,2,Second-line,Former,9.0,36.2,0,None,0,1,1,5,0,2.72,99.2,100.0,1.47,0,MSS,0,2.6,TIL-low,54,2.12,38,883,4,40.4,9,-0.63,-0.707,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,51.0,17,Discontinued_Progression,0,0,1.59,3.41,2.15,326,305,1,23.2,45.7,9.7,6.13,832,279,7.3,7.2,Tier1_FDA-approved,37.0,134,1.38,0,0,0,0,,CR,1,1,-100.0,100.0,40.4,0.0,6.4,9.5,0,0,-100.0,1,1,0,1,10.4,1,9.0,0,0,1,37,3,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,21,20,1.43,0.69,2.425,1.15,16.0,0.0013,186,19.7,0,85.4,0,0,0,0,23.6,None,None
HC-ONC-013-000153,NSCLC,73,Male,1,First-line,Never,0.0,19.5,0,None,0,0,0,2,1,1.95,59.9,71.2,54.9,1,MSS,0,0.0,TIL-low,0,0.62,15,2064,1,77.4,188,-1.233,-0.653,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,49.4,16,Discontinued_Complete_Response,0,0,1.6,4.8,3.01,109,168,0,3.4,7.5,3.5,2.65,1102,585,22.8,8.6,Tier1_FDA-approved,51.0,136,0.5,1,0,0,0,,CR,1,1,-100.0,100.0,77.4,0.0,8.0,60.3,0,0,-99.4,1,1,0,1,11.4,1,3.8,1,0,1,32,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,17,17,0.48,0.76,1.494,0.96,22.9,0.0028,65,42.3,1,149.7,1,0,1,0,44.7,Targeted,Disease_Progression
HC-ONC-013-000154,Melanoma,54,Male,1,Second-line,Never,0.0,32.4,0,None,0,0,1,1,0,3.86,85.2,72.2,23.64,1,MSI-H,1,19.4,TIL-intermediate,473,1.53,145,7605,1,17.1,92,0.429,-0.167,PD-L1-high,Q4,Nivolumab+Ipilimumab,Combination,31.9,10,Active,0,0,1.99,5.2,2.62,168,202,0,5.6,12.3,19.5,3.78,200,448,9.3,3.3,Tier1_FDA-approved,47.1,2394,3.24,0,0,0,0,0.47,CR,1,1,-100.0,100.0,17.1,0.0,18.9,8.2,0,0,-100.0,1,1,0,1,8.1,1,1.0,0,0,1,62,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,17,13,0.64,0.81,2.402,1.61,27.0,0.0275,178,34.1,1,64.3,0,0,0,0,39.9,Chemotherapy,None
HC-ONC-013-000155,Hodgkin,71,Male,0,Third+,Never,0.0,24.7,1,Psoriasis,0,1,2,1,0,3.54,26.9,43.2,10.87,1,MSS,0,56.4,TIL-high,1341,0.93,73,717,5,94.9,58,-1.456,-0.865,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,70.3,23,Discontinued_Progression,0,0,2.07,3.34,1.61,328,145,0,6.7,5.0,14.0,2.54,892,774,10.9,1.3,Tier1_FDA-approved,39.2,76,18.12,0,0,0,0,,CR,1,1,-100.0,100.0,94.9,0.0,15.2,4.0,0,0,-37.4,0,1,0,1,20.7,1,4.5,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,11,11,1.09,0.76,2.585,0.82,15.1,0.0245,150,41.4,0,67.2,0,0,0,0,46.9,Chemotherapy,None
HC-ONC-013-000156,NSCLC,47,Male,1,Third+,Former,30.2,23.5,0,None,0,0,4,1,0,2.43,74.0,100.0,14.05,1,MSI-H,1,36.6,TIL-intermediate,703,1.49,30,6009,3,35.4,88,0.604,0.528,PD-L1-high,Q3,Nivolumab,Anti-PD-1,71.5,23,Discontinued_Progression,0,0,2.64,9.26,3.51,351,458,1,114.5,1.2,15.4,4.62,1138,751,18.6,6.3,Tier1_FDA-approved,58.9,567,20.0,1,0,0,0,0.365,PR,1,1,-48.3,48.3,35.4,18.3,16.1,16.6,0,0,-69.2,0,1,1,3,7.9,1,7.5,1,1,1,150,8,0,0,0,0,1,0,0,0,2,0,4,2,0,0,0,0,0,0,0,182,169,0.64,0.95,3.423,1.14,22.5,0.0369,128,39.5,1,77.6,0,0,0,0,44.4,BSC,None
HC-ONC-013-000157,TNBC,67,Female,1,First-line,Former,36.3,20.9,0,None,0,0,0,4,0,2.77,24.7,24.6,22.77,1,MSS,0,48.3,TIL-intermediate,1384,2.69,59,708,1,68.9,85,0.628,1.216,PD-L1-low,Q4,Pembrolizumab+Chemo,Combination,32.8,10,Discontinued_Progression,1,0,0.99,2.56,2.6,177,189,0,5.4,23.6,20.3,2.5,1198,702,11.1,4.5,Tier1_FDA-approved,38.2,333,20.0,0,0,0,0,,SD,0,1,-3.3,3.3,68.9,66.7,,,0,0,83.9,0,1,1,2,5.3,1,1.0,1,0,1,114,4,0,0,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,0,1,35,32,0.72,0.96,4.284,1.04,14.6,0.0163,168,43.5,1,87.4,1,0,0,0,48.0,Chemotherapy,Disease_Progression
HC-ONC-013-000158,Urothelial,78,Male,0,First-line,Former,42.7,38.6,0,None,0,1,0,4,1,2.83,59.5,77.0,67.6,1,MSI-H,1,5.5,TIL-low,109,1.92,24,654,2,65.1,265,-1.661,-1.652,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,38.3,12,Completed_2yr,0,0,1.66,5.11,3.07,229,126,0,5.3,22.0,10.3,1.97,691,459,12.2,2.3,Tier1_FDA-approved,62.6,1929,4.36,0,0,0,0,0.435,PR,1,1,-55.5,55.5,65.1,29.0,10.6,39.6,0,0,-94.2,1,1,0,1,1.0,0,,0,0,1,14,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,10,9,1.38,0.63,2.515,0.93,22.1,0.0179,49,83.8,1,131.3,1,1,1,0,85.7,None,Disease_Progression
HC-ONC-013-000159,NSCLC,31,Male,0,Second-line,Never,0.0,27.6,0,None,0,0,1,2,0,2.01,83.7,100.0,3.76,0,MSS,0,0.0,TIL-low,0,2.93,64,4829,5,91.2,15,1.55,1.171,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,104.0,34,Discontinued_Progression,0,0,1.08,5.07,4.71,158,140,0,4.3,17.3,24.2,6.58,810,777,10.6,4.8,Tier1_FDA-approved,38.7,986,0.5,0,0,0,0,,SD,0,1,4.9,0.0,91.2,91.2,,,0,0,24.3,0,1,0,1,29.5,1,1.7,0,0,1,29,10,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,11,10,0.95,0.69,1.92,0.97,12.3,0.0036,75,7.8,0,58.3,0,0,0,0,12.8,Targeted,None
HC-ONC-013-000160,Urothelial,51,Female,1,Second-line,Former,32.6,26.6,0,None,0,0,1,1,0,2.55,55.0,86.3,18.13,1,MSS,0,0.0,TIL-low,0,1.96,5,5466,3,57.9,76,0.514,1.049,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,20.1,6,Discontinued_Complete_Response,0,0,1.62,4.36,2.7,186,213,0,21.3,5.9,10.0,7.41,715,294,10.6,6.5,Tier1_FDA-approved,27.3,484,0.5,1,1,0,0,,SD,0,1,1.6,0.0,57.9,57.9,,,0,0,57.3,0,1,1,1,17.8,1,4.8,1,1,1,103,2,0,0,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,0,0,14,12,0.7,0.72,1.535,1.29,22.0,0.0068,52,13.9,1,18.7,1,0,0,0,18.1,Chemotherapy,Disease_Progression
HC-ONC-013-000161,Melanoma,67,Female,0,First-line,Former,32.5,30.9,0,None,0,0,0,6,0,2.29,56.0,72.8,3.35,0,MSS,0,1.0,TIL-low,16,0.86,15,5023,5,56.2,14,0.75,0.829,PD-L1-high,Q1,Nivolumab+Ipilimumab,Combination,21.4,7,Discontinued_irAE,0,0,1.51,2.34,1.56,280,292,1,14.0,15.1,6.2,3.86,782,253,13.9,4.7,Tier1_FDA-approved,25.2,176,1.0,0,0,0,0,,PR,1,1,-50.9,50.9,56.2,27.6,6.8,14.9,0,0,-48.7,0,1,0,3,11.6,1,4.8,1,0,1,28,6,0,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,1,192,202,1.23,0.64,3.039,1.23,21.4,0.0273,182,57.3,1,67.3,0,1,0,0,65.3,Targeted,None
HC-ONC-013-000162,TNBC,58,Female,1,First-line,Never,0.0,23.2,1,RA,0,0,0,1,0,2.87,0.0,0.0,5.73,0,MSS,0,22.2,TIL-intermediate,644,0.47,72,373,1,137.4,29,-0.759,-0.039,PD-L1-negative,Q1,Atezolizumab,Anti-PD-L1,13.8,4,Discontinued_Progression,0,0,1.62,6.93,4.28,190,103,0,36.1,21.6,7.4,13.38,590,345,14.8,3.4,Tier3_exploratory,19.5,25,8.82,0,0,0,0,,PD,0,0,20.0,0.0,137.4,137.4,,,0,0,124.1,0,1,0,1,18.1,1,4.3,0,0,1,28,7,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,20,20,0.38,0.67,4.272,1.32,12.8,0.0099,47,25.1,0,81.7,0,0,0,0,26.5,Targeted,None
HC-ONC-013-000163,TNBC,65,Female,0,Third+,Former,24.2,26.5,0,None,1,0,2,5,0,2.61,20.3,36.1,49.42,1,MSI-H,1,36.8,TIL-intermediate,759,1.78,27,1034,3,91.4,310,0.622,0.667,PD-L1-low,Q5,Atezolizumab,Anti-PD-L1,68.9,22,Discontinued_Progression,0,0,1.2,6.5,5.43,217,505,1,23.8,51.6,7.2,3.64,633,593,8.8,4.6,Tier1_FDA-approved,38.6,584,20.0,1,0,0,0,0.42,SD,0,1,-19.3,19.3,91.4,73.8,,,0,0,137.1,0,1,0,1,17.3,1,5.8,0,0,1,27,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,15,11,0.98,0.74,3.559,1.53,24.4,0.0304,197,27.8,1,94.9,0,0,0,0,30.4,Clinical_Trial,None
HC-ONC-013-000164,RCC,53,Female,0,Second-line,Never,0.0,26.8,0,None,0,0,1,5,1,1.9,54.5,79.7,3.38,0,MSS,0,4.8,TIL-low,78,1.48,39,4854,4,57.6,18,1.126,1.325,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,49.2,16,Discontinued_irAE,0,0,0.91,3.2,3.52,118,234,0,3.1,24.2,4.9,3.52,1030,735,8.2,5.0,Tier1_FDA-approved,19.6,894,1.95,0,0,0,0,,PD,0,0,34.2,0.0,57.6,57.6,,,0,0,41.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,13,10,0.42,0.81,1.324,1.69,22.3,0.0278,49,71.7,1,121.8,0,1,1,0,72.6,Clinical_Trial,None
HC-ONC-013-000165,NSCLC,62,Male,0,Second-line,Former,53.9,23.9,0,None,0,0,1,2,0,4.82,9.4,11.3,14.31,1,MSS,0,25.1,TIL-intermediate,522,1.01,11,1900,3,70.0,98,-0.099,-0.603,PD-L1-low,Q3,Pembrolizumab+Chemo,Combination,9.3,3,Discontinued_Progression,1,0,0.71,6.38,8.95,431,253,1,5.4,8.0,27.3,7.6,939,100,9.0,1.1,Tier1_FDA-approved,12.2,38,20.0,0,0,0,0,,PR,1,1,-51.0,51.0,70.0,34.3,12.9,39.9,0,0,-97.8,1,1,0,1,7.2,1,5.9,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,38,38,0.51,1.07,4.073,0.92,23.2,0.0294,143,25.9,0,45.9,0,0,0,0,29.5,Targeted,None
HC-ONC-013-000166,HNSCC,59,Male,2,Third+,Current,9.0,32.5,0,None,0,0,4,6,0,4.2,78.1,84.3,2.08,0,MSS,0,16.5,TIL-intermediate,396,0.7,145,498,2,145.8,14,2.0,0.507,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,100.9,33,Active,0,0,1.56,5.41,3.46,316,191,0,47.7,1.5,9.4,4.03,1047,865,5.0,4.7,Tier1_FDA-approved,36.2,63,2.71,0,0,0,0,,CR,1,1,-100.0,100.0,145.8,0.0,13.2,72.6,0,0,-86.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37,42,0.37,0.73,3.442,0.88,21.5,0.0272,142,34.0,1,103.9,0,0,0,0,34.5,Targeted,None
HC-ONC-013-000167,Melanoma,75,Male,2,Second-line,Never,0.0,25.4,0,None,0,0,1,1,0,2.58,66.3,100.0,3.21,0,MSS,0,20.2,TIL-intermediate,458,1.14,86,3134,4,70.6,12,0.044,0.023,PD-L1-high,Q1,Nivolumab+Ipilimumab,Combination,48.0,15,Active,0,0,1.39,2.36,1.7,364,202,0,9.9,8.9,8.0,4.8,964,626,4.0,2.3,Tier1_FDA-approved,29.2,589,5.26,0,0,0,0,,SD,0,1,2.0,0.0,70.6,70.6,,,0,0,40.7,0,1,0,3,2.4,1,7.4,0,0,1,35,8,0,0,0,0,0,0,0,0,2,0,0,1,0,1,0,0,0,0,0,52,38,1.38,1.0,1.012,1.12,25.0,0.0279,188,48.7,0,92.3,1,0,0,0,55.1,Chemotherapy,Disease_Progression
HC-ONC-013-000168,NSCLC,64,Female,2,First-line,Former,35.4,18.7,0,None,0,0,0,7,0,3.42,0.0,0.0,12.16,1,MSS,0,37.1,TIL-intermediate,943,1.5,28,767,4,52.4,39,1.141,-0.396,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,61.4,20,Discontinued_irAE,0,0,1.26,2.92,2.32,466,186,0,39.9,10.1,10.1,0.6,1111,286,13.5,6.3,Tier1_FDA-approved,25.3,671,20.0,0,0,0,0,,SD,0,1,3.4,0.0,52.4,52.4,,,0,0,107.0,0,1,0,1,28.5,1,6.6,0,0,1,47,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,18,17,0.36,0.63,3.351,1.35,21.5,0.0218,85,22.9,1,79.0,0,0,0,0,29.1,Targeted,None
HC-ONC-013-000169,NSCLC,65,Female,1,First-line,Current,10.1,25.0,0,None,0,0,0,6,0,3.53,64.3,62.5,7.47,0,MSS,0,2.3,TIL-low,36,2.3,24,15575,2,52.6,55,0.293,0.791,PD-L1-high,Q2,Pembrolizumab+Chemo,Combination,5.4,1,Discontinued_Progression,1,0,2.8,7.92,2.83,162,333,1,10.5,17.3,80.1,4.54,1163,620,16.7,1.9,Tier1_FDA-approved,30.8,91,1.44,1,0,0,0,,PR,1,1,-52.8,52.8,52.6,24.8,7.9,6.5,0,0,-84.4,0,1,1,2,33.5,0,,1,0,1,120,8,1,0,0,0,1,0,0,0,0,0,0,3,0,2,0,0,0,0,0,1716,1931,3.24,0.99,0.162,2.45,28.6,0.0268,86,45.3,1,69.8,0,0,0,0,49.0,Targeted,None
HC-ONC-013-000170,RCC,56,Male,0,First-line,Former,38.0,27.7,0,None,0,0,0,2,0,4.15,32.2,42.8,73.17,1,MSS,0,26.3,TIL-intermediate,506,1.81,75,11543,4,58.0,249,0.586,0.962,PD-L1-low,Q5,Nivolumab+Ipilimumab,Combination,31.6,10,Completed_2yr,0,0,1.17,5.23,4.47,205,200,0,4.6,37.5,3.0,1.04,377,819,16.4,7.0,Tier1_FDA-approved,58.0,171,6.66,0,0,0,0,,PR,1,1,-48.2,48.2,58.0,30.1,20.0,60.0,0,0,-99.6,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,30,21,0.57,1.08,2.466,1.52,29.0,0.021,174,16.3,0,51.6,1,0,0,0,18.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000171,TNBC,55,Female,1,First-line,Never,0.0,22.0,0,None,0,0,0,5,0,2.55,0.0,0.0,63.47,1,MSS,0,39.7,TIL-intermediate,1084,3.68,162,3733,1,56.2,237,-1.671,-1.219,PD-L1-negative,Q5,Atezolizumab,Anti-PD-L1,45.2,15,Discontinued_Progression,0,0,2.91,3.38,1.16,95,294,1,9.0,6.6,3.8,1.69,644,720,0.1,4.2,Tier1_FDA-approved,38.7,26,6.65,0,0,0,0,,CR,1,1,-100.0,100.0,56.2,0.0,15.8,52.7,0,0,-94.3,1,1,0,2,8.4,1,3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,195,163,0.76,0.96,1.701,1.36,25.1,0.0088,196,20.4,1,49.8,0,0,0,0,21.3,Chemotherapy,None
HC-ONC-013-000172,NSCLC,55,Female,1,Second-line,Never,0.0,22.4,0,None,0,0,1,7,0,4.07,76.8,100.0,5.58,0,MSS,0,15.0,TIL-intermediate,243,0.98,71,9258,3,28.8,17,0.371,0.037,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,34.0,11,Discontinued_Progression,0,0,3.16,2.92,1.0,800,161,0,4.6,91.9,2.4,1.54,831,820,10.8,3.9,Tier1_FDA-approved,32.1,3184,3.38,0,0,0,0,,PD,0,0,22.9,0.0,28.8,28.8,,,0,1,32.9,0,1,0,1,9.2,0,,0,0,1,27,5,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,26,30,0.89,0.72,17.501,0.61,28.4,0.0093,35,5.1,1,105.1,1,0,0,0,7.7,BSC,Other
HC-ONC-013-000173,RCC,65,Male,2,Second-line,Never,0.0,23.8,0,None,0,0,1,5,0,2.76,0.0,0.0,20.11,1,MSS,0,33.3,TIL-intermediate,926,2.56,188,1954,3,35.0,124,-0.735,-0.477,PD-L1-negative,Q4,Nivolumab+Ipilimumab,Combination,42.6,14,Active,0,0,0.76,3.46,4.58,227,221,0,6.9,0.9,6.1,1.95,893,327,6.5,5.6,Tier1_FDA-approved,12.7,57,4.9,0,0,0,0,,CR,1,1,-100.0,100.0,35.0,0.0,22.2,20.7,0,0,-74.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,30,22,0.84,0.8,3.574,1.16,28.6,0.0164,138,29.3,0,60.6,1,0,0,0,34.5,Clinical_Trial,Disease_Progression
HC-ONC-013-000174,NSCLC,55,Female,0,Third+,Former,14.4,32.6,0,None,0,0,4,4,0,2.13,0.0,0.0,23.91,1,MSS,0,33.2,TIL-intermediate,544,1.69,16,4530,2,46.8,141,-0.846,-0.482,PD-L1-negative,Q4,Durvalumab,Anti-PD-L1,57.0,19,Completed_2yr,0,0,1.71,3.59,2.1,411,134,0,14.9,12.2,9.0,2.89,699,517,12.7,3.3,Tier1_FDA-approved,16.3,910,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,46.8,0.0,13.0,72.3,0,0,-71.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,26,26,1.2,1.08,3.815,1.2,16.7,0.0015,71,36.1,1,84.5,0,0,0,0,38.5,Chemotherapy,None
HC-ONC-013-000175,TNBC,64,Female,1,First-line,Never,0.0,24.1,1,Psoriasis,0,1,0,2,0,3.78,0.0,0.0,7.12,0,MSS,0,21.1,TIL-intermediate,580,2.33,17,10649,1,103.7,56,1.744,1.11,PD-L1-negative,Q2,Atezolizumab,Anti-PD-L1,24.1,8,Discontinued_Progression,0,0,1.41,2.94,2.09,132,368,1,20.3,2.8,5.1,3.04,1174,415,9.9,5.6,Tier3_exploratory,11.4,383,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,103.7,0.0,7.7,25.7,0,0,-78.0,0,1,0,1,9.8,1,8.3,1,0,1,65,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,22,21,1.39,0.86,1.428,1.61,29.9,0.0348,154,71.4,1,118.6,1,1,1,0,79.2,Targeted,Disease_Progression
HC-ONC-013-000176,NSCLC,85,Female,0,Second-line,Never,0.0,33.6,0,None,0,0,1,2,0,4.23,84.3,67.5,32.56,1,MSI-H,1,17.3,TIL-intermediate,352,1.33,13,2427,4,64.8,242,-0.214,0.151,PD-L1-high,Q4,Pembrolizumab+Chemo,Combination,61.1,20,Discontinued_Progression,1,0,0.51,1.88,3.65,403,132,0,2.5,0.7,4.8,7.62,1494,944,15.0,3.5,Tier1_FDA-approved,56.0,2792,20.0,0,0,0,0,0.464,PR,1,1,-30.0,30.0,64.8,45.4,18.6,40.1,1,0,-75.8,0,1,1,2,1.5,1,7.9,1,1,1,115,6,0,0,0,1,1,0,0,0,0,0,3,0,1,0,0,0,0,0,0,20,16,0.66,0.75,1.459,1.07,16.8,0.0112,161,12.7,0,26.9,1,0,0,0,19.7,None,Disease_Progression
HC-ONC-013-000177,TNBC,71,Female,0,Second-line,Current,27.4,23.4,1,Thyroiditis,0,0,1,1,0,5.0,0.0,0.0,12.05,1,MSS,0,45.6,TIL-intermediate,1103,2.82,47,1331,3,71.7,61,-1.003,-0.688,PD-L1-negative,Q3,Atezolizumab,Anti-PD-L1,12.6,4,Discontinued_Progression,0,0,0.93,7.92,8.57,619,170,0,12.0,5.8,8.3,5.35,956,728,11.9,3.9,Tier1_FDA-approved,22.5,123,20.0,1,0,0,0,,PR,1,1,-57.0,57.0,71.7,30.8,15.0,26.9,0,0,-96.0,1,1,0,3,36.9,1,3.3,1,0,1,26,3,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,33,24,0.33,1.16,2.22,1.18,12.3,0.003,24030,21.1,1,58.9,1,0,0,0,25.1,Chemotherapy,Disease_Progression
HC-ONC-013-000178,Melanoma,57,Female,1,Second-line,Former,31.7,28.1,0,None,0,0,1,1,1,2.24,0.0,0.0,10.43,1,MSS,0,15.9,TIL-intermediate,275,1.91,38,234,3,130.8,51,-0.359,0.256,PD-L1-negative,Q2,Nivolumab,Anti-PD-1,18.6,6,Hold_irAE,0,0,2.25,7.28,3.24,237,171,0,6.8,1.3,4.9,0.98,925,1169,2.5,5.8,Tier1_FDA-approved,2.1,442,7.05,0,0,0,0,,PD,0,0,32.6,0.0,130.8,130.8,,,0,0,105.8,0,1,0,2,7.8,1,9.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,32,31,1.37,0.98,0.134,2.1,29.3,0.0171,104,6.6,1,49.2,1,0,0,0,9.7,BSC,Disease_Progression
HC-ONC-013-000179,MSI-H_CRC,75,Female,1,Second-line,Never,0.0,24.3,0,None,1,0,1,4,0,3.76,78.6,100.0,75.08,1,MSI-H,1,45.5,TIL-intermediate,728,1.17,29,1636,3,131.8,337,-1.3,-0.557,PD-L1-high,Q5,Nivolumab,Anti-PD-1,5.0,1,Discontinued_Progression,0,0,3.7,2.37,1.0,148,168,0,6.4,6.1,9.5,4.79,1155,506,7.2,2.7,Tier1_FDA-approved,78.5,32,20.0,0,0,0,0,0.354,SD,0,1,-5.9,5.9,131.8,124.1,,,0,0,101.8,0,1,0,1,23.9,0,,0,0,1,29,3,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,31,33,1.47,1.08,0.809,1.36,16.0,0.032,57,34.5,1,90.3,1,0,0,0,37.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000180,NSCLC,56,Female,1,First-line,Former,56.2,30.3,0,None,0,1,0,7,0,2.87,18.5,19.1,18.14,1,MSS,0,24.2,TIL-intermediate,442,1.64,63,4857,3,68.7,68,1.434,0.557,PD-L1-low,Q3,Durvalumab,Anti-PD-L1,23.6,7,Completed_2yr,0,0,2.37,4.8,2.03,228,288,1,13.9,7.7,18.0,5.78,340,455,12.0,2.5,Tier1_FDA-approved,17.8,22,6.91,0,0,0,0,,PR,1,1,-56.1,56.1,68.7,30.2,13.7,23.1,0,0,-78.3,0,1,0,3,14.4,1,8.8,0,0,1,27,7,0,0,0,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,0,21,17,0.82,0.61,73.19,0.79,22.5,0.0161,129,94.0,1,139.4,1,1,1,0,101.2,Clinical_Trial,Disease_Progression
HC-ONC-013-000181,Melanoma,36,Male,1,First-line,Former,25.8,20.9,0,None,0,1,0,3,0,3.83,0.0,0.0,6.2,0,MSS,1,47.5,TIL-intermediate,803,1.46,89,5624,5,54.8,23,-0.696,0.25,PD-L1-negative,Q1,Nivolumab+Ipilimumab,Combination,24.4,8,Active,0,0,1.88,2.85,1.52,80,171,0,7.0,28.3,12.7,3.45,909,571,12.5,5.5,Tier2_emerging,19.6,987,8.92,0,0,0,0,,SD,0,1,5.4,0.0,54.8,54.8,,,0,0,55.0,0,1,0,2,5.6,1,5.6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,33,35,0.85,0.8,4.191,0.83,29.5,0.011,164,38.1,1,106.2,0,0,0,0,40.7,Clinical_Trial,None
HC-ONC-013-000182,NSCLC,48,Female,1,First-line,Never,0.0,30.2,0,None,0,0,0,6,0,2.02,98.5,100.0,4.32,0,MSS,0,0.0,TIL-low,0,2.11,10,3312,2,45.4,16,0.529,-0.362,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,55.5,18,Discontinued_Progression,0,0,1.63,3.93,2.41,240,402,1,48.5,1.2,15.0,4.27,1194,876,5.0,4.9,Tier1_FDA-approved,43.7,28,0.5,1,0,0,0,,CR,1,1,-100.0,100.0,45.4,0.0,12.5,40.1,0,0,-73.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,39,38,0.47,0.88,2.746,1.41,12.9,0.0217,185,53.1,1,92.5,0,1,0,0,58.9,Targeted,None
HC-ONC-013-000183,MSI-H_CRC,38,Male,1,First-line,Never,0.0,27.1,0,None,0,0,0,3,0,2.19,0.0,0.0,49.28,1,MSI-H,1,32.8,TIL-intermediate,745,0.91,21,944,4,107.7,176,1.356,0.768,PD-L1-negative,Q5,Nivolumab,Anti-PD-1,41.6,13,Completed_2yr,0,0,3.23,3.77,1.17,369,133,0,40.0,22.0,17.6,5.22,707,527,4.3,5.3,Tier1_FDA-approved,25.9,286,20.0,0,0,0,0,0.439,PR,1,1,-46.5,46.5,107.7,57.6,12.9,44.4,0,0,-52.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,31,27,0.87,0.95,0.742,1.65,16.8,0.0228,107,4.0,1,10.7,1,0,0,0,8.0,Chemotherapy,Other
HC-ONC-013-000184,HNSCC,56,Female,2,First-line,Former,36.4,23.3,0,None,0,1,0,3,0,2.58,71.2,83.6,17.24,1,MSS,0,6.4,TIL-low,152,1.62,64,169,4,71.8,72,-0.5,0.183,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,27.6,9,Discontinued_irAE,0,0,3.89,3.62,1.0,240,218,0,39.7,8.3,9.3,8.26,532,625,12.3,5.7,Tier1_FDA-approved,42.9,1839,2.34,0,0,0,0,,PR,1,1,-51.9,51.9,71.8,34.5,6.0,16.4,0,0,-92.9,1,1,1,1,15.9,1,8.4,1,1,1,98,2,0,0,0,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,0,22,23,0.66,0.71,1.578,1.29,23.0,0.0298,72,24.8,1,78.0,0,0,0,0,30.2,None,None
HC-ONC-013-000185,NSCLC,61,Female,2,Second-line,Former,18.3,25.7,0,None,0,1,1,2,0,3.26,13.2,19.6,4.23,0,MSI-L,0,29.1,TIL-intermediate,780,2.01,23,998,2,64.5,19,0.532,-0.042,PD-L1-low,Q1,Pembrolizumab+Chemo,Combination,41.5,13,Discontinued_Complete_Response,1,0,1.3,12.0,9.2,212,136,0,7.4,25.4,6.5,1.27,844,619,5.0,5.1,Tier3_exploratory,27.9,1236,20.0,0,0,0,0,,PR,1,1,-49.3,49.3,64.5,32.7,13.6,92.1,0,0,-46.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,34,27,1.49,0.9,0.946,1.11,25.7,0.0314,50,62.8,1,127.4,1,1,1,0,65.1,BSC,Disease_Progression
HC-ONC-013-000186,TNBC,81,Female,1,Third+,Former,25.7,34.2,0,None,0,0,2,6,0,2.69,74.3,64.1,28.09,1,MSS,0,7.7,TIL-low,190,1.68,17,1255,1,47.5,219,-1.03,-0.463,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,5.7,1,Completed_2yr,0,0,0.74,3.6,4.85,319,247,0,4.7,4.4,4.0,3.69,882,608,3.7,6.2,Tier1_FDA-approved,48.6,149,10.56,0,0,0,0,,PR,1,1,-55.8,55.8,47.5,21.0,12.0,42.1,1,0,-66.6,0,1,0,1,1.8,1,1.3,0,0,1,21,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,28,26,0.52,1.01,1.537,1.8,26.5,0.0278,166,47.5,1,105.9,1,0,0,0,50.9,Clinical_Trial,Other
HC-ONC-013-000187,HNSCC,64,Female,0,Second-line,Never,0.0,27.2,0,None,0,0,1,2,0,3.73,15.6,18.7,2.48,0,MSS,0,25.2,TIL-intermediate,608,3.23,75,1242,2,49.2,15,2.0,1.472,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,13.6,4,Discontinued_Progression,0,0,0.71,2.99,4.2,331,199,0,13.2,1.5,5.4,14.98,627,470,9.8,5.2,Tier3_exploratory,14.4,37,8.0,0,0,0,0,,PR,1,1,-39.0,39.0,49.2,30.0,6.0,14.6,0,0,-74.4,0,1,0,1,13.6,1,8.0,0,0,1,12,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,36,35,0.75,0.81,3.747,0.86,27.9,0.0012,121,18.4,0,52.5,0,0,0,0,22.3,Targeted,None
HC-ONC-013-000188,RCC,58,Male,1,Second-line,Never,0.0,23.0,0,None,0,0,1,6,0,4.02,0.0,0.0,7.24,0,MSS,0,10.5,TIL-intermediate,223,2.43,12,3798,3,92.8,57,0.936,0.132,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,39.6,13,Active,0,0,2.8,3.06,1.09,107,185,0,10.5,1.7,4.9,13.92,1529,573,9.6,1.0,Tier3_exploratory,4.9,866,17.15,0,0,0,0,,PD,0,0,81.1,0.0,92.8,92.8,,,0,0,110.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,31,29,1.04,1.01,0.723,1.01,15.0,0.0011,145,16.1,1,53.6,1,0,0,0,18.8,Targeted,Disease_Progression
HC-ONC-013-000189,RCC,70,Female,1,First-line,Never,0.0,20.5,0,None,0,1,0,5,0,3.68,0.0,0.0,9.66,0,MSI-L,0,9.0,TIL-low,199,1.64,26,19591,3,27.4,47,-0.193,-0.152,PD-L1-negative,Q2,Atezolizumab+Bevacizumab,Combination,40.7,13,Discontinued_irAE,0,1,1.62,7.55,4.67,256,363,1,6.6,1.6,13.3,8.85,756,564,7.6,1.5,Tier3_exploratory,6.0,3021,7.37,0,0,0,0,,PD,0,0,22.5,0.0,27.4,27.4,,,0,0,29.5,0,1,0,1,4.5,1,3.7,0,0,1,36,7,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,33,30,0.71,0.83,1.635,1.69,18.7,0.0381,57,4.9,0,24.5,1,0,0,0,11.4,BSC,Disease_Progression
HC-ONC-013-000190,NSCLC,34,Female,0,Second-line,Former,31.6,29.0,0,None,0,0,1,2,1,4.5,59.8,65.1,6.87,0,MSS,1,0.0,TIL-low,0,1.84,43,2097,2,119.8,36,-0.773,-0.542,PD-L1-high,Q2,Pembrolizumab+Chemo,Combination,52.1,17,Active,1,0,1.77,1.96,1.11,800,144,0,3.8,13.1,9.8,6.89,554,598,8.5,8.9,Tier1_FDA-approved,23.1,149,0.5,0,0,0,0,,SD,0,1,10.9,0.0,119.8,119.8,,,0,0,10.1,0,1,1,3,14.7,1,7.1,1,1,1,93,6,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,4,0,0,30,32,0.87,3.04,2.568,1.1,24.9,0.011,31,21.7,1,67.8,1,0,0,0,24.2,Chemotherapy,Disease_Progression
HC-ONC-013-000191,NSCLC,63,Female,2,First-line,Never,0.0,27.5,0,None,0,0,0,2,0,3.53,69.5,64.0,7.33,0,MSS,0,13.0,TIL-intermediate,360,1.91,21,1394,2,58.6,34,-0.114,-0.344,PD-L1-high,Q2,Nivolumab,Anti-PD-1,25.7,8,Discontinued_Complete_Response,0,0,0.81,3.06,3.8,126,269,1,11.7,43.5,12.9,16.84,872,789,12.1,5.0,Tier1_FDA-approved,36.3,121,16.36,0,1,0,0,,PD,0,0,40.9,0.0,58.6,58.6,,,0,0,50.6,0,1,0,1,13.2,1,1.8,1,0,1,37,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,13,13,1.47,0.68,3.996,1.62,24.9,0.0117,194,36.5,0,77.7,0,0,0,0,39.4,None,None
HC-ONC-013-000192,MSI-H_CRC,70,Male,0,First-line,Never,0.0,30.0,0,None,0,0,0,2,0,2.23,23.5,35.4,20.21,1,MSI-H,1,54.5,TIL-high,1006,2.02,62,1325,4,74.0,79,-0.34,0.947,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,47.2,15,Discontinued_Complete_Response,0,0,1.22,9.24,7.57,234,136,0,8.1,3.8,2.9,20.79,1172,952,8.4,6.9,Tier1_FDA-approved,29.6,184,15.97,0,0,0,0,0.438,PD,0,0,53.4,0.0,74.0,74.0,,,0,0,70.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,25,0.91,0.99,1.5,1.13,17.5,0.0288,168,3.6,0,8.9,1,0,0,0,10.3,Chemotherapy,Disease_Progression
HC-ONC-013-000193,MSI-H_CRC,43,Male,2,First-line,Former,7.1,19.2,0,None,0,0,0,7,0,4.29,5.8,8.4,17.75,1,MSI-H,1,34.5,TIL-intermediate,521,0.66,21,2099,4,26.5,66,1.953,0.79,PD-L1-low,Q3,Pembrolizumab,Anti-PD-1,44.0,14,Discontinued_Progression,0,0,1.46,5.06,3.46,646,212,0,24.2,15.7,23.2,4.04,905,432,12.4,4.3,Tier1_FDA-approved,11.4,951,20.0,0,0,0,0,0.35,PR,1,1,-34.5,34.5,26.5,17.3,10.8,14.1,0,0,-65.8,0,1,1,1,25.4,1,9.9,0,0,1,101,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,12,13,1.39,0.73,3.613,1.61,17.5,0.0231,1993,37.9,0,66.4,1,0,0,0,44.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000194,TNBC,74,Female,1,First-line,Current,5.8,20.6,0,None,0,0,0,4,0,2.72,32.9,38.6,80.0,1,MSS,0,52.6,TIL-high,1302,1.42,102,669,5,79.5,500,-1.226,-0.233,PD-L1-low,Q5,Pembrolizumab+Chemo,Combination,88.8,29,Discontinued_irAE,1,0,1.79,4.93,2.75,425,110,0,23.7,1.2,5.3,2.06,1046,522,10.1,4.9,Tier1_FDA-approved,65.7,2547,12.64,0,0,0,0,,PR,1,1,-41.9,41.9,79.5,46.2,6.0,22.7,0,0,-69.3,0,1,0,3,13.2,1,7.9,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,124,148,0.35,1.1,2.834,1.49,17.8,0.0186,20616,20.8,1,42.4,0,0,0,0,27.9,Targeted,None
HC-ONC-013-000195,Melanoma,65,Male,1,First-line,Former,39.0,32.2,0,None,0,1,0,2,0,3.93,64.3,100.0,54.1,1,MSI-H,1,45.0,TIL-intermediate,811,0.78,30,2089,5,66.9,429,0.135,-0.116,PD-L1-high,Q5,Nivolumab,Anti-PD-1,15.5,5,Active,0,0,1.41,12.0,8.54,189,144,0,36.6,9.2,3.1,3.61,639,435,12.8,4.1,Tier1_FDA-approved,63.6,63,20.0,0,0,0,0,0.391,PR,1,1,-45.6,45.6,66.9,36.4,14.9,81.6,0,0,-78.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,31,31,0.44,0.93,3.205,1.27,28.1,0.0054,188,123.7,0,150.7,1,1,1,1,123.8,Clinical_Trial,Disease_Progression
HC-ONC-013-000196,Melanoma,56,Male,1,First-line,Current,18.5,28.2,0,None,0,0,0,1,0,4.46,10.3,8.5,13.23,1,MSS,0,24.0,TIL-intermediate,679,3.12,57,3106,3,78.0,43,-0.018,-0.554,PD-L1-low,Q3,Nivolumab+Ipilimumab,Combination,34.5,11,Discontinued_Progression,0,0,1.09,5.07,4.66,271,192,0,3.5,16.5,5.2,53.38,1346,637,16.4,9.9,Tier1_FDA-approved,14.6,43,11.71,0,0,0,0,,SD,0,1,-1.5,1.5,78.0,76.8,,,0,0,-20.0,0,1,0,2,4.0,1,4.1,0,0,1,31,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,23,20,1.43,0.94,3.947,1.32,28.4,0.0041,65,4.2,0,27.7,1,0,0,0,8.6,Chemotherapy,Other
HC-ONC-013-000197,Urothelial,68,Female,2,First-line,Never,0.0,29.2,0,None,0,0,0,1,0,3.57,0.0,0.0,18.7,1,MSS,0,11.6,TIL-intermediate,324,1.6,60,2325,5,138.9,70,-0.117,-0.019,PD-L1-negative,Q3,Atezolizumab,Anti-PD-L1,37.9,12,Discontinued_Progression,0,0,1.2,3.15,2.61,244,496,1,18.2,1.3,53.9,1.28,1069,492,16.2,5.5,Tier1_FDA-approved,5.4,13494,5.31,0,1,0,0,,SD,0,1,-6.5,6.5,138.9,129.9,,,0,0,82.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,10,11,0.45,1.15,0.606,0.98,12.3,0.0277,166,18.1,1,73.5,1,0,0,0,22.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000198,MSI-H_CRC,85,Male,1,Third+,Current,14.1,21.7,0,None,0,0,2,6,0,2.0,0.0,0.0,42.01,1,MSI-H,1,43.4,TIL-intermediate,701,1.5,20,3131,5,87.1,215,-0.109,0.259,PD-L1-negative,Q5,Nivolumab,Anti-PD-1,104.0,34,Completed_2yr,0,0,2.67,3.89,1.46,168,211,0,5.9,5.8,5.4,3.08,1214,648,18.4,3.9,Tier1_FDA-approved,33.4,309,20.0,0,0,0,0,0.402,SD,0,1,3.5,0.0,87.1,87.1,,,0,0,24.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,16,1.18,0.7,2.619,0.92,17.9,0.0057,33,11.4,1,55.6,0,0,0,0,14.3,None,None
HC-ONC-013-000199,MSI-H_CRC,63,Female,1,First-line,Never,0.0,21.6,0,None,0,0,0,5,0,2.47,60.5,67.9,36.67,1,MSI-H,1,25.2,TIL-intermediate,418,2.58,6,3043,1,48.2,144,-0.116,0.391,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,14.8,4,Discontinued_Progression,0,0,1.82,2.54,1.4,236,458,1,3.6,17.4,5.7,1.45,1010,821,16.2,1.7,Tier1_FDA-approved,43.2,590,20.0,0,0,0,0,0.384,PR,1,1,-64.3,64.3,48.2,17.2,11.2,20.2,0,0,-77.6,0,1,1,1,5.8,1,3.4,1,1,1,151,3,1,0,0,0,0,0,1,1,0,4,0,0,0,0,0,0,0,0,0,12,12,0.84,0.92,3.489,1.52,19.1,0.0176,179,72.9,1,136.9,0,1,1,0,77.6,Targeted,None
HC-ONC-013-000200,Urothelial,63,Male,0,First-line,Current,12.6,31.5,0,None,0,0,0,4,0,4.26,0.0,0.0,4.44,0,MSS,0,12.4,TIL-intermediate,279,2.04,44,216,2,51.5,21,0.873,1.305,PD-L1-negative,Q1,Pembrolizumab,Anti-PD-1,32.7,10,Discontinued_Complete_Response,0,0,2.11,8.4,3.99,213,224,0,7.9,0.2,6.3,4.95,1147,100,13.2,8.9,Tier3_exploratory,5.1,143,6.2,1,1,0,0,,SD,0,1,-3.9,3.9,51.5,49.5,,,0,0,122.1,0,1,0,1,29.8,1,3.6,0,0,1,33,4,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,33,32,0.79,0.83,4.038,1.65,29.7,0.029,130,6.8,1,37.9,0,0,0,0,10.2,Chemotherapy,None
HC-ONC-013-000201,TNBC,55,Female,1,First-line,Current,13.0,31.7,0,None,0,0,0,7,0,3.06,0.0,0.0,6.18,0,MSS,0,9.6,TIL-low,232,0.94,35,3883,4,103.8,23,0.609,1.838,PD-L1-negative,Q1,Pembrolizumab+Chemo,Combination,22.6,7,Discontinued_Progression,1,0,1.15,5.97,5.19,259,165,0,35.5,36.7,6.6,1.71,638,698,9.8,4.7,Tier3_exploratory,14.5,841,6.44,1,0,0,0,,SD,0,1,20.0,0.0,103.8,103.8,,,0,0,130.9,0,1,0,2,28.1,1,1.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,111,133,1.09,1.18,1.031,1.52,29.0,0.0361,111,15.6,1,20.7,1,0,0,0,20.0,Chemotherapy,Disease_Progression
HC-ONC-013-000202,NSCLC,50,Male,0,Second-line,Former,31.7,21.1,0,None,0,0,1,6,0,3.26,0.0,0.0,12.54,1,MSS,0,33.9,TIL-intermediate,648,1.59,52,808,5,131.9,66,0.419,0.377,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,32.9,10,Discontinued_Progression,0,0,0.51,7.86,15.54,168,433,1,8.4,11.3,4.0,4.11,753,508,10.1,6.5,Tier1_FDA-approved,19.3,1703,12.23,0,0,1,1,,PD,0,0,42.0,0.0,131.9,131.9,,,0,0,37.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,34,41,1.17,1.08,1.866,1.71,23.3,0.0342,150,9.6,1,28.0,1,0,0,0,20.4,Clinical_Trial,Disease_Progression
HC-ONC-013-000203,NSCLC,70,Female,1,First-line,Current,24.5,20.1,0,None,0,0,0,1,0,3.81,53.8,48.6,2.58,0,MSS,0,14.2,TIL-intermediate,366,1.39,28,485,4,91.3,11,-2.0,-1.532,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,16.5,5,Discontinued_Progression,0,0,1.34,8.22,6.15,129,249,0,58.3,17.5,8.3,0.94,1304,692,7.6,6.7,Tier1_FDA-approved,20.2,633,12.62,0,0,0,0,,CR,1,1,-100.0,100.0,91.3,0.0,6.5,24.8,0,0,-100.0,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,12,1.42,1.05,0.814,1.69,12.8,0.0338,42,57.9,1,106.2,0,1,1,0,62.5,Chemotherapy,None
HC-ONC-013-000204,MSI-H_CRC,50,Female,1,First-line,Former,0.0,26.0,0,None,0,0,0,4,0,3.76,0.0,0.0,19.93,1,MSI-H,1,38.3,TIL-intermediate,916,0.69,23,480,5,107.5,95,0.3,0.406,PD-L1-negative,Q4,Nivolumab+Ipilimumab,Combination,5.3,1,Completed_2yr,0,0,1.17,3.64,3.13,240,145,0,21.1,4.5,17.5,7.35,1368,421,12.0,4.1,Tier1_FDA-approved,14.3,5493,20.0,0,0,0,0,0.409,PR,1,1,-31.6,31.6,107.5,73.5,11.6,87.9,0,0,-100.0,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,10,0.61,0.72,3.84,1.58,15.4,0.0146,63,25.1,1,63.4,1,0,0,0,29.9,Chemotherapy,Disease_Progression
HC-ONC-013-000205,RCC,61,Male,1,First-line,Never,0.0,22.5,0,None,0,0,0,4,0,3.42,67.0,100.0,55.94,1,MSS,0,4.5,TIL-low,89,1.17,165,3042,5,104.4,194,-1.656,-1.126,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,35.9,11,Discontinued_Progression,0,0,1.9,2.79,1.47,577,253,1,8.2,0.9,9.5,11.92,556,839,15.5,6.3,Tier1_FDA-approved,53.4,247,0.54,0,0,0,0,,PR,1,1,-30.0,30.0,104.4,73.1,12.2,27.4,0,0,-59.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37,36,1.14,0.74,3.929,1.7,19.8,0.0362,99,17.3,0,52.0,1,0,0,0,22.9,Targeted,Disease_Progression
HC-ONC-013-000206,NSCLC,55,Female,0,First-line,Former,51.2,22.4,0,None,0,1,0,5,0,3.03,77.9,76.4,13.96,1,MSS,1,26.5,TIL-intermediate,408,1.5,10,1384,3,136.8,72,0.646,0.851,PD-L1-high,Q3,Pembrolizumab+Chemo,Combination,22.0,7,Discontinued_irAE,1,0,4.0,4.37,1.09,255,173,0,38.9,14.0,3.0,3.3,975,783,8.4,3.8,Tier1_FDA-approved,38.7,272,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,136.8,0.0,13.6,36.7,0,0,-99.4,1,1,1,1,1.0,1,6.7,1,1,1,121,8,0,1,0,0,1,0,0,0,0,0,0,3,0,0,0,0,0,0,0,546,469,4.63,0.62,2.434,0.97,29.3,0.027,135,56.2,1,90.1,0,1,0,0,60.6,Chemotherapy,None
HC-ONC-013-000207,NSCLC,66,Female,0,First-line,Former,50.1,20.2,1,RA,0,1,0,4,0,2.95,0.0,0.0,9.36,0,MSS,0,8.6,TIL-low,225,1.56,60,240,1,10.0,74,1.474,0.236,PD-L1-negative,Q2,Durvalumab,Anti-PD-L1,13.7,4,Active,0,0,2.18,2.9,1.33,207,100,0,19.0,6.7,5.6,4.02,771,714,11.8,3.0,Tier3_exploratory,0.0,571,3.69,0,0,0,0,,SD,0,1,2.3,0.0,10.0,10.0,,,0,0,-9.0,0,1,0,1,9.3,0,,0,0,1,65,7,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,30,34,1.16,0.98,0.583,1.53,13.7,0.0347,55,33.4,1,45.5,0,0,0,0,35.2,Chemotherapy,None
HC-ONC-013-000208,TNBC,65,Female,1,First-line,Never,0.0,24.2,0,None,0,0,0,2,1,3.89,55.8,66.1,6.98,0,MSS,0,37.2,TIL-intermediate,677,0.79,21,3209,2,106.7,32,-0.926,0.628,PD-L1-high,Q2,Pembrolizumab+Chemo,Combination,21.4,7,Hold_irAE,1,0,4.0,4.87,1.22,357,320,1,4.8,7.7,4.8,3.93,691,759,8.6,7.3,Tier1_FDA-approved,39.7,810,20.0,0,1,0,0,,PR,1,1,-41.9,41.9,106.7,62.0,27.5,109.5,0,0,-73.9,0,1,0,1,11.2,1,8.5,0,0,1,10,9,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,34,36,0.47,0.82,0.909,1.55,26.2,0.0044,95,33.4,1,98.3,0,0,0,0,34.1,Targeted,None
HC-ONC-013-000209,NSCLC,73,Male,0,First-line,Former,0.0,20.7,0,None,0,0,0,4,0,3.64,22.0,26.4,27.35,1,MSS,0,33.2,TIL-intermediate,913,2.93,25,321,2,119.3,202,-0.262,0.271,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,5.5,1,Discontinued_Progression,0,0,2.07,7.89,3.81,226,346,1,78.2,27.3,7.7,5.18,985,451,13.0,4.7,Tier1_FDA-approved,32.7,568,20.0,1,0,0,0,,CR,1,1,-100.0,100.0,119.3,0.0,6.0,9.0,0,0,-82.4,0,1,0,1,5.2,0,,1,0,1,45,8,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,23,25,0.85,0.79,2.997,0.95,15.4,0.0025,74,29.7,1,42.1,0,0,0,0,33.7,Chemotherapy,None
HC-ONC-013-000210,NSCLC,54,Female,0,First-line,Current,30.9,21.0,0,None,0,1,0,5,0,2.99,0.0,0.0,5.79,0,MSS,0,31.9,TIL-intermediate,679,1.57,26,2138,3,26.5,42,-0.599,-1.202,PD-L1-negative,Q1,Pembrolizumab,Anti-PD-1,83.3,27,Hold_irAE,0,0,1.28,4.12,3.22,623,502,1,15.8,18.4,21.4,4.35,1242,476,9.3,6.0,Tier2_emerging,14.8,59,20.0,1,0,0,0,,PD,0,0,34.0,0.0,26.5,26.5,,,0,0,33.2,0,1,0,1,4.2,1,7.4,1,0,1,46,2,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,26,20,0.52,0.98,4.43,1.71,21.1,0.0173,140,25.5,1,39.1,0,0,0,0,28.9,Chemotherapy,None
HC-ONC-013-000211,RCC,57,Female,0,First-line,Never,0.0,28.0,0,None,0,0,0,6,0,4.07,93.6,100.0,64.18,1,MSS,0,19.7,TIL-intermediate,465,1.68,17,2407,3,44.6,498,1.235,0.387,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,36.5,12,Active,0,0,1.89,4.83,2.55,244,247,0,12.4,74.1,6.6,8.29,1035,750,8.3,5.8,Tier1_FDA-approved,73.0,645,20.0,0,1,0,0,,SD,0,1,-7.2,7.2,44.6,41.4,,,0,0,103.5,0,1,0,1,5.3,0,,0,0,1,46,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,17,15,0.7,1.1,3.855,0.81,25.8,0.0325,186,32.3,1,58.4,0,0,0,0,32.4,Clinical_Trial,None
HC-ONC-013-000212,TNBC,49,Female,2,Second-line,Former,45.8,26.2,0,None,1,1,1,5,0,3.1,80.4,74.5,47.69,1,MSI-H,1,4.6,TIL-low,130,2.01,52,5233,2,46.0,331,0.095,0.465,PD-L1-high,Q5,Atezolizumab,Anti-PD-L1,56.7,18,Discontinued_Progression,0,0,3.36,4.28,1.27,347,177,0,5.2,8.9,6.9,12.02,804,446,8.6,6.3,Tier1_FDA-approved,54.1,230,2.45,0,0,0,0,0.509,SD,0,1,-9.3,9.3,46.0,41.7,,,0,0,42.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,38,37,1.16,0.68,3.692,1.23,24.5,0.0165,58,24.6,1,61.1,0,0,0,0,31.8,Chemotherapy,None
HC-ONC-013-000213,TNBC,55,Female,1,Second-line,Current,20.0,28.9,0,None,1,1,1,7,0,2.52,11.8,14.4,15.35,1,MSS,0,80.0,TIL-high,2000,1.11,101,15337,2,50.8,97,1.728,1.625,PD-L1-low,Q3,Pembrolizumab+Chemo,Combination,26.9,8,Active,1,0,3.43,6.7,1.95,168,304,1,39.6,3.2,30.6,2.34,1054,889,14.5,1.9,Tier1_FDA-approved,33.1,169,19.61,0,0,0,0,,SD,0,1,17.6,0.0,50.8,50.8,,,0,0,34.5,0,1,0,2,3.2,1,1.7,0,0,1,20,9,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,19,15,0.58,1.15,2.172,0.82,26.0,0.0346,28532,12.0,0,128.2,1,0,1,0,16.2,Chemotherapy,Disease_Progression
HC-ONC-013-000214,NSCLC,65,Female,1,First-line,Current,7.0,18.3,0,None,0,0,0,5,0,2.59,0.0,0.0,12.06,1,MSS,0,46.2,TIL-intermediate,950,2.07,48,352,1,60.7,88,0.414,-0.388,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,70.4,23,Discontinued_Progression,0,0,1.31,3.21,2.45,315,306,1,20.4,5.9,14.9,3.5,792,535,11.5,3.8,Tier1_FDA-approved,22.3,424,19.39,0,0,0,0,,SD,0,1,8.1,0.0,60.7,60.7,,,0,0,81.1,0,1,0,1,14.3,1,7.4,0,0,1,37,4,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,17,15,1.12,0.62,4.441,1.32,26.6,0.0099,132,44.6,1,65.6,1,0,0,0,51.4,Clinical_Trial,Disease_Progression
HC-ONC-013-000215,TNBC,70,Female,0,First-line,Current,30.2,26.5,0,None,0,0,0,1,0,2.42,18.6,21.9,21.05,1,MSI-H,1,54.5,TIL-high,987,1.37,36,1698,5,89.7,71,0.242,0.502,PD-L1-low,Q4,Pembrolizumab+Chemo,Combination,30.3,10,Discontinued_Progression,1,0,1.82,1.49,1.0,281,454,1,22.9,12.2,11.7,9.22,1024,700,9.9,4.4,Tier1_FDA-approved,41.3,95,20.0,0,0,0,0,0.381,PR,1,1,-30.0,30.0,89.7,62.8,6.0,12.4,1,0,-75.4,0,1,1,2,7.8,1,8.1,1,1,1,142,4,1,0,0,0,1,0,0,0,1,0,0,3,0,0,0,0,0,0,0,1824,1356,3.27,0.66,3.8,1.21,17.5,0.0025,107,19.7,1,56.3,0,0,0,0,19.3,Clinical_Trial,None
HC-ONC-013-000216,NSCLC,49,Male,0,Third+,Former,26.4,36.9,0,None,0,1,3,2,0,2.98,68.4,79.6,32.63,1,MSS,0,8.7,TIL-low,232,1.05,15,1298,1,114.6,173,0.068,-0.933,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,36.0,11,Discontinued_Progression,0,0,0.93,5.67,6.09,238,196,0,7.3,25.0,35.4,1.44,1319,1020,13.3,3.3,Tier1_FDA-approved,41.8,73,14.5,0,0,0,0,,PD,0,0,59.4,0.0,114.6,114.6,,,0,1,96.3,0,1,0,3,6.6,1,2.9,1,0,1,78,9,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,2,16,19,0.41,1.1,0.252,2.8,18.6,0.0299,33289,7.6,1,51.5,1,0,0,0,14.5,Chemotherapy,Other
HC-ONC-013-000217,Melanoma,71,Female,1,First-line,Current,25.5,24.6,1,Thyroiditis,0,0,0,1,0,4.19,19.4,16.5,5.9,0,MSS,0,18.3,TIL-intermediate,393,2.2,50,3043,2,123.3,47,0.818,0.446,PD-L1-low,Q1,Nivolumab,Anti-PD-1,30.8,10,Active,0,0,2.29,7.34,3.2,190,184,0,28.1,1.3,10.9,0.93,277,459,9.9,5.9,Tier3_exploratory,11.0,8,7.71,0,0,0,0,,PR,1,1,-56.0,56.0,123.3,54.3,19.0,34.2,1,0,-53.2,0,1,1,2,17.1,0,,1,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,3,31,33,0.76,0.9,3.494,1.57,26.7,0.0248,19279,21.2,0,80.6,1,0,0,0,24.2,Clinical_Trial,Disease_Progression
HC-ONC-013-000218,Urothelial,77,Male,1,First-line,Former,63.3,30.6,0,None,1,0,0,6,0,2.56,82.5,100.0,31.15,1,MSI-H,1,11.8,TIL-intermediate,212,3.48,186,2342,5,46.5,213,-1.738,-0.487,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,48.2,16,Discontinued_irAE,0,0,3.07,5.6,1.83,178,140,0,30.3,7.5,1.5,5.37,1139,614,17.6,7.4,Tier1_FDA-approved,44.6,5546,1.13,0,0,0,0,0.35,PR,1,1,-32.4,32.4,46.5,31.4,9.8,14.1,0,0,-36.0,0,1,0,1,9.4,1,6.9,0,0,1,14,12,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,25,26,1.34,1.16,2.23,1.57,12.7,0.0177,123,84.1,0,135.1,0,1,1,0,90.6,None,None
HC-ONC-013-000219,TNBC,65,Female,0,Second-line,Never,0.0,30.6,0,None,0,0,1,3,0,3.35,66.7,82.5,3.71,0,MSS,0,65.3,TIL-high,1865,2.37,24,1184,2,46.2,29,0.085,-0.225,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,35.5,11,Discontinued_irAE,0,0,1.68,3.25,1.94,282,262,1,6.2,51.0,14.4,6.67,438,811,7.1,7.7,Tier1_FDA-approved,44.4,929,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,46.2,0.0,21.6,33.9,1,0,-70.6,0,1,0,1,7.1,1,9.6,0,0,1,56,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,14,12,1.49,0.88,3.142,1.52,21.3,0.0331,96,69.0,1,129.0,0,1,1,0,73.5,None,None
HC-ONC-013-000220,HNSCC,83,Male,0,First-line,Former,33.8,30.8,1,Psoriasis,0,0,0,6,0,2.67,51.9,51.6,17.6,1,MSS,0,23.9,TIL-intermediate,430,2.62,25,1065,1,132.6,121,-0.07,-0.795,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,18.6,6,Discontinued_Progression,0,0,1.26,2.54,2.01,335,100,0,3.0,5.5,2.1,2.51,1268,790,11.1,4.3,Tier1_FDA-approved,36.9,339,16.54,1,0,0,0,,PR,1,1,-49.6,49.6,132.6,66.9,6.0,94.2,0,0,-92.5,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,10,0.74,1.16,4.38,0.9,28.6,0.0323,78,65.6,1,99.5,1,1,0,0,70.6,Clinical_Trial,Other
HC-ONC-013-000221,TNBC,51,Female,0,First-line,Former,16.2,27.3,0,None,0,0,0,2,0,2.99,75.6,100.0,22.2,1,MSS,0,24.3,TIL-intermediate,374,1.27,21,474,1,105.9,164,0.725,0.508,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,11.7,3,Discontinued_Progression,0,0,1.9,5.74,3.01,230,295,1,21.8,22.6,10.6,2.82,709,534,5.0,5.6,Tier1_FDA-approved,36.8,148,17.0,0,0,0,0,,CR,1,1,-100.0,100.0,105.9,0.0,6.0,46.5,0,0,-83.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,11,0.37,0.74,1.486,1.22,27.9,0.0133,154,1.7,1,30.9,0,0,0,0,6.6,Chemotherapy,None
HC-ONC-013-000222,RCC,46,Male,1,First-line,Never,0.0,29.3,0,None,1,0,0,4,0,1.99,24.9,39.8,3.61,0,MSS,0,12.9,TIL-intermediate,198,0.74,22,5916,1,83.3,24,-0.188,-0.415,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,38.2,12,Active,0,0,1.95,4.81,2.47,282,269,1,2.5,13.4,1.9,2.44,535,497,10.3,5.9,Tier3_exploratory,17.8,5,8.61,0,1,0,0,,PD,0,0,64.3,0.0,83.3,83.3,,,0,0,10.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,14,0.46,0.97,3.68,1.62,26.5,0.0328,165,25.0,0,64.2,0,0,0,0,28.1,Targeted,None
HC-ONC-013-000223,NSCLC,39,Male,1,Third+,Former,25.0,30.0,0,None,0,1,4,5,0,3.02,50.6,65.1,8.09,0,MSS,0,36.8,TIL-intermediate,896,3.47,4,3137,5,98.9,55,-1.039,-0.308,PD-L1-high,Q2,Durvalumab,Anti-PD-L1,30.7,10,Discontinued_Progression,0,0,1.7,4.21,2.47,240,268,1,14.2,23.3,5.1,2.24,1109,553,3.6,6.2,Tier1_FDA-approved,38.5,135,20.0,0,0,0,0,,SD,0,1,-2.3,2.3,98.9,96.6,,,0,0,2.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,19,22,1.25,1.2,2.861,1.45,12.4,0.0141,86,10.8,1,74.5,1,0,0,0,13.5,Chemotherapy,Disease_Progression
HC-ONC-013-000224,Melanoma,78,Female,0,First-line,Former,18.2,29.7,0,None,0,0,0,3,1,3.05,72.3,79.5,3.62,0,MSS,0,44.0,TIL-intermediate,1097,4.61,46,5439,4,78.8,20,0.007,-0.438,PD-L1-high,Q1,Nivolumab+Ipilimumab,Combination,8.7,2,Active,0,0,1.77,11.15,6.29,257,215,0,7.8,2.8,5.5,7.81,1009,890,15.7,3.2,Tier1_FDA-approved,35.3,1181,20.0,0,0,0,0,,SD,0,1,-10.8,10.8,78.8,70.3,,,0,0,104.1,0,1,0,3,4.2,1,13.2,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,35,25,1.09,0.83,4.3,1.48,28.0,0.0246,136,59.5,0,112.5,1,1,0,0,62.8,Targeted,Disease_Progression
HC-ONC-013-000225,NSCLC,68,Female,0,Second-line,Never,0.0,20.9,0,None,0,0,1,2,0,3.63,7.6,11.0,78.9,1,MSI-H,1,42.9,TIL-intermediate,844,3.57,17,1246,4,101.0,500,-1.083,-1.036,PD-L1-low,Q5,Pembrolizumab,Anti-PD-1,25.3,8,Completed_2yr,0,0,1.54,2.79,1.82,221,431,1,41.2,2.8,4.0,1.74,600,544,15.8,8.6,Tier1_FDA-approved,46.1,1658,20.0,1,0,1,1,0.363,PR,1,1,-56.9,56.9,101.0,43.5,9.1,11.0,0,0,-100.0,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,9,0.64,0.6,1.038,1.03,28.4,0.0083,60,40.8,0,79.3,0,0,0,0,41.9,None,None
HC-ONC-013-000226,NSCLC,60,Female,0,Third+,Former,36.5,18.0,0,None,0,0,3,1,0,3.38,24.8,27.0,22.28,1,MSI-H,1,31.4,TIL-intermediate,621,1.39,9,822,2,66.6,159,-1.925,-2.166,PD-L1-low,Q4,Atezolizumab,Anti-PD-L1,32.2,10,Completed_2yr,0,0,2.46,10.89,4.43,247,310,1,8.2,7.6,5.6,3.62,524,616,15.9,6.9,Tier1_FDA-approved,29.9,1057,20.0,0,0,0,0,0.444,SD,0,1,-6.2,6.2,66.6,62.5,,,0,0,36.0,0,1,0,1,5.5,1,5.9,1,0,1,79,2,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,172,140,0.77,0.64,3.379,1.13,23.9,0.011,164,24.1,0,56.2,0,0,0,0,27.1,Targeted,None
HC-ONC-013-000227,Hodgkin,64,Male,2,First-line,Former,17.9,18.7,1,Thyroiditis,0,0,0,5,0,2.24,33.6,34.8,6.3,0,MSS,0,34.9,TIL-intermediate,702,0.93,60,496,5,90.8,45,0.727,0.521,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,58.2,19,Discontinued_Progression,0,0,2.21,4.55,2.06,800,148,0,36.9,1.2,16.9,2.17,844,515,12.1,6.9,Tier2_emerging,26.4,512,11.51,0,0,0,0,,CR,1,1,-100.0,100.0,90.8,0.0,21.1,13.7,1,0,-86.4,0,1,0,2,3.2,1,4.3,0,0,1,23,6,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,2,19,20,1.27,1.12,0.649,1.76,17.4,0.018,13299,24.4,0,73.0,0,0,0,0,27.0,Clinical_Trial,None
HC-ONC-013-000228,Melanoma,47,Male,0,First-line,Former,22.9,25.1,0,None,0,0,0,6,0,4.07,47.1,72.2,12.89,1,MSI-H,1,0.0,TIL-low,0,0.97,14,2781,3,19.6,82,0.579,0.267,PD-L1-low,Q3,Pembrolizumab,Anti-PD-1,7.4,2,Discontinued_Progression,0,0,1.11,1.79,1.61,286,149,0,7.3,5.3,4.2,1.4,539,741,7.6,7.4,Tier1_FDA-approved,27.1,2852,0.5,0,0,0,0,0.36,PR,1,1,-57.6,57.6,19.6,8.3,9.5,51.5,0,0,-86.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,27,31,0.8,0.9,1.486,1.65,20.8,0.013,59,39.7,1,79.4,1,0,0,0,40.7,Chemotherapy,Other
HC-ONC-013-000229,MSI-H_CRC,85,Male,1,First-line,Never,0.0,29.5,0,None,0,1,0,1,0,3.37,90.4,75.9,17.61,1,MSI-H,1,40.3,TIL-intermediate,640,0.71,25,519,4,52.5,80,0.467,-0.314,PD-L1-high,Q3,Nivolumab+Ipilimumab,Combination,22.7,7,Discontinued_Progression,0,0,1.1,4.1,3.72,338,129,0,33.1,10.0,11.4,8.99,582,631,8.0,6.1,Tier1_FDA-approved,55.8,246,20.0,1,0,0,0,0.426,PR,1,1,-53.6,53.6,52.5,24.4,6.0,90.7,0,0,-41.6,0,1,0,2,4.8,1,14.8,0,0,1,55,12,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,51,55,1.21,0.92,1.783,0.96,25.7,0.0059,190,57.1,1,110.8,1,1,1,0,62.0,Chemotherapy,Disease_Progression
HC-ONC-013-000230,TNBC,62,Female,1,First-line,Never,0.0,21.0,0,None,0,1,0,2,0,3.36,0.0,0.0,60.13,1,MSI-H,1,40.0,TIL-intermediate,1156,1.56,107,16621,5,52.9,191,1.303,0.879,PD-L1-negative,Q5,Pembrolizumab+Chemo,Combination,57.6,19,Discontinued_Progression,1,0,1.49,7.24,4.86,305,264,1,95.6,62.9,3.4,2.96,935,399,19.7,2.9,Tier1_FDA-approved,45.1,2054,10.7,0,0,0,0,0.367,SD,0,1,17.9,0.0,52.9,52.9,,,0,0,77.5,0,1,0,2,14.7,1,4.6,0,0,1,40,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,38,36,0.65,1.08,2.229,1.34,26.6,0.0193,11493,22.6,1,66.2,0,0,0,0,26.6,None,None
HC-ONC-013-000231,Urothelial,62,Female,1,First-line,Never,0.0,31.1,1,RA,0,0,0,2,0,3.19,17.2,13.9,11.71,1,MSS,0,22.1,TIL-intermediate,405,3.68,11,376,5,65.0,90,-0.665,0.115,PD-L1-low,Q2,Atezolizumab,Anti-PD-L1,41.2,13,Discontinued_Progression,0,0,2.21,3.73,1.69,215,122,0,4.2,12.0,6.3,5.21,610,406,19.2,4.7,Tier1_FDA-approved,17.3,227,20.0,0,0,0,0,,PR,1,1,-30.0,30.0,65.0,45.5,13.4,27.5,0,0,-52.3,0,1,0,1,18.4,1,8.6,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,22,17,1.17,1.09,4.361,1.29,18.2,0.0204,139,43.4,1,69.6,0,0,0,0,47.9,Targeted,None
HC-ONC-013-000232,RCC,69,Male,0,Third+,Current,7.2,24.0,0,None,0,0,2,6,0,2.79,93.1,88.7,6.32,0,MSS,0,20.8,TIL-intermediate,624,1.54,10,2511,4,42.9,37,-1.431,-0.966,PD-L1-high,Q1,Nivolumab+Ipilimumab,Combination,19.6,6,Completed_2yr,0,0,1.75,2.14,1.23,467,344,1,16.3,15.6,9.6,1.34,1028,200,12.6,1.7,Tier1_FDA-approved,41.6,108,20.0,0,0,0,0,,PR,1,1,-65.0,65.0,42.9,15.0,15.9,26.8,0,0,-86.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,13,14,0.86,0.89,0.77,1.24,17.9,0.007,168,36.4,1,73.5,0,0,0,0,41.8,Chemotherapy,None
HC-ONC-013-000233,RCC,66,Female,0,Second-line,Never,0.0,24.0,1,RA,0,0,1,3,0,3.37,0.0,0.0,10.28,1,MSS,0,0.1,TIL-low,2,1.92,41,11852,5,58.7,46,-0.07,0.092,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,60.6,20,Discontinued_Progression,0,0,1.27,4.13,3.24,212,388,1,190.3,29.9,3.3,2.48,1347,434,9.4,5.8,Tier1_FDA-approved,0.0,89,0.5,0,0,0,0,,SD,0,1,20.0,0.0,58.7,58.7,,,0,0,72.1,0,1,0,1,5.3,0,,1,0,1,62,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,16,12,0.95,1.11,1.176,1.27,25.3,0.0076,147,27.7,1,56.1,1,0,0,0,31.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000234,Melanoma,63,Female,1,Second-line,Former,28.0,22.3,0,None,0,0,1,6,1,3.58,0.0,0.0,38.58,1,MSI-H,1,28.4,TIL-intermediate,754,3.28,83,3710,5,19.4,145,-0.348,-0.072,PD-L1-negative,Q5,Nivolumab,Anti-PD-1,30.9,10,Discontinued_Progression,0,0,1.83,2.92,1.59,415,129,0,13.0,2.3,2.6,8.21,855,759,18.8,4.7,Tier1_FDA-approved,29.4,82,8.98,0,0,0,0,0.35,PD,0,0,30.4,0.0,19.4,19.4,,,0,0,68.8,0,1,0,2,12.7,0,,1,0,1,10,8,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,19,16,1.02,0.88,1.312,1.44,24.4,0.0021,2551,40.3,1,60.6,0,0,0,0,42.4,BSC,None
HC-ONC-013-000235,NSCLC,51,Male,1,First-line,Never,0.0,17.1,0,None,0,0,0,4,0,1.8,60.6,66.0,5.85,0,MSS,0,29.5,TIL-intermediate,541,1.35,9,2232,4,101.9,42,-0.842,-1.108,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,31.2,10,Discontinued_Complete_Response,0,0,1.44,5.73,3.97,207,183,0,13.0,6.1,11.0,35.51,939,865,8.5,4.9,Tier1_FDA-approved,36.2,1084,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,101.9,0.0,7.2,39.0,0,0,-56.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,34,29,0.84,1.01,2.196,1.77,21.2,0.0022,93,7.1,0,61.6,0,0,0,0,11.7,Chemotherapy,None
HC-ONC-013-000236,Urothelial,66,Female,1,Second-line,Never,0.0,27.6,0,None,0,0,1,1,0,2.77,77.1,73.2,3.23,0,MSS,0,30.2,TIL-intermediate,490,4.56,46,566,1,76.7,23,-0.08,0.98,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,96.6,32,Discontinued_Progression,0,0,2.34,6.6,2.81,151,202,0,26.8,135.7,18.1,0.92,1505,737,13.1,7.4,Tier1_FDA-approved,44.9,132,10.43,0,0,0,0,,PR,1,1,-39.8,39.8,76.7,46.2,15.9,6.5,1,0,-56.6,0,1,0,1,11.8,1,7.9,0,0,1,34,4,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,55,48,0.86,0.62,0.743,1.68,19.6,0.0146,186,11.7,1,22.0,0,0,0,0,9.8,Clinical_Trial,None
HC-ONC-013-000237,NSCLC,83,Male,1,Third+,Current,21.8,35.1,0,None,0,1,4,3,0,3.0,56.3,58.6,61.87,1,MSS,0,34.2,TIL-intermediate,962,4.46,53,344,2,11.8,438,-0.612,-0.602,PD-L1-high,Q5,Pembrolizumab+Chemo,Combination,82.1,27,Discontinued_Progression,1,0,1.88,2.64,1.4,294,312,1,12.7,6.7,6.9,3.82,544,711,18.8,4.1,Tier1_FDA-approved,63.3,86,17.81,0,0,0,0,,CR,1,1,-100.0,100.0,11.8,0.0,22.1,59.7,0,0,-67.6,0,1,0,1,21.0,1,3.8,0,0,1,25,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,16,14,0.62,0.68,4.362,1.68,23.8,0.0066,53,51.8,1,102.5,0,0,0,0,55.6,Targeted,None
HC-ONC-013-000238,NSCLC,77,Female,0,Second-line,Former,0.0,26.2,0,None,0,0,1,5,0,3.4,0.0,0.0,6.89,0,MSS,0,29.1,TIL-intermediate,810,1.54,6,4555,3,46.6,43,-1.836,-0.774,PD-L1-negative,Q2,Nivolumab,Anti-PD-1,23.3,7,Active,0,0,1.45,3.15,2.17,141,448,1,2.2,28.2,5.1,6.23,1257,575,7.8,4.5,Tier3_exploratory,2.0,1177,20.0,0,0,1,0,,CR,1,1,-100.0,100.0,46.6,0.0,6.0,14.0,0,0,-63.0,0,1,0,3,1.2,1,14.3,0,0,1,25,2,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,35,38,1.48,1.11,2.739,1.5,12.6,0.0359,180,27.7,1,143.4,0,0,1,0,33.3,Targeted,None
HC-ONC-013-000239,TNBC,80,Female,2,First-line,Never,0.0,17.2,0,None,0,0,0,7,0,4.15,97.3,100.0,11.17,1,MSS,0,31.8,TIL-intermediate,669,1.24,63,11019,2,93.5,54,-0.441,0.12,PD-L1-high,Q2,Pembrolizumab+Chemo,Combination,11.4,3,Discontinued_irAE,1,0,1.81,6.54,3.62,320,100,0,37.8,23.5,8.4,2.74,1221,755,16.1,5.0,Tier1_FDA-approved,48.0,660,10.45,1,0,0,0,,CR,1,1,-100.0,100.0,93.5,0.0,11.5,98.6,0,0,-99.6,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,36,28,1.39,0.79,3.753,0.82,13.4,0.0086,151,21.4,0,32.0,0,0,0,0,27.5,Chemotherapy,None
HC-ONC-013-000240,NSCLC,54,Female,1,Second-line,Former,33.9,30.4,0,None,0,0,1,4,0,2.58,16.7,19.4,30.26,1,MSS,0,18.9,TIL-intermediate,484,2.34,67,1068,1,58.3,137,-1.136,-0.752,PD-L1-low,Q4,Pembrolizumab+Chemo,Combination,21.5,7,Active,1,0,2.79,2.92,1.05,135,171,0,1.6,1.3,7.7,8.84,1156,657,14.6,1.3,Tier1_FDA-approved,20.7,1709,7.12,0,0,0,0,,PD,0,0,20.0,0.0,58.3,58.3,,,0,0,69.9,0,1,0,1,17.9,1,5.3,1,0,1,24,9,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,36,41,0.93,0.8,3.59,1.24,22.3,0.0035,127,8.4,0,29.7,1,0,0,0,11.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000241,MSI-H_CRC,49,Male,0,First-line,Never,0.0,18.4,0,None,0,0,0,3,0,2.8,96.5,100.0,30.65,1,MSI-H,1,36.6,TIL-intermediate,856,1.39,26,461,1,52.1,93,0.232,0.442,PD-L1-high,Q4,Nivolumab+Ipilimumab,Combination,3.9,1,Discontinued_Progression,0,0,1.31,2.61,1.99,209,175,0,8.0,10.7,9.0,2.24,1288,961,11.8,4.5,Tier1_FDA-approved,59.4,870,20.0,0,0,0,0,0.43,PR,1,1,-37.1,37.1,52.1,32.8,6.0,38.9,0,0,-93.6,1,1,0,1,15.5,1,3.9,1,0,1,66,8,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,18,21,0.34,1.0,3.143,1.31,15.8,0.0164,85,45.1,1,102.8,1,0,0,0,44.6,Chemotherapy,Disease_Progression
HC-ONC-013-000242,Hodgkin,59,Male,2,First-line,Former,29.3,20.5,0,None,0,0,0,7,0,2.79,99.8,100.0,3.97,0,MSS,0,42.2,TIL-intermediate,1172,0.92,90,100,5,77.0,28,-0.656,-0.271,PD-L1-high,Q1,Nivolumab,Anti-PD-1,3.0,1,Discontinued_Progression,0,0,1.94,2.49,1.28,120,100,0,40.7,8.8,1.0,5.07,984,580,7.0,0.0,Tier1_FDA-approved,52.7,130,12.88,0,0,0,0,,PD,0,0,20.0,0.0,77.0,77.0,,,0,0,55.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,13,0.5,0.96,4.118,1.64,25.9,0.0083,55,13.7,1,24.9,0,0,0,0,12.4,BSC,None
HC-ONC-013-000243,MSI-H_CRC,61,Female,1,First-line,Former,18.5,25.3,0,None,0,0,0,7,1,2.56,0.0,0.0,24.4,1,MSI-H,1,53.0,TIL-high,1045,3.13,82,557,2,93.7,84,1.112,-0.042,PD-L1-negative,Q4,Nivolumab,Anti-PD-1,25.3,8,Completed_2yr,0,0,1.6,5.34,3.33,800,157,0,8.5,11.0,3.1,2.95,725,869,8.4,3.8,Tier1_FDA-approved,32.2,452,12.59,0,0,0,0,0.482,PR,1,1,-40.3,40.3,93.7,55.9,14.3,22.5,0,0,-66.8,0,1,1,1,15.8,1,2.4,1,0,1,116,2,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,13,10,1.32,0.65,4.11,1.72,25.9,0.0033,105,35.7,1,105.4,1,0,0,0,40.9,Clinical_Trial,Disease_Progression
HC-ONC-013-000244,Melanoma,74,Female,1,Second-line,Never,0.0,27.1,0,None,0,0,1,1,0,2.92,0.0,0.0,6.44,0,MSS,0,29.7,TIL-intermediate,678,3.03,36,1578,1,22.5,40,1.604,0.796,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,80.0,26,Discontinued_Progression,0,0,1.96,5.23,2.67,107,248,0,6.1,3.0,3.8,11.89,1228,775,13.4,6.7,Tier3_exploratory,18.1,487,18.32,0,0,0,0,,PD,0,0,45.1,0.0,22.5,22.5,,,0,0,57.5,0,1,0,1,39.1,1,11.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,122,121,1.42,1.06,1.011,1.25,24.8,0.0296,163,47.0,0,50.2,0,0,0,0,50.3,None,None
HC-ONC-013-000245,NSCLC,40,Male,1,Second-line,Former,60.4,21.5,0,None,0,0,1,2,0,3.82,91.0,100.0,7.5,0,MSS,0,51.2,TIL-high,1140,1.78,23,12320,2,102.0,41,0.679,0.101,PD-L1-high,Q2,Atezolizumab,Anti-PD-L1,64.6,21,Discontinued_Progression,0,0,1.27,3.18,2.51,246,174,0,29.3,1.9,8.3,2.61,1240,747,4.9,5.9,Tier1_FDA-approved,54.2,102,20.0,0,0,0,0,,SD,0,1,7.9,0.0,102.0,102.0,,,0,0,89.0,0,1,1,2,15.8,1,7.3,1,0,1,136,5,0,0,0,0,1,0,0,0,1,0,0,0,0,0,3,0,0,0,0,23,25,0.49,0.97,4.108,1.1,1.8,0.0222,157,32.9,1,111.6,0,0,0,0,40.9,Clinical_Trial,None
HC-ONC-013-000246,MSI-H_CRC,79,Female,2,First-line,Never,0.0,25.1,0,None,0,0,0,5,1,2.36,0.0,0.0,44.31,1,MSI-H,1,74.7,TIL-high,1517,0.88,15,4055,1,48.0,250,-1.551,-1.161,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,32.0,10,Discontinued_irAE,0,0,1.72,4.49,2.61,433,100,0,5.2,4.2,8.6,3.38,1232,198,12.7,3.8,Tier1_FDA-approved,41.5,77,20.0,1,0,0,0,0.462,CR,1,1,-100.0,100.0,48.0,0.0,12.1,70.7,0,0,-79.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,36,30,1.18,1.11,2.596,1.14,14.5,0.0032,140,56.3,0,65.4,0,1,0,0,57.5,Chemotherapy,None
HC-ONC-013-000247,Melanoma,59,Female,1,First-line,Current,29.6,30.1,0,None,0,0,0,6,0,3.54,0.0,0.0,4.42,0,MSS,0,21.2,TIL-intermediate,601,0.89,32,2607,3,79.3,34,1.505,0.251,PD-L1-negative,Q1,Nivolumab+Ipilimumab,Combination,35.4,11,Discontinued_Complete_Response,0,0,2.57,9.62,3.75,411,843,1,3.6,6.6,12.3,9.55,913,786,14.7,5.1,Tier3_exploratory,5.0,145,18.21,0,0,0,0,,SD,0,1,-6.0,6.0,79.3,74.5,,,0,0,44.5,0,1,1,4,11.6,1,9.1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,3,0,2,0,0,0,0,0,2,18,20,1.05,0.92,88.908,0.45,16.7,0.0188,23554,6.1,0,85.6,1,0,0,0,10.8,Targeted,Disease_Progression
HC-ONC-013-000248,Hodgkin,55,Female,0,First-line,Current,9.0,30.8,0,None,0,0,0,1,0,1.84,52.8,57.6,11.74,1,MSS,0,0.0,TIL-low,0,1.74,52,1119,1,78.6,37,1.576,1.509,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,1.3,1,Discontinued_Progression,0,0,1.13,2.75,2.43,375,229,0,16.0,30.6,9.1,1.97,685,574,16.9,2.9,Tier1_FDA-approved,26.7,8560,0.5,0,0,0,0,,PR,1,1,-36.8,36.8,78.6,49.7,10.6,76.4,0,0,-74.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,29,30,0.66,0.85,2.934,1.07,16.5,0.0025,195,26.0,1,84.8,1,0,0,0,33.4,Clinical_Trial,None
HC-ONC-013-000249,Hodgkin,48,Male,0,First-line,Never,0.0,32.8,0,None,0,0,0,4,0,2.75,25.3,34.8,3.23,0,MSS,0,64.7,TIL-high,1116,1.28,26,898,2,58.9,22,0.019,0.812,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,15.6,5,Discontinued_Progression,0,0,0.97,1.69,1.74,209,212,0,10.1,65.4,2.6,4.74,957,511,5.0,5.0,Tier2_emerging,32.8,217,20.0,0,0,0,0,,SD,0,1,10.9,0.0,58.9,58.9,,,0,0,46.7,0,1,1,1,29.4,1,2.5,0,0,1,103,3,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,34,40,0.82,0.82,1.624,1.71,26.1,0.0145,98,7.0,0,44.4,1,0,0,0,11.4,Targeted,Disease_Progression
HC-ONC-013-000250,HNSCC,41,Female,2,First-line,Former,42.6,36.0,0,None,0,1,0,7,0,2.94,86.4,74.8,28.56,1,MSS,0,11.9,TIL-intermediate,281,1.39,6,9767,5,39.1,93,1.323,1.283,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,3.4,1,Hold_irAE,0,0,0.98,5.63,5.72,481,116,0,3.5,39.5,23.5,1.04,1183,303,18.6,10.9,Tier1_FDA-approved,54.8,2564,20.0,0,0,0,0,,PR,1,1,-48.1,48.1,39.1,20.3,6.0,28.6,0,0,-59.2,0,1,0,1,21.8,1,5.6,0,0,1,73,4,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,18,20,1.11,0.6,2.416,1.22,21.4,0.0148,63,94.4,0,161.6,0,1,1,0,95.2,Clinical_Trial,None
HC-ONC-013-000251,NSCLC,70,Female,0,First-line,Former,48.7,30.5,0,None,0,0,0,4,0,4.54,30.4,30.1,19.9,1,MSI-H,1,8.0,TIL-low,198,2.75,91,2301,2,68.6,63,-0.552,0.304,PD-L1-low,Q4,Atezolizumab,Anti-PD-L1,50.2,16,Discontinued_Progression,0,0,1.03,4.24,4.11,386,228,0,23.0,20.7,20.4,1.88,1207,599,20.5,8.7,Tier1_FDA-approved,27.4,200,2.15,0,0,1,0,0.45,PR,1,1,-34.9,34.9,68.6,44.6,15.5,35.4,0,0,-64.1,0,1,1,2,10.6,1,6.4,1,1,1,96,2,0,0,0,1,0,0,1,0,1,0,0,0,0,0,3,0,0,0,0,18,14,0.42,0.62,3.766,1.79,4.3,0.0323,109,50.9,1,64.3,1,0,0,0,60.4,Chemotherapy,Disease_Progression
HC-ONC-013-000252,Melanoma,61,Male,1,Second-line,Never,0.0,25.4,0,None,0,0,1,7,0,2.98,77.4,93.4,17.82,1,MSS,0,14.0,TIL-intermediate,251,2.38,39,145,4,145.0,92,-1.866,-1.292,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,11.7,3,Discontinued_Progression,0,0,2.09,3.14,1.5,272,185,0,19.4,2.2,2.7,6.08,771,607,14.1,5.1,Tier1_FDA-approved,31.6,1530,6.28,0,0,0,0,,SD,0,1,3.6,0.0,145.0,145.0,,,0,0,61.0,0,1,0,2,16.2,1,7.6,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,30,28,0.53,0.68,0.629,0.91,14.5,0.0289,174,2.1,1,18.5,1,0,0,0,9.2,BSC,Disease_Progression
HC-ONC-013-000253,HNSCC,45,Male,1,First-line,Former,32.0,30.8,0,None,0,0,0,2,0,1.44,63.0,100.0,8.01,0,MSS,0,13.3,TIL-intermediate,277,3.28,24,806,2,25.5,27,-0.76,-0.774,PD-L1-high,Q2,Nivolumab,Anti-PD-1,64.2,21,Discontinued_Progression,0,0,0.94,6.21,6.61,276,100,0,8.5,4.5,9.6,2.03,995,339,6.8,5.3,Tier1_FDA-approved,32.1,1562,11.08,0,0,0,0,,SD,0,1,12.9,0.0,25.5,25.5,,,0,0,92.8,0,1,0,1,22.5,0,,0,0,1,10,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,32,24,0.34,1.16,1.232,0.99,28.1,0.0351,108,18.4,1,53.0,1,0,0,0,22.0,None,Disease_Progression
HC-ONC-013-000254,Melanoma,45,Female,1,First-line,Current,23.6,28.8,0,None,0,0,0,2,0,1.6,0.0,0.0,8.75,0,MSS,0,29.2,TIL-intermediate,852,1.0,66,646,3,147.7,61,1.729,0.648,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,40.8,13,Completed_2yr,0,0,1.46,6.82,4.66,210,117,0,9.1,9.5,4.6,2.9,507,305,10.4,3.0,Tier3_exploratory,19.9,1684,12.72,1,0,0,0,,SD,0,1,3.1,0.0,147.7,147.7,,,0,0,40.8,0,1,0,3,4.8,1,4.6,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,2,39,29,1.38,1.13,4.326,1.31,24.5,0.0063,20956,11.0,1,49.9,0,0,0,0,16.6,Targeted,None
HC-ONC-013-000255,NSCLC,56,Male,1,First-line,Current,23.4,29.0,0,None,0,0,0,5,0,3.23,0.0,0.0,15.78,1,MSS,0,0.0,TIL-low,0,1.39,112,939,3,69.6,89,-1.491,-0.573,PD-L1-negative,Q3,Atezolizumab,Anti-PD-L1,16.3,5,Discontinued_Complete_Response,0,0,2.11,1.49,1.0,155,298,1,19.5,3.5,8.3,6.65,1195,697,11.8,3.4,Tier1_FDA-approved,4.7,722,0.5,0,0,0,0,,PD,0,0,44.3,0.0,69.6,69.6,,,0,0,96.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,35,37,0.99,0.9,2.28,1.67,21.5,0.0213,156,18.3,0,77.6,1,0,0,0,24.0,BSC,Disease_Progression
HC-ONC-013-000256,RCC,81,Female,2,Third+,Former,0.0,27.4,0,None,0,0,3,6,0,3.69,0.0,0.0,39.78,1,MSI-H,1,3.8,TIL-low,96,2.41,4,3553,3,81.4,125,-0.0,0.113,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,12.4,4,Completed_2yr,0,0,1.95,3.23,1.66,454,530,1,40.1,14.8,17.2,2.82,665,774,13.4,5.7,Tier1_FDA-approved,24.3,3184,19.2,0,0,0,0,0.436,SD,0,1,13.6,0.0,81.4,81.4,,,0,0,95.8,0,1,1,1,8.9,1,2.5,1,1,1,119,11,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,35,40,0.93,0.71,1.713,1.15,29.4,0.0018,141,7.4,1,46.3,1,0,0,0,12.7,Chemotherapy,Disease_Progression
HC-ONC-013-000257,MSI-H_CRC,57,Male,0,Second-line,Never,0.0,21.9,0,None,0,0,1,5,0,3.5,41.3,38.3,21.35,1,MSI-H,1,41.2,TIL-intermediate,1075,2.06,47,1589,1,36.5,68,0.034,-0.018,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,39.7,13,Discontinued_Progression,0,0,1.41,12.0,8.49,472,241,0,9.2,17.5,40.6,8.66,1136,638,12.1,4.0,Tier1_FDA-approved,37.2,712,20.0,1,0,0,0,0.379,CR,1,1,-100.0,100.0,36.5,0.0,18.7,7.6,0,0,-83.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,31,37,1.15,0.69,4.193,1.64,27.3,0.0324,195,8.1,1,50.1,1,0,0,0,9.3,Chemotherapy,Disease_Progression
HC-ONC-013-000258,TNBC,42,Female,0,Second-line,Former,27.2,21.4,0,None,0,0,1,2,0,3.33,89.5,76.8,5.62,0,MSS,0,52.5,TIL-high,1140,3.55,11,1649,3,49.1,34,-0.513,0.34,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,69.9,23,Completed_2yr,0,0,1.78,6.0,3.37,157,348,1,23.4,14.1,13.5,5.33,555,830,13.4,6.8,Tier1_FDA-approved,55.5,5273,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,49.1,0.0,14.1,51.3,0,0,-51.7,0,1,0,1,7.1,1,8.9,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,14,11,1.49,0.75,4.145,1.23,15.2,0.0149,9736,27.5,1,79.1,0,0,0,0,32.2,Targeted,None
HC-ONC-013-000259,RCC,58,Male,0,First-line,Never,0.0,26.0,1,Thyroiditis,0,1,0,2,0,4.13,20.4,22.6,5.47,0,MSS,0,29.6,TIL-intermediate,861,2.03,49,8744,2,59.9,38,-0.444,-0.064,PD-L1-low,Q1,Atezolizumab+Bevacizumab,Combination,46.8,15,Discontinued_Complete_Response,0,1,1.72,6.28,3.65,227,185,0,21.4,25.3,9.4,6.35,1209,583,11.5,8.1,Tier3_exploratory,14.1,36,17.22,1,0,0,0,,SD,0,1,-1.0,1.0,59.9,59.3,,,0,0,11.1,0,1,0,1,13.9,1,2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,34,27,0.51,1.15,0.677,1.65,21.1,0.0036,194,13.2,1,86.0,1,0,0,0,20.1,Targeted,None
HC-ONC-013-000260,NSCLC,57,Female,2,Second-line,Former,26.4,27.2,0,None,0,0,1,4,0,2.77,10.2,9.8,19.33,1,MSI-H,1,8.2,TIL-low,213,4.15,37,784,5,38.2,100,0.072,-0.376,PD-L1-low,Q3,Nivolumab,Anti-PD-1,22.7,7,Hold_irAE,0,0,1.51,8.06,5.34,228,192,0,29.4,2.5,5.6,12.09,997,589,13.3,5.7,Tier1_FDA-approved,9.6,680,5.61,0,0,0,0,0.414,PR,1,1,-63.5,63.5,38.2,13.9,13.3,55.5,0,0,-60.1,0,1,0,3,7.5,1,5.0,0,0,1,50,3,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,2,0,0,38,37,0.46,1.95,1.95,1.08,20.7,0.0133,79,45.1,1,102.0,1,0,0,0,50.1,Clinical_Trial,Disease_Progression
HC-ONC-013-000261,RCC,28,Male,1,First-line,Never,0.0,23.1,0,None,0,1,0,2,0,3.92,0.0,0.0,40.67,1,MSI-L,0,5.3,TIL-low,116,2.16,55,16933,3,71.6,235,-0.562,-0.678,PD-L1-negative,Q5,Nivolumab+Ipilimumab,Combination,36.9,12,Discontinued_Progression,0,0,1.52,4.52,2.98,241,346,1,12.7,22.6,8.5,5.79,666,417,9.7,5.2,Tier1_FDA-approved,23.1,617,2.07,0,0,0,0,,PR,1,1,-40.9,40.9,71.6,42.3,11.9,31.9,0,0,-77.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,22,17,0.65,1.08,4.151,1.27,27.2,0.0119,177,32.9,1,116.5,1,0,1,0,37.7,Clinical_Trial,Disease_Progression
HC-ONC-013-000262,Hodgkin,60,Male,0,Second-line,Former,51.5,28.6,0,None,0,0,1,3,0,1.89,99.5,100.0,6.57,0,MSS,0,29.9,TIL-intermediate,703,2.8,22,808,2,63.7,46,-1.422,-0.512,PD-L1-high,Q2,Nivolumab,Anti-PD-1,20.7,6,Active,0,0,4.0,6.67,1.67,253,460,1,4.9,3.2,21.9,15.35,1107,288,10.3,1.6,Tier1_FDA-approved,56.4,99,20.0,0,0,0,0,,PR,1,1,-30.0,30.0,63.7,44.6,21.6,18.8,0,0,-96.0,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,19,16,1.38,0.9,1.219,1.08,14.7,0.0301,90,25.5,1,30.1,1,0,0,0,28.4,Chemotherapy,Other
HC-ONC-013-000263,NSCLC,58,Male,2,Third+,Never,0.0,36.9,0,None,0,0,3,7,0,2.48,0.0,0.0,34.71,1,MSS,0,23.6,TIL-intermediate,599,1.4,7,2012,1,154.0,210,0.215,0.65,PD-L1-negative,Q4,Pembrolizumab+Chemo,Combination,104.0,34,Active,1,0,2.28,6.42,2.82,393,384,1,7.7,2.4,7.1,9.29,723,971,9.1,6.5,Tier1_FDA-approved,22.7,962,20.0,0,1,0,0,,SD,0,1,9.5,0.0,154.0,154.0,,,0,0,147.8,0,1,0,1,2.7,1,10.6,0,0,1,59,4,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,26,29,0.79,0.97,2.813,1.02,4.3,0.0058,168,18.2,1,38.1,1,0,0,0,20.4,Chemotherapy,Disease_Progression
HC-ONC-013-000264,RCC,69,Female,2,Second-line,Never,0.0,17.8,0,None,0,1,1,1,0,1.75,0.0,0.0,31.88,1,MSS,0,42.3,TIL-intermediate,1010,1.66,23,1290,1,33.4,131,1.073,0.92,PD-L1-negative,Q4,Pembrolizumab,Anti-PD-1,49.6,16,Active,0,0,4.0,5.87,1.47,168,118,0,17.2,14.0,3.6,2.95,1125,826,21.6,2.7,Tier1_FDA-approved,21.0,43,20.0,0,0,0,0,,SD,0,1,9.8,0.0,33.4,33.4,,,0,0,73.8,0,1,0,1,1.1,1,6.5,1,0,1,10,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,39,43,1.25,0.97,1.783,1.22,23.5,0.0221,187,3.9,1,83.6,0,0,0,0,4.8,Chemotherapy,None
HC-ONC-013-000265,HNSCC,83,Male,2,Third+,Current,23.3,29.4,0,None,0,0,3,2,0,2.98,62.6,73.9,22.59,1,MSI-H,1,0.0,TIL-low,0,2.6,46,2097,5,84.1,137,0.87,1.47,PD-L1-high,Q4,Nivolumab,Anti-PD-1,38.7,12,Active,0,0,1.35,3.82,2.82,160,194,0,75.1,31.8,2.0,12.61,818,321,19.3,4.2,Tier1_FDA-approved,35.1,151,0.5,0,0,0,0,0.468,CR,1,1,-100.0,100.0,84.1,0.0,10.6,104.9,0,0,-89.2,0,1,0,1,9.9,0,,0,0,1,31,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,12,13,0.54,0.62,3.446,1.13,29.0,0.0312,136,43.7,0,102.6,0,0,0,0,49.2,None,None
HC-ONC-013-000266,Urothelial,74,Male,2,Second-line,Never,0.0,26.2,0,None,0,0,1,5,0,3.16,85.2,100.0,4.57,0,MSS,0,16.7,TIL-intermediate,340,3.69,75,3083,5,89.9,28,-0.81,0.332,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,26.9,8,Discontinued_Progression,0,0,1.59,4.88,3.06,454,230,0,7.5,13.3,11.1,5.54,384,631,14.8,6.9,Tier1_FDA-approved,47.6,20,4.47,0,0,0,0,,PD,0,0,39.2,0.0,89.9,89.9,,,0,0,46.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,31,29,0.89,0.87,1.133,1.59,28.2,0.0291,154,7.2,0,28.1,1,0,0,0,10.8,Clinical_Trial,Disease_Progression
HC-ONC-013-000267,TNBC,57,Female,0,First-line,Former,25.5,28.8,0,None,0,0,0,6,0,3.29,70.4,96.0,80.0,1,MSI-L,0,13.3,TIL-intermediate,260,2.37,13,3043,2,37.2,500,-1.251,-0.53,PD-L1-high,Q5,Atezolizumab,Anti-PD-L1,39.0,12,Discontinued_Progression,0,0,0.97,3.34,3.45,194,176,0,27.2,7.6,9.0,3.27,605,580,18.6,7.1,Tier1_FDA-approved,76.0,4179,18.57,1,0,0,0,,SD,0,1,16.1,0.0,37.2,37.2,,,0,0,93.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,34,34,0.45,1.12,2.884,1.55,21.6,0.0366,193,15.7,1,98.0,0,0,0,0,17.1,None,None
HC-ONC-013-000268,TNBC,47,Female,1,Third+,Never,0.0,24.3,0,None,0,0,2,7,1,3.25,73.2,81.5,58.9,1,MSS,0,7.0,TIL-low,127,1.58,75,732,5,107.5,360,-0.284,-0.59,PD-L1-high,Q5,Pembrolizumab+Chemo,Combination,22.4,7,Discontinued_irAE,1,0,1.19,4.51,3.78,130,243,0,8.8,10.7,4.4,5.6,771,545,16.0,4.1,Tier1_FDA-approved,55.7,285,1.67,0,0,0,0,,PR,1,1,-47.8,47.8,107.5,56.1,10.4,38.5,0,0,-82.5,0,1,1,3,11.5,1,12.2,1,1,1,133,2,0,0,0,0,1,0,0,0,2,0,0,0,0,0,2,4,0,0,0,34,37,0.8,0.89,0.5,1.16,5.3,0.001,94,23.4,1,92.5,0,0,0,0,29.3,Clinical_Trial,None
HC-ONC-013-000269,Melanoma,85,Female,1,First-line,Never,0.0,25.8,0,None,0,0,0,7,0,2.46,72.5,79.4,11.84,1,MSS,0,34.5,TIL-intermediate,537,3.28,20,470,5,64.1,93,1.568,0.286,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,3.8,1,Discontinued_Progression,0,0,3.53,2.5,1.0,192,302,1,13.6,8.7,16.8,10.91,1310,518,12.9,4.2,Tier1_FDA-approved,36.7,10408,20.0,0,0,0,0,,SD,0,1,-1.8,1.8,64.1,62.9,,,0,0,131.4,0,1,1,1,11.2,0,,1,0,0,0,0,0,0,0,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,0,27,22,0.61,0.86,1.51,1.79,27.3,0.0144,117,18.4,1,32.4,1,0,0,0,21.3,Chemotherapy,Disease_Progression
HC-ONC-013-000270,NSCLC,61,Male,2,First-line,Never,0.0,27.1,0,None,0,0,0,6,0,3.05,0.0,0.0,15.36,1,MSS,0,28.2,TIL-intermediate,441,0.55,44,36454,1,10.0,61,0.646,0.194,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,25.3,8,Discontinued_Complete_Response,0,0,1.34,3.02,2.26,207,331,1,55.4,1.9,5.3,6.45,1170,676,4.5,3.6,Tier1_FDA-approved,19.7,1345,9.8,0,0,0,0,,CR,1,1,-100.0,100.0,10.0,0.0,6.6,4.6,0,0,-86.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,38,42,0.96,0.92,1.149,1.77,25.4,0.015,183,80.4,1,133.6,1,1,1,0,82.7,Clinical_Trial,Disease_Progression
HC-ONC-013-000271,HNSCC,61,Female,1,First-line,Never,0.0,25.0,0,None,0,1,0,6,0,2.0,26.4,44.1,6.9,0,MSS,0,26.7,TIL-intermediate,750,0.81,22,1012,2,106.4,54,0.704,0.799,PD-L1-low,Q2,Nivolumab,Anti-PD-1,76.9,25,Completed_2yr,0,0,3.55,3.89,1.1,532,465,1,26.2,1.7,6.6,19.26,1387,764,10.7,2.6,Tier3_exploratory,20.5,790,20.0,1,0,0,0,,SD,0,1,20.0,0.0,106.4,106.4,,,0,0,104.9,0,1,0,1,7.5,1,6.9,1,0,1,49,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,14,10,1.24,0.83,1.339,1.72,27.8,0.0023,144,12.8,1,69.4,1,0,0,0,15.9,Clinical_Trial,Disease_Progression
HC-ONC-013-000272,HNSCC,60,Male,1,First-line,Current,19.1,18.9,0,None,0,0,0,7,1,4.29,86.8,86.1,17.98,1,MSS,0,33.8,TIL-intermediate,851,2.32,38,4184,5,35.3,102,0.89,1.447,PD-L1-high,Q3,Nivolumab,Anti-PD-1,39.6,13,Discontinued_Progression,0,0,1.0,2.8,2.79,389,170,0,3.5,6.7,7.3,10.69,1396,680,10.3,3.7,Tier1_FDA-approved,57.9,167,20.0,0,1,0,0,,PR,1,1,-53.0,53.0,35.3,16.6,20.1,71.7,0,0,-77.6,0,1,1,1,15.3,0,,1,1,1,90,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,17,19,1.43,0.91,3.942,1.39,28.1,0.0321,16186,23.4,1,44.8,0,0,0,0,27.0,Targeted,None
HC-ONC-013-000273,HNSCC,63,Female,1,First-line,Never,0.0,25.3,0,None,0,1,0,3,0,2.96,55.7,50.0,26.44,1,MSI-H,1,12.8,TIL-intermediate,319,1.66,68,263,2,38.1,168,0.421,0.461,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,7.9,2,Discontinued_Progression,0,0,1.08,3.48,3.22,434,101,0,6.9,8.1,5.6,6.81,740,576,6.3,1.8,Tier1_FDA-approved,39.3,84,4.62,1,0,0,0,0.35,CR,1,1,-100.0,100.0,38.1,0.0,10.5,26.9,0,0,-98.6,1,1,1,2,1.0,1,4.9,1,0,1,140,9,0,1,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,19,21,0.64,0.68,4.159,1.21,27.0,0.0272,135,15.6,1,68.6,1,0,0,0,20.6,Targeted,Disease_Progression
HC-ONC-013-000274,MSI-H_CRC,59,Male,0,First-line,Current,30.2,19.4,0,None,0,1,0,5,0,2.81,75.0,100.0,32.16,1,MSI-H,1,27.2,TIL-intermediate,659,2.23,12,1293,3,107.5,112,0.121,0.657,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,66.9,22,Discontinued_irAE,0,0,1.44,4.13,2.87,369,240,0,42.8,7.5,8.9,1.97,843,569,4.6,6.4,Tier1_FDA-approved,48.2,884,20.0,0,0,0,0,0.399,PR,1,1,-31.7,31.7,107.5,73.5,8.4,87.5,0,0,-84.5,0,1,0,1,3.2,1,6.4,0,0,1,23,8,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,10,9,1.19,1.18,3.52,1.11,12.2,0.0211,156,31.6,1,124.2,1,0,1,0,33.8,Clinical_Trial,Disease_Progression
HC-ONC-013-000275,RCC,54,Female,1,First-line,Former,27.2,29.8,0,None,0,0,0,3,0,4.47,96.0,100.0,3.71,0,MSS,0,52.8,TIL-high,1464,1.7,19,1552,1,66.1,18,0.662,0.275,PD-L1-high,Q1,Nivolumab+Ipilimumab,Combination,18.4,6,Active,0,0,1.61,5.48,3.41,393,514,1,14.0,16.6,18.6,3.88,777,787,14.5,5.8,Tier1_FDA-approved,56.8,362,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,66.1,0.0,6.0,15.5,0,0,-100.0,1,1,1,3,40.4,1,6.5,1,0,1,135,8,0,0,0,0,1,0,0,0,1,3,0,2,0,0,0,0,0,0,0,82,87,1.36,0.62,2.86,0.82,17.6,0.0164,32,17.1,1,66.3,0,0,0,0,23.1,Clinical_Trial,None
HC-ONC-013-000276,RCC,54,Male,3,Second-line,Never,0.0,17.2,0,None,0,0,1,2,0,2.21,0.0,0.0,12.42,1,MSS,0,16.3,TIL-intermediate,362,2.19,38,3189,1,116.7,85,-0.546,-0.016,PD-L1-negative,Q3,Atezolizumab+Bevacizumab,Combination,17.1,5,Active,0,1,2.39,7.2,3.02,173,158,0,3.9,5.7,3.0,4.75,699,693,13.6,6.1,Tier1_FDA-approved,17.1,54,9.28,0,0,0,0,,SD,0,1,20.0,0.0,116.7,116.7,,,0,0,76.9,0,1,0,1,14.7,1,9.0,0,0,1,10,2,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,15,12,0.45,0.89,51.213,0.5,19.3,0.035,88,5.1,1,68.5,0,0,0,0,10.0,Chemotherapy,None
HC-ONC-013-000277,Urothelial,60,Male,2,First-line,Former,19.5,31.6,0,None,0,1,0,1,0,2.3,51.9,60.2,4.4,0,MSS,0,31.0,TIL-intermediate,870,1.1,226,100,1,128.4,29,-1.414,-0.437,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,20.0,6,Discontinued_irAE,0,0,1.97,3.55,1.8,222,282,1,5.4,14.5,10.9,7.82,348,615,6.2,3.1,Tier1_FDA-approved,31.6,41,3.83,0,0,0,0,,SD,0,1,13.5,0.0,128.4,128.4,,,0,0,1.9,0,1,0,1,8.6,1,8.9,0,0,1,72,11,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,32,31,1.0,0.73,1.599,1.35,24.2,0.011,161,32.1,1,45.7,1,0,0,0,35.1,BSC,Disease_Progression
HC-ONC-013-000278,TNBC,54,Female,0,First-line,Former,25.9,28.6,0,None,1,1,0,6,0,2.32,27.0,25.0,38.14,1,MSI-H,1,40.1,TIL-intermediate,818,2.19,17,2207,4,54.2,122,0.723,-0.556,PD-L1-low,Q5,Atezolizumab,Anti-PD-L1,36.2,12,Completed_2yr,0,0,1.4,8.74,6.26,149,284,1,24.6,6.2,8.5,7.46,896,593,8.3,2.6,Tier1_FDA-approved,34.8,96,20.0,0,0,0,0,0.362,PR,1,1,-63.7,63.7,54.2,19.7,16.8,52.4,1,0,-100.0,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,22,24,1.03,0.64,1.74,1.43,17.5,0.0137,99,7.7,1,53.9,0,0,0,0,11.3,Clinical_Trial,None
HC-ONC-013-000279,TNBC,52,Female,0,Second-line,Former,44.1,28.7,0,None,0,0,1,5,0,3.15,0.0,0.0,4.63,0,MSI-L,0,3.0,TIL-low,88,2.71,169,455,2,111.7,27,1.238,0.536,PD-L1-negative,Q1,Atezolizumab,Anti-PD-L1,34.1,11,Active,0,0,1.56,7.17,4.58,220,220,0,32.9,65.9,8.4,5.13,514,669,17.8,5.1,Tier3_exploratory,0.0,6195,0.52,0,0,0,0,,CR,1,1,-100.0,100.0,111.7,0.0,17.8,25.4,0,0,-44.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,31,33,0.63,0.99,3.608,1.38,17.8,0.0372,92,50.4,1,68.0,0,0,0,0,53.5,Clinical_Trial,None
HC-ONC-013-000280,Urothelial,62,Male,0,First-line,Never,0.0,15.7,0,None,0,0,0,6,0,3.55,50.4,66.8,6.02,0,MSS,0,0.0,TIL-low,0,3.04,165,2668,3,49.8,21,-1.118,-0.196,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,30.8,10,Active,0,0,1.45,5.77,3.97,344,201,0,12.4,8.1,14.8,4.93,890,506,7.6,5.1,Tier1_FDA-approved,18.9,11158,0.5,0,0,0,0,,PD,0,0,40.5,0.0,49.8,49.8,,,0,0,100.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,19,22,0.33,1.19,1.512,0.94,19.2,0.0035,192,10.2,1,19.7,0,0,0,0,14.4,BSC,None
HC-ONC-013-000281,MSI-H_CRC,57,Male,1,Second-line,Never,0.0,24.9,0,None,0,0,1,3,1,3.79,0.0,0.0,26.25,1,MSS,0,24.6,TIL-intermediate,463,4.51,31,521,5,169.3,209,0.822,0.63,PD-L1-negative,Q4,Nivolumab,Anti-PD-1,46.8,15,Active,0,0,1.14,4.84,4.23,262,126,0,144.8,122.6,7.7,7.98,1535,764,12.9,4.7,Tier1_FDA-approved,17.1,549,14.47,1,0,0,0,,CR,1,1,-100.0,100.0,169.3,0.0,12.5,34.1,0,0,-88.7,0,1,0,2,6.2,1,3.3,1,0,1,33,11,0,0,0,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,0,14,11,0.61,1.05,23.28,0.45,29.2,0.0307,124,2.7,1,45.0,1,0,0,0,9.7,Chemotherapy,Disease_Progression
HC-ONC-013-000282,Melanoma,79,Male,2,Second-line,Current,25.0,32.3,0,None,0,0,1,4,0,5.0,85.7,100.0,15.22,1,MSI-L,0,35.8,TIL-intermediate,841,1.86,26,648,3,52.3,114,1.681,0.41,PD-L1-high,Q3,Nivolumab+Ipilimumab,Combination,21.0,7,Discontinued_Progression,0,0,1.16,5.26,4.55,471,100,0,27.8,11.3,10.9,2.25,747,385,11.1,4.4,Tier1_FDA-approved,56.2,504,20.0,0,0,0,0,,PR,1,1,-48.0,48.0,52.3,27.2,20.9,43.7,0,0,-70.6,0,1,0,1,9.1,1,6.7,1,0,1,40,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,14,13,1.0,0.75,3.686,1.16,19.9,0.0283,63,58.2,1,118.9,1,1,1,0,61.3,None,Disease_Progression
HC-ONC-013-000283,Melanoma,29,Male,0,Second-line,Current,20.4,23.9,0,None,0,0,1,2,0,1.4,85.3,100.0,3.62,0,MSI-H,1,31.8,TIL-intermediate,732,1.89,19,1302,2,121.0,11,-0.002,-1.216,PD-L1-high,Q1,Nivolumab,Anti-PD-1,53.0,17,Discontinued_irAE,0,0,2.49,8.11,3.26,138,115,0,9.5,5.7,13.1,17.4,958,518,14.5,8.4,Tier1_FDA-approved,40.0,244,20.0,1,0,0,0,0.455,PR,1,1,-52.4,52.4,121.0,57.5,13.1,8.6,0,0,-91.7,1,1,0,1,12.1,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,16,18,0.54,0.9,4.499,1.32,14.5,0.0353,110,54.1,1,105.1,1,1,0,0,58.5,Chemotherapy,Disease_Progression
HC-ONC-013-000284,NSCLC,74,Female,1,Second-line,Current,21.9,21.1,0,None,0,0,1,1,0,3.69,69.7,96.9,26.87,1,MSS,0,33.7,TIL-intermediate,575,0.77,31,511,1,113.8,196,-0.818,-0.674,PD-L1-high,Q4,Nivolumab,Anti-PD-1,13.3,4,Discontinued_Progression,0,0,0.79,8.26,10.41,314,165,0,5.4,2.5,4.9,0.87,1172,722,7.7,5.9,Tier1_FDA-approved,57.9,99,17.97,0,0,1,0,,SD,0,1,7.1,0.0,113.8,113.8,,,0,0,123.9,0,1,0,1,1.9,1,6.0,0,0,1,41,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,13,13,0.64,0.63,2.337,1.17,12.1,0.0044,118,15.3,1,89.2,0,0,0,0,17.9,Chemotherapy,None
HC-ONC-013-000285,RCC,75,Male,2,First-line,Never,0.0,23.3,0,None,0,0,0,2,0,2.75,0.0,0.0,20.4,1,MSI-H,1,5.2,TIL-low,124,1.26,11,1022,4,92.6,155,0.123,0.038,PD-L1-negative,Q4,Pembrolizumab,Anti-PD-1,53.0,17,Active,0,0,3.15,8.74,2.77,131,347,1,4.6,1.3,9.4,14.36,984,373,12.5,8.9,Tier1_FDA-approved,3.9,3174,10.33,1,0,0,0,0.407,PD,0,0,55.4,0.0,92.6,92.6,,,0,0,-8.0,0,1,0,1,25.8,1,10.2,1,0,1,10,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,17,19,1.15,0.92,2.857,0.82,16.3,0.0379,198,3.9,0,52.5,1,0,0,0,8.9,BSC,None
HC-ONC-013-000286,NSCLC,36,Male,1,Second-line,Former,21.6,26.2,0,None,0,0,1,4,0,2.73,0.0,0.0,44.79,1,MSS,0,44.2,TIL-intermediate,872,1.5,31,432,2,53.2,214,-0.551,-0.772,PD-L1-negative,Q5,Atezolizumab,Anti-PD-L1,42.4,14,Discontinued_irAE,0,0,1.44,4.58,3.18,256,190,0,17.0,2.2,6.0,4.32,988,285,12.8,7.5,Tier1_FDA-approved,45.1,6703,20.0,0,0,0,0,,SD,0,1,-1.9,1.9,53.2,52.2,,,0,0,79.0,0,1,0,1,8.0,1,8.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,27,25,0.78,0.66,1.622,1.68,28.9,0.0021,152,15.4,1,29.5,1,0,0,0,20.0,Targeted,Disease_Progression
HC-ONC-013-000287,Melanoma,56,Female,1,First-line,Former,27.1,22.2,0,None,0,0,0,1,0,2.7,33.4,50.2,8.05,0,MSS,0,5.5,TIL-low,87,2.79,110,200,2,73.9,53,-0.617,-0.298,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,43.9,14,Active,0,0,1.21,5.91,4.89,354,155,0,7.5,2.6,6.6,9.99,791,613,13.2,8.4,Tier3_exploratory,27.2,106,0.78,0,0,0,0,,PR,1,1,-47.6,47.6,73.9,38.7,11.2,48.6,0,0,-86.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,18,19,0.38,1.08,2.915,0.95,29.2,0.0138,118,16.0,1,85.8,1,0,0,0,22.7,BSC,Disease_Progression
HC-ONC-013-000288,RCC,56,Female,1,First-line,Former,20.1,32.7,0,None,0,0,0,4,0,2.47,36.1,57.5,26.18,1,MSI-H,1,23.2,TIL-intermediate,678,1.21,20,6134,5,10.0,136,0.433,0.513,PD-L1-low,Q4,Nivolumab+Ipilimumab,Combination,30.2,10,Discontinued_Progression,0,0,2.22,8.77,3.96,220,128,0,65.0,11.9,5.7,6.0,830,261,12.4,2.9,Tier1_FDA-approved,33.8,356,20.0,0,0,0,0,0.398,PR,1,1,-48.6,48.6,10.0,5.1,11.8,4.0,0,0,-100.0,1,1,0,2,22.3,0,,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,51,58,0.78,0.63,4.396,1.38,21.5,0.0042,103,82.5,1,112.7,0,1,0,0,84.8,Targeted,None
HC-ONC-013-000289,NSCLC,44,Male,1,Second-line,Never,0.0,26.2,0,None,0,0,1,2,0,4.55,4.6,6.5,3.78,0,MSS,0,19.8,TIL-intermediate,489,2.46,27,382,3,89.0,24,-1.604,-0.627,PD-L1-low,Q1,Nivolumab,Anti-PD-1,42.6,14,Active,0,0,2.99,3.28,1.1,322,278,1,52.8,3.9,10.8,5.91,612,340,13.7,6.2,Tier3_exploratory,1.4,205,17.46,0,0,0,0,,PR,1,1,-30.0,30.0,89.0,62.3,16.7,75.8,0,0,-100.0,1,1,0,1,2.7,1,8.4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,12,13,1.5,0.61,0.622,1.68,23.6,0.0029,186,34.5,1,87.3,0,0,0,0,39.9,Clinical_Trial,None
HC-ONC-013-000290,RCC,51,Male,0,First-line,Former,25.6,23.7,0,None,0,0,0,3,0,3.87,0.0,0.0,8.28,0,MSS,0,17.4,TIL-intermediate,490,1.65,8,1459,3,94.0,39,-1.444,-2.044,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,7.6,2,Discontinued_Progression,0,0,2.58,3.82,1.48,151,395,1,22.9,9.2,7.9,6.98,1154,751,23.0,4.1,Tier3_exploratory,8.8,215,20.0,0,0,0,0,,SD,0,1,1.1,0.0,94.0,94.0,,,0,0,70.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37,42,0.61,1.12,1.657,1.02,26.3,0.0377,140,52.7,1,67.2,1,1,0,0,59.2,Chemotherapy,Disease_Progression
HC-ONC-013-000291,NSCLC,47,Male,1,Second-line,Never,0.0,20.0,0,None,0,0,1,7,0,3.22,86.2,100.0,29.03,1,MSI-L,0,40.1,TIL-intermediate,1008,1.51,45,4463,5,85.3,134,0.019,-0.646,PD-L1-high,Q4,Pembrolizumab+Chemo,Combination,61.5,20,Discontinued_Progression,1,0,2.02,4.52,2.24,107,341,1,3.7,34.4,10.1,8.56,378,559,24.8,1.7,Tier1_FDA-approved,57.8,2390,20.0,0,0,0,0,,PR,1,1,-63.5,63.5,85.3,31.1,19.0,23.0,0,0,-45.0,0,1,0,2,13.3,0,,1,0,1,20,6,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,14,11,0.62,2.91,1.625,1.21,13.0,0.0283,91,27.7,1,157.3,0,0,1,0,30.8,BSC,None
HC-ONC-013-000292,NSCLC,82,Female,1,Second-line,Former,50.2,28.9,1,IBD,1,0,1,2,0,4.28,55.9,82.6,80.0,1,MSI-H,1,9.4,TIL-low,192,1.87,41,864,4,10.0,410,-0.022,-0.166,PD-L1-high,Q5,Pembrolizumab+Chemo,Combination,5.9,1,Discontinued_Progression,1,0,2.55,7.03,2.76,323,271,1,6.2,6.7,7.3,3.45,1191,857,8.8,8.0,Tier1_FDA-approved,53.9,56,4.57,0,0,0,0,0.45,PR,1,1,-68.6,68.6,10.0,3.1,15.3,9.4,0,0,-59.9,0,1,0,2,7.2,1,4.2,0,0,1,30,3,0,0,0,1,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,20,19,0.5,0.65,48.022,0.72,18.7,0.0202,109,40.8,1,69.4,0,0,0,0,44.5,Chemotherapy,None
HC-ONC-013-000293,HNSCC,72,Female,2,Third+,Current,9.2,28.8,0,None,0,0,2,2,0,1.99,60.5,49.9,28.91,1,MSS,0,0.0,TIL-low,0,1.36,35,672,1,29.4,108,0.344,0.492,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,11.8,3,Discontinued_irAE,0,0,0.83,7.08,8.54,585,100,0,42.8,89.6,2.0,10.26,479,359,0.4,4.4,Tier1_FDA-approved,38.3,812,0.5,0,1,0,0,,CR,1,1,-100.0,100.0,29.4,0.0,15.6,42.0,0,0,-97.3,1,1,0,2,15.6,1,6.2,0,0,1,43,9,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,21,17,0.63,0.77,1.031,0.89,23.6,0.0051,77,15.8,1,55.6,1,0,0,0,20.2,None,Disease_Progression
HC-ONC-013-000294,Melanoma,76,Male,1,Third+,Never,0.0,22.5,0,None,0,1,2,2,0,2.14,0.0,0.0,17.32,1,MSI-H,1,20.3,TIL-intermediate,510,1.33,28,2372,1,50.1,124,1.875,1.37,PD-L1-negative,Q3,Nivolumab,Anti-PD-1,36.2,12,Discontinued_irAE,0,0,1.34,3.99,2.98,149,168,0,6.9,1.8,7.6,1.88,1189,581,15.0,2.9,Tier1_FDA-approved,9.8,1203,17.59,0,1,0,0,0.389,CR,1,1,-100.0,100.0,50.1,0.0,9.3,4.0,0,0,-44.8,0,1,0,1,1.8,1,5.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,33,26,0.99,1.05,3.749,1.22,28.2,0.021,11909,57.5,1,102.0,0,1,0,0,61.0,Targeted,None
HC-ONC-013-000295,NSCLC,69,Female,1,First-line,Never,0.0,15.3,0,None,0,0,0,5,0,1.46,64.1,72.6,32.29,1,MSS,0,14.0,TIL-intermediate,412,0.7,26,6916,4,91.7,153,0.105,0.299,PD-L1-high,Q4,Durvalumab,Anti-PD-L1,48.7,16,Active,0,0,1.15,2.11,1.84,451,530,1,37.4,6.2,7.8,4.46,794,680,12.9,4.2,Tier1_FDA-approved,40.6,326,15.26,0,1,0,0,,SD,0,1,10.4,0.0,91.7,91.7,,,0,0,61.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,23,1.46,0.92,1.598,1.28,25.1,0.0132,149,3.5,0,15.0,0,0,0,0,7.8,Targeted,None
HC-ONC-013-000296,RCC,47,Female,0,First-line,Never,0.0,28.6,0,None,0,0,0,4,0,2.64,58.8,86.5,2.33,0,MSS,0,70.7,TIL-high,1329,1.46,49,444,5,91.6,12,0.598,0.167,PD-L1-high,Q1,Nivolumab+Ipilimumab,Combination,7.4,2,Discontinued_Progression,0,0,2.69,5.07,1.88,250,351,1,19.6,3.9,9.0,8.75,530,366,17.3,3.4,Tier1_FDA-approved,45.6,1540,20.0,0,0,0,0,,PD,0,0,24.8,0.0,91.6,91.6,,,0,1,67.8,0,1,1,2,4.7,1,9.7,1,1,1,108,12,1,0,0,0,1,0,0,0,2,4,0,0,0,0,0,0,0,0,0,21,25,1.03,1.17,3.942,0.83,18.3,0.0113,97,14.0,0,54.0,1,0,0,0,19.3,Chemotherapy,Disease_Progression
HC-ONC-013-000297,Urothelial,54,Female,1,Second-line,Current,13.1,25.6,0,None,0,0,1,4,0,3.33,95.2,96.7,36.51,1,MSI-H,1,30.1,TIL-intermediate,848,1.3,32,1510,2,73.2,273,-0.976,-0.749,PD-L1-high,Q5,Durvalumab,Anti-PD-L1,74.4,24,Discontinued_Progression,0,0,1.41,2.83,2.0,125,100,0,12.8,22.7,4.6,9.93,1074,806,13.4,3.6,Tier1_FDA-approved,60.6,503,20.0,0,1,0,0,0.401,PR,1,1,-35.0,35.0,73.2,47.6,8.6,29.7,0,0,-66.1,0,1,0,1,14.8,1,1.9,0,0,1,19,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,31,31,0.79,0.83,2.451,1.29,28.4,0.0245,35039,30.4,1,49.3,1,0,0,0,34.2,None,Disease_Progression
HC-ONC-013-000298,NSCLC,66,Female,0,First-line,Former,11.2,28.2,0,None,0,1,0,6,0,3.28,33.2,46.1,8.75,0,MSS,0,13.9,TIL-intermediate,400,1.27,43,226,3,105.4,48,0.768,0.097,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,94.6,31,Discontinued_Progression,0,0,2.31,2.13,1.0,139,195,0,6.0,0.5,2.8,6.48,1179,702,12.3,4.6,Tier3_exploratory,31.8,2504,9.09,0,0,0,0,,SD,0,1,-15.0,15.0,105.4,89.6,,,0,0,89.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,31,0.77,0.6,1.469,0.89,24.0,0.0311,60,24.8,0,77.1,0,0,0,0,28.6,BSC,None
HC-ONC-013-000299,TNBC,46,Female,0,Second-line,Never,0.0,36.3,0,None,0,0,1,4,0,3.32,0.0,0.0,22.93,1,MSS,0,18.9,TIL-intermediate,473,2.03,39,1128,2,39.0,131,-0.526,0.068,PD-L1-negative,Q4,Atezolizumab,Anti-PD-L1,38.1,12,Discontinued_Progression,0,0,2.04,2.38,1.17,247,240,0,11.1,1.3,12.2,3.27,769,278,17.6,8.5,Tier1_FDA-approved,13.3,41,11.82,0,0,0,0,,PD,0,0,29.2,0.0,39.0,39.0,,,0,0,63.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,14,0.33,0.61,3.339,1.69,26.9,0.0178,111,23.7,0,99.7,0,0,0,0,28.2,Targeted,None
HC-ONC-013-000300,NSCLC,69,Male,1,Second-line,Current,5.3,26.4,1,Psoriasis,0,0,1,6,0,2.07,66.8,100.0,3.67,0,MSS,0,0.0,TIL-low,0,2.29,81,1884,3,104.4,29,0.071,-0.417,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,30.2,10,Discontinued_Complete_Response,0,0,1.17,5.28,4.52,200,137,0,14.7,6.5,5.9,9.18,1116,592,18.3,3.7,Tier1_FDA-approved,30.5,239,0.5,0,0,0,0,,SD,0,1,-15.0,15.0,104.4,88.8,,,0,0,68.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,19,14,0.3,0.94,3.866,1.45,18.9,0.0197,109,27.5,1,80.4,1,0,0,0,30.7,None,Disease_Progression
HC-ONC-013-000301,NSCLC,58,Male,3,Second-line,Current,18.1,23.9,0,None,0,0,1,5,0,3.84,0.0,0.0,34.95,1,MSS,0,4.6,TIL-low,97,1.85,57,648,2,99.0,260,-0.109,0.36,PD-L1-negative,Q4,Durvalumab,Anti-PD-L1,48.9,16,Discontinued_Progression,0,0,1.3,8.85,6.79,127,100,0,34.2,47.5,8.5,2.62,214,677,5.1,8.3,Tier1_FDA-approved,17.5,362,1.67,0,0,0,0,,SD,0,1,11.5,0.0,99.0,99.0,,,0,0,44.7,0,1,0,1,22.9,1,2.6,1,0,1,28,10,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,39,31,1.26,1.05,2.381,0.86,12.0,0.0258,101,6.7,1,42.8,1,0,0,0,10.0,None,Disease_Progression
HC-ONC-013-000302,RCC,56,Male,0,First-line,Never,0.0,20.8,0,None,0,0,0,3,0,3.39,9.6,17.0,3.26,0,MSS,0,21.7,TIL-intermediate,636,2.71,39,1045,5,95.1,13,1.033,0.724,PD-L1-low,Q1,Nivolumab+Ipilimumab,Combination,21.6,7,Active,0,0,2.77,4.57,1.65,105,210,0,5.0,9.7,5.9,18.19,504,482,7.9,6.7,Tier3_exploratory,13.8,7,15.9,0,0,0,0,,PR,1,1,-35.3,35.3,95.1,61.6,10.2,35.1,0,0,-100.0,1,1,0,1,14.3,1,8.9,0,0,1,10,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,25,21,0.89,1.07,3.356,1.63,15.0,0.0057,175,38.2,0,42.9,0,0,0,0,40.4,Clinical_Trial,None
HC-ONC-013-000303,RCC,69,Male,1,First-line,Former,20.7,24.9,0,None,0,0,0,6,0,3.79,69.9,56.6,80.0,1,MSI-H,1,41.4,TIL-intermediate,1058,2.2,112,334,5,72.7,429,-1.31,-0.809,PD-L1-high,Q5,Atezolizumab+Bevacizumab,Combination,30.9,10,Discontinued_Progression,0,1,1.21,4.98,4.12,160,135,0,9.4,1.5,7.4,4.19,1288,304,11.5,5.8,Tier1_FDA-approved,78.0,79,9.36,0,0,0,0,0.423,CR,1,1,-100.0,100.0,72.7,0.0,11.3,16.5,0,0,-78.5,0,1,0,1,7.9,1,7.0,1,0,1,64,8,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,23,23,0.34,1.15,1.226,1.16,28.7,0.0325,196,33.8,0,44.0,1,0,0,0,37.8,Chemotherapy,Disease_Progression
HC-ONC-013-000304,TNBC,66,Female,2,First-line,Former,56.4,27.3,0,None,1,0,0,2,1,1.69,0.0,0.0,4.96,0,MSI-L,0,62.4,TIL-high,976,1.42,46,1983,4,153.2,39,-2.0,-1.528,PD-L1-negative,Q1,Pembrolizumab+Chemo,Combination,73.3,24,Active,1,0,1.73,8.1,4.67,270,135,0,12.7,1.8,5.2,1.31,833,656,12.5,6.5,Tier2_emerging,26.1,119,20.0,0,0,0,0,,PR,1,1,-39.9,39.9,153.2,92.0,17.2,41.1,0,0,-78.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,11,0.64,0.74,4.25,1.03,12.6,0.0328,90,20.4,1,52.7,0,0,0,0,25.3,Targeted,None
HC-ONC-013-000305,Urothelial,56,Female,0,First-line,Former,25.8,26.8,0,None,0,0,0,3,0,3.45,16.4,19.9,2.51,0,MSS,0,23.4,TIL-intermediate,670,1.31,94,6418,2,99.7,12,-0.213,-0.806,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,85.3,28,Discontinued_Progression,0,0,1.21,2.07,1.72,244,168,0,23.6,55.0,3.4,1.72,341,1042,10.9,5.0,Tier3_exploratory,16.3,1673,7.05,0,0,0,0,,SD,0,1,-11.3,11.3,99.7,88.4,,,0,0,77.8,0,1,0,1,13.4,0,,0,0,1,31,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,35,38,0.73,1.04,0.886,1.05,22.7,0.0216,80,20.2,0,73.8,1,0,0,0,23.7,Targeted,Disease_Progression
HC-ONC-013-000306,Hodgkin,74,Female,1,Third+,Never,0.0,35.1,0,None,0,0,4,7,0,2.25,98.6,100.0,13.26,1,MSS,0,33.5,TIL-intermediate,747,1.93,54,485,2,41.3,64,0.469,-0.043,PD-L1-high,Q3,Nivolumab,Anti-PD-1,76.0,25,Discontinued_irAE,0,0,1.45,5.81,4.0,190,187,0,4.9,3.5,10.8,4.64,690,523,14.2,7.6,Tier1_FDA-approved,56.8,140,13.58,0,0,0,0,,PR,1,1,-56.2,56.2,41.3,18.1,8.7,18.9,0,0,-61.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,10,1.24,1.1,1.388,1.4,19.4,0.0081,161,93.5,1,147.4,0,1,1,0,95.9,Targeted,None
HC-ONC-013-000307,RCC,48,Male,1,First-line,Current,32.9,29.0,0,None,0,0,0,5,1,2.88,42.3,44.5,61.9,1,MSI-L,0,24.0,TIL-intermediate,526,2.2,8,856,4,89.9,246,0.152,-0.074,PD-L1-low,Q5,Nivolumab+Ipilimumab,Combination,18.1,6,Active,0,0,1.62,4.46,2.75,271,199,0,3.3,2.4,4.6,5.01,623,914,17.0,6.1,Tier1_FDA-approved,51.8,118,20.0,0,0,0,0,,PR,1,1,-41.5,41.5,89.9,52.6,19.3,58.8,0,0,-95.2,1,1,0,2,21.0,1,1.7,0,0,1,35,7,0,0,0,1,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,13,10,0.82,1.1,33.687,0.49,19.7,0.02,106,91.3,1,152.0,0,1,1,0,95.1,None,None
HC-ONC-013-000308,Melanoma,68,Male,1,First-line,Former,44.5,25.8,0,None,0,0,0,4,0,3.63,57.9,100.0,80.0,1,MSS,0,12.2,TIL-intermediate,287,3.32,94,3305,4,110.1,286,1.232,-0.445,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,16.5,5,Discontinued_Complete_Response,0,0,1.21,5.95,4.93,412,129,0,23.9,43.5,8.4,21.67,850,450,20.6,1.7,Tier1_FDA-approved,61.3,1375,3.02,0,0,0,0,,CR,1,1,-100.0,100.0,110.1,0.0,13.1,42.3,0,0,-46.1,0,1,0,1,24.2,1,10.2,0,0,1,73,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,23,21,1.25,0.85,1.111,0.86,19.2,0.005,67,23.4,1,117.1,1,0,1,0,28.2,Chemotherapy,Disease_Progression
HC-ONC-013-000309,Urothelial,68,Male,0,First-line,Never,0.0,23.0,0,None,0,1,0,6,0,3.27,75.7,100.0,13.3,1,MSS,1,45.8,TIL-intermediate,789,2.99,37,7743,5,56.5,89,0.437,0.164,PD-L1-high,Q3,Durvalumab,Anti-PD-L1,20.0,6,Discontinued_Progression,0,0,1.12,3.52,3.13,298,179,0,2.7,24.9,10.3,1.95,789,643,14.9,5.6,Tier1_FDA-approved,45.9,36,20.0,1,0,0,0,,SD,0,1,-20.3,20.3,56.5,45.0,,,0,0,88.6,0,1,0,1,17.3,1,8.8,1,0,1,19,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,23,23,1.06,0.98,2.127,1.43,13.2,0.03,61,46.2,1,92.7,1,0,0,0,50.5,BSC,None
HC-ONC-013-000310,NSCLC,57,Female,1,Second-line,Former,26.9,27.8,1,Psoriasis,0,0,1,2,0,2.52,94.5,100.0,15.06,1,MSI-H,1,17.2,TIL-intermediate,378,1.26,32,301,5,123.6,103,-0.564,0.124,PD-L1-high,Q3,Pembrolizumab+Chemo,Combination,27.9,9,Discontinued_irAE,1,0,1.85,2.98,1.61,230,100,0,44.0,34.1,4.6,4.63,954,754,7.7,6.6,Tier1_FDA-approved,49.5,18,11.45,0,0,0,0,0.36,CR,1,1,-100.0,100.0,123.6,0.0,14.9,24.2,1,0,-53.2,0,1,1,2,3.2,0,,1,1,1,108,7,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,3,39,45,0.34,0.93,2.331,1.78,14.2,0.0128,37938,72.9,1,120.8,1,1,1,0,81.4,None,Disease_Progression
HC-ONC-013-000311,Melanoma,64,Male,1,Second-line,Never,0.0,22.0,0,None,0,1,1,1,0,3.21,44.3,39.2,15.01,1,MSS,0,18.7,TIL-intermediate,514,1.57,41,1477,2,95.3,118,-2.0,-0.916,PD-L1-low,Q3,Nivolumab,Anti-PD-1,20.9,6,Active,0,0,1.18,4.81,4.09,389,234,0,10.4,2.4,2.8,1.92,879,598,11.3,4.4,Tier1_FDA-approved,31.3,235,12.24,0,1,0,0,,SD,0,1,1.4,0.0,95.3,95.3,,,0,0,74.1,0,1,1,2,15.1,0,,1,1,1,106,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,14,16,1.46,0.96,2.574,1.28,13.1,0.0128,34124,11.1,1,34.3,0,0,0,0,13.7,BSC,None
HC-ONC-013-000312,NSCLC,45,Male,1,First-line,Never,0.0,27.4,1,Thyroiditis,0,0,0,7,1,1.97,74.4,73.2,19.09,1,MSS,0,0.0,TIL-low,0,2.31,25,2540,5,10.0,131,-0.237,-0.39,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,24.1,8,Discontinued_Progression,0,0,1.19,10.22,8.58,151,100,0,2.6,1.2,51.5,3.02,1308,540,11.6,5.3,Tier1_FDA-approved,40.1,46,0.5,0,0,0,0,,SD,0,1,20.0,0.0,10.0,10.0,,,0,0,39.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,28,0.52,0.77,0.663,1.21,13.0,0.0369,190,23.6,1,48.2,1,0,0,0,27.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000313,NSCLC,72,Male,0,First-line,Former,61.7,28.9,0,None,0,0,0,1,0,4.12,66.3,100.0,8.95,0,MSS,0,17.1,TIL-intermediate,326,2.81,40,1600,5,92.0,38,1.028,0.64,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,39.2,13,Completed_2yr,0,0,1.13,6.89,6.09,219,173,0,7.5,8.7,4.8,17.24,1027,745,14.6,3.8,Tier1_FDA-approved,36.7,49,7.95,0,0,0,0,,PR,1,1,-47.7,47.7,92.0,48.1,10.8,19.4,0,0,-70.5,0,1,0,1,20.4,0,,0,0,1,41,6,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,16,12,0.63,1.01,1.376,1.75,13.5,0.017,103,74.4,1,129.2,1,1,1,0,80.0,Clinical_Trial,None
HC-ONC-013-000314,Hodgkin,58,Male,1,First-line,Never,0.0,25.4,0,None,0,0,0,3,0,3.04,83.4,68.5,14.52,1,MSS,0,56.7,TIL-high,853,2.64,21,100,2,63.8,46,-0.392,-0.513,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,51.0,16,Discontinued_Progression,0,0,1.6,3.48,2.18,221,317,1,17.8,11.0,12.2,1.81,1037,978,13.9,2.2,Tier1_FDA-approved,56.3,954,20.0,0,0,0,0,,PR,1,1,-67.3,67.3,63.8,20.8,10.5,101.8,0,0,-71.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,31,32,1.27,1.03,3.731,1.04,24.5,0.031,44,38.1,1,76.3,1,0,0,0,40.7,BSC,Disease_Progression
HC-ONC-013-000315,HNSCC,54,Female,0,First-line,Never,0.0,23.3,0,None,0,1,0,4,0,4.09,0.0,0.0,19.76,1,MSS,0,4.0,TIL-low,85,1.6,92,3299,4,101.5,157,0.028,0.091,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,48.4,16,Completed_2yr,0,0,2.4,2.29,1.0,132,118,0,7.2,11.4,34.9,7.17,1250,660,22.3,1.9,Tier1_FDA-approved,9.6,1501,0.91,0,0,0,0,,SD,0,1,-4.1,4.1,101.5,97.3,,,0,0,80.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,22,20,0.53,0.72,3.742,1.04,14.1,0.0252,58,15.4,1,41.4,1,0,0,0,23.3,Chemotherapy,Disease_Progression
HC-ONC-013-000316,TNBC,73,Female,1,Second-line,Former,34.0,15.6,0,None,0,0,1,1,0,2.78,30.9,25.2,41.95,1,MSI-H,1,25.0,TIL-intermediate,648,0.88,30,11195,2,117.8,197,0.421,1.023,PD-L1-low,Q5,Atezolizumab,Anti-PD-L1,56.6,18,Active,0,0,3.01,1.93,1.0,198,287,1,12.4,43.5,13.9,6.14,783,497,9.7,1.9,Tier1_FDA-approved,35.8,1317,20.0,0,0,0,0,0.35,SD,0,1,-4.5,4.5,117.8,112.5,,,0,0,74.8,0,1,0,3,12.5,0,,0,0,1,70,8,0,0,0,0,0,0,0,0,1,1,0,0,0,2,0,0,0,0,0,29,22,0.78,0.87,0.293,2.73,16.7,0.013,85,25.4,1,44.3,1,0,0,0,29.4,BSC,Disease_Progression
HC-ONC-013-000317,Melanoma,52,Female,0,Second-line,Never,0.0,32.2,0,None,1,0,1,3,0,2.78,0.0,0.0,11.36,1,MSS,0,31.9,TIL-intermediate,860,1.0,24,2080,1,87.8,52,-1.015,-0.125,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,4.1,1,Discontinued_Progression,0,0,1.23,8.65,7.02,87,357,1,25.5,0.9,5.8,4.4,521,562,13.9,6.3,Tier1_FDA-approved,16.5,2128,20.0,1,0,0,0,,PD,0,0,82.8,0.0,87.8,87.8,,,0,0,77.1,0,1,0,1,1.0,1,7.3,1,0,1,31,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,20,20,1.34,0.85,2.345,1.45,23.8,0.0057,124,9.1,1,39.3,1,0,0,0,14.2,Clinical_Trial,Disease_Progression
HC-ONC-013-000318,NSCLC,44,Male,2,First-line,Current,35.1,28.5,0,None,0,0,0,5,0,2.59,0.0,0.0,11.56,1,MSS,0,0.0,TIL-low,0,1.89,16,525,2,146.6,87,0.623,0.634,PD-L1-negative,Q2,Durvalumab,Anti-PD-L1,5.3,1,Discontinued_Progression,0,0,3.9,2.78,1.0,637,100,0,10.0,20.7,7.0,6.79,1262,1104,23.8,0.0,Tier1_FDA-approved,4.0,2596,0.5,1,1,0,0,,PD,0,0,73.3,0.0,146.6,146.6,,,0,0,71.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,27,24,1.06,1.05,1.234,0.85,14.0,0.0313,150,6.2,1,13.4,1,0,0,0,10.3,Targeted,Other
HC-ONC-013-000319,NSCLC,42,Female,1,First-line,Never,0.0,28.6,0,None,0,0,0,3,0,3.9,17.0,24.0,25.63,1,MSS,0,35.9,TIL-intermediate,865,1.96,41,977,1,72.9,152,1.637,0.736,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,53.8,17,Discontinued_Progression,0,0,1.1,3.81,3.45,153,186,0,4.8,2.0,3.8,1.77,941,627,9.1,3.7,Tier1_FDA-approved,30.1,17,20.0,0,0,0,0,,PD,0,0,54.6,0.0,72.9,72.9,,,0,0,29.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,24,21,0.66,1.0,3.789,1.47,28.4,0.03,82,34.5,1,71.5,1,0,0,0,40.6,BSC,Disease_Progression
HC-ONC-013-000320,NSCLC,68,Female,0,Third+,Former,50.9,18.7,0,None,0,0,2,7,0,2.63,13.6,20.4,4.67,0,MSS,0,12.0,TIL-intermediate,226,0.95,38,15122,2,105.0,19,-0.173,0.271,PD-L1-low,Q1,Pembrolizumab+Chemo,Combination,33.4,11,Active,1,0,2.54,8.68,3.41,541,100,0,9.0,20.6,15.0,16.86,942,481,12.7,3.5,Tier3_exploratory,16.2,793,5.79,0,0,1,1,,CR,1,1,-100.0,100.0,105.0,0.0,6.0,31.0,1,0,-69.6,0,1,1,2,28.0,1,3.6,1,1,0,0,0,0,0,0,0,1,0,1,1,1,3,0,0,0,0,0,0,0,0,0,21,16,1.07,0.89,4.327,1.62,20.6,0.0074,193,6.4,1,35.4,0,0,0,0,8.2,Chemotherapy,None
HC-ONC-013-000321,RCC,45,Female,0,First-line,Never,0.0,33.4,0,None,0,0,0,3,0,3.72,0.0,0.0,11.63,1,MSS,0,14.2,TIL-intermediate,409,1.69,45,5388,1,112.2,87,-1.129,-1.521,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,36.3,12,Discontinued_Progression,0,0,1.24,2.0,1.62,249,189,0,50.1,4.2,11.6,20.9,710,371,7.3,4.4,Tier1_FDA-approved,6.0,182,8.89,0,0,0,0,,PD,0,0,33.1,0.0,112.2,112.2,,,0,0,99.7,0,1,1,3,21.9,1,1.0,1,0,1,127,4,1,0,0,0,1,0,0,0,1,3,0,0,0,0,0,0,0,0,1,26,31,1.28,0.99,1.665,1.07,29.3,0.0105,159,33.4,1,70.7,1,0,0,0,40.5,None,Disease_Progression
HC-ONC-013-000322,TNBC,82,Female,0,Second-line,Never,0.0,24.2,0,None,0,0,1,7,0,2.89,75.7,68.8,68.09,1,MSS,0,17.5,TIL-intermediate,467,2.26,15,3897,1,76.1,500,-0.067,-0.166,PD-L1-high,Q5,Pembrolizumab+Chemo,Combination,5.7,1,Discontinued_Progression,1,0,1.16,9.45,8.12,325,200,0,65.7,2.8,4.9,4.65,715,235,12.4,1.3,Tier1_FDA-approved,68.5,131,20.0,0,0,0,0,,SD,0,1,20.0,0.0,76.1,76.1,,,0,0,28.5,0,1,0,2,16.8,0,,1,0,1,37,6,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,22,23,0.78,0.76,3.628,1.18,15.5,0.0301,170,15.8,1,58.7,1,0,0,0,20.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000323,TNBC,36,Female,2,First-line,Never,0.0,25.1,0,None,0,0,0,3,0,1.62,0.0,0.0,20.46,1,MSI-H,1,47.6,TIL-intermediate,1123,0.93,9,2773,2,111.2,70,-2.0,-0.908,PD-L1-negative,Q4,Atezolizumab,Anti-PD-L1,17.7,5,Discontinued_Progression,0,0,1.22,3.95,3.23,192,100,0,1.6,3.6,3.2,31.14,1154,673,8.1,5.8,Tier1_FDA-approved,24.0,935,20.0,0,0,0,0,0.482,PR,1,1,-62.0,62.0,111.2,42.3,13.0,14.8,0,0,-80.8,0,1,1,3,1.6,1,7.1,1,0,1,160,9,1,1,0,1,1,0,0,0,0,0,0,3,1,0,0,0,0,0,2,1110,933,2.56,0.74,1.91,1.0,12.6,0.0384,20633,31.2,0,78.7,0,0,0,0,36.5,Clinical_Trial,None
HC-ONC-013-000324,NSCLC,81,Male,3,First-line,Former,36.2,21.2,0,None,0,0,0,2,0,2.74,29.4,40.8,24.46,1,MSI-H,1,56.9,TIL-high,1447,2.86,55,818,5,56.2,179,0.337,0.572,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,40.5,13,Discontinued_Progression,0,0,1.61,2.52,1.56,272,524,1,36.3,1.3,2.6,3.26,1195,731,17.2,2.5,Tier1_FDA-approved,50.3,30,20.0,0,0,0,0,0.35,SD,0,1,20.0,0.0,56.2,56.2,,,0,0,95.0,0,1,0,1,7.5,1,3.0,1,0,1,34,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,25,29,1.49,0.74,0.511,1.43,22.6,0.0331,95,17.2,1,60.4,0,0,0,0,19.7,Clinical_Trial,None
HC-ONC-013-000325,Hodgkin,63,Male,1,First-line,Current,27.5,17.6,0,None,0,0,0,3,0,2.26,0.0,0.0,12.45,1,MSS,0,55.6,TIL-high,1606,1.37,109,1421,3,63.1,62,0.452,0.606,PD-L1-negative,Q3,Nivolumab,Anti-PD-1,62.7,20,Discontinued_Progression,0,0,2.08,3.96,1.9,339,231,0,15.6,7.8,16.3,6.17,1135,521,12.7,7.3,Tier1_FDA-approved,21.7,29,14.6,1,0,0,0,,SD,0,1,18.9,0.0,63.1,63.1,,,0,0,41.2,0,1,0,1,13.6,1,4.4,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,37,44,1.46,0.62,2.899,1.46,17.9,0.027,121,29.3,0,66.0,1,0,0,0,34.0,Chemotherapy,Disease_Progression
HC-ONC-013-000326,Urothelial,59,Male,1,First-line,Never,0.0,32.3,0,None,0,0,0,6,0,3.23,0.0,0.0,16.26,1,MSS,0,7.0,TIL-low,181,3.09,15,1647,5,27.5,91,1.676,1.153,PD-L1-negative,Q3,Atezolizumab,Anti-PD-L1,73.5,24,Discontinued_Progression,0,0,2.16,3.12,1.45,341,131,0,30.7,2.9,8.1,14.09,1138,597,7.3,3.8,Tier1_FDA-approved,12.8,1044,11.31,1,0,0,0,,PR,1,1,-47.3,47.3,27.5,14.5,6.0,25.5,0,0,-53.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,18,0.91,1.01,2.142,0.87,22.3,0.0358,107,68.3,1,100.3,1,1,0,0,70.3,Clinical_Trial,Disease_Progression
HC-ONC-013-000327,RCC,54,Female,1,Third+,Former,39.4,32.9,1,IBD,0,0,4,3,0,2.25,0.0,0.0,30.02,1,MSS,0,37.0,TIL-intermediate,760,1.26,118,3496,1,89.7,227,-0.194,-0.214,PD-L1-negative,Q4,Nivolumab+Ipilimumab,Combination,31.4,10,Active,0,0,1.13,5.59,4.94,360,417,1,7.0,19.0,8.8,3.1,1071,366,16.2,4.8,Tier1_FDA-approved,24.8,839,6.39,0,0,0,0,,PD,0,0,62.8,0.0,89.7,89.7,,,0,0,81.4,0,1,1,2,4.7,1,9.5,0,1,1,118,5,0,0,0,0,0,0,1,1,2,0,0,0,0,3,0,0,0,0,0,13,14,0.42,1.19,0.048,2.17,20.5,0.0118,74,31.9,1,99.1,0,0,0,0,38.2,BSC,None
HC-ONC-013-000328,RCC,65,Male,2,First-line,Former,12.8,25.7,0,None,0,0,0,2,0,3.94,87.6,100.0,49.61,1,MSS,0,15.2,TIL-intermediate,392,0.99,42,11056,2,93.0,390,0.408,0.514,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,34.1,11,Discontinued_irAE,0,0,1.11,3.24,2.92,204,100,0,2.1,15.9,3.8,1.48,939,627,12.9,5.0,Tier1_FDA-approved,54.6,495,9.12,0,0,0,0,,PR,1,1,-51.7,51.7,93.0,44.9,11.1,25.5,0,0,-68.3,0,1,1,2,21.0,0,,1,0,1,135,8,0,0,0,0,1,0,0,0,1,0,4,0,0,0,0,0,0,0,0,21,19,1.14,0.79,3.495,1.46,20.2,0.0014,200,39.2,1,81.8,0,0,0,0,40.7,Chemotherapy,None
HC-ONC-013-000329,Melanoma,60,Male,1,First-line,Former,30.9,23.1,0,None,0,0,0,2,1,3.13,85.8,100.0,20.45,1,MSI-H,1,40.6,TIL-intermediate,634,1.31,33,6919,2,127.2,88,-0.861,-0.993,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,59.0,19,Discontinued_Progression,0,0,1.14,1.72,1.51,192,108,0,21.9,56.0,2.3,1.23,847,696,16.8,5.5,Tier1_FDA-approved,53.4,108,18.65,0,1,0,0,0.373,PR,1,1,-64.0,64.0,127.2,45.8,18.3,59.3,0,0,-64.7,0,1,0,1,2.9,0,,0,0,1,42,3,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,16,14,0.62,1.16,4.284,0.84,27.3,0.0132,174,27.3,0,72.8,1,0,0,0,31.6,Targeted,Disease_Progression
HC-ONC-013-000330,NSCLC,74,Male,1,First-line,Former,46.1,24.6,0,None,0,1,0,5,0,3.06,73.8,61.0,21.35,1,MSI-H,1,32.1,TIL-intermediate,668,1.57,24,329,2,111.6,87,-0.356,-0.636,PD-L1-high,Q4,Nivolumab,Anti-PD-1,33.6,11,Completed_2yr,0,0,1.58,4.01,2.55,110,100,0,4.8,11.5,16.0,23.3,1263,493,6.3,5.1,Tier1_FDA-approved,53.3,1231,20.0,0,0,0,0,0.386,PR,1,1,-30.3,30.3,111.6,77.8,17.7,96.3,0,0,-73.1,0,1,0,2,1.5,1,10.4,0,0,1,50,7,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,22,20,1.1,0.96,2.251,1.36,15.5,0.0379,70,38.6,1,137.1,0,0,1,0,41.9,BSC,None
HC-ONC-013-000331,Melanoma,62,Female,1,First-line,Never,0.0,24.8,0,None,0,1,0,7,0,3.72,51.9,59.0,39.59,1,MSS,0,0.0,TIL-low,0,1.36,11,2366,2,68.6,135,-1.525,-0.884,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,32.4,10,Active,0,0,1.52,2.27,1.5,318,493,1,3.0,13.8,7.6,2.94,788,938,13.8,4.1,Tier1_FDA-approved,35.9,1119,0.5,0,0,0,0,,SD,0,1,3.7,0.0,68.6,68.6,,,0,0,-11.9,0,1,0,1,10.9,0,,1,0,1,44,6,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,16,19,0.72,0.73,2.43,1.41,21.0,0.0345,182,2.8,1,21.5,1,0,0,0,3.6,Clinical_Trial,Disease_Progression
HC-ONC-013-000332,Urothelial,62,Male,1,First-line,Never,0.0,20.5,0,None,0,1,0,4,0,3.97,88.9,100.0,9.5,0,MSS,0,4.9,TIL-low,86,1.48,73,4377,3,32.9,55,-0.195,-0.03,PD-L1-high,Q2,Atezolizumab,Anti-PD-L1,70.8,23,Discontinued_Progression,0,0,1.13,4.96,4.4,420,237,0,3.3,39.7,15.3,3.86,1011,433,15.9,5.7,Tier1_FDA-approved,30.1,458,1.16,0,0,0,0,,SD,0,1,14.0,0.0,32.9,32.9,,,0,0,103.4,0,1,0,2,25.8,1,5.2,0,0,1,28,5,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,36,39,1.16,0.61,2.102,1.23,19.5,0.0029,130,10.9,1,62.3,1,0,0,0,13.0,Clinical_Trial,Disease_Progression
HC-ONC-013-000333,NSCLC,56,Female,0,First-line,Former,52.9,25.0,0,None,0,0,0,1,1,3.18,18.2,30.4,6.66,0,MSS,0,34.2,TIL-intermediate,524,1.95,18,3800,4,97.3,20,-0.305,-1.096,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,53.8,17,Discontinued_irAE,0,0,1.84,2.48,1.35,549,279,1,22.2,3.5,5.4,1.84,659,657,9.9,5.9,Tier2_emerging,20.7,69,20.0,0,0,0,0,,PR,1,1,-30.0,30.0,97.3,68.1,6.7,24.4,0,0,-76.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,27,23,0.74,1.03,1.688,1.7,24.1,0.0201,32,28.2,0,59.4,0,0,0,0,33.1,Chemotherapy,None
HC-ONC-013-000334,NSCLC,60,Female,1,Second-line,Current,12.8,27.3,0,None,0,0,1,1,0,2.58,0.0,0.0,3.94,0,MSS,0,22.3,TIL-intermediate,379,1.51,18,850,1,124.4,20,0.299,0.407,PD-L1-negative,Q1,Pembrolizumab,Anti-PD-1,71.7,23,Active,0,0,4.0,3.51,1.0,285,233,0,14.0,1.2,6.1,9.57,702,770,5.7,3.5,Tier3_exploratory,3.2,213,19.95,0,0,0,0,,SD,0,1,-5.8,5.8,124.4,117.1,,,0,0,73.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,25,1.43,1.02,3.051,1.13,12.9,0.004,89,11.7,1,66.8,1,0,0,0,14.0,Clinical_Trial,Disease_Progression
HC-ONC-013-000335,NSCLC,64,Male,1,First-line,Never,0.0,31.6,0,None,0,0,0,3,0,1.78,84.6,100.0,7.39,0,MSS,0,4.6,TIL-low,115,1.6,73,50000,3,110.2,25,-0.624,0.012,PD-L1-high,Q2,Atezolizumab,Anti-PD-L1,15.7,5,Discontinued_Progression,0,0,1.35,4.91,3.64,167,267,1,26.6,9.4,13.1,2.4,829,585,11.8,5.9,Tier1_FDA-approved,39.2,1418,1.55,0,0,0,0,,PD,0,0,37.1,0.0,110.2,110.2,,,0,0,92.5,0,1,0,1,15.3,1,8.8,0,0,1,51,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,34,34,0.46,0.74,3.812,0.87,21.5,0.031,34,5.9,1,38.2,1,0,0,0,8.6,BSC,Other
HC-ONC-013-000336,NSCLC,40,Female,1,First-line,Former,37.9,26.6,0,None,0,0,0,5,0,2.65,67.1,100.0,3.45,0,MSS,0,10.5,TIL-intermediate,284,0.7,7,391,5,123.4,17,0.083,0.011,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,32.8,10,Discontinued_Progression,0,0,1.39,4.03,2.91,105,208,0,23.8,1.3,13.3,3.03,659,562,18.1,7.4,Tier1_FDA-approved,39.4,2954,20.0,1,0,0,0,,SD,0,1,20.0,0.0,123.4,123.4,,,0,0,48.3,0,1,0,1,8.1,1,5.2,1,0,1,65,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,14,15,0.38,0.8,1.131,1.47,20.6,0.0152,45,3.9,1,30.8,1,0,0,0,8.7,Targeted,Disease_Progression
HC-ONC-013-000337,HNSCC,44,Male,0,Third+,Current,21.5,18.6,0,None,0,0,3,3,0,2.71,78.1,96.9,80.0,1,MSS,0,0.0,TIL-low,0,2.01,10,493,4,71.5,256,-0.333,0.987,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,60.2,20,Active,0,0,2.06,5.08,2.46,412,229,0,8.0,140.4,14.0,5.7,1139,314,17.6,6.4,Tier1_FDA-approved,70.1,247,0.5,0,0,0,0,,SD,0,1,15.0,0.0,71.5,71.5,,,0,0,33.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,36,27,1.24,1.14,4.427,1.41,29.5,0.0357,60,21.2,1,39.0,0,0,0,0,27.1,Chemotherapy,None
HC-ONC-013-000338,TNBC,69,Female,1,First-line,Former,28.2,28.3,0,None,1,0,0,1,0,3.29,76.4,62.5,11.94,1,MSS,0,38.2,TIL-intermediate,772,1.58,33,2393,4,61.3,86,-0.331,-0.54,PD-L1-high,Q2,Atezolizumab,Anti-PD-L1,9.6,3,Discontinued_Progression,0,0,1.32,6.3,4.78,100,211,0,11.4,42.4,5.8,1.91,496,871,9.9,6.9,Tier1_FDA-approved,55.4,277,20.0,0,0,0,0,,SD,0,1,-5.5,5.5,61.3,57.9,,,0,0,69.3,0,1,0,2,7.9,1,10.5,0,0,1,30,2,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,41,43,0.78,0.69,3.235,1.79,25.6,0.0031,112,5.4,1,71.0,0,0,0,0,10.7,Chemotherapy,None
HC-ONC-013-000339,Melanoma,63,Female,1,Third+,Current,23.6,25.2,1,RA,0,1,3,7,0,2.92,28.7,25.1,11.56,1,MSS,0,53.2,TIL-high,1275,3.69,42,22929,2,50.5,47,0.08,-0.132,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,54.3,18,Discontinued_Progression,0,0,2.15,2.51,1.17,206,148,0,7.3,99.2,12.1,3.89,930,566,5.6,5.3,Tier1_FDA-approved,30.4,317,20.0,0,0,0,0,,SD,0,1,-9.3,9.3,50.5,45.8,,,0,0,60.1,0,1,0,1,6.6,1,5.9,0,0,1,43,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,14,12,0.86,1.1,3.62,1.03,14.8,0.0289,95,12.2,0,61.5,1,0,0,0,16.1,Clinical_Trial,Disease_Progression
HC-ONC-013-000340,NSCLC,58,Male,1,First-line,Former,33.3,33.4,0,None,1,1,0,7,0,3.75,98.2,100.0,20.68,1,MSS,0,32.1,TIL-intermediate,932,1.03,49,663,3,77.8,96,0.041,-0.173,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,13.8,4,Completed_2yr,0,0,1.24,4.34,3.51,219,196,0,9.9,8.0,17.9,13.76,940,707,9.8,3.1,Tier1_FDA-approved,57.6,609,18.64,0,0,0,0,,PR,1,1,-52.9,52.9,77.8,36.6,6.0,61.4,0,0,-100.0,1,1,0,2,8.3,1,4.8,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,35,26,1.42,0.7,4.495,1.2,21.2,0.0162,55,35.5,1,49.1,0,0,0,0,40.0,Clinical_Trial,None
HC-ONC-013-000341,Melanoma,61,Female,0,Third+,Never,0.0,33.6,0,None,0,0,2,7,0,2.71,0.0,0.0,28.97,1,MSS,0,52.9,TIL-high,925,0.67,26,1314,5,76.9,213,0.761,0.419,PD-L1-negative,Q4,Nivolumab+Ipilimumab,Combination,55.9,18,Active,0,0,3.43,1.0,1.0,236,230,0,4.6,14.3,6.8,6.31,357,735,9.7,3.4,Tier1_FDA-approved,24.0,169,20.0,1,1,0,0,,PR,1,1,-56.1,56.1,76.9,33.8,15.7,18.3,0,0,-72.2,0,1,1,1,17.4,0,,1,0,1,98,12,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,24,25,1.01,0.89,2.516,1.26,26.1,0.0112,97,18.8,1,73.0,1,0,0,0,23.0,Chemotherapy,Disease_Progression
HC-ONC-013-000342,Melanoma,65,Female,1,Second-line,Former,38.1,33.8,0,None,0,0,1,2,0,3.15,0.0,0.0,28.54,1,MSS,0,33.2,TIL-intermediate,856,2.25,251,6586,2,88.3,192,-0.121,-0.237,PD-L1-negative,Q4,Nivolumab+Ipilimumab,Combination,38.6,12,Discontinued_Progression,0,0,1.89,5.07,2.68,249,212,0,18.0,4.3,4.9,4.98,768,474,14.2,5.6,Tier1_FDA-approved,19.4,5,3.4,0,0,0,0,,SD,0,1,8.6,0.0,88.3,88.3,,,0,0,23.3,0,1,0,2,23.1,0,,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,2,0,0,0,28,24,1.09,0.9,0.785,1.66,21.4,0.0207,82,4.8,0,11.7,0,0,0,0,6.8,Targeted,None
HC-ONC-013-000343,NSCLC,54,Female,1,Second-line,Former,51.6,23.7,0,None,0,0,1,4,0,4.15,76.5,66.6,32.02,1,MSS,0,35.4,TIL-intermediate,932,1.96,28,1770,2,74.8,131,-0.35,-0.913,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,14.3,4,Discontinued_Progression,0,0,1.29,3.86,3.0,262,100,0,35.7,21.3,21.6,5.32,977,560,11.5,6.9,Tier1_FDA-approved,51.0,2414,20.0,1,0,0,0,,PR,1,1,-43.8,43.8,74.8,42.0,6.0,41.6,0,0,-70.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37,39,0.32,0.88,3.661,1.21,18.4,0.0194,100,32.3,1,48.7,0,0,0,0,36.9,Clinical_Trial,None
HC-ONC-013-000344,Melanoma,51,Female,1,Third+,Never,0.0,36.4,1,MS,0,0,3,5,0,3.47,74.1,73.3,6.9,0,MSS,0,49.6,TIL-intermediate,810,1.0,28,1210,1,74.7,23,-0.181,-0.382,PD-L1-high,Q2,Nivolumab+Ipilimumab,Combination,29.7,9,Discontinued_irAE,0,0,1.3,2.74,2.1,73,102,0,5.4,1.7,4.4,3.28,1029,867,8.2,10.6,Tier1_FDA-approved,41.6,5955,20.0,0,0,0,0,,SD,0,1,9.2,0.0,74.7,74.7,,,0,0,62.0,0,1,0,2,8.5,1,4.9,0,0,1,18,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,37,29,1.1,0.77,3.983,1.57,18.8,0.0143,59,18.2,0,67.0,1,0,0,0,20.1,Chemotherapy,None
HC-ONC-013-000345,Melanoma,63,Male,1,First-line,Former,41.8,28.3,0,None,0,0,0,2,0,3.15,0.0,0.0,9.32,0,MSS,0,25.7,TIL-intermediate,716,0.77,18,3564,4,48.9,61,-0.715,-0.478,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,43.8,14,Discontinued_Progression,0,0,1.34,5.25,3.91,246,344,1,43.9,0.3,12.2,22.13,839,377,17.5,7.0,Tier3_exploratory,18.9,161,20.0,0,0,0,0,,PD,0,0,23.2,0.0,48.9,48.9,,,0,0,90.1,0,1,1,2,21.7,1,5.2,1,1,1,113,10,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,4,0,37,44,0.77,0.75,1.15,0.96,18.6,6.2341,134,40.3,1,78.7,1,0,0,0,45.5,Chemotherapy,Disease_Progression
HC-ONC-013-000346,RCC,49,Female,1,Third+,Former,34.7,34.6,0,None,0,0,2,4,0,2.72,87.4,100.0,24.34,1,MSS,0,17.2,TIL-intermediate,468,3.56,37,2507,5,117.7,121,-0.36,0.398,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,40.1,13,Discontinued_Progression,0,0,2.86,8.06,2.82,80,172,0,13.6,2.9,7.1,2.34,1103,1026,12.7,2.7,Tier1_FDA-approved,40.5,81,12.32,0,0,0,0,,PR,1,1,-46.1,46.1,117.7,63.5,6.0,83.2,0,0,-96.9,1,1,0,1,1.4,1,2.9,0,0,1,31,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,23,25,0.85,1.04,0.597,1.21,12.4,0.0261,25159,13.0,1,77.6,0,0,0,0,17.3,Clinical_Trial,None
HC-ONC-013-000347,TNBC,65,Female,2,First-line,Never,0.0,24.0,0,None,0,0,0,5,0,2.69,15.7,22.3,7.58,0,MSS,0,60.7,TIL-high,940,3.34,54,6226,4,83.1,52,2.0,2.301,PD-L1-low,Q2,Atezolizumab,Anti-PD-L1,27.1,9,Active,0,0,0.99,3.53,3.56,353,268,1,15.5,1.3,1.7,5.31,867,451,14.2,3.5,Tier2_emerging,35.4,328,17.09,0,0,0,0,,PD,0,0,20.0,0.0,83.1,83.1,,,0,0,54.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,32,27,1.27,0.77,1.043,0.95,25.2,0.0039,96,20.9,1,59.5,0,0,0,0,20.6,BSC,None
HC-ONC-013-000348,NSCLC,40,Female,0,First-line,Former,58.0,25.0,0,None,0,0,0,5,0,2.52,53.6,77.4,12.13,1,MSS,0,41.8,TIL-intermediate,684,0.48,87,8517,3,73.0,63,-0.913,0.12,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,69.6,23,Completed_2yr,0,0,1.26,2.79,2.21,185,116,0,2.2,43.5,18.2,4.91,904,364,3.4,9.6,Tier1_FDA-approved,46.0,305,7.77,0,1,0,0,,PR,1,1,-42.8,42.8,73.0,41.7,6.0,60.3,1,0,-85.1,0,1,1,2,8.4,1,2.8,1,1,1,119,7,0,0,0,0,1,0,0,0,0,0,3,1,0,0,0,0,0,0,0,68,72,0.93,0.97,1.796,1.75,23.0,0.0236,182,26.8,0,119.7,1,0,1,0,32.7,Clinical_Trial,Disease_Progression
HC-ONC-013-000349,Melanoma,73,Female,2,First-line,Former,46.6,27.9,0,None,0,0,0,1,0,2.77,62.8,52.0,17.44,1,MSS,0,12.8,TIL-intermediate,201,1.31,10,2613,1,50.1,83,-0.279,-0.555,PD-L1-high,Q3,Nivolumab+Ipilimumab,Combination,32.5,10,Discontinued_Progression,0,0,1.32,4.87,3.7,83,100,0,2.0,65.3,0.8,10.04,975,626,0.0,4.6,Tier1_FDA-approved,39.2,1796,18.27,1,0,0,0,,PR,1,1,-30.0,30.0,50.1,35.1,8.1,18.0,0,0,-66.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,35,27,1.48,1.11,4.197,0.98,16.8,0.028,101,11.8,0,69.5,0,0,0,0,14.8,BSC,None
HC-ONC-013-000350,TNBC,66,Female,1,First-line,Current,19.1,27.3,0,None,0,0,0,2,0,3.8,96.8,100.0,24.7,1,MSS,0,25.6,TIL-intermediate,512,3.79,27,2566,2,26.7,130,-0.387,-0.58,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,31.7,10,Discontinued_Progression,0,0,1.64,2.3,1.4,163,131,0,14.1,1.4,1.5,10.83,1178,1042,4.8,5.1,Tier1_FDA-approved,52.0,438,18.29,0,0,0,0,,PR,1,1,-66.4,66.4,26.7,9.0,6.0,26.5,0,0,-87.9,0,1,0,1,8.3,0,,1,0,1,43,12,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,20,21,1.26,1.1,0.51,1.22,23.3,0.0039,105,29.9,1,61.6,0,0,0,0,32.7,Clinical_Trial,None
HC-ONC-013-000351,RCC,64,Male,0,First-line,Never,0.0,32.8,1,MS,0,0,0,5,0,3.02,70.7,100.0,2.46,0,MSI-L,0,22.1,TIL-intermediate,500,1.3,47,2338,1,132.3,17,-0.247,-0.228,PD-L1-high,Q1,Atezolizumab+Bevacizumab,Combination,6.4,2,Discontinued_Progression,0,1,1.48,3.22,2.18,184,179,0,26.8,34.8,11.3,4.37,697,218,9.6,3.1,Tier1_FDA-approved,28.4,123,10.42,0,0,0,0,,PD,0,0,49.7,0.0,132.3,132.3,,,0,0,79.8,0,1,0,2,7.8,1,7.2,1,0,1,45,2,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,24,17,1.17,0.7,3.715,0.88,17.6,0.026,42,18.6,0,83.6,1,0,0,0,24.6,BSC,Disease_Progression
HC-ONC-013-000352,HNSCC,72,Female,0,Second-line,Never,0.0,25.3,0,None,1,1,1,6,0,2.12,67.2,71.2,23.18,1,MSS,0,32.5,TIL-intermediate,746,1.29,53,3252,2,102.2,174,-0.331,0.694,PD-L1-high,Q4,Nivolumab,Anti-PD-1,74.7,24,Discontinued_irAE,0,0,0.91,8.26,9.09,444,144,0,6.2,23.1,11.3,5.65,754,572,14.9,8.1,Tier1_FDA-approved,44.4,56,13.81,0,0,0,0,,PR,1,1,-54.2,54.2,102.2,46.8,7.7,32.6,0,0,-93.5,1,1,0,2,15.4,1,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,37,32,1.01,0.99,3.919,1.72,16.4,0.0316,133,29.5,1,106.3,1,0,0,0,33.2,BSC,Other
HC-ONC-013-000353,TNBC,80,Female,0,First-line,Former,11.7,32.3,0,None,0,0,0,7,0,4.61,0.0,0.0,9.87,0,MSS,0,56.0,TIL-high,1064,1.43,33,1932,1,15.0,32,0.279,0.085,PD-L1-negative,Q2,Atezolizumab,Anti-PD-L1,13.4,4,Discontinued_Progression,0,0,1.41,4.62,3.29,270,383,1,64.7,1.1,4.4,5.83,699,695,0.3,6.0,Tier2_emerging,24.9,1478,20.0,0,0,0,0,,SD,0,1,17.0,0.0,15.0,15.0,,,0,0,81.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,34,41,0.79,0.96,3.744,1.42,25.3,0.0326,189,33.4,1,113.6,1,0,1,0,38.6,BSC,Disease_Progression
HC-ONC-013-000354,NSCLC,73,Female,1,Second-line,Former,15.2,30.2,0,None,0,0,1,5,0,3.46,87.5,88.8,23.03,1,MSS,0,0.0,TIL-low,0,0.94,51,1807,2,110.5,129,-1.71,-1.69,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,33.1,11,Discontinued_irAE,0,0,1.58,1.75,1.11,291,219,0,25.4,4.6,8.3,0.73,800,607,20.0,3.5,Tier1_FDA-approved,45.1,992,0.5,0,0,0,0,,PR,1,1,-42.6,42.6,110.5,63.4,15.6,15.4,0,0,-53.2,0,1,1,2,9.1,1,2.7,1,0,1,151,3,0,0,0,1,1,0,0,0,3,0,0,0,1,0,0,0,0,0,0,39,29,0.36,0.77,0.829,1.76,26.6,0.0026,80,66.3,0,79.3,0,1,0,0,69.0,Clinical_Trial,None
HC-ONC-013-000355,NSCLC,38,Female,1,Second-line,Former,44.0,25.4,0,None,0,0,1,4,0,2.07,67.8,56.9,24.51,1,MSS,0,48.7,TIL-intermediate,999,0.7,17,7600,4,116.9,78,1.037,0.372,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,55.3,18,Discontinued_Complete_Response,0,0,1.28,1.82,1.42,442,505,1,4.9,3.7,1.0,1.26,1328,676,12.9,3.0,Tier1_FDA-approved,47.8,1980,20.0,1,0,0,0,,PR,1,1,-38.9,38.9,116.9,71.4,13.6,43.1,0,0,-87.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,21,0.32,0.83,3.217,0.84,23.3,0.0275,97,14.6,1,74.7,1,0,0,0,20.2,None,Disease_Progression
HC-ONC-013-000356,TNBC,45,Female,1,First-line,Former,20.5,29.8,0,None,0,0,0,1,1,2.85,0.0,0.0,51.79,1,MSS,0,27.2,TIL-intermediate,426,2.79,115,11152,4,85.0,277,0.633,0.758,PD-L1-negative,Q5,Atezolizumab,Anti-PD-L1,15.6,5,Active,0,0,2.17,4.86,2.24,233,245,0,12.6,18.1,13.0,2.76,1072,456,18.8,5.6,Tier1_FDA-approved,36.9,94,3.67,0,0,0,0,,SD,0,1,6.0,0.0,85.0,85.0,,,0,0,29.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,15,11,0.36,0.77,4.316,0.97,26.1,0.0313,130,8.6,1,17.9,1,0,0,0,13.0,Chemotherapy,Disease_Progression
HC-ONC-013-000357,NSCLC,53,Male,1,First-line,Never,0.0,24.1,0,None,0,1,0,3,0,3.29,0.0,0.0,41.19,1,MSS,0,16.0,TIL-intermediate,313,0.66,73,296,4,143.9,306,-1.243,-0.401,PD-L1-negative,Q5,Durvalumab,Anti-PD-L1,33.0,11,Hold_irAE,0,0,2.38,6.9,2.9,357,100,0,145.0,1.7,9.0,2.86,561,480,7.6,5.1,Tier1_FDA-approved,31.4,6359,4.23,1,0,0,0,,PR,1,1,-30.0,30.0,143.9,100.7,10.4,6.4,0,0,-96.3,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,37,39,1.45,0.92,0.981,1.18,18.6,0.0161,46,30.3,0,64.4,1,0,0,0,35.1,Chemotherapy,Disease_Progression
HC-ONC-013-000358,RCC,61,Female,1,First-line,Former,14.9,38.3,0,None,0,0,0,7,0,4.56,88.1,100.0,40.93,1,MSS,0,6.5,TIL-low,148,1.87,11,1830,4,88.7,197,-2.0,-1.3,PD-L1-high,Q5,Atezolizumab+Bevacizumab,Combination,16.9,5,Discontinued_Progression,0,1,1.6,2.0,1.25,344,340,1,3.5,6.6,7.1,1.72,720,570,14.5,6.7,Tier1_FDA-approved,54.0,30,12.33,0,0,0,0,,SD,0,1,10.2,0.0,88.7,88.7,,,0,0,69.8,0,1,1,2,11.0,0,,1,1,1,117,2,0,0,0,0,0,0,0,0,0,0,4,4,0,0,0,0,0,0,0,472,396,10.27,1.08,0.627,1.42,13.3,0.0216,192,14.6,1,49.4,1,0,0,0,18.2,BSC,Disease_Progression
HC-ONC-013-000359,MSI-H_CRC,67,Male,0,First-line,Former,18.6,15.0,0,None,0,0,0,1,0,2.31,41.4,50.4,44.67,1,MSS,1,80.0,TIL-high,1690,2.57,14,791,1,23.3,342,-0.977,-0.245,PD-L1-low,Q5,Nivolumab,Anti-PD-1,50.7,16,Discontinued_irAE,0,0,1.81,5.61,3.1,129,100,0,20.7,3.2,7.5,8.16,1012,374,12.4,6.1,Tier1_FDA-approved,61.6,1170,20.0,0,1,0,0,,PR,1,1,-55.6,55.6,23.3,10.3,7.1,26.1,0,0,-89.3,0,1,0,1,12.8,1,3.4,0,0,1,63,4,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,37,31,1.14,1.13,3.995,1.13,22.9,0.0111,109,70.2,1,148.0,0,1,1,0,77.5,BSC,None
HC-ONC-013-000360,RCC,52,Female,0,First-line,Never,0.0,29.9,0,None,0,0,0,3,0,3.98,0.0,0.0,15.84,1,MSS,0,23.6,TIL-intermediate,452,0.8,14,1245,2,94.6,97,-0.243,-1.282,PD-L1-negative,Q3,Nivolumab+Ipilimumab,Combination,35.4,11,Discontinued_Progression,0,0,0.69,8.72,12.55,511,225,0,8.8,13.0,11.0,4.49,628,591,16.1,4.5,Tier1_FDA-approved,6.8,23,20.0,0,0,0,0,,SD,0,1,6.5,0.0,94.6,94.6,,,0,0,67.5,0,1,0,2,1.0,1,1.0,0,0,1,51,9,0,0,0,1,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,32,28,1.01,1.03,3.08,1.51,16.6,0.0128,50,73.6,0,113.6,1,1,0,0,81.4,BSC,Disease_Progression
HC-ONC-013-000361,Melanoma,63,Male,1,First-line,Current,13.1,17.7,0,None,0,1,0,2,0,4.32,12.4,15.8,12.54,1,MSS,0,7.2,TIL-low,123,1.04,57,2931,4,89.8,96,2.0,1.252,PD-L1-low,Q3,Nivolumab+Ipilimumab,Combination,62.2,20,Discontinued_Progression,0,0,1.39,11.52,8.27,120,136,0,24.7,5.7,7.2,3.77,682,522,10.8,3.9,Tier1_FDA-approved,10.6,123,2.12,0,0,0,0,,CR,1,1,-100.0,100.0,89.8,0.0,6.0,17.9,0,0,-69.0,0,1,0,1,7.4,0,,0,0,1,78,6,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,36,29,0.99,0.89,3.086,0.97,26.0,0.0201,87,15.4,1,59.4,0,0,0,0,15.0,None,None
HC-ONC-013-000362,TNBC,51,Female,0,First-line,Former,42.8,25.4,0,None,1,0,0,2,0,2.7,4.5,4.8,26.72,1,MSS,0,57.3,TIL-high,1563,3.02,12,4037,1,55.9,181,0.543,0.756,PD-L1-low,Q4,Atezolizumab,Anti-PD-L1,68.7,22,Discontinued_Complete_Response,0,0,2.46,5.29,2.15,387,585,1,43.3,3.9,1.6,1.64,1303,506,14.4,4.7,Tier1_FDA-approved,33.9,4195,20.0,0,0,0,0,,PD,0,0,32.6,0.0,55.9,55.9,,,0,0,115.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,30,35,1.0,1.17,4.358,1.4,18.4,0.0067,94,34.4,1,78.2,1,0,0,0,40.2,Targeted,Disease_Progression
HC-ONC-013-000363,Melanoma,53,Female,0,Third+,Former,27.6,26.1,0,None,0,0,4,5,0,2.98,61.2,50.7,80.0,1,MSI-H,1,31.5,TIL-intermediate,944,2.15,25,1580,2,102.9,281,-1.808,-1.501,PD-L1-high,Q5,Nivolumab,Anti-PD-1,41.2,13,Discontinued_Progression,0,0,1.39,5.77,4.15,115,411,1,8.3,5.7,42.8,4.32,716,664,17.5,3.9,Tier1_FDA-approved,71.1,1404,20.0,0,1,0,0,0.474,PR,1,1,-42.6,42.6,102.9,59.1,10.1,12.7,0,0,-58.0,0,1,0,3,12.1,1,12.7,0,0,1,10,2,0,0,0,1,0,0,0,0,2,0,0,0,1,0,0,0,0,0,1,34,40,0.66,0.94,3.579,1.2,24.1,0.0151,89,49.0,0,59.1,0,0,0,0,50.8,None,None
HC-ONC-013-000364,RCC,44,Female,1,Second-line,Former,9.4,34.0,0,None,0,0,1,6,0,2.37,71.3,100.0,9.22,0,MSI-L,0,17.2,TIL-intermediate,343,1.21,48,182,1,13.3,38,-0.69,-0.832,PD-L1-high,Q2,Atezolizumab+Bevacizumab,Combination,47.5,15,Discontinued_irAE,0,1,1.23,1.54,1.26,331,138,0,37.3,85.1,19.3,0.55,1186,236,8.7,4.7,Tier1_FDA-approved,35.4,178,7.0,0,0,0,0,,SD,0,1,-1.3,1.3,13.3,13.1,,,0,0,65.3,0,1,0,1,6.3,1,7.5,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,14,15,1.36,0.89,2.09,1.31,22.0,0.0125,148,25.1,1,68.1,1,0,0,0,30.1,Chemotherapy,Disease_Progression
HC-ONC-013-000365,MSI-H_CRC,49,Male,1,First-line,Former,30.5,23.0,0,None,0,0,0,2,0,3.04,77.7,92.9,54.96,1,MSI-H,1,50.1,TIL-high,1039,3.01,31,568,4,119.6,273,-0.053,-0.965,PD-L1-high,Q5,Nivolumab,Anti-PD-1,34.4,11,Active,0,0,4.0,12.0,3.0,621,188,0,112.3,4.5,2.6,3.93,1277,554,13.2,5.0,Tier1_FDA-approved,69.4,185,20.0,0,0,0,0,0.35,PR,1,1,-55.2,55.2,119.6,53.6,6.0,70.7,0,0,-74.6,0,1,0,4,4.9,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,1,0,1,39,29,1.4,1.11,2.243,1.37,26.7,0.0101,89,22.9,1,63.1,1,0,0,0,23.4,None,Disease_Progression
HC-ONC-013-000366,Melanoma,44,Female,3,Second-line,Current,22.2,33.0,0,None,0,0,1,5,0,3.17,50.3,55.2,64.14,1,MSI-H,1,7.6,TIL-low,185,3.01,41,5302,3,44.9,247,0.254,0.947,PD-L1-high,Q5,Nivolumab+Ipilimumab,Combination,24.7,8,Discontinued_irAE,0,0,3.41,3.36,1.0,220,226,0,13.0,2.1,5.6,4.71,680,1063,2.6,3.2,Tier1_FDA-approved,48.3,469,4.4,0,0,0,0,0.484,PR,1,1,-42.0,42.0,44.9,26.0,12.1,16.0,0,0,-100.0,1,1,0,2,4.3,1,2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,15,13,1.07,0.71,1.079,0.86,27.0,0.0194,85,9.6,1,50.0,0,0,0,0,14.4,Clinical_Trial,None
HC-ONC-013-000367,Hodgkin,49,Male,2,First-line,Former,22.8,20.6,0,None,0,0,0,7,1,3.73,95.2,100.0,5.65,0,MSS,0,30.1,TIL-intermediate,777,1.89,14,100,1,40.6,31,-1.315,-1.149,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,41.2,13,Discontinued_Progression,0,0,1.99,2.81,1.41,215,308,1,26.7,14.9,6.1,5.44,633,383,15.5,6.3,Tier1_FDA-approved,48.6,872,20.0,0,0,0,0,,SD,0,1,5.8,0.0,40.6,40.6,,,0,0,40.3,0,1,0,4,7.5,1,5.7,0,0,1,53,2,0,0,0,0,0,0,0,0,1,2,2,0,0,0,0,0,0,0,2,11,11,1.34,0.69,1.716,1.72,13.2,0.0329,27644,19.6,0,31.9,1,0,0,0,22.0,Chemotherapy,Disease_Progression
HC-ONC-013-000368,MSI-H_CRC,73,Female,1,First-line,Former,47.3,33.2,1,Thyroiditis,0,0,0,1,0,4.07,0.0,0.0,44.49,1,MSI-H,1,0.0,TIL-low,0,1.05,53,7517,4,75.4,238,-0.135,0.04,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,71.5,23,Discontinued_Progression,0,0,2.6,3.94,1.52,332,203,0,6.8,6.2,17.5,1.28,817,857,21.8,4.3,Tier1_FDA-approved,21.6,2637,0.5,0,0,0,0,0.463,CR,1,1,-100.0,100.0,75.4,0.0,6.0,11.4,0,0,-68.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,26,31,0.37,1.07,2.282,1.59,17.3,0.0102,162,41.8,0,50.0,0,0,0,0,44.9,BSC,None
HC-ONC-013-000369,NSCLC,49,Female,1,Second-line,Current,15.8,24.1,0,None,0,1,1,2,0,2.6,0.0,0.0,12.63,1,MSI-H,1,0.1,TIL-low,4,1.34,20,3379,5,97.3,98,-0.718,-0.129,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,26.5,8,Active,0,0,0.68,9.54,14.1,208,120,0,12.4,1.4,1.3,5.36,573,611,5.8,3.3,Tier1_FDA-approved,0.0,203,0.5,1,0,0,0,0.35,PD,0,0,61.3,0.0,97.3,97.3,,,0,0,40.4,0,1,0,1,3.0,1,4.5,0,0,1,20,4,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,31,31,0.42,1.12,1.544,1.24,27.7,0.0261,82,44.3,1,71.1,0,0,0,0,47.4,Chemotherapy,None
HC-ONC-013-000370,NSCLC,85,Female,1,First-line,Former,46.6,26.9,0,None,0,0,0,1,0,1.63,45.8,59.3,41.97,1,MSI-H,1,47.1,TIL-intermediate,1102,1.9,26,8773,2,86.6,217,-1.104,0.094,PD-L1-low,Q5,Nivolumab,Anti-PD-1,20.9,6,Active,0,0,1.2,12.0,9.97,607,140,0,10.2,107.5,5.0,1.95,936,479,11.5,4.3,Tier1_FDA-approved,51.0,36,20.0,0,0,0,0,0.496,PR,1,1,-51.2,51.2,86.6,42.2,11.4,21.3,0,0,-90.0,1,1,0,1,6.8,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,31,27,0.97,0.64,4.163,1.35,19.3,0.0107,32,49.6,1,126.1,1,0,1,0,52.1,Chemotherapy,Disease_Progression
HC-ONC-013-000371,NSCLC,66,Female,1,First-line,Current,26.0,24.8,0,None,0,0,0,1,0,3.18,26.3,24.5,2.82,0,MSS,0,44.6,TIL-intermediate,971,1.5,40,1425,4,50.3,20,0.26,0.079,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,24.9,8,Discontinued_irAE,0,0,1.37,4.77,3.49,269,200,0,27.0,4.8,1.8,2.34,838,336,16.4,5.5,Tier2_emerging,27.4,511,20.0,0,0,0,0,,PD,0,0,20.0,0.0,50.3,50.3,,,0,0,-1.4,0,1,0,1,11.4,1,11.7,0,0,1,10,9,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,20,22,1.32,1.06,0.547,0.83,21.3,0.0064,92,17.0,0,48.5,0,0,0,0,19.6,Chemotherapy,None
HC-ONC-013-000372,NSCLC,63,Female,0,Third+,Never,0.0,32.9,0,None,0,0,3,6,0,3.43,0.0,0.0,7.38,0,MSS,0,21.0,TIL-intermediate,518,2.64,36,152,5,59.8,57,0.774,0.195,PD-L1-negative,Q2,Pembrolizumab+Chemo,Combination,27.6,9,Discontinued_irAE,1,0,1.5,7.38,4.92,208,371,1,40.6,4.7,5.9,7.96,1008,628,12.2,5.2,Tier3_exploratory,6.9,203,14.0,0,0,0,0,,PD,0,0,32.7,0.0,59.8,59.8,,,0,0,51.6,0,1,1,2,3.2,1,4.8,1,0,1,122,3,0,0,0,0,0,0,0,0,2,4,0,0,0,0,0,0,0,0,0,33,25,0.68,0.85,2.848,1.3,15.3,0.0368,77,68.5,0,114.5,1,1,0,0,71.7,Chemotherapy,Disease_Progression
HC-ONC-013-000373,NSCLC,50,Male,1,Third+,Former,43.9,31.9,0,None,0,0,2,2,0,3.4,0.0,0.0,12.55,1,MSS,0,44.9,TIL-intermediate,1317,0.77,34,3030,1,34.7,93,0.841,0.591,PD-L1-negative,Q3,Pembrolizumab+Chemo,Combination,7.2,2,Discontinued_irAE,1,0,1.36,4.58,3.38,187,248,0,10.9,9.0,5.1,22.45,1319,891,12.8,5.8,Tier1_FDA-approved,17.1,57,20.0,0,0,0,0,,PD,0,0,20.0,0.0,34.7,34.7,,,0,0,99.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,35,40,0.96,1.02,3.586,1.23,21.9,0.0251,185,14.1,1,41.2,0,0,0,0,17.8,BSC,None
HC-ONC-013-000374,TNBC,69,Female,2,Second-line,Never,0.0,28.7,1,IBD,0,0,1,1,0,2.94,54.4,67.5,33.91,1,MSS,0,36.8,TIL-intermediate,991,0.78,18,8346,1,71.0,137,0.574,0.987,PD-L1-high,Q4,Pembrolizumab+Chemo,Combination,31.2,10,Discontinued_Progression,1,0,0.59,2.67,4.49,153,136,0,56.5,58.9,7.9,4.67,1145,522,10.0,6.8,Tier1_FDA-approved,45.8,630,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,71.0,0.0,6.0,37.9,0,0,-91.9,1,1,1,3,1.1,1,8.6,1,1,0,0,0,0,0,0,0,1,0,0,0,2,0,0,3,0,0,0,0,0,0,1,386,459,3.92,0.68,3.428,1.17,16.8,0.005,111,14.4,1,67.5,1,0,0,0,19.1,Targeted,Disease_Progression
HC-ONC-013-000375,NSCLC,54,Male,1,Second-line,Current,9.0,20.7,0,None,0,0,1,6,0,3.3,95.7,82.8,17.45,1,MSS,0,16.3,TIL-intermediate,255,1.8,26,5484,5,123.0,96,-0.497,-0.384,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,31.0,10,Discontinued_irAE,0,0,1.92,9.38,4.87,179,277,1,56.3,1.0,4.6,2.33,1047,584,9.9,7.6,Tier1_FDA-approved,48.6,293,9.44,0,1,0,0,,PR,1,1,-38.8,38.8,123.0,75.3,6.0,11.4,0,0,-46.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,22,26,1.48,1.18,3.075,1.62,26.9,0.025,70,44.8,1,65.3,0,0,0,0,52.5,None,None
HC-ONC-013-000376,Melanoma,62,Female,1,Second-line,Current,21.0,22.9,0,None,0,0,1,6,0,4.41,0.0,0.0,16.11,1,MSS,0,20.8,TIL-intermediate,417,1.29,33,816,5,79.8,76,0.715,-0.049,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,36.9,12,Discontinued_Progression,0,0,2.05,3.28,1.6,205,165,0,28.4,10.3,4.1,5.21,310,802,11.6,5.6,Tier1_FDA-approved,13.6,639,12.26,0,0,0,0,,SD,0,1,-20.1,20.1,79.8,63.8,,,0,0,34.7,0,1,0,1,3.9,1,1.0,0,0,1,40,7,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,28,22,1.22,1.13,2.141,0.98,15.6,0.0077,197,10.7,0,23.3,1,0,0,0,12.9,Targeted,Disease_Progression
HC-ONC-013-000377,HNSCC,85,Female,1,First-line,Former,29.2,21.4,1,IBD,0,0,0,2,0,3.51,53.9,49.9,4.42,0,MSS,0,18.1,TIL-intermediate,400,1.2,11,2006,2,114.4,22,0.309,-0.585,PD-L1-high,Q1,Nivolumab,Anti-PD-1,23.5,7,Discontinued_Progression,0,0,3.13,9.66,3.09,192,313,1,7.3,90.4,12.1,9.5,1033,668,12.2,2.9,Tier1_FDA-approved,29.8,105,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,114.4,0.0,6.0,22.6,0,0,-74.6,0,1,0,3,10.0,1,7.3,0,0,1,72,3,0,0,0,1,0,0,0,0,2,0,0,0,1,0,0,1,0,0,0,36,35,0.73,0.84,4.174,0.98,18.5,0.0347,72,79.0,0,119.0,1,1,1,0,83.3,BSC,Disease_Progression
HC-ONC-013-000378,NSCLC,59,Female,0,First-line,Former,8.7,15.3,0,None,0,0,0,6,0,2.9,58.2,99.1,4.3,0,MSS,0,16.8,TIL-intermediate,331,0.68,23,954,1,138.2,21,0.134,-0.53,PD-L1-high,Q1,Nivolumab,Anti-PD-1,38.6,12,Active,0,0,1.2,8.58,7.13,176,709,1,6.6,8.6,10.6,7.37,1417,286,6.1,4.5,Tier1_FDA-approved,19.9,837,13.79,0,0,0,0,,CR,1,1,-100.0,100.0,138.2,0.0,6.8,5.1,0,0,-72.0,0,1,0,2,8.4,0,,0,0,1,54,5,0,0,0,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,0,37,37,1.48,1.14,57.655,0.58,13.7,0.0104,160,32.0,1,91.7,0,0,0,0,37.5,None,None
HC-ONC-013-000379,HNSCC,74,Female,1,First-line,Former,46.6,32.8,0,None,0,0,0,2,0,2.8,65.1,100.0,16.29,1,MSS,0,37.2,TIL-intermediate,947,1.66,45,676,5,56.5,116,-0.612,0.065,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,65.7,21,Discontinued_Progression,0,0,1.16,6.09,5.23,699,167,0,5.4,1.7,11.5,40.23,200,620,11.7,3.0,Tier1_FDA-approved,48.1,56,20.0,0,0,0,0,,PR,1,1,-59.8,59.8,56.5,22.7,17.6,20.1,1,0,-98.3,1,1,0,1,6.2,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,11,9,0.41,1.14,3.501,1.49,22.6,0.0317,140,14.7,1,94.4,1,0,0,0,17.3,Chemotherapy,Disease_Progression
HC-ONC-013-000380,NSCLC,52,Male,0,First-line,Current,11.8,24.9,0,None,0,0,0,2,0,3.06,29.8,37.7,3.57,0,MSS,0,22.3,TIL-intermediate,610,1.61,12,5690,3,72.5,19,-0.497,-0.458,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,85.3,28,Discontinued_Progression,0,0,0.56,11.18,19.82,146,299,1,31.5,3.5,6.4,2.53,1107,902,19.8,8.4,Tier3_exploratory,19.0,117,20.0,0,0,0,0,,PD,0,0,32.8,0.0,72.5,72.5,,,0,0,90.6,0,1,0,2,18.2,1,11.7,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,152,147,0.86,0.88,4.207,0.82,29.0,0.0086,109,8.0,1,17.6,1,0,0,0,7.5,Chemotherapy,Disease_Progression
HC-ONC-013-000381,NSCLC,60,Female,0,First-line,Former,20.9,24.8,0,None,0,0,0,3,0,4.51,0.0,0.0,7.55,0,MSS,0,30.7,TIL-intermediate,797,2.29,84,430,3,166.8,42,0.074,-0.259,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,36.6,12,Discontinued_Progression,0,0,1.47,12.0,8.19,263,138,0,3.6,9.5,4.7,5.48,852,593,9.9,9.0,Tier2_emerging,22.6,280,9.38,0,0,0,0,,SD,0,1,20.0,0.0,166.8,166.8,,,0,0,40.9,0,1,0,1,9.3,1,5.5,0,0,1,10,6,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,10,10,0.37,1.17,1.014,1.35,15.1,0.0222,99,27.1,0,90.1,0,0,0,0,27.2,Targeted,None
HC-ONC-013-000382,TNBC,82,Female,0,First-line,Never,0.0,34.0,0,None,0,0,0,1,0,3.05,65.1,92.5,19.12,1,MSS,0,60.6,TIL-high,1809,1.71,91,619,5,137.8,151,2.0,0.842,PD-L1-high,Q3,Pembrolizumab+Chemo,Combination,4.9,1,Discontinued_Progression,1,0,2.36,4.11,1.74,329,189,0,24.0,36.5,6.7,15.47,645,100,5.8,6.3,Tier1_FDA-approved,47.4,5501,19.66,0,0,0,0,,PR,1,1,-61.1,61.1,137.8,53.6,7.8,39.1,0,0,-58.1,0,1,1,5,2.3,1,9.2,1,1,1,123,4,0,0,0,0,1,0,1,1,1,0,3,1,0,0,0,1,0,0,1,79,68,0.7,1.19,4.288,1.1,12.4,0.0357,178,29.8,1,40.9,0,0,0,0,29.4,None,None
HC-ONC-013-000383,TNBC,53,Female,2,Third+,Never,0.0,24.1,0,None,0,1,3,4,0,3.18,57.9,92.8,5.03,0,MSS,0,47.8,TIL-intermediate,912,1.54,12,481,2,13.1,17,0.301,0.223,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,91.9,30,Active,0,0,1.29,2.99,2.32,335,203,0,4.1,4.9,11.0,14.72,1140,678,11.2,6.7,Tier1_FDA-approved,36.0,1309,20.0,0,0,0,0,,PR,1,1,-44.8,44.8,13.1,7.2,15.7,22.6,0,0,-48.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,23,20,0.56,0.73,3.604,1.56,19.6,0.0122,111,25.3,0,49.4,0,0,0,0,32.4,BSC,None
HC-ONC-013-000384,HNSCC,82,Male,0,Third+,Former,14.8,22.3,0,None,0,1,3,2,0,2.81,56.4,69.5,51.67,1,MSS,0,5.4,TIL-low,153,2.97,98,302,1,95.5,281,-0.611,-0.486,PD-L1-high,Q5,Nivolumab,Anti-PD-1,45.8,15,Discontinued_Complete_Response,0,0,3.89,1.76,1.0,238,182,0,27.8,19.9,1.3,0.94,1413,560,8.4,5.5,Tier1_FDA-approved,45.8,2030,1.55,0,0,0,0,,SD,0,1,13.7,0.0,95.5,95.5,,,0,0,90.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,26,19,0.68,0.64,2.966,1.27,25.5,0.0041,94,27.6,1,32.5,1,0,0,0,32.9,Targeted,Disease_Progression
HC-ONC-013-000385,Urothelial,69,Female,1,Second-line,Former,40.5,25.4,0,None,0,0,1,1,0,4.08,12.9,20.4,36.65,1,MSS,0,0.0,TIL-low,0,0.86,30,2155,3,80.0,252,-0.832,-0.636,PD-L1-low,Q5,Pembrolizumab,Anti-PD-1,22.1,7,Discontinued_Progression,0,0,1.49,12.0,8.07,217,686,1,12.4,1.3,10.1,4.47,1133,234,5.3,5.7,Tier1_FDA-approved,23.3,3380,0.5,0,0,0,0,,PD,0,0,69.7,0.0,80.0,80.0,,,0,0,52.3,0,1,0,1,31.0,0,,0,0,1,37,12,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,31,36,1.44,0.8,1.994,1.63,29.6,0.022,90,9.8,0,81.7,0,0,0,0,15.3,Chemotherapy,None
HC-ONC-013-000386,HNSCC,54,Male,0,First-line,Never,0.0,20.8,0,None,0,0,0,7,0,4.77,63.1,79.7,63.04,1,MSI-H,1,22.2,TIL-intermediate,454,2.16,46,7287,5,113.1,237,-0.492,0.38,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,11.7,3,Discontinued_Progression,0,0,1.75,3.6,2.06,307,172,0,46.2,1.3,9.5,14.7,789,264,12.7,1.8,Tier1_FDA-approved,50.0,89702,9.66,0,0,0,0,0.413,PR,1,1,-33.3,33.3,113.1,75.4,6.0,101.1,0,0,-38.0,0,1,0,1,5.0,0,,0,0,1,10,6,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,21,23,0.81,0.89,4.117,1.2,12.9,0.0075,77,15.4,1,72.1,1,0,0,0,21.4,BSC,Disease_Progression
HC-ONC-013-000387,NSCLC,68,Male,2,Third+,Never,0.0,28.2,0,None,0,0,2,6,0,3.56,94.6,100.0,5.26,0,MSS,0,17.4,TIL-intermediate,453,0.71,22,1448,5,50.2,32,2.0,1.969,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,11.5,3,Discontinued_Complete_Response,0,0,0.96,7.91,8.27,280,269,1,38.1,4.1,7.8,45.26,617,795,8.4,4.9,Tier1_FDA-approved,41.4,429,19.7,0,0,0,0,,CR,1,1,-100.0,100.0,50.2,0.0,23.3,13.1,0,0,-69.6,0,1,0,1,3.6,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,16,18,0.69,0.66,0.676,1.63,26.1,0.0287,100,44.0,1,83.7,0,0,0,0,46.8,Clinical_Trial,None
HC-ONC-013-000388,NSCLC,72,Male,0,First-line,Current,4.7,24.6,0,None,0,1,0,5,1,3.27,0.0,0.0,1.56,0,MSS,0,21.3,TIL-intermediate,353,1.08,69,297,4,46.4,7,-0.399,-1.045,PD-L1-negative,Q1,Durvalumab,Anti-PD-L1,12.9,4,Discontinued_Progression,0,0,1.85,3.09,1.67,215,100,0,51.2,41.5,6.6,7.87,943,454,8.9,3.2,Tier3_exploratory,10.3,3397,5.04,0,0,1,0,,SD,0,1,20.0,0.0,46.4,46.4,,,0,0,53.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,22,16,1.07,0.68,2.227,1.52,18.6,0.0235,50,1.0,0,27.4,0,0,0,0,9.6,Chemotherapy,None
HC-ONC-013-000389,Urothelial,68,Male,1,Second-line,Never,0.0,24.0,0,None,0,0,1,2,0,3.23,54.4,68.7,6.02,0,MSS,0,19.8,TIL-intermediate,530,0.9,46,4954,5,53.0,44,0.907,0.708,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,5.2,1,Discontinued_Progression,0,0,0.75,9.67,12.95,112,249,0,52.5,8.0,0.9,3.34,1162,419,12.8,5.6,Tier1_FDA-approved,25.8,1843,11.28,0,0,0,0,,PD,0,0,57.3,0.0,53.0,53.0,,,0,0,-20.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,10,10,1.12,1.18,3.527,1.63,14.8,0.0142,41,40.5,1,81.0,1,0,0,0,45.2,BSC,None
HC-ONC-013-000390,HNSCC,42,Female,2,First-line,Former,39.3,23.5,0,None,0,0,0,6,0,1.29,35.2,55.9,24.28,1,MSS,0,58.8,TIL-high,1350,2.44,17,13668,2,57.1,113,-0.376,-0.614,PD-L1-low,Q4,Nivolumab,Anti-PD-1,70.2,23,Discontinued_Progression,0,0,2.18,3.16,1.45,194,355,1,14.1,10.5,5.2,2.0,784,593,4.3,4.9,Tier1_FDA-approved,49.9,1797,20.0,0,0,0,0,,PR,1,1,-63.1,63.1,57.1,21.0,21.1,13.1,0,0,-89.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,35,28,1.48,1.04,3.745,1.61,15.5,0.0278,122,15.8,1,26.6,0,0,0,0,19.7,None,None
HC-ONC-013-000391,Hodgkin,52,Male,2,Second-line,Current,30.4,26.0,0,None,0,0,1,6,0,3.8,81.2,100.0,8.39,0,MSS,0,13.4,TIL-intermediate,260,1.6,13,833,3,112.6,39,0.261,0.033,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,33.8,11,Discontinued_Progression,0,0,2.2,2.47,1.12,138,154,0,3.8,10.3,30.9,26.44,813,471,3.3,8.9,Tier1_FDA-approved,38.1,5775,18.57,0,0,0,0,,SD,0,1,10.4,0.0,112.6,112.6,,,0,0,95.8,0,1,0,1,9.8,1,8.0,0,0,1,35,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,22,22,0.96,1.12,1.309,1.29,28.6,0.0101,107,15.7,1,34.5,0,0,0,0,22.0,Chemotherapy,None
HC-ONC-013-000392,Melanoma,58,Male,0,First-line,Never,0.0,26.9,0,None,0,1,0,6,0,3.31,0.0,0.0,18.44,1,MSS,0,0.0,TIL-low,0,1.64,10,1018,4,32.8,110,0.792,0.63,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,45.3,15,Discontinued_Progression,0,0,2.84,4.04,1.42,175,100,0,4.3,28.0,7.5,8.03,1747,620,15.4,6.8,Tier1_FDA-approved,3.6,215,0.5,0,0,0,0,,PR,1,1,-32.3,32.3,32.8,22.2,8.4,12.1,1,0,-66.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,29,29,1.2,1.18,0.69,1.17,26.6,0.0358,59,18.1,1,74.8,0,0,0,0,23.4,Chemotherapy,None
HC-ONC-013-000393,Melanoma,60,Male,2,Third+,Never,0.0,23.9,0,None,0,0,3,6,0,3.54,5.9,5.8,3.1,0,MSS,0,25.0,TIL-intermediate,615,0.95,38,3357,3,55.1,12,-0.572,-0.45,PD-L1-low,Q1,Nivolumab+Ipilimumab,Combination,58.3,19,Active,0,0,1.1,3.44,3.13,249,197,0,1.5,3.6,5.8,2.27,1224,559,2.3,5.6,Tier3_exploratory,14.6,191,15.77,0,0,0,0,,PR,1,1,-59.3,59.3,55.1,22.4,6.0,17.3,0,0,-78.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,20,22,0.76,0.83,3.711,1.57,17.6,0.0142,48,16.4,0,33.9,1,0,0,0,23.1,BSC,Other
HC-ONC-013-000394,Urothelial,68,Male,1,Third+,Former,38.1,24.7,0,None,1,0,3,6,0,2.63,75.2,95.3,24.98,1,MSS,0,14.4,TIL-intermediate,260,1.42,52,12661,3,10.0,111,-0.641,-0.269,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,54.0,17,Active,0,0,1.76,6.04,3.43,293,202,0,4.1,16.9,7.5,3.81,1245,360,7.1,4.5,Tier1_FDA-approved,53.5,652,4.91,1,0,0,0,,PD,0,0,28.4,0.0,10.0,10.0,,,0,0,42.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,24,0.51,1.01,2.188,1.16,28.9,0.03,54,38.1,1,84.3,1,0,0,0,44.9,Clinical_Trial,Disease_Progression
HC-ONC-013-000395,Melanoma,63,Male,1,First-line,Former,40.7,26.1,0,None,0,0,0,2,1,2.89,62.4,100.0,19.85,1,MSI-H,1,24.7,TIL-intermediate,382,1.13,56,969,2,120.3,101,1.659,1.332,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,66.5,22,Discontinued_Complete_Response,0,0,2.07,4.37,2.11,596,288,1,13.1,2.7,9.8,5.74,462,498,3.0,8.4,Tier1_FDA-approved,43.4,307,6.7,0,0,0,0,0.414,PR,1,1,-57.0,57.0,120.3,51.7,14.3,43.2,0,0,-100.0,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,26,19,0.82,0.71,1.074,0.89,13.9,0.0108,84,41.8,0,60.6,1,0,0,0,45.1,None,Disease_Progression
HC-ONC-013-000396,MSI-H_CRC,44,Male,0,First-line,Former,41.4,25.6,0,None,0,0,0,7,1,2.87,17.0,26.5,59.1,1,MSI-H,1,45.5,TIL-intermediate,979,2.0,30,365,5,130.8,282,0.985,0.738,PD-L1-low,Q5,Nivolumab,Anti-PD-1,90.8,30,Active,0,0,1.97,6.13,3.12,187,548,1,7.0,79.8,12.5,6.92,688,689,9.6,4.9,Tier1_FDA-approved,53.2,651,20.0,0,0,0,0,0.35,PR,1,1,-33.4,33.4,130.8,87.1,20.7,26.7,0,0,-76.9,0,1,0,1,3.1,0,,1,0,1,63,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,16,19,0.8,0.93,0.842,1.66,17.8,0.0282,107,26.6,1,43.9,1,0,0,0,31.0,None,Disease_Progression
HC-ONC-013-000397,HNSCC,65,Female,0,Third+,Current,10.5,26.7,0,None,0,0,3,4,0,4.02,0.0,0.0,11.21,1,MSS,0,39.3,TIL-intermediate,924,1.0,13,3857,2,66.9,63,0.791,0.151,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,27.8,9,Active,0,0,1.17,3.87,3.32,360,166,0,10.2,2.8,6.2,2.18,922,608,14.1,5.7,Tier1_FDA-approved,25.6,4205,20.0,0,0,0,0,,PR,1,1,-46.0,46.0,66.9,36.1,9.6,33.7,0,0,-54.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,29,33,0.8,0.73,3.063,1.2,23.8,0.0022,63,21.4,1,85.0,1,0,0,0,23.6,Chemotherapy,Disease_Progression
HC-ONC-013-000398,Melanoma,68,Female,1,First-line,Never,0.0,23.1,0,None,0,0,0,3,0,2.9,39.6,32.9,50.53,1,MSI-H,1,0.0,TIL-low,0,3.21,19,4717,5,68.1,303,0.787,0.158,PD-L1-low,Q5,Nivolumab+Ipilimumab,Combination,83.2,27,Discontinued_Progression,0,0,0.63,3.21,5.07,285,131,0,19.9,2.6,10.4,2.74,600,584,12.6,5.1,Tier1_FDA-approved,33.3,197,0.5,0,0,0,0,0.35,SD,0,1,0.2,0.0,68.1,68.1,,,0,0,44.5,0,1,0,2,8.1,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,13,12,1.13,1.97,2.831,0.93,30.0,0.0122,158,10.0,0,82.7,1,0,0,0,10.7,Clinical_Trial,Disease_Progression
HC-ONC-013-000399,Urothelial,67,Female,1,Third+,Former,51.5,31.5,0,None,0,0,3,6,1,4.87,75.9,96.2,4.32,0,MSS,0,11.6,TIL-intermediate,337,0.71,83,1821,4,98.1,25,0.46,-0.444,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,47.3,15,Active,0,0,1.89,3.35,1.77,468,112,0,9.0,14.3,28.3,1.19,1380,987,24.0,4.2,Tier1_FDA-approved,40.6,255,4.01,0,0,0,0,,CR,1,1,-100.0,100.0,98.1,0.0,16.2,63.0,0,0,-74.7,0,1,0,1,5.6,0,,0,0,1,10,2,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,24,18,0.79,0.66,3.916,1.45,20.4,0.0045,63,39.5,0,89.0,0,0,0,0,45.1,Clinical_Trial,None
HC-ONC-013-000400,Urothelial,73,Male,1,Second-line,Former,23.1,27.0,0,None,0,0,1,6,0,3.54,2.5,3.6,29.11,1,MSS,0,26.4,TIL-intermediate,606,1.1,22,925,2,139.0,183,2.0,0.773,PD-L1-low,Q4,Atezolizumab,Anti-PD-L1,7.0,2,Hold_irAE,0,0,1.55,12.0,7.74,326,221,0,4.0,8.1,16.5,10.3,1323,746,17.4,5.1,Tier1_FDA-approved,14.4,524,20.0,0,0,0,0,,PD,0,0,20.0,0.0,139.0,139.0,,,0,0,86.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,32,30,1.44,0.95,0.626,1.69,26.6,0.0181,51,26.6,1,57.3,1,0,0,0,32.5,Chemotherapy,Disease_Progression
HC-ONC-013-000401,NSCLC,71,Male,1,First-line,Current,19.3,24.0,0,None,0,0,0,3,0,2.18,50.7,82.6,17.45,1,MSS,0,31.6,TIL-intermediate,830,3.81,37,5963,2,96.3,79,0.044,1.007,PD-L1-high,Q3,Nivolumab,Anti-PD-1,43.8,14,Discontinued_Progression,0,0,1.31,5.02,3.82,148,255,1,11.6,10.9,48.0,3.41,740,770,7.3,1.1,Tier1_FDA-approved,39.9,286,20.0,0,0,0,0,,PR,1,1,-46.0,46.0,96.3,52.0,13.6,23.4,0,0,-100.0,1,1,0,1,8.4,1,5.5,1,0,1,34,11,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,26,25,1.48,1.17,3.974,1.66,28.5,0.0175,199,20.9,1,67.4,0,0,0,0,20.9,Chemotherapy,None
HC-ONC-013-000402,MSI-H_CRC,66,Female,1,First-line,Never,0.0,28.2,0,None,0,0,0,7,0,3.1,74.5,63.2,80.0,1,MSI-H,1,74.5,TIL-high,1608,1.33,14,3407,1,52.1,291,0.577,-0.05,PD-L1-high,Q5,Nivolumab+Ipilimumab,Combination,44.2,14,Discontinued_Progression,0,0,2.24,1.66,1.0,103,153,0,5.0,9.7,4.4,6.51,1435,567,6.0,1.9,Tier1_FDA-approved,87.7,23,20.0,0,1,0,0,0.441,SD,0,1,-3.5,3.5,52.1,50.3,,,0,0,49.5,0,1,0,2,10.9,1,8.2,0,0,1,50,6,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,2,32,36,0.93,0.67,4.049,1.35,12.2,0.0146,4640,16.9,1,47.9,0,0,0,0,19.5,Clinical_Trial,None
HC-ONC-013-000403,RCC,60,Male,0,First-line,Former,25.0,26.1,0,None,0,0,0,7,0,2.68,45.4,75.0,16.32,1,MSS,0,34.3,TIL-intermediate,899,0.85,43,719,2,15.2,111,-1.451,-1.467,PD-L1-low,Q3,Nivolumab+Ipilimumab,Combination,71.0,23,Discontinued_Progression,0,0,1.62,3.46,2.13,286,296,1,9.3,2.0,28.2,13.98,899,644,25.5,5.7,Tier1_FDA-approved,42.2,169,20.0,1,0,0,0,,PD,0,0,44.9,0.0,15.2,15.2,,,0,0,135.5,0,1,1,2,8.2,1,10.2,1,1,1,109,6,1,0,0,0,0,0,1,1,2,3,0,0,0,0,0,0,0,0,0,18,19,0.97,0.9,2.285,0.89,17.2,0.0383,59,32.8,1,89.2,0,0,0,0,36.9,Targeted,None
HC-ONC-013-000404,HNSCC,41,Male,1,Second-line,Former,37.4,17.8,0,None,0,0,1,2,0,1.44,0.0,0.0,13.86,1,MSS,0,19.1,TIL-intermediate,346,1.84,23,1918,1,35.4,101,-0.825,-0.335,PD-L1-negative,Q3,Pembrolizumab,Anti-PD-1,24.1,8,Discontinued_Progression,0,0,0.97,4.7,4.84,188,253,1,46.7,51.2,3.9,5.34,1677,514,17.3,8.1,Tier1_FDA-approved,17.9,1131,14.42,1,0,0,0,,SD,0,1,-12.1,12.1,35.4,31.1,,,0,0,52.6,0,1,0,1,2.1,1,5.4,1,0,1,52,10,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,11,8,0.79,1.01,0.807,1.5,13.8,0.0103,182,27.3,0,88.3,1,0,0,0,31.6,Clinical_Trial,Other
HC-ONC-013-000405,Melanoma,66,Male,0,First-line,Never,0.0,28.2,0,None,0,0,0,1,0,4.48,77.4,77.2,25.77,1,MSI-H,1,6.6,TIL-low,137,1.3,77,357,5,82.9,110,-1.201,-0.776,PD-L1-high,Q4,Nivolumab+Ipilimumab,Combination,36.7,12,Discontinued_Progression,0,0,0.76,11.28,14.81,150,205,0,9.3,21.6,9.8,4.09,943,756,14.9,5.7,Tier1_FDA-approved,47.1,3485,1.76,0,0,0,0,0.423,CR,1,1,-100.0,100.0,82.9,0.0,22.6,44.7,0,0,-66.4,0,1,0,2,11.2,1,5.7,0,0,1,60,3,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,12,12,0.73,0.9,4.287,1.41,26.0,0.0311,69,19.6,1,81.6,1,0,0,0,27.7,Chemotherapy,Disease_Progression
HC-ONC-013-000406,MSI-H_CRC,63,Male,1,First-line,Never,0.0,21.4,0,None,0,0,0,5,0,3.76,0.0,0.0,9.55,0,MSS,0,24.8,TIL-intermediate,609,1.09,61,4118,5,53.8,48,1.274,0.667,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,2.1,1,Discontinued_Progression,0,0,1.05,7.5,7.14,130,128,0,71.6,37.7,13.3,5.23,1073,578,12.4,3.6,Tier3_exploratory,13.4,71,9.82,0,0,0,0,,PR,1,1,-42.3,42.3,53.8,31.0,15.6,43.4,0,0,-64.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,18,14,1.48,1.15,0.788,1.01,22.2,0.018,187,26.8,1,60.7,0,0,0,0,29.6,Clinical_Trial,None
HC-ONC-013-000407,Melanoma,64,Male,1,First-line,Current,14.6,31.2,0,None,0,0,0,5,0,3.63,32.3,35.0,17.14,1,MSI-H,1,11.1,TIL-intermediate,170,0.95,22,1320,5,87.8,94,-2.0,-0.495,PD-L1-low,Q3,Nivolumab+Ipilimumab,Combination,21.8,7,Discontinued_Progression,0,0,4.0,2.83,1.0,265,157,0,51.0,3.9,4.9,4.71,1320,644,13.4,2.1,Tier1_FDA-approved,26.4,71,7.39,0,0,0,0,0.459,SD,0,1,-1.6,1.6,87.8,86.4,,,0,0,65.6,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,22,17,0.35,0.7,2.863,1.7,13.7,0.0137,50,36.9,1,89.1,0,0,0,0,40.6,Targeted,None
HC-ONC-013-000408,NSCLC,45,Male,2,Second-line,Never,0.0,25.3,0,None,0,0,1,1,0,3.33,50.0,66.6,26.66,1,MSI-H,1,29.8,TIL-intermediate,771,5.0,30,1072,1,57.9,151,-0.402,0.033,PD-L1-high,Q4,Nivolumab,Anti-PD-1,6.4,2,Discontinued_Progression,0,0,2.2,12.0,5.45,520,100,0,6.8,12.2,7.9,12.15,1283,632,4.6,6.6,Tier1_FDA-approved,41.3,422,20.0,0,0,0,0,0.355,CR,1,1,-100.0,100.0,57.9,0.0,6.5,84.1,0,0,-82.7,0,1,0,1,11.2,1,6.8,0,0,1,42,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,26,23,0.79,0.61,2.473,0.89,19.6,0.0087,173,50.8,1,76.0,0,0,0,0,56.1,None,None
HC-ONC-013-000409,MSI-H_CRC,48,Female,0,Third+,Never,0.0,30.4,0,None,1,1,4,2,0,2.09,58.2,49.6,78.36,1,MSI-H,1,39.6,TIL-intermediate,1091,1.45,21,1738,5,37.7,493,-2.0,-1.465,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,32.7,10,Discontinued_Complete_Response,0,0,1.78,4.41,2.48,199,225,0,4.0,9.4,15.3,5.75,1053,596,12.8,3.9,Tier1_FDA-approved,69.6,18,20.0,0,0,0,0,0.412,PR,1,1,-63.7,63.7,37.7,13.7,18.6,31.8,0,0,-89.7,0,1,0,1,1.0,1,5.6,1,0,1,28,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,33,24,0.48,0.83,3.84,1.17,21.3,0.0251,61,17.3,1,26.5,0,0,0,0,20.6,Targeted,None
HC-ONC-013-000410,NSCLC,73,Female,0,Third+,Former,31.0,23.3,0,None,0,0,3,5,0,2.81,0.0,0.0,48.54,1,MSS,0,0.1,TIL-low,3,0.63,11,1898,3,32.9,156,-0.831,-0.711,PD-L1-negative,Q5,Atezolizumab,Anti-PD-L1,57.0,18,Discontinued_irAE,0,0,1.53,8.36,5.45,329,203,0,11.6,28.6,4.2,2.9,858,1188,12.4,6.3,Tier1_FDA-approved,28.5,207,0.5,0,0,0,0,,PR,1,1,-64.9,64.9,32.9,11.5,15.8,28.4,0,0,-96.3,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,35,39,1.17,0.93,2.51,0.89,24.6,0.0137,190,29.9,1,70.9,1,0,0,0,32.9,None,Disease_Progression
HC-ONC-013-000411,Melanoma,60,Female,0,First-line,Current,7.6,26.8,0,None,0,0,0,7,0,3.87,0.0,0.0,20.86,1,MSS,0,13.5,TIL-intermediate,292,3.48,17,5292,2,142.5,138,-0.491,-0.546,PD-L1-negative,Q4,Nivolumab,Anti-PD-1,15.1,5,Discontinued_irAE,0,0,1.49,2.52,1.68,232,220,0,38.6,29.7,28.1,10.36,1054,467,7.5,5.8,Tier1_FDA-approved,21.2,30,16.22,0,0,0,0,,PR,1,1,-62.7,62.7,142.5,53.2,6.0,17.3,0,0,-61.7,0,1,1,2,16.2,1,4.6,1,1,1,100,5,0,0,0,0,0,0,1,1,1,0,4,0,0,0,0,0,0,0,0,31,29,0.53,0.75,2.376,1.71,26.0,0.0319,128,103.1,1,133.9,0,1,1,0,105.9,Targeted,None
HC-ONC-013-000412,Hodgkin,69,Female,0,Second-line,Former,47.5,32.6,0,None,0,0,1,3,0,2.36,0.0,0.0,6.42,0,MSS,0,57.6,TIL-high,1598,2.24,39,3675,1,115.6,21,1.385,1.268,PD-L1-negative,Q2,Nivolumab,Anti-PD-1,33.0,11,Active,0,0,2.63,1.35,1.0,128,258,1,7.5,9.3,2.4,11.99,655,465,9.3,6.0,Tier2_emerging,20.1,3145,20.0,1,1,0,0,,PR,1,1,-48.1,48.1,115.6,60.0,15.2,8.9,0,0,-57.7,0,1,0,1,1.2,1,7.7,0,0,1,24,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,24,24,1.36,0.7,4.023,0.84,13.6,0.0378,62,38.3,0,87.0,0,0,0,0,42.8,Clinical_Trial,None
HC-ONC-013-000413,Hodgkin,61,Female,0,Second-line,Former,40.1,25.2,0,None,0,0,1,1,1,1.17,0.0,0.0,13.54,1,MSS,0,47.0,TIL-intermediate,1253,1.12,43,1499,5,149.2,72,0.397,0.084,PD-L1-negative,Q3,Nivolumab,Anti-PD-1,14.9,4,Discontinued_Progression,0,0,1.35,2.22,1.64,353,243,0,30.2,1.2,34.9,1.54,946,739,19.6,5.1,Tier1_FDA-approved,21.8,127,20.0,0,0,0,0,,PD,0,0,42.4,0.0,149.2,149.2,,,0,0,11.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,18,18,0.75,1.08,4.356,1.23,20.8,0.0096,174,30.4,1,76.2,1,0,0,0,34.1,Chemotherapy,Disease_Progression
HC-ONC-013-000414,RCC,61,Female,2,Second-line,Never,0.0,23.5,0,None,0,1,1,7,1,3.02,65.8,82.4,15.07,1,MSS,0,28.5,TIL-intermediate,551,1.03,37,4521,3,101.6,108,-0.833,-1.396,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,10.2,3,Active,0,0,2.08,1.0,1.0,142,190,0,40.8,62.5,16.5,15.28,567,481,11.4,5.8,Tier1_FDA-approved,42.2,4814,14.5,0,0,0,0,,PD,0,0,45.4,0.0,101.6,101.6,,,0,0,72.0,0,1,0,1,26.2,1,5.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,82,97,1.4,0.71,2.697,1.66,14.9,0.0059,96,5.2,1,35.3,1,0,0,0,10.5,BSC,Other
HC-ONC-013-000415,TNBC,72,Female,0,Third+,Former,25.6,29.8,1,Psoriasis,0,1,3,4,0,3.09,0.0,0.0,11.06,1,MSI-H,1,47.7,TIL-intermediate,946,2.31,26,2925,2,62.8,58,1.066,0.615,PD-L1-negative,Q2,Atezolizumab,Anti-PD-L1,32.0,10,Discontinued_Progression,0,0,1.43,12.0,8.37,247,205,0,5.6,14.4,6.9,6.0,366,542,22.4,4.8,Tier1_FDA-approved,11.7,2144,20.0,0,0,0,0,0.38,PR,1,1,-40.4,40.4,62.8,37.4,12.8,32.8,0,0,-68.4,0,1,0,1,3.6,1,8.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,175,202,1.48,0.87,2.319,1.05,25.6,0.013,155,64.9,0,83.7,1,1,0,0,69.6,BSC,Disease_Progression
HC-ONC-013-000416,Melanoma,54,Female,0,First-line,Former,23.0,29.7,0,None,0,0,0,2,0,3.31,0.0,0.0,8.62,0,MSS,0,44.4,TIL-intermediate,1118,1.46,70,1084,2,132.9,32,0.018,-0.758,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,7.6,2,Discontinued_Progression,0,0,3.58,4.99,1.39,206,100,0,6.2,3.6,5.4,5.62,915,383,3.3,3.7,Tier2_emerging,16.0,153,15.75,0,0,0,0,,SD,0,1,-6.4,6.4,132.9,124.4,,,0,0,47.7,0,1,0,2,7.7,0,,0,0,1,49,2,0,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,29,32,1.23,1.17,0.233,2.94,23.8,0.0188,139,24.4,1,96.3,1,0,0,0,22.6,BSC,Disease_Progression
HC-ONC-013-000417,NSCLC,62,Male,1,First-line,Current,26.4,23.8,0,None,0,0,0,1,0,3.78,92.7,100.0,9.57,0,MSI-H,1,23.5,TIL-intermediate,552,0.63,35,1557,5,78.7,76,0.038,1.115,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,36.9,12,Discontinued_Progression,0,0,2.22,2.82,1.27,382,150,0,24.8,12.0,4.9,10.03,1279,698,9.4,3.1,Tier1_FDA-approved,56.6,81,15.33,0,0,1,0,0.492,PR,1,1,-30.0,30.0,78.7,55.1,12.9,59.7,1,0,-48.5,0,1,0,1,10.7,1,2.9,1,0,1,48,5,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,35,31,1.05,0.97,3.824,0.93,25.0,0.0124,151,16.7,0,26.1,1,0,0,0,17.2,Clinical_Trial,Disease_Progression
HC-ONC-013-000418,Melanoma,55,Male,1,Third+,Current,12.9,16.6,0,None,0,0,2,5,0,3.71,0.0,0.0,34.94,1,MSI-H,1,14.2,TIL-intermediate,248,4.03,58,1513,3,88.8,260,-1.203,-1.204,PD-L1-negative,Q4,Nivolumab+Ipilimumab,Combination,4.0,1,Hold_irAE,0,0,2.71,5.62,2.07,144,205,0,14.2,1.2,6.6,2.85,1178,701,4.3,0.2,Tier1_FDA-approved,16.0,302,4.2,0,0,0,0,0.413,SD,0,1,-1.6,1.6,88.8,87.3,,,0,0,72.7,0,1,0,1,8.3,1,5.9,0,0,1,36,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,26,20,0.48,0.9,1.778,1.2,13.3,0.0379,88,14.3,1,92.9,1,0,0,0,17.3,Targeted,None
HC-ONC-013-000419,TNBC,55,Female,1,First-line,Never,0.0,23.4,0,None,0,0,0,2,1,3.41,0.0,0.0,25.39,1,MSI-H,1,21.7,TIL-intermediate,426,1.33,8,3315,1,78.3,174,-0.99,-0.675,PD-L1-negative,Q4,Atezolizumab,Anti-PD-L1,9.3,3,Discontinued_Progression,0,0,1.31,4.93,3.78,298,139,0,6.1,26.2,7.1,9.62,875,537,6.0,4.6,Tier1_FDA-approved,28.5,345,20.0,1,1,0,0,0.354,SD,0,1,11.8,0.0,78.3,78.3,,,0,0,51.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,11,1.42,0.82,2.805,1.23,21.2,0.0306,190,5.2,1,13.1,1,0,0,0,11.1,Clinical_Trial,Disease_Progression
HC-ONC-013-000420,Urothelial,57,Male,0,Second-line,Former,31.9,29.9,0,None,0,0,1,3,0,4.16,0.0,0.0,33.27,1,MSI-H,1,23.7,TIL-intermediate,677,3.48,1,1164,5,10.0,168,-0.825,-0.366,PD-L1-negative,Q4,Durvalumab,Anti-PD-L1,34.4,11,Hold_irAE,0,0,2.52,6.11,2.43,161,308,1,8.6,1.3,20.2,3.32,1424,743,7.9,8.0,Tier1_FDA-approved,27.8,678,20.0,0,0,0,0,0.35,PR,1,1,-47.5,47.5,10.0,5.3,26.8,60.2,0,0,-72.7,0,1,0,1,7.5,1,9.0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,38,35,1.23,0.91,1.116,1.52,27.1,0.0377,125,60.3,1,120.5,0,1,1,0,63.0,None,None
HC-ONC-013-000421,Urothelial,63,Female,1,Third+,Never,0.0,22.6,0,None,0,0,4,2,0,1.98,0.0,0.0,5.24,0,MSS,0,0.0,TIL-low,0,3.12,42,1132,2,144.2,21,0.046,-0.116,PD-L1-negative,Q1,Pembrolizumab,Anti-PD-1,37.1,12,Discontinued_Progression,0,0,1.45,8.21,5.64,190,144,0,11.4,5.7,35.7,1.38,729,228,13.6,6.5,Tier3_exploratory,4.3,126,0.5,0,0,0,0,,PD,0,0,47.5,0.0,144.2,144.2,,,0,0,72.6,0,1,0,1,3.3,1,3.7,0,0,1,59,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,19,15,0.65,1.04,3.042,1.04,24.8,0.0152,11302,26.0,0,109.6,1,0,0,0,30.8,Clinical_Trial,Disease_Progression
HC-ONC-013-000422,Urothelial,55,Female,0,First-line,Former,47.4,26.4,0,None,0,0,0,2,0,3.6,0.0,0.0,3.54,0,MSS,0,17.2,TIL-intermediate,513,1.0,11,19197,2,99.6,27,0.078,-0.098,PD-L1-negative,Q1,Atezolizumab,Anti-PD-L1,3.8,1,Discontinued_Progression,0,0,1.72,3.88,2.25,50,223,0,2.5,9.9,8.7,2.02,325,459,13.3,5.5,Tier3_exploratory,9.7,1236,20.0,0,0,0,0,,PD,0,0,35.7,0.0,99.6,99.6,,,0,0,128.3,0,1,0,1,2.2,1,4.3,0,0,1,44,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,37,28,0.86,1.09,3.836,1.5,27.5,0.0126,41,19.5,1,95.4,0,0,0,0,24.7,None,None
HC-ONC-013-000423,NSCLC,76,Male,0,Third+,Former,17.8,23.2,0,None,0,0,2,3,0,3.7,12.0,14.4,35.23,1,MSS,0,16.9,TIL-intermediate,448,2.76,28,5584,2,93.2,199,1.544,1.137,PD-L1-low,Q4,Nivolumab,Anti-PD-1,35.9,11,Active,0,0,3.17,2.89,1.0,696,212,0,26.2,25.7,3.8,7.05,245,566,8.6,3.5,Tier1_FDA-approved,20.9,601,15.45,0,0,0,0,,PR,1,1,-39.1,39.1,93.2,56.8,12.1,22.4,0,0,-97.2,1,1,0,2,15.0,1,3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,34,32,0.38,0.99,1.25,1.8,15.7,0.0165,155,33.5,1,113.3,0,0,0,0,38.6,Targeted,None
HC-ONC-013-000424,Melanoma,50,Female,2,First-line,Never,0.0,16.8,0,None,0,1,0,6,0,2.21,13.2,20.3,23.54,1,MSS,0,0.0,TIL-low,0,1.19,26,726,5,77.5,171,0.385,0.994,PD-L1-low,Q4,Nivolumab,Anti-PD-1,59.7,19,Completed_2yr,0,0,1.09,6.78,6.24,322,291,1,7.5,8.4,4.8,2.1,546,366,0.9,7.0,Tier1_FDA-approved,14.3,242,0.5,0,0,0,0,,PR,1,1,-45.1,45.1,77.5,42.5,6.9,50.3,0,0,-52.3,0,1,0,1,4.7,1,4.1,0,0,1,36,10,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,115,118,1.09,1.07,1.792,1.66,17.2,0.0209,174,29.3,0,96.4,1,0,0,0,32.2,BSC,Disease_Progression
HC-ONC-013-000425,NSCLC,58,Male,0,First-line,Former,35.5,23.1,0,None,0,0,0,3,0,2.0,95.3,100.0,37.68,1,MSS,0,6.1,TIL-low,111,0.65,118,3587,4,86.5,177,-2.0,-0.816,PD-L1-high,Q5,Nivolumab,Anti-PD-1,47.2,15,Active,0,0,1.79,6.69,3.74,167,314,1,0.8,15.8,6.4,16.25,1145,250,19.4,4.8,Tier1_FDA-approved,63.7,139,0.93,0,0,0,0,,PR,1,1,-32.8,32.8,86.5,58.1,11.7,16.3,0,0,-100.0,1,1,0,1,18.8,1,7.2,0,0,1,32,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,12,12,0.45,0.65,2.296,1.44,19.9,0.0292,148,6.5,0,46.3,1,0,0,0,8.2,BSC,Disease_Progression
HC-ONC-013-000426,RCC,55,Female,1,Second-line,Former,34.7,29.9,0,None,0,1,1,7,0,2.6,67.7,80.5,58.39,1,MSI-H,1,32.1,TIL-intermediate,854,1.33,46,2084,4,56.1,273,0.263,0.897,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,10.8,3,Completed_2yr,0,0,1.96,4.71,2.4,139,283,1,11.9,7.1,3.2,11.6,710,538,10.6,8.1,Tier1_FDA-approved,59.6,306,18.17,0,1,0,0,0.493,PR,1,1,-57.3,57.3,56.1,24.0,6.0,39.5,0,0,-100.0,1,1,0,2,14.9,1,7.8,0,0,1,19,2,0,0,0,1,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,38,42,1.08,0.61,29.061,0.41,21.4,0.0345,77,28.9,0,69.4,1,0,0,0,30.2,BSC,Disease_Progression
HC-ONC-013-000427,Melanoma,78,Male,1,Third+,Never,0.0,15.0,0,None,0,0,2,2,0,2.67,20.8,20.2,23.77,1,MSI-H,1,23.5,TIL-intermediate,359,2.01,38,2892,4,104.7,188,-1.45,-1.393,PD-L1-low,Q4,Nivolumab+Ipilimumab,Combination,37.2,12,Active,0,0,2.03,12.0,5.91,191,100,0,5.8,7.1,2.9,13.02,1038,739,6.4,3.0,Tier1_FDA-approved,31.4,118,9.21,0,0,0,0,0.387,PR,1,1,-71.5,71.5,104.7,29.8,8.4,45.7,0,0,-77.1,0,1,1,3,1.4,1,9.2,1,1,1,130,6,1,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,2,30,28,1.11,1.04,3.425,1.79,16.5,0.0186,31536,12.8,1,56.4,0,0,0,0,22.7,BSC,None
HC-ONC-013-000428,MSI-H_CRC,63,Male,0,First-line,Former,28.5,27.8,0,None,0,0,0,3,0,3.8,72.6,74.5,10.76,1,MSI-H,1,36.8,TIL-intermediate,923,1.31,65,2132,3,27.7,60,-0.966,-0.421,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,43.0,14,Hold_irAE,0,0,1.38,3.6,2.62,350,364,1,65.9,8.2,39.6,4.95,1394,856,13.4,3.5,Tier1_FDA-approved,38.4,440,13.98,0,0,0,0,0.443,PR,1,1,-59.6,59.6,27.7,11.2,11.7,48.9,1,0,-100.0,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,15,0.69,0.76,1.767,1.37,18.9,0.012,126,17.7,1,80.7,1,0,0,0,22.6,Targeted,Disease_Progression
HC-ONC-013-000429,Melanoma,73,Male,2,First-line,Never,0.0,20.6,0,None,0,0,0,6,0,2.71,97.2,100.0,10.58,1,MSS,0,24.6,TIL-intermediate,542,1.41,44,7537,5,87.4,39,-0.812,-0.41,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,4.5,1,Active,0,0,3.8,2.86,1.0,95,430,1,6.8,5.9,9.4,5.51,570,491,13.0,3.3,Tier1_FDA-approved,45.2,459,12.04,0,1,0,0,,PR,1,1,-30.0,30.0,87.4,61.2,6.0,15.1,0,0,-50.5,0,1,0,1,5.6,1,1.8,0,0,1,55,7,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,26,25,1.44,1.13,1.472,1.07,24.4,0.0131,63,89.2,1,157.5,1,1,1,0,96.9,Clinical_Trial,Disease_Progression
HC-ONC-013-000430,NSCLC,43,Male,0,Second-line,Never,0.0,29.5,0,None,0,0,1,7,0,2.51,27.9,34.2,16.59,1,MSS,0,21.4,TIL-intermediate,432,2.92,23,2737,2,102.5,68,-0.663,-0.222,PD-L1-low,Q3,Pembrolizumab,Anti-PD-1,62.1,20,Active,0,0,0.98,5.52,5.62,228,157,0,4.1,1.0,3.8,1.72,1044,747,10.4,2.0,Tier1_FDA-approved,34.6,597,18.0,1,0,0,0,,PD,0,0,36.9,0.0,102.5,102.5,,,0,0,33.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,29,35,1.23,0.92,3.283,1.71,23.6,0.0275,94,13.0,1,63.7,1,0,0,0,15.4,None,Other
HC-ONC-013-000431,NSCLC,64,Male,1,Second-line,Former,22.4,30.1,0,None,0,0,1,1,0,2.71,0.0,0.0,37.3,1,MSS,0,38.6,TIL-intermediate,1080,1.74,78,1678,3,72.1,202,-1.375,-0.137,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,71.0,23,Discontinued_Progression,0,0,2.96,3.2,1.08,593,226,0,20.2,2.9,14.2,9.94,1062,727,12.7,3.1,Tier1_FDA-approved,28.3,5707,13.67,0,0,0,0,,CR,1,1,-100.0,100.0,72.1,0.0,6.2,26.7,1,0,-43.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,12,0.9,0.89,2.42,1.64,14.0,0.0226,137,33.8,1,76.6,1,0,0,0,40.3,Targeted,Disease_Progression
HC-ONC-013-000432,Urothelial,71,Male,2,Second-line,Never,0.0,25.6,0,None,0,0,1,3,0,4.09,0.0,0.0,6.04,0,MSS,0,21.9,TIL-intermediate,608,1.08,14,6315,4,94.8,19,0.203,0.012,PD-L1-negative,Q1,Durvalumab,Anti-PD-L1,61.4,20,Discontinued_Progression,0,0,2.68,5.74,2.14,139,128,0,6.3,9.9,2.9,6.07,642,844,6.2,5.2,Tier3_exploratory,6.8,331,20.0,0,0,0,0,,PD,0,0,41.8,0.0,94.8,94.8,,,0,1,71.8,0,1,0,2,1.7,0,,0,0,1,40,8,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,13,12,1.4,1.06,2.874,0.88,29.7,0.0195,78,6.5,0,49.6,0,0,0,0,9.6,None,None
HC-ONC-013-000433,RCC,61,Female,1,First-line,Never,0.0,25.7,0,None,0,1,0,3,0,3.21,10.9,15.9,6.78,0,MSS,0,0.0,TIL-low,0,2.34,43,2392,1,40.3,36,-1.411,-1.049,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,57.9,19,Discontinued_Progression,0,0,3.53,2.95,1.0,255,100,0,5.6,5.5,3.1,7.06,1306,530,15.8,3.6,Tier3_exploratory,14.1,1821,0.5,0,0,0,0,,PD,0,0,20.0,0.0,40.3,40.3,,,0,0,54.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,18,16,1.33,1.04,3.095,1.74,22.1,0.0087,94,15.1,1,82.5,1,0,0,0,19.1,Chemotherapy,Other
HC-ONC-013-000434,NSCLC,73,Female,2,First-line,Former,48.2,22.5,0,None,0,0,0,2,0,3.06,57.9,95.7,9.23,0,MSS,0,44.5,TIL-intermediate,1073,1.82,10,2092,3,41.4,47,0.357,0.481,PD-L1-high,Q2,Nivolumab,Anti-PD-1,49.3,16,Hold_irAE,0,0,0.87,3.67,4.2,736,138,0,20.3,6.1,3.9,17.3,814,240,7.0,0.0,Tier1_FDA-approved,47.3,569,20.0,0,0,0,0,,PR,1,1,-44.0,44.0,41.4,23.2,25.1,63.3,0,0,-37.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,9,1.13,1.02,2.735,1.17,20.7,0.0343,91,35.8,0,52.7,0,0,0,0,39.2,Chemotherapy,None
HC-ONC-013-000435,NSCLC,54,Male,0,First-line,Former,21.0,19.8,0,None,0,0,0,7,1,3.11,30.1,31.8,1.83,0,MSS,0,25.6,TIL-intermediate,524,0.47,39,2635,3,89.5,13,2.0,0.311,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,40.1,13,Discontinued_Progression,0,0,1.16,11.54,9.9,336,153,0,4.3,5.0,27.8,2.76,785,614,9.0,7.1,Tier3_exploratory,25.4,282,13.1,0,0,0,0,,SD,0,1,-10.3,10.3,89.5,80.2,,,0,0,42.6,0,1,0,1,3.8,1,2.4,0,0,1,40,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,12,11,0.48,1.01,2.952,1.12,29.4,0.0307,108,9.2,1,29.2,1,0,0,0,11.5,Targeted,Disease_Progression
HC-ONC-013-000436,TNBC,77,Female,1,Second-line,Never,0.0,35.0,0,None,0,1,1,1,0,4.23,69.2,89.3,13.79,1,MSS,0,28.2,TIL-intermediate,599,2.04,39,1616,5,107.1,66,-1.329,-0.916,PD-L1-high,Q3,Pembrolizumab+Chemo,Combination,43.5,14,Discontinued_Progression,1,0,2.99,3.66,1.22,261,168,0,2.8,2.6,6.0,4.05,1533,397,15.2,1.6,Tier1_FDA-approved,39.7,337,14.98,0,0,0,0,,SD,0,1,-8.1,8.1,107.1,98.4,,,0,0,13.0,0,1,0,2,10.1,1,7.4,0,0,1,37,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,15,15,0.9,0.91,4.05,1.14,14.5,0.0063,145,12.6,1,110.2,1,0,0,0,14.9,BSC,Disease_Progression
HC-ONC-013-000437,NSCLC,85,Female,0,First-line,Former,2.8,22.2,0,None,0,0,0,4,0,2.6,78.4,100.0,2.23,0,MSS,0,1.2,TIL-low,33,2.01,127,1828,3,10.0,18,-0.285,-0.238,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,55.7,18,Discontinued_Progression,0,0,0.78,3.01,3.86,315,124,0,68.4,4.1,1.0,5.82,1057,455,18.0,6.2,Tier1_FDA-approved,31.3,369,0.5,0,0,0,0,,PR,1,1,-51.0,51.0,10.0,4.9,7.5,4.0,0,0,-77.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,15,14,1.34,1.16,3.973,1.12,21.8,0.015,163,37.9,1,73.4,1,0,0,0,41.8,Chemotherapy,Disease_Progression
HC-ONC-013-000438,HNSCC,56,Female,1,First-line,Current,26.4,34.3,0,None,0,0,0,4,0,4.25,4.2,4.8,12.78,1,MSS,0,25.9,TIL-intermediate,510,1.67,9,894,5,100.9,50,-2.0,-1.66,PD-L1-low,Q3,Pembrolizumab,Anti-PD-1,42.3,14,Discontinued_Progression,0,0,0.87,8.05,9.28,200,139,0,21.7,5.1,19.5,2.12,1178,540,19.9,5.1,Tier1_FDA-approved,16.9,614,20.0,0,0,0,0,,PD,0,0,48.9,0.0,100.9,100.9,,,0,0,52.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,12,1.03,1.13,1.096,1.32,26.5,0.0216,143,13.9,1,45.6,0,0,0,0,16.7,Clinical_Trial,None
HC-ONC-013-000439,TNBC,55,Female,3,Third+,Former,12.0,22.2,0,None,0,0,2,5,0,3.37,40.4,56.4,26.54,1,MSS,0,37.7,TIL-intermediate,1098,2.58,20,734,1,58.3,158,-0.301,0.348,PD-L1-low,Q4,Atezolizumab,Anti-PD-L1,21.6,7,Discontinued_Progression,0,0,1.36,2.65,1.95,469,199,0,9.4,7.4,5.8,3.86,1306,532,17.3,9.2,Tier1_FDA-approved,43.0,96,20.0,0,0,0,0,,PD,0,0,51.0,0.0,58.3,58.3,,,0,0,34.9,0,1,0,1,9.6,1,1.4,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,38,38,0.95,0.8,2.846,1.38,19.2,0.0183,34,2.5,1,70.3,1,0,0,0,6.8,Clinical_Trial,None
HC-ONC-013-000440,NSCLC,78,Male,0,First-line,Former,40.4,29.1,0,None,0,1,0,3,0,3.07,91.6,81.5,7.93,0,MSS,0,43.6,TIL-intermediate,772,1.18,64,546,2,72.3,27,0.643,-0.145,PD-L1-high,Q2,Pembrolizumab,Anti-PD-1,24.2,8,Active,0,0,1.78,3.17,1.78,200,136,0,12.1,11.8,1.7,6.65,705,628,10.4,7.0,Tier1_FDA-approved,51.2,45,11.88,0,0,0,0,,SD,0,1,13.7,0.0,72.3,72.3,,,0,0,165.7,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,27,22,1.45,1.08,2.257,1.23,25.3,0.0161,182,19.2,1,76.2,1,0,0,0,21.5,Chemotherapy,Disease_Progression
HC-ONC-013-000441,NSCLC,79,Male,1,Third+,Former,50.0,20.8,0,None,0,1,4,3,0,5.0,6.7,9.4,80.0,1,MSI-H,1,14.8,TIL-intermediate,369,1.95,43,340,2,26.4,500,0.721,0.364,PD-L1-low,Q5,Pembrolizumab,Anti-PD-1,69.2,23,Discontinued_Progression,0,0,3.12,5.98,1.92,92,263,1,20.2,5.9,5.7,3.45,1275,741,4.3,4.0,Tier1_FDA-approved,43.2,1076,8.39,0,0,0,0,0.381,SD,0,1,-18.8,18.8,26.4,21.4,,,0,0,101.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,23,20,0.32,1.13,1.642,1.21,28.2,0.0283,129,35.1,0,51.2,0,0,0,0,40.5,Chemotherapy,None
HC-ONC-013-000442,Hodgkin,54,Male,0,Second-line,Never,0.0,29.1,0,None,0,1,1,1,0,2.36,0.0,0.0,3.27,0,MSS,0,23.3,TIL-intermediate,583,0.75,38,629,4,45.9,26,0.077,0.193,PD-L1-negative,Q1,Nivolumab,Anti-PD-1,2.7,1,Discontinued_Progression,0,0,1.53,7.16,4.68,201,282,1,32.2,2.1,11.2,12.77,749,526,19.0,3.6,Tier3_exploratory,10.0,1552,14.95,0,0,0,0,,PD,0,0,39.9,0.0,45.9,45.9,,,0,0,102.2,0,1,0,1,5.2,1,6.3,0,0,1,25,9,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,27,23,0.31,0.97,3.025,1.54,16.7,0.0031,186,6.8,0,26.3,1,0,0,0,9.8,Chemotherapy,Other
HC-ONC-013-000443,Melanoma,55,Male,1,Second-line,Never,0.0,24.9,0,None,0,0,1,6,0,2.92,34.5,60.7,35.59,1,MSS,1,33.4,TIL-intermediate,628,2.02,15,1467,4,118.6,253,0.889,1.21,PD-L1-low,Q5,Nivolumab+Ipilimumab,Combination,45.2,15,Discontinued_Progression,0,0,1.29,8.25,6.38,151,659,1,5.7,1.4,10.2,1.34,737,679,18.9,8.0,Tier1_FDA-approved,46.2,1235,20.0,0,0,0,0,,SD,0,1,2.0,0.0,118.6,118.6,,,0,0,148.1,0,1,0,1,10.0,0,,0,0,1,55,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,10,11,1.37,0.93,2.544,0.8,16.3,0.0189,194,2.1,1,63.5,0,0,0,0,9.4,Clinical_Trial,None
HC-ONC-013-000444,Melanoma,57,Female,1,First-line,Former,39.4,24.9,0,None,0,1,0,4,0,2.21,64.8,98.2,22.37,1,MSS,0,33.9,TIL-intermediate,673,4.38,21,2046,1,81.3,129,2.0,1.195,PD-L1-high,Q4,Nivolumab,Anti-PD-1,85.0,28,Active,0,0,1.87,3.08,1.65,213,352,1,17.6,166.8,31.1,11.0,818,603,8.6,2.0,Tier1_FDA-approved,50.1,509,20.0,0,0,0,0,,SD,0,1,-18.0,18.0,81.3,66.7,,,0,0,92.1,0,1,1,4,8.2,1,1.0,1,0,1,92,10,0,0,0,0,0,1,0,0,1,0,0,2,0,0,0,0,3,0,1,144,105,0.35,7.82,3.6,1.75,18.5,0.011,110,7.1,1,61.5,0,0,0,0,11.0,Targeted,None
HC-ONC-013-000445,HNSCC,44,Male,2,First-line,Never,0.0,29.6,0,None,0,0,0,5,0,3.96,21.2,33.7,2.6,0,MSS,0,22.5,TIL-intermediate,620,1.0,90,1306,2,64.7,14,1.712,1.495,PD-L1-low,Q1,Pembrolizumab,Anti-PD-1,45.8,15,Hold_irAE,0,0,1.99,6.04,3.03,215,226,0,7.3,1.9,3.7,7.61,713,787,16.6,5.4,Tier3_exploratory,9.1,1275,6.81,1,0,0,0,,SD,0,1,5.2,0.0,64.7,64.7,,,0,0,29.2,0,1,0,2,4.0,1,4.4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,26,23,0.7,0.7,0.874,1.51,19.5,0.0042,186,20.8,1,46.8,1,0,0,0,24.6,Chemotherapy,Disease_Progression
HC-ONC-013-000446,MSI-H_CRC,49,Female,1,Second-line,Never,0.0,24.2,0,None,1,0,1,1,0,4.55,12.1,18.2,18.2,1,MSI-H,1,47.2,TIL-intermediate,1247,1.13,32,107,4,75.3,131,-0.523,0.037,PD-L1-low,Q3,Nivolumab+Ipilimumab,Combination,104.0,34,Discontinued_irAE,0,0,1.97,3.55,1.8,445,147,0,10.1,4.0,7.7,2.84,1147,562,10.3,4.7,Tier1_FDA-approved,26.5,1176,20.0,1,0,0,0,0.476,PR,1,1,-48.8,48.8,75.3,38.6,14.7,54.5,0,0,-100.0,1,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,24,21,1.41,0.65,1.711,1.51,14.0,0.0187,92,58.2,1,114.3,1,1,1,0,65.4,None,Disease_Progression
HC-ONC-013-000447,Hodgkin,48,Female,0,Second-line,Never,0.0,19.4,0,None,0,0,1,3,0,4.54,0.0,0.0,11.5,1,MSS,0,39.2,TIL-intermediate,782,1.16,45,11962,3,99.6,88,-1.451,-0.809,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,44.2,14,Hold_irAE,0,0,1.54,3.31,2.16,346,232,0,14.3,13.7,4.2,2.14,980,584,19.5,4.3,Tier1_FDA-approved,12.6,1315,17.0,0,0,0,0,,PR,1,1,-37.3,37.3,99.6,62.4,9.3,24.0,0,0,-81.1,0,1,0,2,3.3,1,6.9,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,38,39,1.13,1.09,0.603,1.22,16.2,0.0075,74,7.0,1,44.1,0,0,0,0,10.0,BSC,None
HC-ONC-013-000448,Urothelial,51,Male,0,Second-line,Never,0.0,30.3,0,None,0,0,1,4,0,4.18,0.0,0.0,17.54,1,MSI-H,1,23.5,TIL-intermediate,541,1.76,30,6659,5,97.6,139,-0.406,-0.788,PD-L1-negative,Q3,Atezolizumab,Anti-PD-L1,4.3,1,Active,0,0,0.75,8.18,10.84,279,236,0,12.1,11.4,2.2,0.85,753,525,9.4,5.7,Tier1_FDA-approved,17.9,111,17.45,0,0,0,0,0.374,SD,0,1,6.2,0.0,97.6,97.6,,,0,0,-20.0,0,1,0,2,1.3,1,4.9,0,0,1,16,7,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,68,74,1.08,0.94,3.484,1.77,27.7,0.0108,40641,42.0,0,77.0,1,0,0,0,45.2,Clinical_Trial,Disease_Progression
HC-ONC-013-000449,Melanoma,60,Female,0,First-line,Current,30.7,20.8,0,None,0,1,0,7,0,3.04,0.0,0.0,3.43,0,MSS,0,37.5,TIL-intermediate,597,0.97,13,3087,4,77.0,17,-0.947,-1.285,PD-L1-negative,Q1,Nivolumab+Ipilimumab,Combination,58.2,19,Discontinued_Progression,0,0,1.14,3.4,2.98,244,155,0,25.4,13.8,15.0,2.37,1102,568,21.9,5.4,Tier2_emerging,17.8,78,20.0,0,0,0,0,,PR,1,1,-53.2,53.2,77.0,36.0,12.0,21.1,0,0,-98.7,1,1,1,1,8.0,1,3.8,1,0,1,144,3,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,20,21,1.09,0.67,4.15,0.8,22.2,0.0203,107,45.4,0,160.2,0,0,1,0,48.0,Clinical_Trial,None
HC-ONC-013-000450,NSCLC,63,Male,0,Second-line,Never,0.0,29.1,0,None,0,1,1,5,1,2.91,0.0,0.0,9.99,0,MSS,0,29.4,TIL-intermediate,533,2.04,70,17836,1,123.7,79,0.451,0.324,PD-L1-negative,Q2,Pembrolizumab+Chemo,Combination,19.3,6,Discontinued_Progression,1,0,2.91,5.15,1.77,144,296,1,19.8,4.3,10.7,10.36,817,443,15.9,5.9,Tier3_exploratory,14.1,225,7.51,0,0,0,0,,PD,0,0,58.5,0.0,123.7,123.7,,,0,1,-20.0,0,1,0,1,4.5,1,1.5,0,0,1,16,8,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,38,41,0.68,0.85,2.85,0.88,16.8,0.038,147,7.7,1,45.6,0,0,0,0,12.1,Chemotherapy,None
HC-ONC-013-000451,Urothelial,79,Female,0,Second-line,Former,60.3,31.4,0,None,0,0,1,2,0,1.86,0.0,0.0,10.86,1,MSS,0,17.5,TIL-intermediate,389,2.52,50,560,2,118.8,41,-1.181,-0.98,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,28.2,9,Discontinued_Progression,0,0,1.78,4.84,2.73,82,100,0,2.7,9.8,9.3,4.29,802,423,21.0,5.3,Tier1_FDA-approved,8.9,393,7.63,0,0,0,0,,SD,0,1,-28.3,28.3,118.8,85.2,,,0,0,64.0,0,1,1,1,7.8,1,6.1,1,0,1,134,8,0,0,0,0,1,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1878,1495,6.72,0.78,2.968,1.6,29.0,0.027,196,11.5,1,29.1,1,0,0,0,14.1,Clinical_Trial,Disease_Progression
HC-ONC-013-000452,RCC,49,Male,2,Second-line,Never,0.0,24.6,0,None,0,0,1,4,0,4.83,65.8,100.0,13.36,1,MSS,0,40.3,TIL-intermediate,656,2.15,209,17416,1,96.5,57,-0.073,0.416,PD-L1-high,Q3,Nivolumab+Ipilimumab,Combination,20.8,6,Active,0,0,1.45,2.62,1.81,259,177,0,3.1,8.0,10.4,11.36,915,755,9.7,5.8,Tier1_FDA-approved,45.1,281,3.12,0,0,0,0,,SD,0,1,4.0,0.0,96.5,96.5,,,0,0,94.2,0,1,0,1,6.2,1,3.6,0,0,1,16,5,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,39,45,1.06,1.13,0.686,1.54,6.0,0.0116,119,13.9,1,38.3,0,0,0,0,19.5,None,None
HC-ONC-013-000453,Melanoma,72,Female,1,Second-line,Current,29.7,32.4,0,None,0,0,1,5,0,3.58,59.7,82.6,9.32,0,MSS,0,0.0,TIL-low,0,0.68,15,568,5,82.2,32,0.838,0.876,PD-L1-high,Q2,Nivolumab,Anti-PD-1,18.4,6,Completed_2yr,0,0,2.58,7.26,2.82,364,265,1,8.4,5.1,4.3,2.73,1039,383,14.0,5.2,Tier1_FDA-approved,29.0,24,0.5,0,0,0,0,,PR,1,1,-71.4,71.4,82.2,23.5,7.4,59.6,0,0,-73.5,0,1,1,1,10.0,1,10.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,13,12,0.67,0.9,2.515,1.07,18.5,0.0155,155,86.1,1,121.2,1,1,1,0,90.0,None,Disease_Progression
HC-ONC-013-000454,MSI-H_CRC,58,Female,1,Second-line,Never,0.0,28.9,0,None,0,1,1,1,0,2.81,18.2,24.3,64.21,1,MSI-H,1,71.9,TIL-high,1854,2.71,64,2408,5,106.3,280,-0.101,-0.153,PD-L1-low,Q5,Pembrolizumab,Anti-PD-1,27.3,9,Active,0,0,1.05,5.93,5.65,232,174,0,75.8,9.9,3.3,7.89,1017,536,7.2,3.7,Tier1_FDA-approved,54.6,5338,20.0,0,0,0,0,0.38,PR,1,1,-58.7,58.7,106.3,43.9,21.5,69.8,0,0,-92.6,1,1,1,1,14.4,1,6.5,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,3,0,0,0,0,0,0,0,0,39,27,1.25,0.95,2.607,1.39,25.8,0.0164,182,80.8,0,182.3,1,1,1,0,86.5,Chemotherapy,None
HC-ONC-013-000455,NSCLC,60,Male,0,Second-line,Former,35.0,23.0,0,None,0,0,1,2,0,4.26,0.0,0.0,8.59,0,MSS,0,0.0,TIL-low,0,2.63,12,392,1,92.6,59,-0.946,-1.147,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,24.4,8,Discontinued_Progression,0,0,1.51,1.66,1.1,187,181,0,5.2,26.2,7.6,2.52,791,803,16.2,5.0,Tier3_exploratory,0.0,267,0.5,1,1,0,0,,PR,1,1,-37.1,37.1,92.6,58.2,9.9,29.5,0,0,-34.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,26,27,0.69,0.74,0.656,1.33,22.7,0.0068,122,43.5,1,64.2,0,0,0,0,49.0,Chemotherapy,None
HC-ONC-013-000456,Melanoma,69,Female,2,First-line,Former,54.5,33.5,1,RA,0,0,0,5,0,2.42,51.6,52.1,2.14,0,MSS,0,10.6,TIL-intermediate,269,2.5,38,1840,4,122.4,16,1.175,0.96,PD-L1-high,Q1,Nivolumab+Ipilimumab,Combination,40.1,13,Completed_2yr,0,0,1.74,5.15,2.96,309,187,0,9.9,7.2,18.7,2.07,1154,529,16.5,3.6,Tier1_FDA-approved,14.6,523,6.9,0,0,0,0,,PR,1,1,-64.1,64.1,122.4,43.9,11.3,16.9,0,0,-58.4,0,1,0,3,1.7,0,,0,0,1,24,7,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,2,30,30,0.39,1.08,3.63,1.33,24.3,0.0071,40650,36.0,1,78.0,0,0,0,0,39.0,None,None
HC-ONC-013-000457,NSCLC,47,Female,1,First-line,Former,56.3,20.8,0,None,0,0,0,5,0,3.53,94.6,76.0,10.65,1,MSS,0,19.4,TIL-intermediate,564,1.99,72,2874,4,116.0,73,-1.879,-1.636,PD-L1-high,Q2,Nivolumab,Anti-PD-1,56.5,18,Discontinued_Progression,0,0,1.38,3.05,2.2,235,132,0,7.1,7.3,26.7,4.11,833,766,24.0,3.4,Tier1_FDA-approved,54.9,2609,7.73,0,0,0,0,,PR,1,1,-66.4,66.4,116.0,39.0,6.0,81.4,0,0,-63.9,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,16,12,0.54,1.16,1.613,1.4,17.8,0.0066,174,18.9,0,66.8,0,0,0,0,21.4,Chemotherapy,None
HC-ONC-013-000458,Melanoma,65,Female,0,First-line,Never,0.0,24.6,0,None,0,0,0,3,1,3.06,27.1,28.2,1.45,0,MSS,0,17.8,TIL-intermediate,415,1.84,6,1502,2,39.3,9,-0.328,-0.576,PD-L1-low,Q1,Nivolumab+Ipilimumab,Combination,20.0,6,Completed_2yr,0,0,1.72,7.76,4.52,568,360,1,7.0,26.6,14.0,2.63,704,482,14.4,4.3,Tier3_exploratory,19.5,12,20.0,0,0,0,0,,PD,0,0,87.6,0.0,39.3,39.3,,,0,0,68.5,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,17,0.79,1.08,3.394,1.79,15.8,0.0208,128,52.2,0,73.5,0,1,0,0,55.6,Clinical_Trial,None
HC-ONC-013-000459,NSCLC,62,Female,1,First-line,Former,56.5,25.5,0,None,0,0,0,6,0,3.71,69.4,90.8,16.75,1,MSS,0,35.1,TIL-intermediate,842,2.76,28,4258,2,36.6,93,-0.042,-0.515,PD-L1-high,Q3,Atezolizumab,Anti-PD-L1,15.5,5,Discontinued_Progression,0,0,1.53,2.18,1.42,453,120,0,14.6,23.4,7.6,1.3,460,390,15.6,4.8,Tier1_FDA-approved,47.9,187,20.0,0,0,0,0,,PR,1,1,-65.4,65.4,36.6,12.7,15.2,40.6,0,0,-70.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,12,1.39,0.9,2.112,1.79,16.6,0.0266,159,56.7,1,101.2,1,1,0,0,60.7,Chemotherapy,Disease_Progression
HC-ONC-013-000460,NSCLC,66,Female,1,First-line,Former,22.6,29.5,0,None,0,1,0,4,0,3.15,52.2,61.6,5.05,0,MSS,0,4.1,TIL-low,123,4.31,21,2036,3,52.0,33,0.016,-0.06,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,42.6,14,Active,0,0,0.94,3.75,3.98,395,235,0,49.4,49.4,9.2,3.87,1195,281,9.6,5.1,Tier1_FDA-approved,30.7,226,5.59,1,0,0,0,,SD,0,1,20.0,0.0,52.0,52.0,,,0,0,35.6,0,1,0,1,1.3,1,6.0,0,0,1,26,10,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,23,21,0.8,1.1,4.483,1.78,13.5,0.0234,142,15.2,1,34.9,1,0,0,0,19.9,BSC,Disease_Progression
HC-ONC-013-000461,NSCLC,64,Male,0,First-line,Former,9.7,32.1,0,None,0,0,0,3,1,2.04,0.0,0.0,14.11,1,MSS,0,23.9,TIL-intermediate,589,1.02,19,966,3,119.0,70,0.18,0.693,PD-L1-negative,Q3,Atezolizumab,Anti-PD-L1,42.9,14,Active,0,0,1.77,5.37,3.03,357,246,0,19.2,0.9,7.5,4.88,904,863,14.7,6.8,Tier1_FDA-approved,7.4,244,20.0,0,1,0,0,,SD,0,1,2.4,0.0,119.0,119.0,,,0,0,124.8,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,17,15,0.41,0.71,1.349,1.35,20.5,0.0382,40,34.4,0,54.0,1,0,0,0,39.3,Chemotherapy,Disease_Progression
HC-ONC-013-000462,TNBC,85,Female,1,First-line,Never,0.0,31.8,0,None,0,0,0,7,0,3.26,27.4,48.8,39.75,1,MSS,0,28.4,TIL-intermediate,440,2.83,45,916,2,16.9,286,0.61,0.364,PD-L1-low,Q5,Atezolizumab,Anti-PD-L1,70.0,23,Discontinued_irAE,0,0,0.97,4.61,4.75,128,125,0,5.5,21.9,3.3,12.36,963,373,10.1,4.0,Tier1_FDA-approved,28.5,311,9.57,0,0,0,0,,CR,1,1,-100.0,100.0,16.9,0.0,15.1,6.8,0,0,-75.0,0,1,0,1,20.9,1,1.0,0,0,1,20,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,12,10,0.54,0.67,0.733,1.12,19.3,0.0058,59,17.9,1,114.0,0,0,1,0,21.8,Clinical_Trial,None
HC-ONC-013-000463,Urothelial,53,Male,1,First-line,Former,21.7,27.6,0,None,0,0,0,2,0,4.04,55.2,63.5,5.19,0,MSS,0,24.4,TIL-intermediate,632,1.58,81,4784,3,95.8,33,-0.035,-0.243,PD-L1-high,Q1,Atezolizumab,Anti-PD-L1,2.5,1,Active,0,0,1.76,6.56,3.73,341,208,0,191.2,15.2,7.5,9.48,1214,749,12.6,5.4,Tier1_FDA-approved,33.9,3536,7.71,0,0,0,0,,PR,1,1,-52.9,52.9,95.8,45.1,13.7,12.1,0,0,-62.3,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,39,45,0.95,0.86,4.42,1.36,12.0,0.0385,79,18.2,1,44.2,1,0,0,0,20.8,Chemotherapy,Disease_Progression
HC-ONC-013-000464,RCC,54,Female,0,Second-line,Never,0.0,25.1,1,IBD,0,0,1,6,0,3.18,60.5,75.8,31.66,1,MSS,1,19.0,TIL-intermediate,544,1.55,30,825,1,94.5,205,-0.368,-0.984,PD-L1-high,Q4,Atezolizumab+Bevacizumab,Combination,61.7,20,Discontinued_Progression,0,1,2.86,2.1,1.0,295,127,0,13.2,2.6,2.5,11.89,757,400,12.9,5.2,Tier1_FDA-approved,45.5,1108,17.55,0,0,0,0,,CR,1,1,-100.0,100.0,94.5,0.0,9.3,11.8,0,0,-43.5,0,1,0,1,26.1,1,11.5,0,0,1,43,6,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,32,34,0.51,0.71,1.475,1.42,27.4,0.0187,78,64.2,0,132.1,1,1,1,0,67.1,Chemotherapy,Disease_Progression
HC-ONC-013-000465,Hodgkin,53,Male,2,Third+,Never,0.0,17.4,1,MS,0,1,2,5,0,3.82,16.2,15.1,8.25,0,MSS,0,41.9,TIL-intermediate,1127,0.76,39,5423,4,126.5,47,-0.408,0.032,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,32.6,10,Hold_irAE,0,0,1.47,10.24,6.95,331,402,1,6.8,10.0,6.7,7.97,488,863,10.2,3.8,Tier2_emerging,14.5,1698,20.0,0,0,0,0,,PD,0,0,51.3,0.0,126.5,126.5,,,0,0,9.8,0,1,0,2,19.3,1,7.4,0,0,1,10,3,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,26,25,0.38,0.76,3.041,1.11,24.3,0.0093,173,17.2,1,83.2,1,0,0,0,22.2,Clinical_Trial,Disease_Progression
HC-ONC-013-000466,Melanoma,54,Female,2,First-line,Former,40.6,19.9,0,None,0,0,0,3,0,2.36,8.2,7.0,59.02,1,MSS,0,11.8,TIL-intermediate,279,1.43,36,7842,3,87.2,438,-0.612,-0.757,PD-L1-low,Q5,Nivolumab+Ipilimumab,Combination,39.2,13,Discontinued_Progression,0,0,1.03,5.83,5.65,313,113,0,50.0,26.1,27.4,5.85,921,1041,12.3,5.1,Tier1_FDA-approved,34.6,433,7.54,0,0,0,0,,SD,0,1,20.0,0.0,87.2,87.2,,,0,0,78.4,0,1,1,1,18.1,0,,1,1,1,139,7,0,0,0,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,0,32,33,1.16,0.95,1.998,1.43,20.0,0.0368,132,18.8,1,49.6,0,0,0,0,21.5,Chemotherapy,None
HC-ONC-013-000467,NSCLC,53,Female,1,Third+,Current,21.6,35.3,0,None,0,0,2,6,1,3.18,39.5,62.2,8.77,0,MSS,0,12.3,TIL-intermediate,310,1.0,33,244,3,26.3,37,0.788,0.531,PD-L1-low,Q2,Pembrolizumab,Anti-PD-1,8.4,2,Discontinued_irAE,0,0,1.57,8.85,5.64,307,144,0,7.6,2.7,14.3,1.68,992,263,10.1,7.0,Tier3_exploratory,21.5,49,9.12,0,0,0,0,,SD,0,1,-12.2,12.2,26.3,23.1,,,0,0,-7.9,0,1,0,2,19.6,0,,0,0,1,15,3,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,28,32,1.24,0.84,3.059,1.42,29.4,0.0188,44,21.0,1,54.4,1,0,0,0,26.1,Chemotherapy,Disease_Progression
HC-ONC-013-000468,HNSCC,75,Male,1,First-line,Former,26.9,17.3,0,None,0,0,0,7,0,2.7,24.5,33.6,26.29,1,MSI-H,1,24.3,TIL-intermediate,726,1.31,14,7041,1,41.6,129,-0.647,-0.565,PD-L1-low,Q4,Pembrolizumab,Anti-PD-1,27.4,9,Discontinued_Progression,0,0,1.18,6.94,5.87,800,109,0,64.3,12.6,3.5,5.05,821,383,10.1,5.4,Tier1_FDA-approved,24.9,18,20.0,0,1,0,0,0.452,SD,0,1,-2.7,2.7,41.6,40.5,,,0,0,46.6,0,1,0,1,2.0,1,4.6,0,0,1,55,8,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,15,16,1.32,1.12,2.884,1.7,28.9,0.0142,96,6.7,0,67.2,1,0,0,0,11.9,Chemotherapy,Disease_Progression
HC-ONC-013-000469,NSCLC,78,Male,1,First-line,Never,0.0,22.6,0,None,0,0,0,4,0,3.8,85.3,100.0,22.61,1,MSS,0,34.2,TIL-intermediate,559,0.95,80,21429,5,32.7,156,0.847,0.927,PD-L1-high,Q4,Atezolizumab,Anti-PD-L1,16.2,5,Completed_2yr,0,0,2.09,4.46,2.13,236,102,0,5.1,21.0,7.0,7.22,1342,755,17.4,5.5,Tier1_FDA-approved,53.0,41,6.9,0,0,0,0,,CR,1,1,-100.0,100.0,32.7,0.0,16.3,23.8,0,0,-55.3,0,1,0,2,3.3,1,8.9,1,0,1,43,4,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,84,64,1.31,0.74,3.329,1.04,13.7,0.0091,125,27.3,0,76.0,1,0,0,0,34.4,Chemotherapy,Disease_Progression
HC-ONC-013-000470,Hodgkin,54,Female,1,First-line,Never,0.0,32.2,0,None,0,0,0,7,0,3.23,13.4,12.7,8.23,0,MSS,0,28.0,TIL-intermediate,701,1.32,42,2446,2,58.5,45,0.019,-0.067,PD-L1-low,Q2,Nivolumab,Anti-PD-1,17.7,5,Active,0,0,1.55,2.36,1.52,391,444,1,50.9,2.0,3.8,14.38,200,703,12.9,3.6,Tier3_exploratory,5.5,692,16.3,0,0,0,0,,PD,0,0,56.9,0.0,58.5,58.5,,,0,0,155.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,30,32,0.76,1.2,0.574,1.5,23.1,0.0112,73,19.5,0,45.1,0,0,0,0,22.5,None,None
HC-ONC-013-000471,NSCLC,51,Male,1,First-line,Current,25.6,27.5,0,None,0,0,0,2,0,3.75,78.9,100.0,5.71,0,MSS,0,7.0,TIL-low,134,1.35,45,3710,1,72.7,43,-0.521,-0.342,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,31.6,10,Discontinued_Progression,0,0,3.27,3.38,1.03,193,263,1,14.9,6.2,7.0,7.76,1236,755,13.7,8.9,Tier1_FDA-approved,33.3,423,2.91,0,0,0,0,,PD,0,0,45.8,0.0,72.7,72.7,,,0,0,72.7,0,1,0,1,2.6,0,,0,0,1,18,12,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,17,17,1.18,0.82,3.845,1.25,26.7,0.0382,37,11.1,1,63.5,0,0,0,0,14.4,Targeted,None
HC-ONC-013-000472,Hodgkin,66,Female,0,Second-line,Never,0.0,31.1,0,None,0,0,1,1,1,4.07,0.0,0.0,7.92,0,MSS,0,52.3,TIL-high,1286,1.73,17,6275,5,33.4,37,0.618,0.614,PD-L1-negative,Q2,Nivolumab,Anti-PD-1,56.4,18,Discontinued_Progression,0,0,2.63,9.92,3.78,363,215,0,44.3,10.6,17.0,12.09,1137,485,4.7,3.7,Tier2_emerging,16.3,294,20.0,0,0,0,0,,PD,0,0,62.0,0.0,33.4,33.4,,,0,0,65.6,0,1,0,1,6.2,1,2.2,0,0,1,47,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,20,23,1.0,0.91,2.415,0.93,15.1,0.0126,95,20.5,1,89.1,1,0,0,0,19.9,None,Disease_Progression
HC-ONC-013-000473,NSCLC,54,Male,1,Second-line,Never,0.0,29.2,0,None,0,0,1,3,0,3.75,0.0,0.0,11.7,1,MSS,0,19.5,TIL-intermediate,471,0.74,23,1299,1,138.8,57,-0.727,0.617,PD-L1-negative,Q2,Atezolizumab,Anti-PD-L1,49.1,16,Active,0,0,1.55,8.96,5.78,391,144,0,81.6,2.8,12.5,1.96,1037,998,14.1,1.7,Tier1_FDA-approved,14.0,232,19.62,0,0,0,0,,PR,1,1,-37.3,37.3,138.8,87.1,6.0,49.1,0,0,-68.1,0,1,1,2,18.1,1,9.5,1,0,1,103,10,0,0,0,0,1,0,0,0,2,0,3,0,0,0,0,0,0,0,0,21,23,0.33,0.68,2.575,1.12,14.3,0.0382,108,37.3,1,62.5,0,0,0,0,39.4,Targeted,None
HC-ONC-013-000474,MSI-H_CRC,68,Female,2,First-line,Former,7.9,33.8,0,None,0,0,0,2,0,3.42,52.2,42.4,31.88,1,MSI-H,1,49.9,TIL-intermediate,864,0.8,29,2250,4,27.0,237,0.638,0.827,PD-L1-high,Q4,Pembrolizumab,Anti-PD-1,37.1,12,Discontinued_Progression,0,0,2.2,3.29,1.5,294,315,1,3.9,2.6,53.9,3.45,200,624,14.7,6.7,Tier1_FDA-approved,49.6,8247,20.0,0,0,0,0,0.35,PR,1,1,-30.0,30.0,27.0,18.9,6.0,55.2,0,0,-62.0,0,1,0,1,5.0,1,13.5,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,28,24,0.78,0.95,2.144,0.86,16.7,0.0135,184,82.9,0,96.8,1,1,0,0,85.0,Chemotherapy,Disease_Progression
HC-ONC-013-000475,RCC,63,Male,1,First-line,Former,32.1,28.0,0,None,0,0,0,1,0,2.4,56.5,52.6,2.14,0,MSS,0,6.4,TIL-low,116,1.98,10,374,1,133.8,11,0.213,0.083,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,33.8,11,Discontinued_irAE,0,0,1.41,1.1,1.0,564,133,0,43.6,6.3,19.2,6.32,1285,357,10.0,4.8,Tier1_FDA-approved,28.7,117,10.55,0,1,0,0,,SD,0,1,7.7,0.0,133.8,133.8,,,0,0,63.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,11,0.36,1.18,4.458,1.12,17.0,0.0098,184,10.8,1,32.1,0,0,0,0,15.8,Clinical_Trial,None
HC-ONC-013-000476,Hodgkin,42,Female,0,First-line,Former,46.8,29.8,0,None,0,0,0,3,0,3.2,69.7,77.4,12.44,1,MSS,0,4.4,TIL-low,107,1.11,9,2135,1,127.4,69,-0.596,-0.356,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,27.1,9,Discontinued_Progression,0,0,1.67,4.03,2.41,157,298,1,3.0,19.3,8.7,11.34,592,549,22.4,4.4,Tier1_FDA-approved,21.9,1623,10.7,0,0,0,0,,PD,0,0,44.4,0.0,127.4,127.4,,,0,0,64.1,0,1,0,1,13.1,1,10.2,1,0,1,73,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,32,30,0.4,1.05,3.706,0.87,29.4,0.008,115,18.6,1,72.5,0,0,0,0,26.2,Chemotherapy,None
HC-ONC-013-000477,NSCLC,79,Male,1,First-line,Former,38.2,22.9,0,None,0,0,0,2,0,2.77,43.3,39.7,44.24,1,MSI-H,1,12.0,TIL-intermediate,203,2.82,20,3287,4,115.9,206,0.529,0.055,PD-L1-low,Q5,Pembrolizumab,Anti-PD-1,94.0,31,Discontinued_Progression,0,0,1.43,3.88,2.72,192,130,0,4.3,16.0,12.7,3.99,748,359,0.6,3.9,Tier1_FDA-approved,36.2,405,9.67,0,0,0,0,0.567,PD,0,0,46.4,0.0,115.9,115.9,,,0,0,21.3,0,1,0,1,2.3,1,4.6,0,0,1,46,8,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,20,21,0.37,0.75,1.746,1.73,26.0,0.0167,110,58.5,1,139.2,1,1,1,0,63.6,Clinical_Trial,Disease_Progression
HC-ONC-013-000478,RCC,82,Female,0,First-line,Never,0.0,29.4,0,None,0,1,0,7,0,2.92,26.8,47.9,63.44,1,MSI-H,1,8.5,TIL-low,161,1.85,50,3359,2,52.2,278,0.547,-0.147,PD-L1-low,Q5,Atezolizumab+Bevacizumab,Combination,35.1,11,Discontinued_Progression,0,1,2.24,3.96,1.77,272,145,0,5.5,2.6,6.3,4.2,849,918,15.9,8.7,Tier1_FDA-approved,43.9,368,3.16,0,0,0,0,0.4,PR,1,1,-47.1,47.1,52.2,27.6,29.2,20.5,0,0,-82.8,0,1,0,2,6.7,0,,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,31,24,1.45,0.87,3.632,0.9,13.1,0.01,139,18.1,1,86.6,1,0,0,0,24.1,Chemotherapy,Disease_Progression
HC-ONC-013-000479,Hodgkin,53,Male,0,First-line,Current,26.9,24.5,0,None,0,1,0,2,0,2.9,0.0,0.0,39.6,1,MSS,0,38.4,TIL-intermediate,1058,2.23,20,6493,5,93.7,249,1.158,0.418,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,17.6,5,Discontinued_Progression,0,0,2.92,5.84,2.0,380,293,1,20.2,16.2,3.0,7.77,1022,468,15.6,5.7,Tier1_FDA-approved,27.8,2357,20.0,0,0,0,0,,SD,0,1,17.7,0.0,93.7,93.7,,,0,0,40.7,0,1,0,3,5.7,1,6.8,0,0,1,34,7,0,0,0,1,0,0,0,0,1,0,0,0,0,0,2,0,0,0,2,38,39,1.31,0.86,2.248,1.62,1.1,0.0275,21664,34.7,1,58.1,0,0,0,0,37.3,Clinical_Trial,None
HC-ONC-013-000480,RCC,56,Female,0,Second-line,Never,0.0,24.2,0,None,0,0,1,6,0,2.42,0.0,0.0,11.39,1,MSS,0,10.4,TIL-intermediate,208,3.34,15,714,3,28.9,41,0.966,0.194,PD-L1-negative,Q2,Nivolumab+Ipilimumab,Combination,16.4,5,Active,0,0,2.27,6.95,3.06,268,309,1,12.6,2.7,21.0,1.82,1092,698,14.7,6.1,Tier1_FDA-approved,12.5,3618,13.0,0,0,0,0,,PD,0,0,44.7,0.0,28.9,28.9,,,0,0,62.6,0,1,1,3,18.8,1,2.4,1,0,0,0,0,1,0,0,0,0,0,0,0,1,4,2,0,0,0,0,0,0,0,0,36,40,0.83,0.66,3.98,1.71,15.1,0.0101,79,9.1,1,83.6,1,0,0,0,10.7,None,Disease_Progression
HC-ONC-013-000481,TNBC,64,Female,0,Third+,Former,54.0,31.0,0,None,1,0,2,7,0,1.63,0.0,0.0,27.11,1,MSI-H,1,54.8,TIL-high,1224,1.41,17,954,2,116.4,201,0.491,0.621,PD-L1-negative,Q4,Pembrolizumab+Chemo,Combination,38.5,12,Discontinued_Progression,1,0,2.38,7.35,3.08,465,270,1,10.3,1.1,16.6,16.21,1168,506,12.9,5.3,Tier1_FDA-approved,20.0,282,20.0,1,0,0,0,0.365,PR,1,1,-33.2,33.2,116.4,77.8,14.6,74.8,0,0,-72.5,0,1,0,2,9.5,1,5.9,1,0,1,45,6,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,32,25,0.6,1.13,0.623,1.27,18.4,0.0327,30,68.6,1,139.0,0,1,1,0,72.2,None,None
HC-ONC-013-000482,TNBC,65,Female,1,First-line,Former,29.0,31.0,0,None,1,0,0,3,0,2.67,56.1,77.8,20.76,1,MSS,0,34.2,TIL-intermediate,997,1.24,23,17582,1,77.0,143,-1.128,-1.212,PD-L1-high,Q4,Pembrolizumab+Chemo,Combination,32.7,10,Discontinued_Complete_Response,1,0,2.39,5.6,2.35,176,119,0,14.1,4.8,6.1,2.22,1145,477,14.8,5.5,Tier1_FDA-approved,45.9,1338,20.0,0,0,0,0,,SD,0,1,19.2,0.0,77.0,77.0,,,0,0,18.0,0,1,1,1,12.3,1,1.2,1,1,1,129,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,16,17,0.39,0.83,1.922,0.85,6.3,0.0327,43,19.9,0,70.0,0,0,0,0,22.7,Clinical_Trial,None
HC-ONC-013-000483,Melanoma,68,Female,1,Third+,Former,20.2,34.9,0,None,0,0,3,2,0,3.35,0.0,0.0,80.0,1,MSI-H,1,22.3,TIL-intermediate,410,2.55,25,1510,3,63.6,316,2.0,1.867,PD-L1-negative,Q5,Pembrolizumab,Anti-PD-1,1.6,1,Discontinued_Complete_Response,0,0,2.06,1.82,1.0,138,160,0,22.0,28.4,9.2,0.97,976,218,16.3,7.8,Tier1_FDA-approved,38.8,696,15.77,0,0,0,0,0.422,PR,1,1,-38.6,38.6,63.6,39.1,17.6,70.9,0,0,-23.2,0,1,0,1,2.9,1,7.4,0,0,1,65,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,32,23,0.82,0.9,2.219,1.4,16.9,0.0119,60,99.6,1,156.1,0,1,1,0,101.9,Clinical_Trial,None
HC-ONC-013-000484,TNBC,85,Female,0,First-line,Never,0.0,34.6,1,RA,0,1,0,5,0,2.12,32.1,53.4,8.57,0,MSS,0,43.2,TIL-intermediate,899,2.13,187,2299,4,31.1,55,-1.404,-0.466,PD-L1-low,Q2,Pembrolizumab+Chemo,Combination,58.6,19,Discontinued_Progression,1,0,1.05,3.78,3.62,285,217,0,23.8,16.2,19.9,4.52,1025,720,8.4,4.5,Tier2_emerging,26.4,408,4.78,0,0,0,0,,PR,1,1,-37.5,37.5,31.1,19.4,14.2,5.8,0,0,-98.4,1,1,0,3,24.0,0,,1,0,1,40,5,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,2,29,20,1.02,0.77,3.477,1.03,17.6,0.0296,23959,16.3,1,82.9,0,0,0,0,20.8,Chemotherapy,None
HC-ONC-013-000485,RCC,58,Male,2,First-line,Never,0.0,31.1,0,None,0,0,0,3,0,3.21,58.9,100.0,19.39,1,MSS,0,22.9,TIL-intermediate,552,1.5,77,1668,2,10.0,117,0.949,0.58,PD-L1-high,Q3,Atezolizumab+Bevacizumab,Combination,45.6,15,Discontinued_irAE,0,1,3.26,12.0,3.69,235,131,0,36.4,7.4,14.5,17.44,573,860,13.5,2.1,Tier1_FDA-approved,44.2,548,7.08,1,1,0,0,,PR,1,1,-60.2,60.2,10.0,4.0,13.9,7.9,0,0,-91.1,1,1,0,1,6.1,1,4.1,1,0,1,12,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,33,24,1.26,0.69,1.229,0.98,25.6,0.0336,66,46.7,1,125.7,1,0,1,0,48.3,BSC,Disease_Progression
HC-ONC-013-000486,MSI-H_CRC,51,Male,2,First-line,Former,47.8,17.9,1,RA,0,0,0,2,0,4.72,0.0,0.0,9.19,0,MSI-H,1,34.6,TIL-intermediate,910,3.31,75,675,5,38.5,36,0.431,0.259,PD-L1-negative,Q2,Pembrolizumab,Anti-PD-1,42.2,14,Completed_2yr,0,0,3.39,5.4,1.59,321,398,1,75.2,4.5,2.3,7.16,675,417,11.1,6.7,Tier1_FDA-approved,20.6,144,11.97,0,0,0,0,0.375,SD,0,1,-3.3,3.3,38.5,37.2,,,0,0,37.5,0,1,1,1,13.9,1,5.5,1,1,1,112,5,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,4,36,37,0.36,1.14,1.645,1.37,16.8,0.0234,12851,22.3,0,86.3,0,0,0,0,28.0,None,None
HC-ONC-013-000487,NSCLC,44,Male,2,Second-line,Current,31.7,35.6,0,None,0,1,1,6,1,4.02,63.0,78.8,7.03,0,MSI-L,0,27.7,TIL-intermediate,789,1.48,84,12686,2,124.5,31,-1.174,-0.983,PD-L1-high,Q2,Atezolizumab,Anti-PD-L1,6.9,2,Discontinued_irAE,0,0,1.5,5.39,3.59,241,100,0,11.9,4.6,9.0,8.17,1169,291,6.5,6.0,Tier1_FDA-approved,42.1,255,9.28,1,1,0,0,,PD,0,0,56.9,0.0,124.5,124.5,,,0,0,83.8,0,1,0,1,26.9,1,5.6,0,0,1,71,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,19,23,0.8,0.62,3.396,1.16,26.4,0.0149,135,25.8,1,43.9,0,0,0,0,29.0,Targeted,None
HC-ONC-013-000488,NSCLC,52,Female,0,Third+,Current,25.6,31.1,0,None,0,1,2,1,0,4.51,93.2,76.6,7.57,0,MSS,0,8.1,TIL-low,232,1.68,15,960,2,63.9,38,-0.124,0.06,PD-L1-high,Q2,Durvalumab,Anti-PD-L1,23.5,7,Discontinued_Progression,0,0,1.42,5.36,3.77,206,136,0,7.2,8.4,6.5,4.63,1151,761,15.6,5.2,Tier1_FDA-approved,53.3,169,14.5,1,1,0,0,,SD,0,1,20.0,0.0,63.9,63.9,,,0,0,52.4,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,29,32,1.47,0.84,0.807,1.53,13.6,0.0178,141,7.2,0,53.1,1,0,0,0,11.1,BSC,Disease_Progression
HC-ONC-013-000489,Hodgkin,60,Female,1,Second-line,Never,0.0,22.7,0,None,0,0,1,1,0,3.51,58.4,84.2,41.17,1,MSS,0,68.0,TIL-high,1812,1.67,12,467,3,73.2,267,-0.079,0.497,PD-L1-high,Q5,Pembrolizumab,Anti-PD-1,78.3,26,Active,0,0,2.11,5.52,2.62,236,155,0,22.5,2.1,18.0,3.97,1117,271,9.2,5.9,Tier1_FDA-approved,69.0,1559,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,73.2,0.0,13.7,11.1,0,0,-77.3,0,1,0,1,9.4,1,7.2,0,0,1,55,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,18,15,0.44,1.04,1.304,1.39,22.7,0.0309,40,24.4,1,93.2,0,0,0,0,28.6,BSC,None
HC-ONC-013-000490,MSI-H_CRC,82,Female,3,First-line,Never,0.0,30.1,0,None,0,0,0,5,0,4.13,88.5,100.0,52.24,1,MSI-H,1,30.7,TIL-intermediate,566,1.03,14,1053,4,106.2,324,1.306,0.432,PD-L1-high,Q5,Nivolumab+Ipilimumab,Combination,63.2,21,Completed_2yr,0,0,2.06,1.36,1.0,248,100,0,3.9,4.9,16.9,1.3,746,844,4.5,4.3,Tier1_FDA-approved,63.9,350,20.0,0,0,0,0,0.405,PR,1,1,-74.1,74.1,106.2,27.5,9.3,21.9,0,0,-50.8,0,1,0,1,2.7,0,,0,0,1,32,7,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,20,15,0.78,0.79,3.513,1.63,27.5,0.0121,161,23.8,0,48.1,0,0,0,0,26.9,BSC,None
HC-ONC-013-000491,Melanoma,54,Male,1,Second-line,Current,18.4,21.3,1,Thyroiditis,0,0,1,3,0,2.62,66.9,71.5,17.39,1,MSS,0,0.3,TIL-low,5,1.71,96,164,4,152.2,98,-0.713,-1.195,PD-L1-high,Q3,Pembrolizumab,Anti-PD-1,19.3,6,Discontinued_Progression,0,0,1.52,3.98,2.61,210,100,0,6.2,5.7,21.2,0.74,1173,419,9.3,5.0,Tier1_FDA-approved,35.2,58,0.5,0,0,0,0,,SD,0,1,-3.5,3.5,152.2,146.8,,,0,0,74.1,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,26,26,0.63,0.87,4.002,0.86,13.4,0.0137,133,13.7,0,31.8,0,0,0,0,20.2,BSC,None
HC-ONC-013-000492,TNBC,63,Female,0,First-line,Former,30.0,29.6,0,None,0,0,0,6,1,2.68,0.0,0.0,12.56,1,MSS,0,43.8,TIL-intermediate,908,3.31,21,828,2,133.0,86,-0.262,0.194,PD-L1-negative,Q3,Atezolizumab,Anti-PD-L1,12.3,4,Discontinued_Progression,0,0,1.0,4.4,4.4,221,274,1,33.1,1.5,3.0,5.24,552,379,8.0,4.7,Tier1_FDA-approved,17.4,136,20.0,0,0,0,0,,SD,0,1,5.4,0.0,133.0,133.0,,,0,0,55.2,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,23,16,0.46,0.94,3.415,1.03,23.4,0.0071,98,27.7,1,78.6,1,0,0,0,28.5,Chemotherapy,Disease_Progression
HC-ONC-013-000493,NSCLC,60,Male,0,Third+,Current,7.2,19.9,0,None,0,1,4,2,0,1.01,0.0,0.0,2.68,0,MSS,0,7.2,TIL-low,124,2.06,12,566,4,41.1,18,-2.0,-1.038,PD-L1-negative,Q1,Atezolizumab,Anti-PD-L1,28.3,9,Active,0,0,1.86,8.51,4.57,200,203,0,10.8,2.7,3.9,12.81,1223,650,17.1,3.8,Tier3_exploratory,13.6,3,9.54,0,0,0,0,,SD,0,1,-8.2,8.2,41.1,37.7,,,0,0,-2.8,0,1,0,1,3.0,1,1.0,0,0,1,71,2,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,28,31,1.31,1.2,88.492,0.51,21.2,0.0162,197,4.2,1,32.7,1,0,0,0,10.8,BSC,Other
HC-ONC-013-000494,NSCLC,75,Female,1,First-line,Never,0.0,22.5,0,None,0,1,0,2,0,4.15,29.1,35.4,16.1,1,MSS,0,30.0,TIL-intermediate,769,1.67,23,3793,3,10.0,98,1.735,0.481,PD-L1-low,Q3,Atezolizumab,Anti-PD-L1,23.1,7,Discontinued_Progression,0,0,2.06,4.59,2.23,376,440,1,3.6,12.1,18.0,5.9,822,392,12.8,7.4,Tier1_FDA-approved,33.6,192,20.0,0,0,0,0,,CR,1,1,-100.0,100.0,10.0,0.0,6.1,85.0,1,0,-82.0,0,0,0,0,,0,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,33,27,1.14,1.05,0.896,1.68,18.0,0.0043,32,52.5,0,80.0,0,1,0,0,55.8,Chemotherapy,None
HC-ONC-013-000495,Melanoma,85,Male,2,First-line,Former,46.7,30.0,0,None,0,0,0,1,1,4.43,23.8,23.3,18.69,1,MSS,0,53.1,TIL-high,1324,1.52,27,806,3,174.4,130,-1.07,-1.009,PD-L1-low,Q3,Nivolumab,Anti-PD-1,43.8,14,Discontinued_Progression,0,0,2.2,1.97,1.0,270,434,1,2.7,7.5,4.6,7.38,1405,459,18.9,2.2,Tier1_FDA-approved,33.3,427,20.0,0,0,0,0,,PD,0,0,23.5,0.0,174.4,174.4,,,0,0,140.7,0,1,0,2,12.8,1,2.3,0,0,1,35,9,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,28,24,0.79,1.18,0.16,2.02,13.8,0.0132,123,17.8,1,46.9,0,0,0,0,23.6,BSC,None
HC-ONC-013-000496,Melanoma,54,Female,1,Second-line,Former,46.2,31.9,0,None,0,0,1,6,0,2.76,31.8,47.3,20.71,1,MSS,0,8.2,TIL-low,128,1.95,41,5247,5,170.8,97,0.327,-0.233,PD-L1-low,Q4,Nivolumab,Anti-PD-1,90.3,30,Discontinued_Progression,0,0,1.9,5.56,2.93,756,249,0,12.8,5.1,2.2,15.91,444,671,8.7,9.7,Tier1_FDA-approved,28.7,329,3.05,0,0,0,0,,PD,0,0,49.5,0.0,170.8,170.8,,,0,0,-0.3,0,1,0,1,7.8,1,5.0,0,0,1,14,9,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,39,34,0.74,1.02,0.996,1.48,24.2,0.0152,57,8.5,0,30.3,1,0,0,0,12.9,Chemotherapy,Other
HC-ONC-013-000497,RCC,55,Male,1,Second-line,Former,10.3,28.1,0,None,0,1,1,7,0,3.0,58.2,79.4,1.12,0,MSS,1,25.0,TIL-intermediate,688,2.4,40,9684,4,87.5,8,-0.101,-0.423,PD-L1-high,Q1,Nivolumab+Ipilimumab,Combination,23.5,7,Hold_irAE,0,0,1.48,3.0,2.03,265,234,0,38.2,2.5,11.3,5.83,1429,114,16.4,6.8,Tier1_FDA-approved,25.4,7865,16.78,0,0,0,0,,PR,1,1,-30.0,30.0,87.5,61.2,6.0,44.8,0,0,-42.6,0,1,0,2,10.1,1,8.2,1,0,1,38,7,0,0,0,1,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,32,35,1.29,0.76,2.04,1.37,4.9,0.0107,86,18.6,0,104.1,1,0,0,0,24.3,None,Disease_Progression
HC-ONC-013-000498,NSCLC,73,Female,0,First-line,Former,43.0,25.1,0,None,0,0,0,5,0,2.6,7.8,12.9,41.67,1,MSS,0,0.0,TIL-low,0,2.24,17,4617,5,29.2,253,-0.098,-0.221,PD-L1-low,Q5,Pembrolizumab,Anti-PD-1,6.4,2,Discontinued_Progression,0,0,2.45,2.44,1.0,186,207,0,37.7,49.0,4.8,4.06,792,928,26.2,1.4,Tier1_FDA-approved,22.6,956,0.5,0,0,1,1,,PD,0,0,20.0,0.0,29.2,29.2,,,0,0,59.3,0,1,0,1,3.3,1,1.4,0,0,1,13,5,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,40,33,0.41,0.77,0.702,1.43,18.1,0.0049,53,6.3,1,65.8,0,0,0,0,10.1,BSC,None
HC-ONC-013-000499,Hodgkin,69,Male,1,Second-line,Never,0.0,15.9,0,None,0,0,1,1,0,3.51,86.4,79.3,6.27,0,MSS,0,49.1,TIL-intermediate,1054,1.4,57,1396,1,118.5,45,0.81,0.353,PD-L1-high,Q1,Pembrolizumab,Anti-PD-1,69.3,23,Active,0,0,1.69,2.95,1.74,800,100,0,13.6,2.7,30.9,2.33,786,609,13.8,4.6,Tier1_FDA-approved,48.0,894,18.17,0,0,0,0,,PD,0,0,36.6,0.0,118.5,118.5,,,0,0,72.8,0,1,0,1,4.4,1,9.3,0,0,1,34,8,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,32,27,0.48,1.09,3.339,1.01,24.9,0.0208,144,19.0,0,44.0,1,0,0,0,23.5,Clinical_Trial,Disease_Progression
HC-ONC-013-000500,Hodgkin,83,Male,2,First-line,Former,36.1,25.5,0,None,0,0,0,1,0,4.1,63.9,100.0,22.6,1,MSS,0,22.3,TIL-intermediate,558,1.94,20,2142,3,75.7,130,1.671,0.677,PD-L1-high,Q4,Nivolumab,Anti-PD-1,4.6,1,Discontinued_Progression,0,0,1.37,5.88,4.29,301,100,0,90.8,10.0,9.4,22.6,958,341,16.3,4.7,Tier1_FDA-approved,34.0,34,20.0,0,0,0,0,,SD,0,1,11.9,0.0,75.7,75.7,,,0,0,0.1,0,1,0,1,5.5,0,,0,0,1,39,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,25,24,1.39,0.86,2.514,1.4,29.0,0.0339,98,20.1,1,35.4,0,0,0,0,26.3,Chemotherapy,None